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Abstract
Objec��ves: Bone tumor o��en requires a surgical resec��on of the tumor. Some
tools have been developed to assist the surgeon during the pre-opera��ve and
intra-opera��ve steps. The planning leads to accurately define the extension of
the tumor, plan resec��on trajectories (including a safe margin) and select an
op��mal allogra�� (if required). The transfer into the opera��ve room has been
achieved using a specifically modified naviga��on system. Since few months,
pa��ent-specific devices have came up to guide the saw blade during bone
cu��ngs, such as total knee arthroplasty. This technology has been transposed
to resect bone tumors. An experimental study has been led on sawbones to
assess the accuracy of the method and compare the results with the one of a
previous experiment using conven��onal and navigated methods. We present
the preliminary results of this new experiment and some clinical cases that have
already benefited from the technique. Materials a...
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PELVIC LESIONS: DIAGNOSIS AND TREATMENT OF 258 CASES
The experience of the G.Pini Orthopaedic InsƟtute in Milan from 1998 to 2011
*S.Mapelli, P.A.Daolio, F.Lazzaro, R.Zorzi, P.Zacconi, S.Bastoni.                           
^A.ParafioriƟ, “G.Arborio, °F.Giardina,                                                               
*Orthopaedic Oncology Department; ^ Pathology Department;  “Radiology Department.
Gaetano Pini Orthopaedic InsƟtute – Milan – Italy.                                                      
°Course of SpecializaƟon in Orthopaedics - University of Milan
ObjecƟve: The number of the paƟents and the importance of the pelvic lesions that occurred in the Orthopaedic 
Oncology Unit of the G.Pini Orthopaedic InsƟtute are progressively increased during the last 15 years. Compared 
to surgical treatment on the extremiƟes, surgery of pelvic malignancies remains challenging. For this reason we 
decided to revise the data of the complete series of these lesions in order to get indicaƟons for the future cases
Materials and methods: The pathological and the surgical files of the paƟents that were registered in the Unit for a 
pelvic lesion from 1998 to 2011, were revised, compared and analyzed. 258 paƟents were idenƟfied and divided in 
3 groups. a)109 paƟents had only a core or/and a surgical biopsy but did not require a surgical therapy: 69 lesions 
were malignant, 7 were benign and in 33 cases the lesions were not oncologic or the biopsy was not diagnosƟc. b)64 
paƟents underwent to a surgical treatment for benign or not neoplasƟc lesions: the more frequent histotypes were 
Osteocondroma (15), Osteoid osteoma (9), Osteoblastoma, Simple Cyst and Langherans cell HisƟocitosis (6), ABC 
and GCT (4). c)The others 85 paƟents received an excision and reconstrucƟon, if needed, for a malignant tumor: the 
data are reported in the results.                                                                                                                    
Results: In the malignant group there were 54 males and 31 females; the minimum age was 6 years and the 
maximum 80, with a mean age of 46; the more frequent tumor was the Chondrosarcoma (20 central, 12 peripheral, 
2 dediﬀerenƟated) followed by the pPNET/Ewing tumor (14), the Metastasis (12), the Leiomyosarcoma (7), the 
Osteosarcoma (6), the Angiosarcoma (4) and other types (8). 10 paƟents had an amputaƟon; 5 had a simple cureƩage; 
the resecƟons were classified as: type I (25); type II (8); type III (9); type II+III (11); II+I (7); I+IV (8); I+II+III (1), II+I+IV 
(1). The margin, evaluated only in the primary lesions, was intralesional in 9 cases, marginal in 15, wide in 39 and 
radical in 10. The bone reconstrucƟon was not necessary in 27 paƟents and was not done in 6 (simple coaptaƟon); 
8 lesions were filled or replaced with PMMA; 3 paƟents had  an hip transposiƟon; 20 hip joint were reconstructed 
with prosthesis; bone graŌs were used in 15 cases (10 auto and 5 allo); 11 paƟents had soŌ Ɵssue or capsular 
reinforcement with mesh, Marlex or Trevira tube. ComplicaƟons, funcƟonal results, recurrences and follow-up are 
reported in an arƟculated analysis.                                                                                                           
Conclusions: In the group of simple biopsies, the relevant number of not oncologic and not diagnosƟc/not conclusive 
reports  suggest the need to check more accurately the indicaƟons for the biopsies but also the importance to follow 
the paƟents with the not conclusive reports to avoid a possible delay in the diagnosis of a latent tumor (mainly 
lymphomas). In the group of malignant lesions there are many types of surgical reconstrucƟons. The experience 
of the team and their learning curve are decisive in a correct balance of the mulƟple factors influencing the final 
surgical soluƟon: histotype and extension of the tumor, prognosis, risk of fracture, age, possible alternaƟve therapies 
and funcƟonal expectaƟons has to be considered. Anyway the complexity and the diﬃculty of this kind of surgery in 
the pelvic locaƟon jusƟfy the high percentage of complicaƟons that are to be considered before every decision.      
192
225
th
 E
M
SO
S 
An
nu
al
 M
ee
Ɵ
ng
SURGICAL TREATMENT OF MALIGNANT PELVIC BONE TUMORS 
INVOLVING THE SACROILIAC JOINT. EXPERIENCE OF SINGLE INSTITUTION
Sushentsov E., Musaev E., Schipahin S., Valiev A., Nered A., Aliev M. 
N.N.Blokhin Cancer Research Center, Russia, Moscow
IntroducƟon: Bone tumors of the sacroiliac joint oŌen have a poor prognosis because of late diagnosis and diﬃcult 
treatment.
Purpose: To assess the surgical technic using for resecƟon and reconstrucƟon of bone tumors involving the sacroiliac 
joint and esƟmate their eﬀects on oncological and funcƟonal results.
Materials and methods: Between 2004 and 2012 years thirteen paƟents were operated with primary and metastaƟc 
bone tumors involving the sacroiliac joint. In study included 7 female and 6 male, age range 19 – 61, mean 39 years. 
Histology rate was presented with hondrosarcoma – 3 cases, Ewing sarcoma – 3, Metastasis of renal-cell carcinoma 
– 3, Alveolar sarcoma and Osteosarcoma in one case, respecƟvely. The grading of primary tumors was based on 
Enneking classificaƟon.  The funcƟonal results was based on the MSTS scoring system. Surgical technic included 
tumor removing, pelvic ring reconstrucƟon with bone cement and instrumentaƟon and followed by recto-abdominal 
flap reconstrucƟon. BrainLab navigaƟon system was used for radical resecƟon and instrumentaƟon in two cases.
Results: The mean surgical Ɵme was 7 hours, bloodloss  was 4660 ml. Large resecƟon with adequate margins was in 
10 cases, marginal in 2 cases, and contaminated once. The mean follow-up was 35 months, from 3 to 83 months. Two 
paƟents with Ewing sarcoma died from metastaƟc disease, one died from recurrence of disease (with contaminated 
margin of hondrosarcoma) and one  - from renal failure.  The deep infecƟon occurred in 3 paƟents without recto-
abdominal flap reconstrucƟon, other paƟents had good wound healing and early ambulatory. The mean MSTS score 
was 66,9%.
Conclusion: Tumor resecƟon of the sacroiliac joint is diﬃcult surgical procedure with uncertain prognosis. PaƟent 
with Ewing sarcoma had poor oncology results. Today gold standard of surgical treatment of this pathology is bone 
resecƟon with pelvic ring reconstrucƟon and followed by recto-abdominal flap. 
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POROUS TANTALUM IMPLANTS IN PRIMARY AND REVISION 
TUMOR SURGERY OF THE PELVIS AND LOWER EXTREMITY 
G. Bianchi, M. De Paolis, P. Ruggieri, N. Fabbri
1IsƟtuto Ortopedico Rizzoli, Bologna, ITALY
ObjecƟves: Porous tantalum has been has been successfully used during the last decade in joint revision surgery 
associated with severe bone defects. Purpose of this study is to analyse clinical results obtained using modular 
porous tantalum implants in primary reconstrucƟon aŌer tumor resecƟon or in revision surgery of a pre-exisƟng 
failed tumor reconstrucƟon of the pelvis and lower extremity. 
Materials and Methods: It is a retrospecƟve study of 19 paƟents (8 males, 11 females) who underwent revision 
surgery for a failed tumor implant (16 cases) of hip-pelvis (10 cases), knee (5 cases) and ankle (1 case), and of 
2 primary reconstrucƟon of hip-pelvis aŌer surgical management of bone malignancy (2 cases) or reconstrucƟon 
of a massive non-oncologic pelvic defect (1 case); average age at the Ɵme of surgery was 35 years (22-55 yrs). 
Cause of failure in revision cases was asepƟc loosening (8 cases) or deep infecƟon (9 cases). Revision of infected 
cases was  managed in 2 or more stages. All paƟents presented severe segmental bone defect as result of primary 
tumor management and/or recent cause of failure. Bone defect has been managed in all cases with modular porous 
tantalum implants uncemented at the host bone interface and cemented in contact areas  with “augments”, always 
used, in associaƟon with morcellised bone graŌs to fill residual cavitary defects, and with a megaprosthesis in 9 cases 
(6 proximal femur, 2 distal femur, 1 proximal Ɵbia). Minimum follow-up in all cases is 2 years, average follow-up is 5 
years (2.5-8.5 yrs). 
Results: One case of refractory infecƟon and one case of recurrent dislocaƟon required further surgery. Porous 
tantalum implant made revision surgery easier and has shown excellent features also when used for primary pelvic 
reconstrucƟon. In all cases the porous tantalum implant is well-fixed and funcƟoning at last follow-up. Porous tantalum 
has provided solid and reliable fixaƟon in challenging biomechanic seƫngs, where it seems to be potenƟally superior 
to alternaƟve reconstrucƟve techniques. 
Conclusions: Porous tantalum clinical performance was very saƟsfactory at a medium follow-up approaching 5 years 
and is extremely promising in musculoskeletal oncology as arƟcular and segmental reconstrucƟve technique. Longer 
follow-up is necessary to idenƟfy possibly later failures.
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TREATMENT OF MALIGNANT OR AGGRESSIVE BONE TUMORS 
OF PELVIC GIRDLE BY MICROWAVE ABLATION 
Qing-Yu Fan, Ma Boan, Zhou Yong, Zhang Minhua, He, Yang Tong Tao, Long Hua, Zheng Lian He, Wang Yu Chai, Li Zhao
Department of Orthopedic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi’an, China, 710038
Correspondence to: Prof. Qing-Yu Fan 
(E-mail: bonetm@fmmu.edu.cn)
Tumors in the pelvis not only carry a worse prognosis but their resecƟon and reconstrucƟon are a challenge, even to 
the most experienced orthopaedic oncologist.( From  What’s New in Musculoskeletal Oncology Valerae O. Lewis J 
Bone Joint Surg Am. 2009;91:1546-1556. doi:10.2106/JBJS.I.00375)
The current widely used surgical treatment is en blot resecƟon of tumor-bearing bone followed by reconstrucƟon. 
The high rate of complicaƟon and mechanical instability oŌen contribute to poor results.
Main Concept & Method - AŌer careful dissecƟon of the tumor-bearing bone from surrounding normal Ɵssues, 
the microwave antennae array was inserted into the tumor mass for emiƫng electromagneƟc microwave which 
produces tumor cellular death via thermo-coagulaƟon. The main concept here is to achieve a safe margin tumor en 
bloc ablaƟon (assuming that the tumor is localized in the region of diagnosis) using antenna-guided hyperthermia 
therapy. Form the preliminary animal and model studies, all Ɵssues including the underlying bone and marrow 
will be completely devitalized (cell death and protein denatured) aŌer heated to 85-120°C for 20 minutes. During 
surgery, mulƟple thermocouples were placed in various criƟcal locaƟons to monitor the temperature within and 
around the tumor bulk. These died Ɵssues were removed and/or cureƩed leaving behind the defecƟve bone for 
reconstrucƟon using any of the currently accepted methods, materials and implants including segmental prosthesis. 
When the lesion is close to the hip joint but not within the joint, this technique could be used with special cooling 
system to protect the carƟlage, thus saving the joint. If the tradiƟonally defined wide margin could be idenƟfied 
using en bloc resecƟon technique, MW ablaƟon can achieve a similar goal while retaining the cureƩed corƟcal bone 
intact, thus making reconstrucƟon easier and more durable. 
Clinic Data:
From May 1994 to December 2009, 204 paƟents with pelvic malignant or aggressive tumors received radical 
thermotherapy. (Table 1)
Table 1
ClassificaƟon Name Total number Gender Average age
-Tumors with High 
Malignancy 
osteosarcoma/     osteogenic 
sarcoma    36 Male: 26; Female: 10 24 
Ewing’s sarcoma    10 Male: 5; Female: 5 19 
malignant fibrous hisƟocytoma 7 Male: 3; Female: 4 47
 synoviosarcoma           3 Male: 2; Female: 1 42 
lymphoma             3 All male 18
leiomyosarcoma         2 All male 33
myeloma             2 All male 53
malignant hemangioma         2 All female 42
malignant neurofibloma 2 Male: 1; Female: 1 38
mesenchymal sarcoma         1 Female 33
fibrosarcoma           1 Female 22 
clear cell sarcoma      1 Male 75
reƟcular cell sarcoma          1 Male 44 
Tumors with Low 
Malignancy 
chondrosarcoma    48 Male: 36; female: 12 38
chordoblastoma   2 Male: 1; female: 1 44
osteoblastoma  2 Male: 1; female: 1 50
hemangio-perithelioma   1 Female 50
ependymoma 1 Male 50
synovial chondroma 1 Female 16
hemangioblastoma 1 Female 32
Aggressive Tumors
giant cell tumor of bone    32 Male: 15; Female: 19 31
aneurysmal bone cyst 12 Male: 5; Female: 7 22
Aggressive fibromatosis 3 Male: 2; Female: 1 40
giant fibroma     3 Male: 2; Female: 1 24
neurofibroma     1 Male 38
chondromyxoid fibroma 1 Male 59
MetastaƟc Tumors metastaƟc carcinoma        25 Male: 19; Female: 6 51
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The over three-years survival rate for high grade malignancy bone tumor or for low grade malignancy (mainly are 
chondrosarcoma) is 54.9% and 89% respecƟvely. Almost all aggressive tumor (mainly GCT) got local and system 
control (only one got amputaƟon). Of 25 paƟents with isolated pelvic metastaƟc lesions, 11 paƟents sƟll lived without 
evidence of disease for at least three years.
FuncƟonal results: 
sixty-five paƟents who died or lived with disease were excluded from the funcƟon analysis. Among the remained 1. 
148 paƟents with high or low malignancy, 127 had excellent hip funcƟon, stable, painless, and almost full range of 
moƟon although 61 paƟents have a mild Trendelenberg gait because the gluteus minimus or/and medius had to be 
sacrificed. They sƟll can be categorized as excellent result according to the standards. Nine paƟents had good and 
12 cases had poor.   
ComplicaƟon: Local recurrence occurred in 18 paƟents (8% local recurred rate), 3 cases had revision surgery 2. 
and were under following-up, the other nine cases died from lesion. Six paƟents had deep infecƟon, which resolved 
by irrigaƟon, debridement, and administraƟon of system anƟbioƟcs. A fistula developed in two paƟents. One had 
lumbosacral trunk damaged during heaƟng due to that the nerve could not be separated from the tumor. Two 
paƟents sustained sciaƟc notch fractures, which healed in a non-anatomic posiƟon. Four paƟents had hip joint 
degeneraƟon change.
In the majority of the paƟents, funcƟonal and cosmeƟc acceptable limbs were reserved.
Overall Advantages –
1  Greatly simplified the surgery process. Making reconstrucƟve procedure more conservaƟve and less costly.
2  Increased the local and system control rate. 
3  Greatly improved the funcƟonal outcome because it could keep the leg length and stability of pelvic girdle. 
A typical case
  
                  1.1                                                    1.2                                                1.3
 
                   1.4                                      1.5                                         1.6                                1.7
                  1.8                                         1.9    
Fig 1: Chandrosarcoma of pelvis. 
1.1—1.3: image data shows the great sciaƟc foramen was filled fully with tumor. 
1.4—1.5: intra- and extra-pelvic were explored.
1.6: microwave generator(made by Sea.. company, Nanjing, China)
1.7: antenna
1.8: microwave ablaƟon was carried out.
1.9: remove the devitalized soŌ Ɵssues. Pelvic skeletal structure was kept perfect with suﬃcient strength.
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COMPUTER ASSISTED SURGERY FOR PELVIC TUMOURS : 
LESSONS LEARNT FROM THE FIRST 25 CASES
Lee Jeys, Rob Grimer
Royal Orthopaedic Hospital, Birmingham, UK
ObjecƟves: The pelvis and sacrum remain one of the most challenging locaƟons for surgery in Orthopaedic Oncology. 
The complex 3D structure, proximity of vital structures, consistency of the tumour and variable posiƟon of the 
paƟent during surgery. Previous studies have shown that the probability of experienced surgeons achieving a 1cm 
margin in all 3 planes on a simulated tumour model of the pelvis was less than 50%. Our previously presented series 
prior to the use of navigaƟon showed that our intralesional rate for pelvic bone tumours was 29% and our long term 
local recurrence rate was 26%. The aim of the study was to report the experience of the first 25 cases of computer 
navigaƟon for tumours of the pelvis and sacrum.
Methods: From April 2010 to date we have conducted 25 cases of resecƟon of bone tumours of the pelvis and 
sacrum using the Stryker Orthomap NavigaƟon system, which is uses technology to fuse and MRI & CT scan, to 
accurately create a model of the tumour and normal anatomy. At surgery the paƟent model is correlated with 
the paƟents anatomy allowing accurate resecƟon of the tumour. PaƟents were idenƟfied from the database, their 
demographics and outcomes were analysed.
Results: ResecƟon of malignant tumours have been undertaken in 25 paƟents. These were for 16 primary malignant 
bone tumours (8 chondrosarcomas, 4 chordomas, 3 osteosarcomas and 1 Ewings sarcoma) and 9 metastases (4 
primary rectal tumours with direct invasion into the sacrum, 3 periacetabular breast metastases and 2 solitary renal 
metastases). In all 22 cases where a clear surgical margin was intended (some iniƟal case in series the navigaƟon was 
used for implant posiƟoning) then the mean registraƟon error was less than 1mm and the bony resecƟon margins 
were wide by greater than 5mm. In 2 cases there was tumour contaminaƟon (one case a cysƟc chondrosarcoma 
ruptured on removal of specimen from the pelvis aŌer resecƟon, and in one case there was a posiƟve soŌ Ɵssue 
medial margin on a chordomas where the peritoneum was adherent to the tumour and it torn on tumour removal 
aŌer resecƟon). There have been no cases of locally recurrent disease to date. The technique allowed more complex 
resecƟon and reconstrucƟon than would have been possible previously, avoided a hindquarter amputaƟon in 3 
cases, saved nerve roots in 4 paƟents which would have led to inconƟnence and allowed resecƟon of the primary 
rectal carcinoma in 4 cases, which would have previously been deemed inoperable.
Conclusions: The authors feel this technique has parƟcular merit for use in pelvic surgery and has significantly 
reduced our intralesional resecƟon rate and allowed more complex surgery and reconstrucƟon. 
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INFECTIONS IN PELVIC SURGERY FOR BONE TUMORS: AN 
ANALYSIS OF 274 CASES
Andrea Angelini, MD; Roberto Casadei, MD; Elisa Pala, MD; Gabriele Drago, MD; MaƩeo RomanƟni, MD; Pietro Ruggieri, MD, 
PhD
IV Department of Orthopaedics, University of Bologna, IsƟtuto Ortopedico Rizzoli, Bologna, Italy 
ObjecƟves: Surgical treatment of pelvic tumors with or without acetabular involvement is challenging. Primary goals 
of surgery include local control and maintenance of good quality of life. Purpose of this study was to evaluate the 
incidence and outcome of infecƟon aŌer limb salvage surgical resecƟon with or without reconstrucƟon for pelvic 
bone tumors.
Material and Methods: From 1975 to 2010, 274 paƟents (162 males-112 females) with pelvic bone tumors were 
treated by surgical resecƟon. Mean follow-up was 7.1 years (range 1-32). Chondrosarcoma (161), Ewing’s sarcoma 
(82) and osteosarcoma (47) were the most common histotypes. According to Enneking’s classificaƟon, 66 paƟents 
had type I (ilium), 24 type II (periacetabular) and 25 type III (anterior arch) pelvic resecƟon. Combined resecƟons 
were performed in 42 cases (type I-II), 79 cases (type II-III), 25 cases (type I-II-III) and 13 cases (type I-IV). In 139 cases 
reconstrucƟon was performed, in 135 there was no reconstrucƟon. Special aƩenƟon was given to the assessment of 
deep infecƟons, their treatment and outcome.
Results: Deep infecƟons were observed in 54 cases (19.7%) at mean follow-up of 11 months. There were 19 
infecƟons in 135 cases without reconstrucƟon (14%) and 35 over 139 with reconstrucƟon (25%). In 33 paƟents (61%) 
infecƟon occurred within 4 weeks postoperaƟvely, in 12 within 6 months and in 10 aŌer 6 months. Most frequent 
bacteria causing infecƟon were Stafilococcus species (40%), Enterococcus and Escherichia Coli (31%), Pseudomonas 
Aeruginosa (9%). Actuarial survival to infecƟon was 88%,83% and 79% at one month, one and ten years respecƟvely. 
Surgical treatment consisted in one (37%) or more (26%) surgical debridements, combined with anƟbioƟcs therapy 
according to coltures. In 16 cases the implant was removed, while 5 cases (9.3%) had an external hemipelvectomy 
(one due to both persistent infecƟon and local recurrence). The incidence of infecƟon in paƟents with  reconstrucƟon 
was staƟsƟcally higher than in paƟents without reconstrucƟon (p<0.01). No staƟsƟcal diﬀerence was found between 
periacetabular resecƟons and others. Average MSTS score aŌer treatment of infecƟon was 68.3%.
Conclusions: Favourable oncologic and funcƟonal outcome can be achieved in selected paƟents with pelvic bone 
tumors. ComplicaƟon rates are  high. ReconstrucƟon aŌer resecƟon is related with risk of infecƟon. 
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EVALUATION OF THE EFFECTIVENESS OF TREATMENT FOR CHILDREN AND 
ADOLESCENTS WITH EWING’S SARCOMA FAMILY TUMOR OF PELVIS
Nisichenko O.A., Shvarova A.V., Glekov I.V., Hestanov D.B., Musaev E.R., Ivanova N.M.
InsƟtute of Paediatric Oncology and Hematology N. N. Blokhin Cancer Research Center, Moscow, Russian 
FederaƟon
Aim: The aim of this study was to evaluate and compare the eﬀecƟveness of the treatment of various treatment 
protocols for children and adolescents with Ewing’s Sarcoma Family Tumor of pelvis.
Materials and methods: Ninety paƟents with ESFT of the pelvis were treated at InsƟtute of Paediatric Oncology 
and Hematology between 1972 and 2007. Three diﬀerent protocols of chemotherapy were used. Between 1972 to 
1988 protocol consisted of VAC for control group (CG) I: 32 pts, nonmetastaƟc  - 25, disseminated -7,  between 1988 
to 1997 of VACP for control group II: 30 pts, nonmetastaƟc  - 23, disseminated -7.  From 1997 Ɵll 2007 inducƟon 
chemotherapy (CT) for pts (28, nonmetastaƟc  - 18, disseminated -10) of invesƟgaƟon group (IG) III consisted of 
vincrisƟne 1,5 mg/m2/d, days 1,8,15, adriamycin 37,5 mg/m2/d, days 1,2 as a 24-h infusion, cyclophosphamide 2,1 
gr/m2/d, days 1,2 (1, 3, 5 cycles), and ifosfamide 2,4 gr/m2/d, days 1 through 5, etoposide 100 mg/m2/d, days 1 
through 5 (2, 4 cycles).  Local treatment consisted of radiotherapy in all cases. AŌer local treatment pts of IG received 
HD CT with melphalan 140 mg/m2, busulfan 16 mg/kg. PBCS were reinfused mean 6,0 x106 CD34+/kg. 
Results: The 5- year disease-free survival rates were 3,1% for CG I; 13,3% for CG II and 69,8% for IG III. These results 
are significantly worse for CG I and II than the ones achieved in 28 paƟents of IG III with new innovaƟve methods for 
the treatment. 
Only one paƟent had surgical treatment in the amount of resecƟon of the ischium and pubic bone defect with 
endoprosthesis reconstrucƟon of the pelvis and hip replacement.
Conclusion: The use of an innovaƟve program of intensive therapy significantly improved clinical outcomes and 
increase the 5-year disease-free survival in 28 paƟents of Group III to 69.8%.
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OSTEOSARCOMA OF THE PELVIS. A MONOINSTITUTIONAL 
EXPERIENCE IN PATIENTS YOUNGER THAN 41 YEARS
 
Stefano Ferrari1, Emanuela Palmerini1, Nicola Fabbri2, Eric Staals2, CrisƟna Ferrari1, Emanuela Marchesi1, Pietro Rugieri2 Marco 
Alberghini3, Piero Picci1
1Oncology Department, Rizzoli InsƟtute, Bologna, Italy
2Surgical Oncology Department, Rizzoli InsƟtute,  Bologna, Italy
3 Surgical Pathology Department, Rizzoli InsƟtute,  Bologna, Italy
Background: InformaƟon is scarce on treatment of pelvic osteosarcoma (POS) as most study  protocols for 
osteosarcoma include paƟents with extremity tumors and aged up to 30-40 years.
PaƟents younger than 41 years with high grade POS were enrolled in a monoinsƟtuƟonal prospecƟve study. Whenever 
possible paƟents were  surgically treated. The systemic treatment was given according to two chemotherapy protocols 
consisƟng of methotrexate, cisplaƟn, doxorubicin (MAP) and standard dose (SD) or high-dose (HD) ifosfamide (IFO).
Results: Forty paƟents (9 with synchronous lung metastases)  ranging between 11 and  36 years (median age 22 
years), with POS were included. The most frequent histological subtype was the osteoblasƟc one  followed by the 
chondroblasƟc histotype that was observed in 37.5% of paƟents.  Complete surgical remission (CSR) was achieved in 
65% of the paƟents. Chemotherapy: 18 paƟents had MAP/SDIFO, 22 MAP/HDIFO. Primary chemotherapy was given 
to 25 paƟents and 6 (24%) of them  had a good histological response. Median follow-up was 32 months (4-134), 
5-year overall survival (S) was 27.5%: 33% in localized and 0 in metastaƟc paƟents (p=0.02); 45% in paƟents with CSR 
and 0 for no CSR (p=0.001). Local recurrence rate was 46%. In paƟents with CSR, 5-year probability of S was 32% with 
MAP/SDIFO regimen and 59% with MAP/HDIFO regimen (p = 0.3).
Conclusions: Local control is the major issue in treatment of pelvic osteosarcoma. Poor pathological response and 
the high incidence of chondroblasƟc variant indicate diﬀerent biological characterisƟcs between pelvic and extremity 
osteosarcoma. A  chemotherapy treatment with MAP and high-dose ifosfamide might be beneficial paƟents with 
pelvic osteosarcoma and warrant further invesƟgaƟon .
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A OUTCOME ASESSMENT OF HIGH GRADE CHONDROSARCOMA 
EXPERIENECES FROM THE VIENNA BONE AND SOFT TISSUE REGISTRY
Philipp T. Funovics, MarƟn Dominkus, Joannis Panotopoulos, Susanna Lang, Reinhard Windhager
Medical University of Vienna Department of Orthopaedics, Vienna, Austria
Background: Chondrosarcoma is the second most common primary bone tumor, yet a rare enƟty, and the idenƟficaƟon 
of prognosƟc factors is sƟll regarded a diﬃcult challenge. Aim of this study was to retrospecƟvely present a single 
insƟtuƟon experience with high grade chondrosarcoma over a forty year Ɵme span.
Methods: Between January 1972 and December 2011, a total of 175 paƟents have been treated for high grade 
chondrosarcoma at the Medical University of Vienna Department of Orthopaedics. Low-grade lesions and tumors 
of the small bones have been included from this invesƟgaƟon. The cohort included 102 males (58%) and 73 females 
(42%) with an average age of 52 years (range, 16 to 87; median, 54). Mean follow-up was 67 months (range, 1 to 412; 
median, 44). Ninety-five tumors were located in the trunk (54%), including 62 pelvic lesions (35%) and 80 tumors 
arose in the extremiƟes (46%) with the femur being the most predominant site (46 lesions; 26%). Eleven tumors 
were regaded as extraskeletal chondrosarcoma (6%), and 18 paƟents presented with primary metastaƟc disease 
(10%). Eight tumors (5%) were regarded irresectable and conveyed to conservaƟve treatment, 167 paƟents (95%) 
underwent surgery including endoprostheƟc reconstrucƟon in 68 (39%) and iniƟal amputaƟon in 24 (14%).
Results: Eighty-seven paƟents (50%) died throughout follow-up. Median overall survival of all paƟents was 80 
months with a five- and ten-year survival rate of 56% and 45%, respecƟvely. Age (p<0.001), female gender (p=0.013), 
tumor site in the trunk (p=0.003) and primary metastaƟc disease (p=0.008) were strong negaƟve predictors of 
outcome. Local recurrence was observed in 19 of 167 operated paƟents (11%). Local recurrences occured up to 117 
months postoperaƟvely with a five- and ten-year local recurrence-free survival rate of 83% and 81%, respecƟvely. 
Women showed a beƩer local recurrence-free survival (p=0.046). Metastases were observed in 33 cases (19%). 
Correspondingly, the five- and ten-year metastasis-free survival rate was 75% and 71%, respecƟvely, with a trend 
towards worse outcome of soŌ Ɵssue chondrosarcoma (p=0.053). In mulƟvariate analysis age (HR=1.04), site (HR 
for extremity=0.42) and primary metastaƟc disease (HR=2.59) were staƟsƟcally significant predictors for overall 
survival.
Conclusion: High grade chondrosarcoma is an aggressive enƟty, especially outcomes of truncal tumors can be limited 
by the unability to achieve surgically adequate margins, leading to a considerable rate of local recurrence. Also, the 
unfavourable outcome for paƟents with metastaƟc disease underlines the need for further adjuvant therapies.
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ARADIOFREQUENCY ABLATION OF LOWGRADE 
CHONDROSARCOMAS: EFFICACY AND INITIAL EXPERIENCES 
OF A NOVEL TECHNIQUE IN PRIMARY BONE TUMOUR 
SURGERY.  
 
Dierselhuis EF1, vd Eerden PJM2, Hoekstra HJ3, Bulstra SK1, Suurmeijer AJH4, JuƩe PC1
1Department of Orthopaedic Surgery, University Medical Center Groningen, University of Groningen, the Netherlands
2Department of Radiology, University Medical Center Groningen, University of Groningen, the Netherlands
3Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, the Netherlands
4Department of Pathology, University Medical Center Groningen, University of Groningen, the Netherlands
IntroducƟon: To date, central chondrosarcoma (CS) grade I within the long bones is treated either by resecƟon or 
cureƩage with local adjuvant. Recent reports suggest that local treatment is suﬃcient in most cases, with beƩer 
funcƟonal outcome as a result. Given the fact that CS grade I typically has a very mild biological behaviour, we 
hypothesized that minimal invasive treatment would be the next step using radiofrequency ablaƟon (RFA). The 
purpose of the study is to demonstrate an eﬀecƟve ablaƟon of central CS grade I tumour cells in the long bones 
using RFA. 
PaƟents and methods: A prospecƟve study was designed to evaluate the tumour kill eﬃcacy of RFA in central CS 
grade I. A total number of 20 paƟents were treated by CT guided RFA. Three months later, paƟents received usual care 
by cureƩage with phenol/ethanol and bone cement as local adjuvant. Material retrieved during cureƩage was send 
for histopathological analysis to assess the percentage of tumour necrosis as primary endpoint. In addiƟon, paƟent 
and tumour characterisƟcs were documented. MSTS scores were noted 6 and 12 weeks aŌer RFA and cureƩage. In 
10 paƟents, MSTS scores aŌer one year were also calculated. 
Results: 
Primary endpoint
In 9 paƟents, 100 percent necroƟc Ɵssue was found in material obtained during cureƩage (R0). In 5 other paƟents, 
the amount of non viable cells was esƟmated 95-99% (R1). In 6 paƟents, the percentage of necrosis was <95% (R2). 
Of all tumours localised in the diaphysis (n=6), 5 (83%) were completely destructed, compared to 4/14 (29%) in the 
epimetaphysis (p=0.02). Of all tumours ablated > 30 mm, only 5/11 (45.5%) were R0 or R1, compared tot 9/9 (100%) 
in tumours <30 mm (p=0.006).
Secondary endpoints
All paƟents with a tumour in the lower extremity (n=16) had a 50% weight-bearing regime for the first six weeks, 
increased to 100% aŌer three months. Mean MSTS scores 6 weeks aŌer RFA were 27.1 (23-30) compared to 18.1 
(12-25) 6 weeks aŌer cureƩage (p<0.001). 12 weeks aŌer RFA, MSTS scores were 27.2 (23-30) versus 22.9 (15-30) 
12 weeks aŌer cureƩage respecƟvely (p<0.001). One year aŌer cureƩage, scores averaged 27.4 (24-30). No adverse 
events were seen aŌer RFA. In two paƟents, a pathological fracture occurred aŌer cureƩage. All paƟents were 
discharged from the hospital several hours aŌer the RFA procedure. For cureƩage, paƟents were admiƩed three to 
five days. 
Conclusions: In conclusion, we have demonstrated that RFA is capable of complete eradicaƟon of small grade I CS in 
the long bones. Hereby, minimal invasive surgery can be used as an alternaƟve in the treatment of these tumours. It 
can be safely performed in day-care, with a very quick return to daily acƟvity. For the long term, it has to be proven 
that oncological outcome will be as saƟsfying. Currently, size of tumour and localisaƟon within the bone are the 
main predictors of success, with varying eﬃcacy rates. Therefore, more consistency is needed and further research 
is being done at present to improve accuracy of the ablaƟon procedure.
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A PELVIC CHONDROSARCOMAS: REVIEW OF THE ISTITUTO 
RIZZOLI EXPERIENCE
Pietro Ruggieri, MD, PhD; Andrea Angelini, MD; Nicola Fabbri, MD; Andreas F. Mavrogenis, MD; Gabriele Drago, MD; Carlo 
Romagnoli, MD; Marco Manfrini, MD.
IV Department of Orthopaedics, University of Bologna, IsƟtuto Ortopedico Rizzoli, Bologna, Italy 
ObjecƟves: Aim of this retrospecƟve study was to review the long-term oncologic and funcƟonal outcome of surgical 
management in a large series of paƟents with pelvic chondrosarcomas (CS) treated at a single insƟtuƟon. 
Material and Methods: We analyzed 235 paƟents treated at our insƟtuƟon between 1975 and 2008: 144 males 
(61%) and 91 females (39%) with a mean age of 46.6 years (range, 15 to 81 years). There were 101 central CSs (16, 
66 and 19 cases grade 1, 2 and 3 respecƟvely), 83 peripheral CSs (42, 40 and 1 cases grade 1, 2 and 3 respecƟvely), 33 
dediﬀerenƟated CSs, 4 clear cell CSs, 2 mesenchymal CSs and 2 periosteal CSs, while in 10 cases it was not possible 
to define the histologic variant. Tumor involved the iliac wings in 57 cases, iliac wing and sacro-iliac joint in 8 cases, 
iliac wing and periacetabular bone in 34 cases, anterior arch and periacetabulum in 49 cases, anterior arch only 
in 22 cases and the enƟre hemi-pelvis in 33. Forty-one paƟents had an external hemipelvectomy (17%), whereas 
194 paƟents (83%) underwent a limb-salvage procedure: 105 resecƟons without reconstrucƟon and 89 resecƟons 
with reconstrucƟon.  Margins were wide in 151 cases, wide but contamined in 30 cases, marginal in 41 cases and 
intralesional in 13 cases (in 7 of these cases a debulking procedure was performed due to extension of the tumor).
Results: The overall survival evaluated with Kaplan Meier curve was 82%, 73% and 70% at 5, 10 and 15 years 
respecƟvely. At a mean follow up of 9 years (2–32 years), 158 paƟents (68%) were conƟnuously disease free, 13 were 
alive without evidence of disease aŌer treatment of local recurrence, 49 paƟents (21%) died of their disease, 12 
paƟents (5%) died of other causes and 16 paƟents (6.8%)  alive with disease. Incidence of local recurrence was 29.8% 
(70 paƟents) and survival to local recurrence was 74%, 68% and 65% at 5, 10 and 15 years respecƟvely. Incidence 
of LR was staƟsƟcally higher in surgery involving periacetabular areas than iliac wing (p=0.0372) or anterior arch 
(p=0.0137). In central and peripheral CSs, high-grade tumors correlated with worse survival (p=0.012). There was no 
staƟsƟcal diﬀerence in survival between peripheral and central CSs (p=0.0763), while comparing both central CSs 
and peripheral CSs with dediﬀerenƟated CS, this laƩer had a significantly worst prognosis (p<0.0001). 
Conclusions: Surgery is the mainstay of treatment for pelvic CS. External hemipelvectomy is reserved to cases where 
it is not otherwise possible to achieve adequate margins. Pelvic locaƟon, especially the acetabulum, oﬀers challenging 
technical problems to reliable and lasƟng reconstrucƟon. There is a significant correlaƟon between tumor grading 
and survival. The lack of adjuvant suitable chemotherapeuƟc agents leads to a worsening of prognosis at long-
term. 
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ACHONDROSARCOMA OF THE PELVIS. ANALYSIS OF RISK 
FACTORS FOR LOCAL AND SYSTEMIC CONTROL
Domenico A. Campanacci, Massimiliano Ippolito, Filippo Frenos, Giuseppe Caﬀ, Giovanni Beltrami, Guido ScoccianƟ, Rodolfo 
Capanna
Department of Orthopaedic Oncology, Azienda Ospedaliera Universitaria Careggi,Firenze, Italy
ObjecƟves: The pelvis and proximal femur are the most frequent sites of occurrence of chondrosarcoma (CS) of bone, 
and axial CS were seen to behave more aggressively than appendicular skeleton lesions. Currently, surgical excision 
remains the elecƟve treatment opƟon for pelvic chondrosarcoma due to its scarce response to chemotherapy and 
radiaƟontherapy. The purpose of the present study was to review the paƟents treated for a chondrosarcoma of the 
pelvis at authors’ InsƟtuƟon and to idenƟfy the risk factors for local and systemic control of the disease.
Materials and Methods: Fortytwo paƟents with diagnosis of pelvic CS, treated at author’s InsƟtuƟon between 1994 
to 2011, were included in the study. They were 26 males and 16 females with a median age of 50 years (min 15 - max 
75). The diagnosis was central CS (CCS) in 34 cases and peripheral CS (PCS) in 8 cases. In 2 cases, the CCS was a local 
recurrence aŌer a previous surgical treatment. The hystological grading of 34 CCS was: G1 in 4 cases, G2 in 20, G3 in 
4 and G4 (dediﬀerenƟated) in 6 cases. The hystological grading of 8 PCS was: G1 in 6 cases, G2 in 2 cases. The tumor 
localizaƟon was ihe iliac wing in 7 cases (Type I resecƟon), the anterior pelvic arch in 6 (Type III), the acetabular area 
in 26 (Type II in 6; Type I-II or II-III in 13; Type I-I-II in 7) and the sacroiliac joint in 3 cases (Type I-IV). The surgical 
treatment of 34 CCS was resecƟon in 24 cases, intralesional cureƩage in 3 cases and hemipelvectomy in 7 cases. 
Surgical margins aŌer CCS excision resulted radical in 4 cases, wide in 19, marginal in 8 and intralesional in 3 cases 
(intenƟonal intralesional cureƩage). The surgical treatment of 8 PCS was conservaƟve resecƟon in all cases. Surgical 
margins aŌer PCS excision resulted wide in 6 and marginal in 2 cases. AŌer conservaƟve resecƟon of the tumor (35 
paƟents), no reconstrucƟon was performed in 17 cases while a massive allograŌ with THA was used in 15 cases, an 
ischiofemoral artrhodesis in 1, a saddle prosthesis in 1 and a hip rotaƟonplasty in 1 case.
Results: At a median follow up of 52 months (min 2- max 209), 25 paƟents were conƟnuosly disease free (59.5%), 3 
paƟents were alive with disease, 12 paƟents had died of disease and 2 paƟents had died of another cause. A local 
recurrence was observed in 11 paƟents (26%), 9 in CCS and 2 in PCS. Local recurrence was observed aŌer conservaƟve 
resecƟon in 8 cases and aŌer hemipelvectomy in 3 cases. Pulmonary metastases occurred in 13 paƟents (30.9%), 11 
in CCS and 2 in PCS. Local recurrence free survival was 64.1% at 5, and 15 years and overall survival was 62.9% and 
47.1% respecƟvely at 5 and 15 years. A staƟsƟcally significaƟve correlaƟon was found between local recurrence and 
type of resecƟon showing the tumor locaƟon in the sacroiliac joint (Type I/IV resecƟon) a risk factor for local control 
of the disease. Histological grading resulted a staƟsƟcally significant risk factor for survival.
Conclusions: The review of our experience on pelvic CS confirmed their worse prognosis on respect to appendicular 
skeleton localizaƟons. In 62% of cases the tumor involved the acetabular area. CCS were most frequently G2 (59%) 
and PCS were most frequently G1 (75%). Limb salvage rate in our series of pelvic CS was 83.3%. In three G1 CCS, an 
intralesional cureƩage was performed (grading was confirmed at final histologic examinaƟon) and no local recurrence 
was observed so far (average 64 months, min 38-max 99). In the remaining 39 paƟents, adequate surgical margins 
were achieved in 74% of cases. StaƟsƟcal analysis showed a correlaƟon between local recurrence and tumor locaƟon 
(higher risk in the sacroiliac area) and between paƟents’ survival and tumoral histologic grading.
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A MEGAPROSTHETIC RECONSTRUCTION FOR 
CHONDROSARCOMA OF THE EXTREMITIES: EVALUATION OF 
THE FUNCTIONAL AND ONCOLOGICAL OUTCOME 
Markus NoƩroƩ, Marcel Henrichs, Georg Gosheger, Jendrik Hardes, Arne Streitbürger
Department of Orthopaedics, University Hospital Münster, Münster, Germany
ObjecƟves: The treatment of Chondrosarcoma of bone is sƟll challenging. Surgery keeps the only eﬀecƟve treatment 
opƟon, while sƟll missing adjuvant therapies. The wide tumour resecƟon according to Enneking is the treatment 
of choice in high- and intermediate-grade chondrosarcoma. Only for low-grade chondrosarcoma of the long bones 
conservaƟve surgery is feasible for special indicaƟons. The use of megaprosthesis for defect reconstrucƟon is superior 
to allograŌ or biological reconstrucƟons, however, despite aggressive surgery high rates of local recurrences and 
metastasis are common. Further, infecƟon sƟll remains a severe implant related complicaƟon.
Material and Methods: Between 1992 and 2006 we used megaprostheses in 78 paƟents (32 women, 46 men) with 
the diagnosis of chondrosarcoma of the limb. Of these, eight were treated iniƟally for the primary tumour at another 
insƟtuƟon, of whom all were treated intralesionally. Most frequent tumour site was the distal femur (n=24) and the 
proximal femur (n=24) followed by the proximal humerus (n=21).
Mean age at primary diagnosis was 55.2 years. Tumour grading was grade I (GI) in 17 paƟents, GII in 42, GIII in 7, and 
de-diﬀerenƟated (DD) chondrosarcoma in 12 paƟents.
Results: Median follow-up was 62 months with a minimal follow up of 20 months or unƟl death. Overall survival 
was significantly linked to the tumour grade. 21 paƟents died of disease (G II 19.0%, G III 28.5%, DD 91.7%) aŌer a 
medium of 24 months. In 91% wide resecƟon margins were achieved. Local recurrence rate was 7.6% for all tumours 
but even higher (41.7%) for high-grade chondrosarcoma. Local recurrence was not linked to the achieved margin. 
Primary metastases were found in five paƟents and 26% developed metastases within the follow-up. Although there 
was no influence of the resecƟon margins on development of metastaƟc disease. Adjuvant therapy was given to 13 
paƟents however, there was no eﬀect on the overall prognosis (one alive). 
FuncƟonal results were good in most of the paƟents. The main prosthesis related complicaƟon was infecƟon in 4 
cases followed by asepƟc loosening (n=3). 11.5% of the paƟents required surgical revision due to implant related 
complicaƟons and 23.1% due to oncological complicaƟons. Secondary amputaƟon was necessary in eight paƟents 
because of oncological complicaƟons and one due to infecƟon. ProstheƟc survival at the latest follow up was 77.3% 
for the primary implant.  
Conclusions: The endoprostheƟc replacement of chondrosarcoma of the limb provides good funcƟonal outcome 
with low rates of implant related complicaƟon and a long prostheƟc survival.
However, in absence of eﬀecƟve adjuvant therapies, even the wide tumour resecƟon results in high rates of local 
recurrences and metastaƟc disease in high grade chondrosarcoma compared to other primary bone sarcoma. 
This is certainly founded in tumour biology and shows that addiƟonal adjuvant treatment opƟons are needed. 
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ATHE NATURAL HISTORY OF ADVANCED INOPERABLE CENTRAL 
CHONDROSARCOMA
P. Picci, A. van Maldegem, E. Palmerini, P.D.S. Dijkstra, M. Alberghini, J.V.M.G.Bovee, P. Ruggieri, C. Ferrari, S. Ferrari, H. 
Gelderblom 
IsƟtuto Ortopedico Rizzoli, Bologna, Italy and Leiden University Medical Center, The Netherlands
ObjecƟves: LiƩle is known about the survival of central chondrosarcoma when surgical removal of local or metastaƟc 
disease is considered unfeasible. ParƟcularly no informaƟon is available on survival in this condiƟon. Furthermore 
this histology is considered chemoresistant and no treatment has been shown eﬀecƟve for these paƟents (pts).
Materials and Methods: To answer this quesƟon, pts with non-resectable (“inoperable”) central chondrosarcoma 
from two major European Centers (Rizzoli InsƟtute in Bologna, and Leiden University Medical Center) were pooled 
for invesƟgaƟon. 171 pts were considered inoperable: 49 cases at first presentaƟon, 122 cases aŌer one or more 
relapses.
Results: The Ɵme to development of inoperable disease for the 122 pts who relapsed ranged from 1 to 233 months 
from first treatment, with a median of 23.5 months.
The site of the inoperable disease was local only in 45 cases, lung only in 72 cases, lung plus local in 39 cases, and 
also with visceral involvement in 15 cases. 
The overall survival for all 171 pts was 48% at 1 year, 24% at 2 years, 12% at 3 years, 6% at 4 years, and 2% at 5 years. 
The median Ɵme to death was 11 months with a range of 1-106 months. In paƟents with local only unresectable 
disease, survival was 26% at 36 months (median 18, range 1-104) compared to 7% (median 11, range 1-51) and 8% 
(median 9, range 1-106) respecƟvely for those presenƟng with lung disease only or lung plus local disease. In pts with 
visceral disease median survival was 7 months (range 2-24). The diﬀerence between pts with local disease only and 
the other paƩerns is highly staƟsƟcally significant with a p value of 0.0014. Regarding the role of other treatments, 
37 pts received systemic anƟtumour treatment, with a survival of 26% at 36 months, compared to 8% for those pts 
who did not receive it. Radiotherapy was given in 36 pts and their survival was 27% at 36 months vs 8% for those who 
did not receive it. EvaluaƟon of the eﬀect of these non-surgical treatments will require further invesƟgaƟons.
Conclusions: This pooled analysis of the largest series of inoperable chondrosarcoma pts allowed us to gain insight 
in the prognosis of these pts, that can serve as benchmark for future studies.
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A CHEMOTHERAPY IN CHONDROSARCOMAS. 
RECENT EXPERIENCE OF N.N. BLOKHIN CANCER CENTER
Gennady Machak, Igor Chernov, Teimuraz KharaƟshvili
Purpose: To evaluate the eﬀecƟveness of recent chemotherapy regimens in the treatment of paƟents with 
chondrosarcoma.
 
PaƟents and methods: Since 1997, 36 paƟents received chemotherapy for primary (19) or recurrent/metastaƟc (17) 
chondrosarcoma. In primary tumors chemotherapy consisted in combinaƟon of doxorubicin (DOX) 60-90 mg/m2 
and cis-plaƟnum (CDDP) 100-120 mg/m2 (11) administrated IV or IA. Last years ifosfamide (IFO) containing regimens 
(IFO 6 g/m2 +DOX 60 mg/m2 +CDDP 100-120 mg/m2 or CARBO 300-450 mg/m2) were used in 8 paƟents. Eight tumors 
in this group had axial locaƟon and were considered inoperable at presentaƟon. In relapsed chondrosarcomas 
14 paƟents (82%) received chemotherapy with (IFO+DOX+CDDP or CARBO). In this preliminary analysis we have 
evaluated the short-term results assessed by clinical/imaging response, tumor necrosis rate in surgical specimen or 
RECIST criteria. 
Results: In 8 paƟents with locally advanced and inoperable primary chondrosarcomas no major clinical or imaging 
responses were seen.  Among 11 operated paƟents no good histological responders were documented. In relapsed 
tumors 8 paƟents progressed despite chemotherapy (53%), 7 paƟents (47%) had clinical benefit as stable disease (5) 
or parƟal response (2). Two paƟents were not evaluated for response. 
Conclusions: In primary chondrosarcoma chemotherapy had a liƩle impact on disease evoluƟon, especially in locally 
advanced inoperable tumors.  AƩempts to improve local response by intra-arterial administraƟon or adding of IFO 
were unsuccessful.  In relapsed tumors  selected paƟents can achieve SD or PR aŌer chemotherapy and could be 
considered as candidates for the second surgical remission. The impact of this combined approach on long-term 
results remains to be defined. 
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GYINSTITUTIONAL VARIABLES IN THE EUROPEAN AND AMERICAN OSTEOSARCOMA STUDY EURAMOSͳ1: PEDIATRIC AND 
ADOLESCENT VS. YOUNG ADULT OSTEOSARCOMA PATIENTS.
Stefan Bielack1,2, Jane Hook3, Gordana Jovic3, Neyssa Marina4; Sigbjørn Smeland5, MaƩhew R Sydes3, Jeremy Whelan6, Mark 
Bernstein7 
Klinikum StuƩgart - Olgahospital1 and University Hospital Muenster2, Germany; MRC Clinical Trials Unit3 & UCL Hospitals NHS 
Trust6, London, UK; Stanford University Medical Center, USA4; Norwegian Radium Hospital, Oslo, Norway5; IWK Health Centre, 
Dalhousie University, Halifax, Canada7
IntroducƟon: Osteosarcoma is a typical cancer of adolescents and young adults (AYA). We used the final enrolment 
data for EURAMOS-1, open for paƟents aged 0-40 years, in order to determine how the insƟtuƟonal background 
through which young adult paƟents enter “AYA-trials” is diﬀerent from that of younger paƟents.
Material and Methods: Analysis of paƟent- and tumor-related variables as well as insƟtuƟonal variables and 
randomizaƟon rates for paƟents aged ≤18yr (children and adolescents) and >18yrs (young adults) at diagnosis 
of resectable high-grade osteosarcoma entered into EURAMOS-1/AOST0331 (NCT00134030; ISRCTN67613327; 
EUDRACT-2004-000242-20) between Apr-2005 and Jun-2011. 
Results: 2,260 paƟents from 326 insƟtuƟons were registered, including 1,108 paƟents from 13 European countries 
(AUT=28, BE=52, CH=39, CZ=9, DK=27, FIN=3, D=432, H=24, IRE=6, NL=101, N=41, SE=48, UK=298). Younger paƟents 
(≤18yr, median: 13yr) comprised 85% (n=1,930) of the registered populaƟon and were recruited from 93% (303/326) 
of trial sites (average recruitment: 6.4 pts ≤18yr/site). Older paƟents (>18yr, median: 22yr) comprised only 15% of the 
registered populaƟon (n=330) but were recruited from 41% of trial sites (133 sites, average: 2.5 pts >18yr/site). Only 
23/326 sites limited recruitment to only pts >18yrs and contributed 41/330 such paƟents. The randomizaƟon rates 
were 59% (1,135/1,930) for younger and 54% (177/330) for older paƟents, but only 52/133 (39%) sites registering 
older paƟents managed to randomize at least one of their >18 year olds, whereas 229/303 (76%) sites registering 
paƟents≤18yr randomized at least one of those younger paƟents. As expected, the proporƟons of males (71% vs. 
57%) and of axial primaries (12% vs. 4%) were higher in older compared to younger paƟents, while the proporƟon of 
paƟents with definite and possible primary metastases was similar (24% vs. 23%). 
Conclusions: CentralizaƟon of treatment was low overall, especially for older paƟents (young adults) with 
osteosarcoma. Most paƟents aged >18yr entered our trial through insƟtuƟons also caring for pediatric or adolescent 
paƟents. Eﬀorts which target “adult” oncology seem to be warranted.
Supported by the European Science FoundaƟon (ESF) under the EUROCORES Program European Clinical Trials (ECT), 
through contract No. ERASCT-2003-980409 of the European Commission, DG Research, FP6
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GY OUTCOME OF 66 PATIENTS WITH A LATE SOLITARY LUNG METASTASIS AS FIRST RECURRENCE MORE THAN 3 YEARS 
AFTER INITIAL DIAGNOSIS OF OSTEOSARCOMA OF THE 
EXTREMITIES
Miriam Wilhelm, M.D.1*, Marilena Cesari, M.D.2, Katja Zils, M.D.1, Stefano Ferrari, M.D.2, Godehard Friedel, M.D.5, Leo Kager, 
M.D.4, Thekla v. Kalle, M.D.3, MaƩhias Kevric1, Thomas Kühne, M.D.6, Anna Paioili, M.D.2, Michele Rocca, M.D.2, Benjamin Sorg1, 
Stefan Bielack, M.D.1 
1CooperaƟve Osteosarcoma Study Group (COSS), Klinikum StuƩgart -Olgahospital, Pediatrics 5 (Oncology, Hematology, 
Immunology; Gastroenterology, Rheumatology, General Pediatrics), StuƩgart, Germany
2Italian Sarcoma Group (ISG), Bone Tumor Center, IsƟtuto Ortopedico Rizzoli, Bologna, Italy
3Department of Paediatric Radiology, Klinikum StuƩgart – Olgahospital, StuƩgart, Germany
4St. Anna Kinderspital, Vienna, Austria
5Department of Surgery, Schillerhöhe, Gerlingen, Germany 
6Department of Hematology and Oncology, Basel, Switzerland 
IntroducƟon: Late, solitary pulmonary osteosarcoma metastases are believed to carry a favorable prognosis. We 
invesƟgated this hypothesis and which factors contribute to outcome in this cohort. 
PaƟents and Methods: This joint analysis of the CooperaƟve Osteosarcoma Study Group (COSS) and the Italian 
Sarcoma Group (ISG) retrospecƟvely invesƟgated characterisƟcs, treatment, outcome and prognosƟc factors in 
paƟents with high-grade central osteosarcoma of the extremiƟes who – aŌer mulƟmodal therapy and first complete 
surgical remission (CR1) of disease - developed a late (>3 years from iniƟal diagnosis/date of biopsy) solitary lung 
metastasis.
Results: 66 evaluable paƟents (44 male, 22 female; median age at iniƟal diagnosis 13 years). Lung metastases were 
detected via rouƟne follow-up imaging (N=44/57 with relevant data) or through symptoms (N=13/57). Median 
interval of 4.4 years (range: 3.0-19.0). CharacterisƟcs of the solitary lung metastases: Median diameter 2.5 cm (range: 
0.6-16 cm; N=56); 7/41 with relevant data pleural disrupƟon; 18/45 adjacent to pleura and 6/40 pleural eﬀusion. 
All but 3 metastases were operated and a second macroscopically complete surgical remission (CR2) was achieved 
in 60/66 paƟents. In 6/65 paƟents with relevant data, first recurrence treatment included radiotherapy, in 22/63 
chemotherapy. 
Median follow up aŌer diagnosis of first recurrence was 4.7 years (range: 0.1-20.1). Events were reported in 36 
paƟents: No CR2 (N=6), second recurrence (N=28; 10/28 at the site of the first recurrence) or death in CR2 (N=2). In 
all but 2/28 paƟents with second recurrence the interval from first to second recurrence was shorter (median: 1.2 
years) than the interval from iniƟal diagnosis to first recurrence (median: 4.4 years). 
24 paƟents died aŌer a median of 2.8 years from diagnosis of relapse, 42 paƟents were alive in CR2 (N=30), CR3 
(N=7) or with disease (N=5) aŌer a median of 8.4 years. Actuarial overall survival aŌer first recurrence at 5, 10 and 
15 years was 65.1%, 57.3% and 52.9% and event free survival (EFS) 41.9%, 39.1% and 39.1%, respecƟvely. 
PosiƟve prognosƟc factors for EFS were: DetecƟon of first recurrence by imaging rather than symptoms (p<0.001), 
diameter of metastasis <5 cm (p<0.01), no pleural disrupƟon (p<0.05), no pleural eﬀusion (p=0.05), no macroscopic 
or microscopic tumor residuals aŌer surgery (p<0.01). PaƟents not receiving chemotherapy (p<0.01) or radiotherapy 
(p<0.001) had beƩer EFS than others, but the groups were posiƟvely selected.
Conclusion: Approximately one half of all paƟents with late solitary pulmonary metastases can become long term 
survivors with appropriate therapy. Our results do not support the use of chemotherapy for this indicaƟon.
Supported by Deutsche Krebshilfe, Förderkreis Krebskranke Kinder StuƩgart e.V., and AXIS-ForschungssƟŌung.
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GYPROGRESSIONͳFREE SURVIVAL AFTER FIRST AND SECOND RELAPSE IN EWING SARCOMAS 
Heribert Jürgens1, Uta Dirksen1, Susanne Jabar1, Andreas RanŌ1
1University Hospital, Pediatric Hematology and Oncology, Muenster, Germany
ObjecƟves: The prognosis in Ewing sarcoma has improved with a current 5-year survival rate of 75% for localized 
disease. Survival aŌer relapse is sƟll poor with less than 30% surviving. The purpose of the newly established 
Ewing sarcoma relapse registry is to analyze the course of disease aŌer relapse in a large cohort of Ewing sarcoma 
paƟents. 
Material and Methods: Standardized relapse documentaƟon was obtained from 705 Ewing sarcoma paƟents 
treated first-line according to consecuƟve Ewing sarcoma trials of the German Society of Pediatric Oncology and 
Hematology (GPOH) from 1992 to 2009. Time to relapse and progression-free survival (PFS) aŌer first (PFS1) and 
second relapse (PFS2) were analyzed. PFS aŌer relapse was defined as stable disease or beƩer (<25% increase to 
smallest measurement). PaƟents with death of complicaƟons or death not related to cancer were censored at date 
of death.
Results: The median Ɵme from primary diagnosis to first relapse was 481 days (46-5949), 260 days from first to 
second relapse (7-3081), and 212 days from second to third relapse (14-1191). Median PFS aŌer first relapse was 
0.64 years (95%CI 0.58-0.70), and 0.35 years (95%CI 0.29-0.41) aŌer second relapse. PFS1 and PFS2 at 1 year were 
0.33 (SE=0.02; n=705) and 0.16 (SE=0.02; n=319). In mulƟvariate analysis, major prognosƟc factors were idenƟfied as 
early relapse <2 years aŌer primary diagnosis (Risk RaƟos [RR] PFS1 and PFS2: 2.64 and 2.27; p<.001) and combined 
relapse (vs. local relapse; RR: 1.66 and 1.78; p<.001). 
Conclusions: Progression-free survival aŌer first and second relapse is poor especially for paƟents with early relapse 
aŌer iniƟal diagnosis, and for combined distant and local recurrences. 
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GY EWING SARCOMA IN PATIENTS OVER 40 YEARS
M. Cesari1, A. Paioli1, M. Colangeli2, E. L. Staals2, E. Barbieri3, S. Cammelli3, M. Alberghini4, E. Palmerini1, M. Abate1, E. Marchesi1, 
P. Ruggieri2, P. Picci5, S. Ferrari1
1 Chemotherapy SecƟon, Rizzoli Orthopaedic InsƟtute, Bologna, Italy
2 Department of Orthopaedic Surgery, Rizzoli Orthopaedic InsƟtute, Bologna, Italy
3 Department of Radiotherapy, S. Orsola- Malpighi Hospital, Bologna, Italy
4 Department of Surgical Pathology, Rizzoli Orthopaedic InsƟtute, Bologna, Italy
5 Laboratory of Experimental Oncology, Rizzoli Orthopaedic InsƟtute, Bologna, Italy
Background: PaƟents aged 40 years or more  are usually excluded from clinical trials. For this reason informaƟon on 
this subset of paƟents are scarce.
PaƟents and methods: A retrospecƟve analysis was carried out at our InsƟtuƟon. Clinical charts, imaging and 
histological features of paƟents treated at Rizzoli InsƟtute between 1999 and 2011 with Ewing sarcoma aged 40 
years or more were reviewed.
Results: Twenty-height  paƟents with Ewing sarcoma, 40 to 70 years old (median age 45 years), treated at Rizzoli 
InsƟtute between 1999 and 2011 were idenƟfied. Twenty-four  (86%) had localised disease, 3 paƟents presented with 
lung metastases and 1 paƟent with mulƟple metastases (bone, lung, abdominal nodes, bone marrow). Primary tumour 
was in the bones in 15 (57%) paƟents while 13 (43%) had extra-skeletal disease. Local treatment was surgery alone 
in 7 paƟents, radiotherapy in 6 and surgery  plus radiotherapy in 15 paƟents. Two paƟents underwent amputaƟon. 
Median dose of radiotherapy was 54 Gy. All paƟents received chemotherapy according to diﬀerent regimens including 
Adriamycin (ADM), Cyclophosphamide (CTX), Etoposide (ETO), VincrisƟne (VCR), AcƟnomycine (ACT-D), Ifosfamide 
(IFO). Median cumulaƟve dose of ADM was 300 mg/m2, IFO 75 g/m2, ETO 1,600 mg/m2, CTX 6,200 mg/m2, VCR 10 
mg, ACT-D 7 mg. Data about chemotherapy toxicity were available in 25 paƟents. Haematological toxicity CTCvs1 
WBC grade 4 was reported in all paƟents. RBC and PLT transfusion were required in 14 (56%) and in 5 paƟents (20%) 
respecƟvely. Febrile neutropenia occurred in 28% of paƟents and hospitalizaƟon was required in 48%. Neurological 
toxicity occurred in 40% of paƟents (grade 1 in 9 paƟents and grade 2 in 1). Two paƟents experienced grade 1 renal 
toxicity and 1 paƟent grade 4 toxicity requiring permanent dialysis. Other toxicity included congesƟve heart failure 
(1 paƟent), deep venous thrombosis (2), grade 2/3 mucosiƟs (3), vomiƟng requiring parenteral rehidraƟon (1). A 
dose-reducƟon toxicity-related was required in 11 paƟents (44%). With a follow up ranging from 7 to 154 months 
(median 35 months) 13 paƟents (48%) remained conƟnuously free of disease, 3 paƟents were free of disease aŌer 
relapse, 2 paƟents were alive with disease, 8 paƟents died of disease, 1 paƟent died of second tumor (AML) and 
1  paƟent was lost to follow up. The 5 years disease-free survival (DFS) and overall survival (OS) were 53% and 60% 
respecƟvely. Bone tumors showed beƩer survival than tumors located in soŌ Ɵssues (5-y OS 72% for Ewing sarcomas 
of the skeleton and 46% for extra-skeletal lesions, 5-y DFS 71% and 34% respecƟvely). According to local treatment 
5-y OS was 80% for paƟents treated with surgery and radioterapy, 56% for the paƟents treated with radiotherapy, 
29% for paƟents treated with surgery .
Conclusions: In older paƟents the incidence of extra-skeletal Ewing Sarcoma is high. The oncologic results are 
comparable with younger paƟents, but a higher chemotherapy toxicity must be expected.
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GYSYNOVIAL SARCOMA ΈSYSAΉ IN CHILDREN AND ADOLESCENTS. TREATMENT RESULTS OF FOUR 
CONSECUTIVE PROSPECTIVE CWS ͳ STUDIES.
Ewa Koscielniak1, D. Kosztyla1, I. Leuschner2, T. Dantonello1, A. Schuck3, S. Kube1, R. Ladenstein4, M. Greulich5, S. Bielack1, B. 
Kazanowska6, G. Ljungman7, J. Greiner8, T. Klingebiel9
1 Klinikum StuƩgart, Olgahospital StuƩgart, Germany, 2Dep. Pathology, Univ. of Kiel, Germany, 3InsƟtut for RadiaƟon Oncology, 
Ingolstadt, Germany, 4St.Anna Kinderspital, Vienna, Austria, 5Diakonissenkrankenhaus, StuƩgart, Germany, 6Dep.of Paediatric 
BMT, Oncology /Haematology, Wroclaw, Poland, 7Children`s University Hospital, Uppsala, Sweden, 8Kinderspital St. Gallen, 
Switzerland, 9University Children`s Hospital Frankfurt, Germany
There is sƟll much controversy about the opƟmal treatment for paƟents with SySa. Especially the role of chemotherapy 
is sƟll being debated by pediatric and medical oncologists.
The CWS Group has been treaƟng paƟents with SySa in the so called “RMS-like” Group together with 
Rhabdomyosarcoma (RMS) and soŌ Ɵssue Ewing tumors (STET) since 1981, similarly to the STS ICG AIEOP. This 
report presents the treatment results in paƟents with SySa in 4 consecuƟve, prospecƟve CWS Studies 86,-91, 96 and 
2002P. 
Material and Methods: 200 paƟents < 21 yrs have been enrolled between 1986 and 2005. Histological diagnosis was 
confirmed in all cases by a reference pathologist. 103 pts had iniƟal gross total resecƟon (IRS I and II), 81 pts primary 
unresected tumor (IRS III), 16 (8%) pts had distal metastases at diagnosis. 152 pts had primary tumor located at 
extremiƟes. All paƟents received chemotherapy consisƟng of the four-drug regimen VAIA (Ifosfamide, AcƟnomycin 
D, Doxorubicine, VincrisƟne) or in CWS-91 the five-drug regimen EVAIA (plus VP16): adjuvant 6 cycles, neoadjuvant 
9 cycles. The cumulaƟve dose of Doxorubicine varied slightly between the studies. 146 pts were irradiated.
Results: 193 pts achieved complete remission, and 48 pts (25%) relapsed. 24/56 (43%) pts who received primary 
chemotherapy and for whom response could be evaluated, showed tumor volume reducƟon > 33% aŌer 3 therapy 
cycles. In primary localized disease the local relapse rate LRR (isolated and combined) was 14%, metastaƟc relapse 
10%, combined 2%. The LRR rate in irradiated paƟents IRS I-III was 12%, in non-irradiated pts 23% (n.s). With a 
median follow up of 7,5 yrs (2,4-15,7) the EFS for localized disease at 5 yrs was 77%, OS 88%, for metastaƟc disease 
25% and OS 31% respecƟvely. EFS and OS rates at 5 yrs by IRS Group were 85/95%, 82/90% and 68/82% respecƟvely. 
Tumor size, invasiveness, IRS group (I, II vs. III) and irradiaƟon correlated significantly with EFS (but not - local relapse 
free survival LRFS) in univariate analysis in paƟents with localized disease whereas age, sex, histology (biphasic vs. 
monophasic), site, and trial did not. In mulƟvariate analysis tumor size and irradiaƟon remained relevant for EFS.
Conclusion: PaƟents with localized disease had a good cure rate whereas only 25% of paƟents with metastaƟc 
disease remained disease free at 5 yrs. Our EFS rates compared favorably with other large published series suggesƟng 
that treatment on prospecƟve mulƟmodal trials results in beƩer outcome. It is however sƟll unclear whether 
chemotherapy could be omiƩed in young pts with small, noninvasive tumors. This quesƟon could only be answered 
by an internaƟonal randomized mulƟcenter study.  
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GY BONE METASTASES IN SOFT TISSUE SARCOMA PATIENTS: A SURVEY OF NATURAL, PROGNOSTIC VALUE AND TREATMENT.
Bruno Vincenzi1, Daniele SanƟni1, Gaia Schiavon2, Anna Maria Frezza1,3, Palma Dileo3, Marianna SilleƩa1, Francesco Bertoldo4, 
Giuseppe BadalamenƟ5, Giacomo G. Baldi6, Stefania Zovato7, Rossana Berardi8, Franco Silvestris9, Marco Tucci 9, Jeremy Whelan3, 
Roberto Tirabosco10, Angelo Paolo Dei Tos11, Giuseppe Tonini1.
1 DiparƟmento di Medicina Oncologica, Università Campus Bio-Medico di Roma, Rome, Italy; 
2 Department of Medical Oncology, Erasmus University Medical Center - Daniel den Hoed Cancer Center, RoƩerdam, 
Netherlands;
3 University College of London Hospital, London, England; 
4 Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy; 
5 Medical Oncology, University of Palermo, Palermo, Italy; 
6 Medical Oncology, Civil Hospital, Pisa, Italy; 
7 Unità Tumori Ereditari, IsƟtuto Oncologico Veneto, IRCCS, Padova, Italy;
8 Clinica di Oncologia Medica, A. O. Ospedali RiuniƟ-Universitá Politecnica delle Marche, Ancona, Italy; 
9 University of Bari, Bari, Italy;
10 Royal NaƟonal Orthopaedic Hospital, London, london, England; 
11 Azienda ULSS 9 Treviso, Treviso, Italy
Background:  Given the limited data currently available in the literature, we surveyed the natural history of bone 
metastases in paƟents aﬀected by soŌ Ɵssue sarcoma (STS). 
Methods:  This mulƟcenter, retrospecƟve, observaƟonal study evaluated data from 135 paƟents with STS metastaƟc 
to the bone who presented between 2001 and 2011. For all paƟents, we recorded the primary tumor histological 
subtype, bone metastases characterisƟcs (onset, site), type of treatment received (surgery, radiotherapy, zoledronic 
acid), type and frequency of skeletal related events (SRE) and disease outcome. 
Results:  The most represented histological subtypes among the enrolled paƟents were leiomyosarcoma (27%), 
angiosarcoma (13%) and spindle cell sarcoma (8%). The spine was the most common site for bone involvement 
(51%), followed by hip/pelvis (20%), long bones (15%) and other sites (14%). In 27% of cases, bone metastases 
were present at the Ɵme of diagnosis. FiŌy-four paƟents (40%) developed SREs and the median Ɵme to first SRE 
(if developed) was 4 months (range 1-9 months). The most common SRE was the need for radiotherapy, occurring 
in 28% of paƟents, followed by pathologic fracture (22%). PaƟents survived for a median of 6 months (range 1-14 
months) aŌer bone metastases diagnosis. The occurrence of a SRE was associated with decreased overall survival 
(OS) (P=0.04). A subgroup analysis revealed that zoledronic acid significantly prolonged median Ɵme to first SRE (5 
versus 2 months; P = 0.002). Conversely, it did not determine an improvement in terms of OS, even if a favorable 
trend was idenƟfied (median: 7 versus 5 months, respecƟvely; P = 0.105). 
Conclusions:  This study illustrates the burden of bone disease from STS and supports the use of zoledronic acid in 
this seƫng.
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GYiSPINAL METASTASES THERAPY ΈISMTΉ, THE NEW INTERACTIVE VERSION OF THE ALGORITHM FOR DECISIONͳ
MAKING PROCESS OF SPINE METASTATIC DISEASE
Gasbarrini Alessandro MD*, Colangeli Simone MD*, Bandiera Stefano MD*, BarbanƟ Brodano Giovanni MD*, Cappuccio Michele 
MDç, Cuzzocrea Fabrizio MD§, Pellisè Ferran MD•, Tancioni Flavio MD°, Terzi Silvia MD*, Varga Peter Paul MD^ and Boriani 
Stefano MD*
*Rizzoli Orthopaedic InsƟtute, çOspedale Maggiore, §Policlinico San MaƩeo, •Hospital Vall d’Hebron, °Humanitas IsƟtuto Clinico, 
^Department of Spinal Disorders
Bologna, Pavia, Barcelona, Milano, Budapest 
Italy, Spain, Hungary
ObjecƟves staƟng concisely why the study was conducted: New interacƟve version of the algorithm for decision-
making process of spine metastaƟc disease is proposed by Author’s with the objecƟve to spread this flow chart in 
semple and eﬀecƟve manner.
Materials and methods: The decision making process includes: anesthesiological evaluaƟon, sensiƟvity to medical 
and radiaƟon oncology treatments, neurological condiƟon, pathological fractures, systemaƟc spread of the disease 
and possible treatment. The treatment opƟons are: decompression and fixaƟon, debulking, en bloc excision, non 
surgical treatment.
In all cases treated by decompression and fixaƟon or debulking, proposed an prevenƟve embolizaƟon of the lesion 
to reduce the bleeding during the surgery.
In September 2009 started a MulƟcentric prospected study to evaluaƟon of the algorithm in the treatment of spinal 
metastases. We propose the preliminary results on 246 paƟents enrolled in this study to 1 year of follow up.
Results: In 80% of cases (196 of 246), the treatment performed was the same as proposed by the flowchart. In 185 
(85%) paƟents evaluated on 217 (28 paƟents excludes for incomplete data) that performed the treatment proposed 
by algorithm, the Surgeons of the Centres involved in the study obtained a good result according their experience.
In 50 cases (20%) the algorithm was not followed, usually to prevent overtreatment (32 cases). In these paƟents 
that were performed an overtreatment the opinion of the Surgeons involved in the study was that a good result was 
obtained in 21 on 32 cases (65%), while in the group of paƟents undertreatment the result was good in 12 on 18 
cases (67%).
Conclusion: In the study proposed the principal objecƟve of the Authors is to taste the applicability and reproducibility 
of the algorithm. The principal result obtained is that there is an common opinion from Surgeons of the diﬀerent 
Centres about a good applicability and reproducibility of the algorithm in the treatment of paƟent aﬀected by spinal 
metastases.
New interacƟve version of the algorithm for decision-making process of spine metastaƟc disease is proposed by 
Authors.
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GY THE EVALUATION OF FOUR PROGNOSTIC MODELS FOR PREDICTING SURVIVAL IN PATIENTS WITH SYMPTOMATIC 
SPINAL METASTASES
Bollen L.1, de Ruiter G.C.W. 2, LobaƩo D.1, Arts M.3, Pondaag W.2, Peul W.C.2, Dijkstra P.D.S.1
1Department of Orthopedic Surgery, Leiden University Medical Center Leiden, the Netherlands.
2Department of Neurosurgery, Leiden University Medical Center, Leiden, the Netherlands.
3Department of Neurosurgery, Medical Center Haaglanden, The Hague, the Netherlands.
ObjecƟves: Accurate predicƟon of survival in paƟents with symptomaƟc spinal metastases (SSM) is of the utmost 
importance in order to ensure a proper relaƟon between extent of surgery and actual survival Ɵme. In this study we 
evaluated the accuracy of four commonly used prognosƟc models.
Materials and Methods: All paƟents who were surgically treated for SSM between January 2001 and December 
2010 were included in this bi-center retrospecƟve study (n=106, male n=53, female n=53, mean age 59.1 ± 10.9 
years). Medical records were reviewed to obtain seven items necessary to uƟlize scoring systems according to Tomita 
(modified), Bauer (modified), Tokuhashi (revised) and Van der Linden (modified). Most common primary sites of 
cancer were breast (n=25), lung (n=20), kidney (n=19) and prostate (n=11). Scoring systems were adapted based on 
median survival Ɵmes for each type of primary tumor. Based on their respecƟve scores, all paƟents were arranged 
in groups as defined by the scoring systems. Survival analysis and overall comparisons were performed using Kaplan-
Meier survival analysis and univariate log-rank tests.
Results: Overall median survival is 10.7 months with a minimum follow-up of 11 months and no loss to follow-up. All 
scoring systems have a significant overall predicƟve value for survival. Bauer (modified) and Van der Linden (modified) 
are unable to diﬀerenƟate between medium- and long-term survival. Tokuhashi (revised) is able to diﬀerenƟate 
between short- and long-term survival but not between medium- and long-term, nor medium- and short survival. 
Tomita (modified) is the only score able to accurately reflect survival in all three groups (short-medium p=0.045, 
short-long p<0.001 and medium-long p<0.001, see Figure 1).
Conclusions: When considering surgery for symptomaƟc spinal cord metastases, clinicians must ensure that no 
needlessly extended surgery takes place in those paƟents that do not live long enough to fully benefit from the 
intervenƟon. An accurate scoring system can be a helpful tool. The modified Tomita score is the most reliable score 
for predicƟng survival in paƟents with SSM.
Figure 1. Survival funcƟon for the modified Tomita scoring system
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GYPREOPERATIVE PROGNOSTIC SCORING SYSTEMS FOR PATIENTS WITH SPINAL METASTASES ͳ EVALUATION IN A 
RECENT PATIENT COLLECTIVE
Dardic M1, Wibmer C1, Berghold A3, Stadlmueller L3, Zacherl M1, Leithner A1 Hofmann G2  
1Department of Orthopaedic Surgery,
2Department of Internal Medicine, Division of Oncology, and
3InsƟtute for Medical InformaƟcs, StaƟsƟcs and DocumentaƟon at 
Medical University of Graz
Graz, Austria.
ObjecƟves: PaƟents with advanced cancer disease frequently develop metastases in their vertebral column. Through 
pain, neurological dysfuncƟon and mechanical instability, these metastases can severely decrease paƟent´s funcƟon 
and quality of life. Correct esƟmaƟon of the survival Ɵme is crucial in order to implicate the right course of palliaƟve 
treatment. Based on concluded studies at our department, we conducted a sequel evaluaƟon with an updated 
dataset in order to analyze the parameters and prognosƟc scoring systems in more recently treated paƟents.     
Materials and Methods: This retrospecƟve study included 196 paƟents with confirmed spinal metastases of diverse 
cancer origin treated either surgically (35%) or conservaƟvely (65%) between 2005-2010. Possible prognosƟc factors, 
such as  primary tumor, general condiƟon (Karnofsky Performance Scale KPS), visceral metastases, numbers of spinal 
and extra spinal metastases, pathological fracture, pre- and post-op. neurologic status, spinal surgery and others 
were evaluated retrospecƟvely. We esƟmated the survival Ɵme from the date of confirmed spinal metastases to 
the date of death or last follow-up. (minimum follow up: 12 months). StaƟsƟcal analysis comprised univariate and 
stepwise mulƟvariate Cox regression (p-value ≤0.05 regarded significant) and Kaplan-Meyer-Curve.       
Results: Median overall survival for all paƟents was 7 months (minimum 5 days, maximum 70 months). At the Ɵme 
of analysis 178 paƟents had deceased (91%) and 18 paƟents were sƟll alive (9%).  Using univariate survival analysis 
primary tumor, visceral metastases, KPS, number of spinal metastases, spinal surgery, gender and age presented 
staƟsƟcal significance. In stepwise mulƟvariate analysis primary tumor, visceral metastases, KPS, number of spinal 
metastases and spinal surgery showed significant influence on survival. All evaluated scoring systems (Tokuhashi 
original and revised, Tomita, van der Linden and Bauer original and modified) showed significant impact in esƟmaƟng 
the survival. 
Conclusions: Our study showed reliability of the analyzed scoring systems in a recent paƟent collecƟve. Based on 
these results we recommend the Bauer modified score for its impact and addiƟonally for its simplicity.  
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GY MALIGNANT BONE TUMORS OF THE FOOT HAVE A DIFFERENT BIOLOGICAL BEHAVIOR THAN TUMORS AT OTHER SKELETAL 
SITES
AH Krieg1, M Brotzmann1, D Baumhoer2, F HeŌi1
AH Krieg, MD, Orthopaedic Surgeon
1University Children´s Hospital (UKBB), Basel, Switzerland
2Bone Tumor Reference Center at the InsƟtute of Pathology, University Hospital, Basel, Switzerland
IntroducƟon: In a retrospecƟve study, we analyzed the delay in diagnosis and tumor size of malignant bone tumors 
of the foot. To our knowledge, there is a lack of informaƟon regarding these factors in the literature. We compared 
the oncological and surgical long-term results with idenƟcal tumors at other anatomical sites in order to analyze 
the biological behavior of malignant bone tumors that are found in the foot.
Methods: Thirty-two paƟents (17 male, 15 female) with a histologically proven malignant bone tumor between the 
years 1969−2008 were included in the study. The median age was 41.2 years (range 9.8-72.9 years), and median 
follow up was 11.9 years (3−26.3 years). FiŌeen chondrosarcomas, nine osteosarcomas, and eight Ewing sarcomas 
were included in the study.
Results: There was an overall median Ɵme gap of 10 months (range 3−128 months) between the beginning 
of symptoms and diagnosis in the study group. Ewing sarcoma presented with the longest delay in diagnosis 
(median 18 months, range 3−34 months), followed by osteosarcoma (median 15 months, range 1−23 months) 
and chondrosarcoma (median 7.5 months, range 1−128 months). The delay in diagnosis of these tumors was 
significantly longer than that of equivalent tumors at other skeletal sites, but the 5- and 10-year survival rates and 
the occurrence of distant metastases were comparable. In contrast, the average size of foot tumors was 5- to 30-
fold less than that of tumors analyzed at other skeletal sites.
Conclusions: This study indicates that sarcomas of the foot present the disƟnct biological behavior of slower 
growth compared to tumors at other skeletal sites.
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GYHOW LONG AND HOW FREQUENTLY SHOULD WE FOLLOW UP PATIENTS WITH SOFT TISSUE SARCOMAS?
Chigusa Sawamura1,2, Seiichi Matsumoto2, Keisuke Ae2, Shimoji Takashi2, Atsushi Okawa1
Orthopaedics, Tokyo Medical and Dental University, Tokyo, Japan. 1. 
Orthopaedics, Cancer InsƟtute Hospital of Japanese FoundaƟons for Cancer Research, Tokyo, Japan.2. 
 
ObjecƟve: NCCN (NaƟonal Comprehensive Cancer Network) guidelines suggests that follow up for low-grade soŌ 
Ɵssue sarcomas should be every 3-6 months for 2-3 years then annually and for high-grade sarcomas every 3-6 
months for 2-3 years then every 6 months for the next 2 years then annually, although there are very limited evidence 
to support this strategies.  We evaluated incidence of local recurrence and metastasis for diﬀerent Ɵme periods to 
see the trend of events. We expected higher incidence of local recurrence and metastasis within the first 2 years.
 
Materials and Methods: PaƟents diagnosed with soŌ Ɵssue sarcomas and who underwent surgical excision of 
tumor at Cancer InsƟtute Hospital in Tokyo between 1978 to 2008 were retrospecƟvely reviewed. PaƟents who 
had metastasis at diagnosis (M1) were excluded. Age, histologic diagnosis, grade, tumor locaƟon, size, adjuvant 
treatments were reviewed for each paƟent.  Incidence of local recurrence and metastasis were calculated for every 
2-year period and presented per 1000 person-years. 
Results: 881 paƟents with a median age at diagnosis of 52-years were eligible for analysis. 32 % of paƟents were 
diagnosed with malignant fibrous hisƟocytoma, 15% had liposarcoma and 12% had well diﬀerenƟated liposarcoma. 
92 paƟents (10%) developed local recurrence at a median Ɵme of 18.5 months and 90% of paƟents had local 
recurrence within 5.1 years, 95% in 7.3 years and 99% in 20.4 years.  195 paƟents (22%) developed distant metastasis 
at median Ɵme of 11.7 months and 90% of paƟents had metastasis within 4.1 years, 95% in 7.1 years and 99% in 20.5 
years respecƟvely.  The rate of local recurrence was 38/1000 person-years (Fig.1) and for metastasis was103/1000 
person-years in first 2 years (Fig.2). These incidences were higher than those of aŌer 2 years and this trend was more 
evident for incidence of metastasis than that of local recurrence. 
Conclusions: Since incidence rate of local recurrence and metastasis were higher at first 2 years, it is reasonable 
to follow up frequently during this period. 95% of local recurrence and metastasis would be found if paƟents were 
followed up for a period of 8 years.  Follow-up beyond 10 years does not yield a suﬃcient number of recurrences or 
metastases to warrant this further monitoring.
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GY PSYCHOͳONCOLOGICAL ASPECTS IN THE TREATMENT OF TUMOR PATIENTS AT ORTHOPEDIC TUMOR CENTERS IN 
GERMANͳSPEAKING COUNTRIES 
U. Lenze*,  F. Pohlig*, G. Gradl*, J. Schauwecker*,  H. Rechl*, P. Herschbach+, R. von Eisenhart-Rothe*
* Department for Orthopedics, Klinikum rechts der Isar der Technischen Universität München
+ Roman Herzog Comprehensive Cancer Center (RHCCC), Klinikum rechts der Isar der Technischen Universität München
IntroducƟon: Psycho-social distress is a common problem in a considerable number of paƟents suﬀering from 
malignant diseases. However, in German-speaking countries psychosocial screenings haven`t been implemented 
into diagnosis related guidelines for the treatment of orthopedic tumor paƟents.  
Therefore, aim of the study was to evaluate the significance of psycho-oncology in orthopedic insƟtuƟons specialized 
in musculoskeletal tumors as well as the opinion and clinical experience of the treaƟng physicians.
Methods: In total 60 orthopedic insƟtuƟons in Germany, Austria and Switzerland were recruited from the German 
society for Orthopedics and Orthopedic Surgery as well as from the internet. Data regarding the role of psycho-
oncology as well as individual experiences of the physicians working at the enrolled insƟtuƟons were assessed and 
analyzed by a newly developed, standardized quesƟonnaire. To detect specific, demographic diﬀerences results were 
addiƟonally analyzed according to gender, age (≤40, >40 years) and professional experience (≤10, >10 years).  
Results: A total of 118 physicians from 47 of the enrolled 60 insƟtuƟons (85,5%) parƟcipated. The majority of 
respondents (57,3%) indicated that psycho-social aspects play a minor role within the tumorboards of the enrolled 
insƟtuƟons. Significant diﬀerences between professional experience groups were obtained regarding the wish 
for psychosocial treatment in case of own illness (p=0,032) and the diﬃculty of addressing the paƟents` feelings. 
Significant diﬀerences with respect to age groups and gender were not obtained. 
Conclusion: Although orthopedic physicians deemed psycho-oncology important liƩle aƩenƟon is paid within the 
tumorboards of the enrolled insƟtuƟons. To ensure a holisƟc approach to the treatment of orthopedic tumor paƟents 
psycho-oncological aspects should be implemented more in clinical pracƟce and diagnosis related guidelines.
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IEERCC1 PROTEIN EXPRESSION PREDICTS SURVIVAL 
IN PATIENTS WITH HIGHͳGRADE, NONͳMETASTATIC 
OSTEOSARCOMA TREATED WITH NEOADJUVANT 
CHEMOTHERAPY
Claudia Maria Haƫnger1, Massimo Serra1, Emanuela Palmerini2, Federica Sella1, Stefano Zagnoni1, Stefania Benini3, Marco 
Alberghini3, Piero Picci1, Stefano Ferrari2
1Laboratory of Experimental Oncology, 2Chemotherapy Ward of Muscoloskeletal Tumors and 3Anatomy and Pathological 
Histology, Orthopaedic Rizzoli InsƟtute, Bologna, Italy
ObjecƟves: CisplaƟn is an important drug of standard neo-advjuvant chemotherapy protocols for paƟents with 
high-grade non-metastaƟc osteosarcoma. PosiƟve excision repair cross-complementaƟon group 1 (ERCC1) protein 
expression has been reported to be associated with resistance to cisplaƟn and to influence survival in a number 
of human neoplasms. To assess ERCC1 protein expression in high-grade osteosarcoma and to evaluate its possible 
clinical impact, immunohistochemistry was performed on surgical biopsies from paƟents enrolled in two diﬀerent 
neoadjuvant chemotherapy protocols based on the use of cisplaƟn in associaƟon with doxorubicin, methotrexate 
and ifosfamide. Immunohistochemical data were correlated with clinicopathologic parameters and survival.
Materials and Methods: Immunohistochemistry was performed using the anƟ-ERCC1 monoclonal anƟbody 8F1 
(abcam) with a bioƟn-avidin peroxidase and diaminobenzidine detecƟon system. Samples were scored as negaƟve 
(percentage of posiƟve nuclei ranging from 0 to 10%) or posiƟve (more than 10% of posiƟve nuclei) for ERCC1 
protein expression.
In a first study, immunohistochemical detecƟon of ERCC1 was performed on Ɵssue secƟons of tumour biopsies 
from 31 paƟents with non-metastaƟc, high-grade osteosarcoma of the extremiƟes enrolled in the ISG/A/OSS study 
protocol from 2007 to 2009 (median follow-up 39 months). The findings obtained in this series were validated on 
tumour biopsies from 68 Italian paƟents treated according to the ISG/SSG 1 protocol from 1997 to 2000 (median 
follow-up 136 months, 5-year probability of EFS 59%).
The ISG/A/OSS protocol included high-dose ifosfamide only in the post-operaƟve protocol for paƟents who poorly 
responded to a pre-operaƟve therapy consisƟng of high-dose methotrexate, cisplaƟn and adriamycin. The the ISG/
SSG 1 protocol included all four drugs, both pre- and postoperaƟvely, administered with diﬀerent schedules according 
to the extent of tumor necrosis aŌer the preoperaƟve treatment. 
Results: In the ISG/A/OSS paƟents, immunohistochemical posiƟvity for ERCC1 was found in 8/31 (26%) samples. 
The event-free survival (EFS) rate was 25% in ERCC1-posiƟve cases and 65% in ERCC1-negaƟve paƟents (P = 0.01). 
The significant associaƟon between ERCC1 posiƟvity and worse clinical outcome was evident also for overall 
survival (OVS), which was 50% in ERCC1-posiƟve and 95% in ERCC-1 negaƟve paƟents (P = 0.003). 
In the validaƟon series, 22/68 ISG/SSG 1 paƟents (32%) paƟents were scored as posiƟve for ERCC1 expression. The 
5-year EFS was 36% in ERCC1 posiƟve and 69% in ERCC1 negaƟve paƟents (P = 0.026). ERCC1 posiƟvity was also 
associated with worse OVS, which was 50% and 74% in ERCC1-posiƟve and negaƟve paƟents, respecƟvely (P = 
0.047).
CorrelaƟon analyses for ERCC1 posiƟvity and clinicopathological parameters revealed a staƟsƟcally significant 
associaƟon between high serum LDH levels and ERCC1 posiƟvity (Fisher’s test, P = 0.012 for ISG/A/OSS paƟents and 
P = 0.025 for ISG/SSG 1 paƟents) and a trend towards higher relapse rate in ERCC1-posƟve cases in both studies.
Conclusions: ERCC1 posiƟvity assessed by immunohistochemistry on biopsies Ɵssue secƟons is predicƟve for 
outcome of paƟents with non-metastaƟc, high-grade osteosarcoma treated with cisplaƟn-including chemotherapy. 
The associaƟon between ERCC1 posiƟvity and worse survival suggests an important role of ERCC1 in the resistance 
to cisplaƟn and/or in treatment unresponsiveness in human osteosarcoma paƟents. 
Acknowledgements
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IE MASSIVE GENOMIC REARRANGEMENT AND CHROMOSOMAL 
ALTERATION STAGING ARE CRUCIAL FACTORS IN 
OSTEOSARCOMA PROGNOSIS
Smida J. 1-2, Baumhoer D. 3, Rosemann M. 4-5, Bielack S. 6, Korsching E. 7, Burdach S. 2, Jundt G. 3, Atkinson M.J. 4-5, and 
Nathrath M. 1-2
1 Clinical CooperaƟon Group Osteosarcoma, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, 
Germany
2 Department of Pediatrics, Technische Universitaet Muenchen and Pediatric Oncology Center, Germany
3 Bone Tumor Reference Center at the InsƟtute of Pathology, University Hospital Basel, Switzerland
4 InsƟtute of Pathology and 5 InsƟtute of RadiaƟon Biology, Helmholtz Zentrum Muenchen, German Research Center for 
Environmental Health, Germany
6 Klinikum StuƩgart Olgahospital, Pediatrics 5 - Oncology, Hematology, Immunology, Germany
7 InsƟtute of BioinformaƟcs, University of Muenster, Germany
IntroducƟon: Based on a study performed in 45 pretherapeuƟc osteosarcoma samples we found a clear correlaƟon 
between genomic rearrangement and the outcome of disease. We proposed a chromosomal alteraƟon staging 
(CAS) system, which was shown to have superior predicƟve potenƟal compared to the histologic regression grading. 
Tumors were defined as CAS posiƟve, when at least two out of four genomic alteraƟons including amplificaƟons of 
chromosome 6p21, 8q24 (harboring MYC) and 12q14 (harboring CDK4) as well as LOH of 10q21.1 occurred. 
Strategy and Results: To validate these findings we invesƟgated an independent collecƟve of 58 high-grade 
osteosarcomas samples using most recent methods (SNP Arrays 6.0, Aﬀymetrix). This verificaƟon supports our 
previous results that the genomic rearrangement and the CAS system have prognosƟc impact for osteosarcoma 
paƟents. Furthermore, we were able to examine the previously described regions with striking higher resoluƟon, 
including a new dimension in quality of CNV (copy number variaƟons) analysis. Three out of four CAS components 
were found to be adequately distributed in the new collecƟve. The primarily observed LOH frequency (exemplarily 
at 10q21.1) could not be verified because of the use of a new analysis technique, therefore the LOH component of 
the CAS system has to be redefined as massive genomic rearrangement of specific CNV paƩerns.
Summary: The CAS system could be verified in an independent collecƟve and proofed to predict the prognosis very 
accurately in more than 100 osteosarcomas already at the Ɵme of iniƟal diagnosis. Therefore, this molecular staging 
system might help to modify neoadjuvant treatment strategies in molecular high risk paƟents in future treatment 
protocols.
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IETENOVIN 6, A NOVEL  SIRTUIN DEACETYLASE INHIBITOR 
WITH  ANTI TUMOR ACTIVITY IN SYNOVIAL SARCOMA AND 
RABDOMYOSARCOMA.
Bertha Brodin1*, Wessen Maruwge1, Padraig D’Arcy1, Barry Wolahan, Asle Hesla2, and 3Sonia Lain.3
1Department of Oncology and Pathology,  3 Department of Microbiology, Tumor and Cell Biology,  Karolinska InsƟtutet, 2Orthopedic 
Tumor Surgery, Karolinska University Hospital, Stockholm, Sweden.
Sirtuins  are a subclass  of histone deacetylases (class III), with  histone and non-histone substrates.  They act in a 
NAD+ dependent maner and are involved in several cellular processes including metabolism, cell survival, muscle 
diﬀerenƟaƟon and aging.
In the present study, we have evaluated the acƟvity of  tenovin 6, a newly discovered, sirtuin deacetylase inhibitor 
and p53 acƟvator, in preclinical models of synovial sarcomas and rhabdomyosarcomas with  wild type p53. In vitro, 
tenovin-6 inhibited tumor cell proliferaƟon and restored trans-acƟvaƟon funcƟon of p53.  In SCID mice, tenovin 6 
significantly reduced tumor growth. The treated tumors were characterized by increased nuclear p53 and sirtuin 2 
expression.
InteresƟngly, combinaƟon treatment of rhabdomyosarcoma and synovial sarcoma cells with tenovin-6 induced an 
increased response to the mulƟkinase inhibitor Sorafenib. Our  results show that tenovin 6 is a drug with therapeuƟc 
potenƟal for synovial sarcoma and rhabdomyosarcoma and indicate that the  pharmacologic blocade of SIRT 1 can 
be used to restore response in  sarcomas that develop resistance to  kinase inhibitors. 
081
32
25
th
 E
M
SO
S 
An
nu
al
 M
ee
Ɵ
ng
SE
SS
IO
N
  N
EW
 D
RU
GS
/S
TR
AT
EG
IE
  
INVESTIGATING THE ROLE OF A DUAL KINASE INHIBITOR, 
OSIͳ906 IN EWING SARCOMA PRIOR TO APPPLICATION TO A 
PHASE II CLINICAL TRIAL.
Branford White HA, Barnes DJ, Buehnemann C, Li S, Yu H, Noble A, Scotlandi K, de Alava E, Hassan AB.
Treatment with a monoclonal anƟbody to the IGF1 Receptor has demonstrated tumour regression in approximately 
30% of paƟents with Ewing Sarcoma. This agressive primary bone tumour aﬀecƟng young adults is characterised by 
the presence of the chimeric transcripƟon factor EWS-FLI1 in 90% of paƟents resulƟng in acƟvaƟon of the Insulin 
Growth Factor (IGF) pathway via IGFBP3 supression. The mechanism reponsible for such a diverse reponse to an 
IGF1R inhibitor remains obscure however recent evidence suggests that supression of the IGF1 Receptor (IGF1R) is 
accompanied by a  compensatory upregulaƟon of Insulin Receptor (IR) which drives the downstream PI3K and MEK/
ERK pathways. We postulate that using dual kinase inhibitor to both IGF1R and IR will alter proliferaƟon and promote 
apoptosis of Ewing sarcoma as well as demonstrate heterogeneity of reponse between diﬀerent cell lines. 
Using well characterised Ewing sarcoma cell lines (EuroBoNet) we first opƟmised an assay with read outs of 
proliferaƟon, apoptosis, cell cycle, and the cell surface markers of IGF1 and Insulin Receptors. These were then 
combined and cells analysed using flow cytometry for diﬀering reponses to OSI-906, a dual kinase inhibitor alone 
and in combinaƟon with common chemotherapeuƟc agents such as doxorubicin.  
Our validated cell labelling assay demonstrated that OSI-906  aﬀects both proliferaƟon and apoptosis in Ewing cancer 
cells and alters sensiƟvity of cell lines when combined with mainstay chemotherapeuƟcs. This outcome therefore 
supporƟng the role for a straƟfied approach in a clinical trial.
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IEPRECLINICAL EVALUATION OF ETͳ743 ΈTRABECTEDIN, 
YONDELISΉ EFFECTS ON EWING’ S SARCOMA CELLS
Maria CrisƟna Manara,1,2 Cecilia Garofalo, 1,2  Caterina Mancarella, 1,2  Piero Picci, 1 and KaƟa Scotlandi1,2
CRS Development of Biomolecular Therapies, Laboratory of Experimental Oncology, Orthopaedic Rizzoli InsƟtute, Bologna, Italy
Background: IdenƟficaƟon of new acƟve agents against sarcoma is considered an important challenge in medical 
oncology. We previously reported a potent acƟvity of ET-743 (Trabectedin, Yondelis)  against both drug-sensiƟve and 
drug-resistant (mulƟdrug-resistant, methotrexate- and cisplaƟn-resistant) bone tumor cells. Ewing sarcoma (EWS) 
cells appeared to be parƟcularly sensiƟve to the eﬀects of this drug. However ET-743 exposure over sustained periods 
of treatment will result in the development of drug resistance. The analysis of molecular mechanisms responsible 
for resistance to ET-743 in EWS cells indenƟfied increased IGF-IR signaling, together with higher P-glycoprotein 
expression as significant contributors to ET-743 resistance. 
ObjecƟves: Eﬀects of ET-743 and of its analog Zalypsis was evaluated in a panel of EWS cell lines, as single agents 
and in combinaƟon with convenƟonal agents (VincrisƟne, Doxorubicin, Gemcitabine). In addiƟon combinatory 
treatments with  specific inhibitors of IGF-IR (Hab AVE1642, TKI NVP-AEW541), was assessed to define future possible 
therapeuƟc opƟon for EWS paƟents refractory to convenƟonal agents.
Results: Both ET-743 and of its analog Zalypsis induced a slower progression through the diﬀerent phases of the cell 
cycle in EWS cells. ET-743 showed higher eﬃcacy than Zalypsis. In addiƟon a diﬀerenƟaƟve eﬀects was observed, 
as indicated by increased expression of markers of neural diﬀerenƟaƟon (beta-III tubulin and H-neruofilament) and 
by the appearance of a phenotype “neurite-like” following treatment. Drug-drug interacƟons with convenƟonal 
drugs showed a synergisƟc associaƟons with doxorubicin, while addiƟve eﬀects were observed with vincrisƟne and 
Gencitabine.  Very posiƟve associaƟons were observed when ET-743 or Zalypsis were combined with anƟ-IGF-1R 
agents (Hab AVE1642, TKI NVP-AEW541),indicaƟng that IGF-IR system is involved in regulaƟng EWS cell sensiƟvity 
to these drugs.  
Conclusions: Overall, these results encourage the inclusion of this drug in the treatment of paƟents with Ewing’s 
sarcoma. Moreover, associaƟon with several available IGF-IR inhibitors may represent a promising and concrete 
answer to overcome resistance for paƟents refractory to convenƟonal agents. (Grants: AIRC IG-10452 to KS, MinSan 
bando 2009; EuroSarc).  
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RECONSTRUCTION OF LONG BONE DEFECTS ͵ CASE REPORT
S Dadia, Y Gortzak, Y Kollender, J Bickels, I Meller 
ObjecƟve: The reconstrucƟon of wide long bone diaphyseal defects is oŌen a major challenge in limp salvage 
whatever the eƟology of bone loss. The reconstrucƟon methods common used are: diaphyseal implants, vascular 
fibular graŌ and bone transport. As these procedures do not always succeed, there is an uncommon opƟon, lately 
introduced by Masquelet & Begue (2010), of an induced membrane concept as a salvage procedure.
This case report was aiming to check if induced membrane could successfully be used as salvage where other opƟons 
failed.
Materials: 8 year old boy, with stage II B osteosarcoma in his leŌ mid femur aŌer neo adjuvant chemotherapy and 
intercalary resecƟon of his mid femur (14cm), reconstructed with micro vascular fibular graŌ. Diagnosed with acute 
deep infecƟon of the graŌ aŌer a month. 3 consecuƟve procedures of washout, debridement & aggressive anƟbioƟc 
treatments led to 17cm bone defect aŌer removal of the infected graŌ.
Induced membrane concept was decided to be introduced: A) InserƟon of cement spacer into the bone defect. 
Simultaneously remaining bone fixed with Ilizarov frame & IM nail. B) 3 months later, aŌer addiƟonal clearance of 
the infecƟon, spacer was removed and induced membrane which grew over the cement was leŌ in place. C) The 
cavity was filled by morcellized cancellous bone autograŌ harvested from the Iliac crest. D) The membrane sutured 
over the bone graŌ.
Results: 4 months aŌer last procedure, the paƟent did not show any sign of deep infecƟon (clinical & laboratory). 
ConsecuƟve x-rays shows a good and progressing bone healing in the membrane chamber. PaƟent is ambulaƟng 
with no-weight bearing with good thigh muscle strength and hip & knee moƟon.
Conclusions: In our case study, induced membrane concept was a good alternaƟve salvage for large bone defect. 
4 months aŌer bone graŌing, there is good bone regeneraƟon in the membrane cavity. We can assume that the 
role of cement as biological spacer, inducing a foreign body surrounding membrane, which then aŌer is filled, the 
membrane avoids resorpƟon of the cancellous bone and has a posiƟve eﬀect of healing of the auto graŌ.
There is further need to see the future consolidaƟon of the bone. But, although this is a single case report, it suggests 
a potenƟal treatment which seems to be interesƟng to invesƟgate even for primary cases.
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YTHE ROLE OF THE MUSCULOSKELETAL TISSUE BANK IN LIMB 
SALVAGE SURGERY OF CHILDREN: ANALYSIS OF  RECENT 
RIZZOLI INSTITUTE EXPERIENCE
Marco Manfrini, Marco Colangeli, Luca Boriani, Massimiliano De Paolis, Pietro Ruggieri & Pier Maria Fornasari
IsƟtuto Ortopedico Rizzoli, Bologna, Italy
IntroducƟon:  During the 1980s, as massive bone allograŌs (MBA) started to be used for limb salvage procedures, 
orthopedic oncology became one of the primary specialƟes to promote the development of musculoskeletal Ɵssue 
banking. 
At the Rizzoli InsƟtute, the pioneering bone bank iniƟated in 1962 was transformed in 1997 into the Cell and Musculo-
Skeletal Tissue Bank (CMSTB), a non-profit unit of the regional-naƟonal health care system, that follows European 
Union standards and guidelines and is recognized by the Italian Drug Agency and NaƟonal Transplant Center. 
ObjecƟves: To analyze the current impact of bone banking in limb salvage procedures, especially in pediatric 
populaƟon.
Methods: This retrospecƟve study from 2005-2009 involved analysis of CMSTB files and all limb salvage procedures 
performed at the Rizzoli InsƟtute in children below age 15 with primary malignant tumors of humerus, femur, and 
Ɵbia. 
Results:  During this five year period, CMSTB harvested 317 cadaveric donors from which 3832 bone and tendon 
specimens were stored.  Some specimens were further processed into freeze-dried graŌs, frozen morcellized bone, 
and/or demineralized bone matrix.  MBAs were uƟlized for surgical reconstrucƟon in 639 paƟents. 
In the same period, at Rizzoli InsƟtute, limb salvage surgery was performed in 111 skeletally immature paƟents 
(mean age 10,3 years; range 4-14). Histological diagnoses included 82 (74%) osteosarcomas, 28 (25%) Ewing’s Family 
Tumors, 1 (1%) adamanƟnoma.  Neoplasms were located in the femur in 67 paƟents (60%), the Ɵbia in 30 (27%), and 
the humerus in 14 (13%). 
Femoral reconstrucƟon uƟlized megaprostheses in 41 cases (61%) and MBA in 20  (30%), while in 6 
children (9%) the combinaƟon of MBA and convenƟonal  prostheƟc components (AllograŌ-Prosthesis-
Composite, APC) was used. The Ɵbia was reconstructed in 15 paƟents with MBA (50%), 10 cases with 
APC (33%),  and 5 paƟents with megaprostheses (17%). In 17 cases of intercalary reconstrucƟons of the 
lower limb (8 femurs and 9 Ɵbias) MBA was used in conjuncƟon with a vascularized fibula graŌ (VFG). 
The humerus was reconstructed with APC in 5 cases (36%), modular prostheses in 3 (21%), MBA in 3 (21%) and with 
VFG alone in 3 (21 %). 
In summary, 49 skeletally immature paƟents (44%) had the limb reconstrucƟon obtained by a megaprosthesis; in 59 
children (53%) a MBA was used : alone in 21 cases, with VFG in 17, and with standard prostheƟc components in 21. 
VFG alone was used in the last 3 cases 
No allograŌ related disease was observed.
PostoperaƟve deep infecƟon occurred in 4 paƟents reconstructed by megaprostheses (8%) , in 1 case with APC (5%) 
but no sepƟc complicaƟon was noted in intercalary or osteoarƟcular MBAs and in VFG reconstrucƟons..
Conclusions: MBAs allow custom reconstrucƟons with unique biologic and biomechanic properƟes, parƟcularly 
helpful in restoring the bone stock lost in growing paƟents due to tumor resecƟon. In bone reconstrucƟons, the 
use of MBA do not increase the risk of postoperaƟve infecƟon and may be biologically augmented with vascularized 
autograŌs  Tissue banking allows for access to a greater number of reconstrucƟve opƟons, oŌen at a significantly 
lower cost than mega- prostheƟc counterparts.  In this series, more than half of the limb salvage procedures in 
children involved the use of MBA from our CMSTB, evidence of the safe strong role that bone banking can play in 
limb-sparing reconstrucƟon of young oncologic paƟents.
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Y LONG TERM OUTCOMES FOLLOWING ENDOPROSTHETIC 
REPLACEMENTS
H. Wafa, R.J. Grimer, M.S. Bartoli, S.R. Carter, R.M. Tillman, A. Abudu, L. Jeys
The Royal Orthopaedic Hospital Oncology Service, Birmingham, United Kingdom. 
Corresponding author: Hazem Wafa email: hazem.wafa@nhs.net
ObjecƟves: To establish what happens to paƟents in the long term (>20 years) following endoprostheƟc 
replacement.
IntroducƟon: Limb salvage surgery had replaced amputaƟon as the preferred treatment modality in more than 90% 
of the paƟents with extremity sarcomas. EndoprostheƟc reconstrucƟon has the advantage of providing immediate 
stability, thus allowing early mobilizaƟon, rehabilitaƟon, and weight bearing. However, the long term results of these 
megaprostheses are sƟll lacking.
Methods: A prospecƟve database contains details of all paƟents treated at our unit with musculoskeletal tumours. 
All paƟents who underwent an endoprostheƟc replacement more than 20 years ago (prior to 31/12/1990) and who 
were sƟll alive were idenƟfied and their outcomes invesƟgated with parƟcular reference to the development of 
complicaƟons and the need for further surgery. 231 paƟents who had complete follow up and were alive at 1/1/2011 
were idenƟfied. The mean age at diagnosis was 20.8 years (range, 5-62 years). The most common diagnoses were 
osteosarcoma (132) followed by Ewing’s sarcoma (31) and chondrosarcoma (23). There were 102 distal femoral, 60 
proximal Ɵbial, 26 proximal femoral, 20 proximal humeral, 8 intercalary, 5 total femoral, 5 total humeral, 4 hemipelvic, 
and 1 distal humeral endoprostheƟc replacements. 
Results: All paƟents were followed up for a mean period of 23.1 years (range, 20 to 40.1 years). The 231 paƟents 
had a total of 612 further operaƟons (excluding lengthening of expandable prostheses).  This averaged 2.4 further 
operaƟons per paƟent over a minimum of 20 years. The risk of amputaƟon was 12% at 20 years and 15% at 30 years 
in this group. Of the 31 paƟents who had an amputaƟon, 18 were due to infecƟon and 9 due to local recurrence. Only 
one paƟent had an above knee amputaƟon for fixed flexion deformity of the knee while none of the amputaƟons 
were done purely for mechanical failure. 
The risk of infecƟon persisted throughout the life of the prosthesis and averaged about 1% per year. Of the 60 paƟents 
who developed an infecƟon, only 11 developed it within 6 months of a previous surgery – suggesƟng that the risk 
of infecƟon following any further surgery was around 2%. The biggest risk sites for infecƟon were the proximal Ɵbia 
(43.3%), proximal femur (26.9%) and the distal femur (22.5%) and for amputaƟon were the proximal Ɵbia (26.7%) 
and the proximal femur (15.4%).
MSTS funcƟonal scores were calculated on all paƟents with an exisƟng prosthesis. A hundred and eighty-eight 
paƟents (94%) had excellent or good results (MSTS score of 15-30), while the remaining twelve paƟents (6%) had 
fair or poor results (MSTS score of 0-14).
Conclusions: EndoprostheƟc replacement is a valid reconstrucƟve technique in limb salvage surgery with saƟsfactory 
long term results. PaƟents should be warned of the likelihood for the need for revision surgeries. The life-long 
potenƟal risks of infecƟon and amputaƟon should also be considered. 
Fig. 1 Risk of infecƟon aŌer endoprostheƟc replacement
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YPROXIMAL TIBIAL MEGAPROSTHESES AFTER RESECTION FOR 
BONE TUMOR: SURVIVAL OF THE IMPLANTS AND FUNCTIONAL 
RESULTS
Elisa Pala, MD; Andrea Ferraro, MD; Gabriele Drago, MD; MaƩeo RomanƟni, MD; Andreas F. Mavrogenis, MD; Douglas Letson, 
MD, PhD; Pietro Ruggieri, MD, PhD;
IV Department of Orthopaedics, University of Bologna, IsƟtuto Ortopedico Rizzoli, Bologna, Italy
Sarcoma Program, H. Lee MoﬃƩ Cancer and Research InsƟtute, Tampa, Florida, USA.
ObjecƟves: Previous studies reported variable outcome and complicaƟons rates aŌer proximal Ɵbial resecƟons and 
diﬀerent types of megaprostheƟc and extensor mechanism reconstrucƟons. Therefore, we performed this study 
to evaluate the survival, Musculoskeletal Tumor Society (MSTS) funcƟon and complicaƟons of the paƟents, the 
megaprostheƟc and the extensor mechanism reconstrucƟons in this locaƟon.
Material and Methods: We retrospecƟvely studied the files of 225 paƟents with tumors of the proximal Ɵbia treated 
at our insƟtuƟon with proximal Ɵbial resecƟon, megaprostheƟc and extensor mechanism reconstrucƟon from March 
1985 to August 2010. 
ReconstrucƟon of the extensor mechanism and wound coverage was performed with the present technique: direct 
aƩachment of the extensor mechanism to the megaprosthesis with non-absorbable sutures, mechanical clamping 
with a polyethylene plate, or an arƟficial ligament, with or without a gastrocnemius muscle flap in 58 cases, LARS® 
arƟficial ligament in 7 cases, Leeds-Keio® arƟficial ligament in 2 cases, equine pericardium xenograŌ in 3 cases, 
gastrocnemius muscle flap and non-absorbable sutures inserted through the anterior holes of the prosthesis in 167 
cases.
The mean follow up was 7 years (median, 56; range, 2-294). The survival, MSTS funcƟon, and complicaƟons of the 
paƟents and the megaprostheƟc and extensor mechanism reconstrucƟons were analyzed.
Results: Survival of the paƟents with sarcomas was 68% and 62% at 5 and 10 years. Survival of the megaprostheƟc 
reconstrucƟons was 82% and 78% at 5 and 10 years, without any diﬀerence between fixed and rotaƟng hinge 
megaprostheses. At univariate and mulƟvariate analysis, the only predictor of MSTS funcƟon was the type of 
hinge. The mean MSTS funcƟonal score of paƟents was 77% (range, 27% to 100%). MSTS funcƟon was staƟsƟcally 
significantly beƩer for paƟents with rotaƟng hinge megaprostheses (p= 0.042, Kruskal-Wallis test). MSTS funcƟon in 
the diﬀerent types of extensor mechanism reconstrucƟons was not significantly diﬀerent. Overall complicaƟons rate 
was 25%: infecƟon (12%), asepƟc loosening (6%), and this rupture of the extensor mechanism (3%). According to 
Letson et al. classificaƟon of failures these were classified as: type I  3%; type II 6%, type IV 12%.
Conclusions: The type of hinge was the only univariate and mulƟvariate factor staƟsƟcally influencing funcƟon 
of paƟents with proximal Ɵbial resecƟons and reconstrucƟons. PaƟents with rotaƟng hinge megaprostheƟc 
reconstrucƟons have beƩer funcƟon regardless of the type of extensor mechanism reconstrucƟon. Overall survival 
of the implants was saƟsfactory.
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Y FUNCTIONAL RECONSTRUCTION AROUND THE KNEE WITH 
MEGAPROSTHESIS
Domenico A. Campanacci, Giuseppe Caﬀ, Filippo Frenos, Sarah Chacon, Nicola Mondanelli, Giovanni Beltrami, Guido ScoccianƟ, 
Rodolfo Capanna
Department of Orthopaedic Oncology, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
ObjecƟve: Extensive bone loss around the knee may be due to bone tumor resecƟons, convenƟonal prostheses 
failure and postraumaƟc sequelae. Distal femoral and proximal Ɵbial defects can be eﬀecƟvely reconstructed by 
modular prostheses but in selected cases the use of an allograŌ-prosthesis composite (APC) may provide a funcƟonal 
advantage. The objecƟve of the present study was to review our series of funcƟonal prostheƟc reconstrucƟons 
around the knee (with and without allograŌ) with the aim to evaluate morbidity and implant survival.
Materials and Methods: From 2001, 194 paƟents (90 F, 103 M) were treated at authors’ InsƟtuƟon with modular 
prostheƟc reconstrucƟon of the knee joint aŌer resecƟon of a malignant bone tumor in 142 cases, benign bone 
tumor in 36 cases and in bone loss due to non oncologic condiƟons in 16 cases. Megasystem C, Waldemar Link, 
was used in all reconstrucƟons. A distal femur prosthesis was implanted in 135 cases (in one case a distal femur 
prosthesis was associated to an APC of proximal Ɵbia) while a proximal Ɵbia reconstrucƟon was performed in 45 
cases. Proximal Ɵbial replacement was done with modular prosthesis in 23 cases and with APC in 22 cases. In 14 
cases, due to the extension of the tumour into the joint space, an extra-arƟcular resecƟon was performed, with 
funcƟonal reconstrucƟon by an APC with complete allogenic extensor apparatus.
Results: At an average follow up of 30 months, 54 major complicaƟons in 35 paƟents (18%) were observed and 44 
prostheƟc surgical revision were performed. Deep infecƟon was observed in 20 cases (10.3%).  Eighteen prostheƟc 
mechanical complicaƟons were seen (morse taper failure in 11 cases, arƟcular joint failure in 5 cases, disassembling 
in 2 cases). An asepƟc loosening occurred in 2 cases requiring surgical revision with a total femur prosthesis in 1 
case. Two paƟents developed a wound dehiscence treated with a rotaƟonal flap. A patellar tendon detachment was 
seen in 7 cases, requiring surgical revision in 5 cases. Two traumaƟc patella’s fractures and 1 traumaƟc periprosheƟc 
fracture were observed. A local recurrence occurred in 12 cases and surgical treatment was an amputaƟon in 6 
cases. Among the evaluable paƟents with at least a 12 months follow up, 72% showed saƟsfactory funcƟonal results 
(excellent or good following MSTS funcƟonal evaluaƟon). 
Conclusions: In our experience, Megasystem C showed to be an eﬀecƟve tool in arƟcular reconstrucƟon of segmental 
bone loss around the knee. The convenƟonal modular assembling was the preferred choice in distal femur. In 
proximal Ɵbia reconstrucƟons, convenƟonal modular implants showed a higher incidence of infecƟons and lower 
funcƟonal score than APC assembling. AŌer exra-arƟcular knee resecƟons, an eﬀecƟve funcƟonal reconstrucƟon 
was achieved combining the convenƟonal modular assembling of distal femur to an APC of the proximal Ɵbia with 
allogenic extensor apparatus. 
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YCOMPLICATIONS AND FUNCTIONAL OUTCOME AFTER 
RECONSTRUCTION OF THE KNEE EXTENSOR MECHANISM 
USING A LARS®ͳLIGAMENT FOR MUSCULOSKELETAL 
TUMORS
GM.  Hobusch,  C. Hourscht,  M. Dominkus,  R. Windhager, PT. Funovics
Department of Orthopaedic Surgery - Medical University of Vienna – Austria
ObjecƟves: The aim of this retrospecƟve, single centre study was to examine funcƟonal results and complicaƟons 
in paƟents undergoing reconstrucƟon of the knee extensor mechanism  using a LARS®-ligament aŌer 
musculoskeletal tumour resecƟon and endoprostheƟc reconstrucƟon.
Material and Methods: The study cohort comprised 56 paƟents (32 men and 24 women; mean age, 29 years; 
range 12-86 years) with a minimum follow-up of 24 months (mean, 57 months; range, 24-117 months).  Data 
was retrospecƟvely retrieved from the prospecƟve Vienna Bone and SoŌ Tissue Tumour Registry and paƟent 
files. IndicaƟons for tumor resecƟons were 34 osteosarcomas, 5 chondrosarcomas, 3 ewingsarcomas, 5 
leiomyosarcomas, 2 synovialsarcoma, 1 myxofibrosarcoma, 1 histocytoma, 2 giantcelltumor, 1 plasmocytoma 
and one metastasis. EndoprostheƟc reconstrucƟons included proximal Ɵbia reconstrucƟons in 26 paƟents, distal 
femur reconstrucƟons in 17 paƟents, combined proximal Ɵbia and distal femur reconstrucƟons in 12 and one total 
femur reconstrucƟon. 40 paƟents received the LARS®-ligament during index surgery, 16 paƟents had the ligament 
implanted during a revision of their prostheses. ComplicaƟons were analysed according to the classificaƟon of 
Hendersen et al.  as soŌ Ɵssue failures  (Type I), ascepƟc loosening (Type II), structural failures (Type III), infecƟon 
(Type IV) and tumour progression (Type V).
Results: At latest follow-up, the mean acƟve ROM in flexion was 97° (SD ± 21°) with a lack of extension of 20° (SD 
± 26°). In paƟents with pimary implantaƟon of the LARS®-ligament, soŌ Ɵssue failures occurred in 18%, asepƟc 
loosening in 10% and structural failures in 15% of the cases. In paƟents with secondary ligament implantaƟon 
respecƟve rates were 10%, 18% and 18%. The infecƟon rate in primary implantaƟons of the LARS®-ligament was 
26%, however, this rate rose to 45% when the LARS®-implant was used in the course of a revision operaƟon.  Local 
tumour progression was observed in 6% of primary implantaƟons and 5% of the revision paƟents.
Conclusion: The LARS®-ligament oﬀers the possibility of excellent extensor system reconstrucƟon in primary 
implantaƟon. In the case of repeated revisions the secondary use of  
the implant is to be indicated very restricƟvely due to the potenƟal risk of consecuƟve infecƟon.  
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Y CUSTOM IMPLANTS FOR PRIMARY AND REVISION LIMB 
SALVAGE SURGERY IN MUSCULOSKELETAL ONCOLOGY 
N. FABBRI, M. Manfrini, P. Unwin, P. Ruggieri
 1 IsƟtuto Ortopedico Rizzoli, Bologna, ITALY
ObjecƟves: While represenƟng the only available opƟon in the beginning of the limb salvage era of musculoskeletal 
oncology, custom made implants have been falling out of favor in many centers with the advent of modular “oﬀ 
the shelf” massive implants. However, there seems to be currently a resurgence and renovated interest for custom 
implants to address specific and oŌen challenging paƟent-related issues, such as marked bone loss, unfavorable 
geometry, poor bone biology, and skeletal immaturity. Goal of this paper is to to review and analyse indicaƟons and 
results of tretment in a selected group of paƟents managed by a custom made implant to address diﬀerent clinical 
needs.  
Materials e Methods: It is a retrospecƟve study of 11 paƟents; indicaƟon to a custom made implant was due to 
skeletal immaturity in 7 paƟents (all 7 noninvasive distal femur extendible implant), mainly to bone loss in 2 paƟents 
(one distal Ɵbia segmental defect, one failed DF extendible with well-fixed femoral stem), to bone loss and skeletal 
immaturity in one paƟent (one failed DF extendible with well-fixed femoral stem), and to a diﬃcult geometry in the 
remaining paƟent (low-grade chondrosarcoma of the glenoid region of the scapula). It seems that the indicaƟon to a 
custom implant is oŌen mulƟ-factorial. There has been no implant failure in this series other than 1 local recurrence 
in a DF extendible. 
Results: Implant was available within 4 weeks from the formal implant order. Costs have been considered comparable 
to alternaƟve reconstrucƟve opƟons. The custom implant is funcƟonal at latest follow-up in all the paƟents who 
remained conƟnuously disease-free. 
Conclusions: The use of custom made implants is currently increasing when compared to 10-20 years ago and it 
appears related to improved manufacturing eﬃciency, faster delivery and saƟsfactory clinical results.
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YTHE TREATMENT STRATEGY OF INTRAARTICULAR SOFT 
TISSUE TUMOURS OF THE KNEE JOINT
Murat Hiz, Atakan Karabiber, Hüseyin Botanlıoglu, FaƟh Kantarcı, Sergülan Dervisoglu
Departments of Orthopaedics and Traumatology, Radiology, Pathology, Cerrahpasa Faculty of Medicine, İstanbul University, 
Istanbul, Turkey
ObjecƟves: IntraarƟcular soŌ Ɵssue tumours of the knee joint create some parƟcular problems regarding to obtain 
accurate histopathological diagnosis prior to definiƟve surgery. Even though most of these tumours are benign in 
nature, highly malignant tumours such as synovial sarcoma should be kept in mind before biopsy. Arthroscopic or 
cuƫng needle core biopsy yield to intraarƟcular contaminaƟon necessitaƟng extraarƟcular resecƟon of the knee 
joint. Open frozen biopsy during surgery with a thorough invesƟgaƟon of the knee joint with gadolinium enhanced 
MRI prior to operaƟon could be an eﬀecƟve strategy to avoid catastrophic contaminaƟon of the joint space by other 
means of biopsy.
Materials and methods: 19 paƟent with intraarƟcular soŌ Ɵssue tumours were treated with open frozen biopsy 
and resecƟon by the senior author in last two decades. 10 female 9 male with a mean age of 38,78 (min 19, max 58 
years). All paƟents had a history of swelling of the knee joint, restricƟon of acƟve knee extension and moderate pain 
during stair climbing. All paƟents invesƟgated by plain X-rays and gadolinium enhanced MRI prior to operaƟon 11 
paƟents had giant cell tumour of the tendon sheaths,1 paƟent had juxtaarƟcular chondrom, 6 had synovial sarcoma, 
1 paƟent had fibrosarcoma. Ill defined borders, invasion of the joint capsule, presence of necrosis in the mass and 
marked gadolinium enhancement on MRI predicted malignant tumour. Presence of blood stained joint fluid during 
frozen biopsy was also a marked diagnosƟc feature of synovial sarcoma. Adjacent bony invasion was present in 3 
giant cell tumour of the tendon sheath paƟents. Frozen biopsy was successful enough to disƟnct malignant tumours 
from benign tumours. Permanent secƟons of the resected specimens revealed no false posiƟve or false negaƟve 
results.  All paƟents had resecƟon with tumour free margin. Hoﬀa Fat pad, synovium and joint capsule were removed 
when indicated. Capsular repair was performed by prolene mesh in 4 paƟents with synovial sarcoma. Vacuum sucƟon 
drains were removed 24 hours aŌer the operaƟon. An adjustable knee brace was used for 6 weeks in the paƟents 
who required capsular repair. 3 paƟents required local fasciocutaneous rotaƟonal flaps to cover the prolene mesh. 
Results: At 74 months mean follow up, 1 paƟent with synovial sarcoma developed local recurrence and converted to 
extraarƟcular resecƟon and fixed hinge tumour resecƟon prosthesis. All synovial sarcoma paƟents received 50 Gys 
irradiaƟon postoperaƟvely. 6 PaƟents also received chemotherapy. Oncological results in malignant tumours were: 
2 paƟent died of disease, 5 paƟents showed no evidence of disease. No benign tumours recurred yet. 3 benign 
tumour paƟents had cementaƟon of bony defects. FuncƟonally all paƟent regained full ROM and weight bearing at 
3. months.
Conclusions: IntraarƟcular soŌ Ɵssue masses should be examined thoroughly before surgical removal. Arthroscopic 
biopsy or removal of these tumours by shavers without any histological diagnosis or leakage of malignant tumours 
to the joint cavity aŌer cuƫng needle core biopsy would result with intraarƟcular contaminaƟon leading to 
extraarƟcular resecƟon and prostheƟc reconstrucƟon. Open frozen biopsy during definiƟve surgery with clear margin 
is a reasonable strategy in such condiƟons.
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Y RESULTS OF USING OF GROWING ENDOPROSTHESIS OF HIP 
JOINT WITH DOUBLE CUP IN THE CHILDREN WITH BONE 
SARCOMAS 
A.Z. Dzampaev, D.B. Khestanov, D.V. Nisichenko, N.M. Ivanova, M.D. Aliev
Purpose: To invesƟgate results of using of growing endoprosthesis of hip joint with double cup in children with bone 
sarcomas.
Materials and methods: In the InsƟtute of Pediatric Oncology and Hematology Russian Cancer Research Center from 
2006 to present days were implanted 31 growing endoprosthesis with double cup. The age of paƟents are ranged 
from 5 to 15 years. In 16 cases were implanted total endoprosthesis of  femur, in 12 — proximal femur and in 3 
cases was performed revision procedure. In all cases were implanted double cup D38-D46.We use endoprosthesis 
LINK, Implantcast (MUTARS) and WRIGTH. ElongaƟon procedures were microinvasiv for LINK type or non-invasive 
for other types of endoprosthesis. 
Results: The prostheses were lengthened by a mean of 15 mm (5 to 20). The mean Musculoskeletal Tumour 
Society score was 80%. We not observed no one cases of dislocaƟon in hip joint, deformaƟon of acetabular or local 
osteoporosis.  
Conclusion: The early results from paƟents treated with this device have been encouraging. The use of endoprosthesis 
of hip joint with double cup are less invasive and provide good funcƟonally results.
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YANALYSIS OF DIFFERENT STEM LENGTHS AND FIXATION 
TECHNIQUES IN HINGED TOTAL KNEE ARTHROPLASTY
S. Fuchs-Winkelmann(1), B. El-Zayat(1), T. Heyse(1), N. Fanciullacci (2), Y. Chevalier(3), B. InnocenƟ(3)
(1) Department of Orthopaedics, University Hospital Marburg, Marburg ,Germany
(2) Department of Mechanics and Industrial Technology, University of Florence, Florence, Italy
 (3) European Centre for Knee Research, Smith&Nephew, Leuven, Belgium 
ObjecƟve: To improve component stability in hinged Total Knee Arthroplasty (TKA), diﬀerent stem lengths could 
be included during surgery. The stem, which can be either cemented or uncemented, transfers stress from the 
damaged proximal bone surface to the distal corƟcal bone. However, no evidence-based guidelines are available to 
help surgeons decide on the length of stem and whether to cement it or not. A numerical model was developed to 
compare diﬀerent fixaƟon techniques and stem lengths in a hinged TKA during a lunge and a squat. 
Methods: A physiological 3D Ɵbia model was created from Computed Tomography images of a leŌ mechanical-
equivalent Sawbone Ɵbia. A hinged TKA (RT-PLUS, Smith&Nephew, Memphis, TN) was selected for the study. Four 
diﬀerent configuraƟons were considered: a short cementless stem, a long cementless stem, a short cemented stem 
and a long cemented stem. The short and long stems had a length of 95 and 160 mm respecƟvely. Stem lengths and 
sizes were selected based on experimental tests. Loading condiƟons for squat and lunge moƟons were calculated 
using a validated musculoskeletal model and were applied in the finite element model. For all the movements and 
configuraƟons stresses in selected regions of interest and micromoƟons between the implant and the bone were 
computed and compared. 
Results: Figures 1 illustrates the distribuƟon of the average compressive stress for the four analyzed configuraƟons 
in the squat movements as a funcƟon of the distance from the Ɵbial cut. For both movements, the most stressed 
regions were situated around the stem Ɵps and the presence of cement reduced the stresses along the bone-
cement interface compared to the cementless configuraƟon. The maximal average compressive stress was higher 
for the cementless long stem configuraƟon (squat 18.2 MPa, lunge 17.7 MPa) and lower for the cemented long stem 
configuraƟons (squat 11.5 MPa, lunge 10.1 MPa). Also, for the short stem, the cementless configuraƟon showed a 
higher average compressive stress (squat 13.3 MPa, lunge 14.6 MPa) compared to the cemented configuraƟon (squat 
9.5 MPa, lunge 10.4 MPa) in the region situated around the stem Ɵps. However, cemented and cementless short 
stems showed similar maximal stresses in a region below the stem Ɵp. Cementless stems show higher micromoƟons 
compared to cemented stems (~50%). Long cemented stems result in lower micromoƟons (~50 μm) compared to 
short cementless stems (~120 μm). 
Conclusions: The presence of cemented stem induces lower stresses in the Ɵbial bone-stem interface and lower 
micromoƟons between implant and bone compared to cementless stem. A short stem shows similar maximal 
stresses in a region below the stem Ɵp.
Figure 1: Average principal stress (Compressive) in the 20 region of interest analyzed during the lunge. The two 
verƟcal black lines in the figures represent the region of interest corresponding to the short stem Ɵp (doƩed line) 
and to the long stem Ɵp (conƟnuous line).
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Y THE FIRST NONͳINVASIVE JOINTͳSPARING GROWING 
PROSTHESIS WORLDͳWIDE FOR AN OSTEOSARCOMA OF THE 
PROXIMAL TIBIA
K.Modaressi, B.Fuchs
University Hospital Balgrist, Orthopedic Research, Forchstrasse 340, 8008 Zürich
IntroducƟon: Malignant bone sarcomas of the growing skeleton represent a parƟcular challenge. AmputaƟon is very 
muƟlaƟng, and rotaƟonplasty although funcƟonally a good alternaƟve, is not opted for because of its disfiguring 
aspect. A growing prosthesis may represent an alternaƟve, parƟcularly when there is considerable growth leŌ. 
Further, sparing the joint may oﬀer great funcƟonal advantages whereas –in contrast to resecƟng the joint- a closer 
margin must be accepted. We herein represent the world-wide first non-invasive joint sparing growing prosthesis 
which was implanted in a 10 year old child.
Results/Case Report: A 10 year old male represented with pain in the proximal Ɵbia aŌer a fall. A non-displaced 
pathological fracture at the proximal Ɵbia was seen, and a biopsy revealed an osteosarcoma. The boy underwent 
neoadjuvant chemotherapy according to the EURAMOS protocol, and then resecƟon of the proximal Ɵbia sparing 
the epiphysis was performed. A custom made growing prosthesis (Stanmore Implants) was manufactured. This 
uncemented HA-coated growing prosthesis has a plateau which receives the remaining epiphysis (of ca 1cm thickness) 
and which allows the fixaƟon of the Ɵbial plateau with screws. The extensor mechanism was reconstructed using 
a medial gastrocnemius flap together with a split skin graŌ. The soŌ Ɵssues healed unevenƞully, and adjuvant 
chemotherapy was resumed 3 weeks postoperaƟvely. Six months later, the prosthesis was non-invasively lengthened 
using an external magnet. The paƟent has full extension and walks without walking aids.
Conclusions: A non-invasive joint sparing growing prosthesis represents a valuable alternaƟve for young children 
with bone sarcomas. Although technically certainly challenging, it leads to good funcƟon, and the non-invasive 
growing can be performed on an outpaƟent basis. However, the costs are high.
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YLONGͳTERM RESULTS AFTER ROTATIONPLASTY FOR 
TREATMENT OF FEMORAL TUMORS
G. Gradl, C. Kirchhoﬀ, L. Postl, H. Rechl, R. v. Eisenhart-Rothe
Klinik für Orthopädie und Unfallchirurgie, Klinikum Rechts der Isar, Technische Universität München
Corresponding author:
Guntmar Gradl
Klinik für Orthopädie und Sportorthopädie,
Klinikum Rechts der Isar, Technische Universität München
email: guntmar.gradl@mri.tum.de
IntroducƟon: Malignancies of the lower extremity can have a devastaƟng eﬀect on the paƟents’ mental status and 
quality of life aŌer treatment. Recently, due to significant advances in modern megaprostheses, amputaƟon and 
rotaƟonplasty seem to have lost some of their importance. RotaƟonplasty has proved to be an eﬀecƟve, highly 
funcƟonal opƟon in treaƟng malignant tumors of the femur. Therefore the aim of this study was to assess long term 
results of rotaƟonplasty, compare it to known alternaƟve opƟons of treatment and to evaluate the psychosocial 
impact. 
Material & Methods: 23 paƟents who underwent rotaƟonplasty at our University Department of Orthopaedics 
between the years 1991 and 2001 were contacted. Twelve out of these 23 paƟents were enrolled in the study. AŌer a 
physical examinaƟon they were evaluated regarding funcƟon of the aﬀected extremity and their psychosocial status. 
The long term outcome was assessed using the Tegner-AcƟvity score, the SF-36 test and the musculoskeletal society 
tumor score (MSTS).
Results: Average follow up for the 12 enrolled paƟents was 14±3 years. Average age at the Ɵme of surgery was 19±10 
years and 32±11 years at the Ɵme of follow up. The Tegner score resulted in 4.1 (±0.6) , the average MSTS accounted 
for 64% (±12%). The results of the SF-36 were 46.6 (±8.3) in the Physical Component Summary Scale and 58.9 (±5.5) 
in the Mental Component Summary Scale.
Conclusion: In comparison with the outcome data available for alternaƟve treatment opƟons in malignancies of the 
lower extremity, rotaƟonplasty is viable alternaƟve, leaving the paƟent with relaƟvely high levels of health-related 
quality of life and funcƟon as well as a high degree of social integraƟon.
Keywords: malignant bone tumor, distal femur, rotaƟonplasty, outcome, funcƟon, quality of life
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Y PERIPHERAL NERVE RECONSTRUCTION IN LIMB SALVAGE 
SURGERY ͳ EXPERIENCES FROM THE VIENNA BONE AND SOFT 
TISSUE TUMOR REGISTRY
V. Stockhammer, T. Tiefenböck, J. Panotopoulos, M. Dominkus, R. Windhager, P. T. Funovics
Departement of Orthopaedics, Medical University of Vienna, Austria
ObjecƟves: The surgical treatment of malignant musculoskeletal tumors requires wide resecƟon. In case of 
entrapment of peripheral nerves, resecƟon of these structures may become inevitable and can require segmental 
reconstrucƟon by use of transplants. Reports on the outcomes of peripheral nerve reconstrucƟon aŌer sarcoma 
resecƟon, however, are sparse.
Material and methods: We therefore evaluated prospecƟvely collected data of the Vienna Bone and SoŌ Tissue 
Registry of paƟents who underwent wide sarcoma resecƟon of the extremiƟes accompanied by nerve resecƟon 
and reconstrucƟon. Twenty-nine paƟents (13 men, 16 women; mean age 35 years; range, 6-79 years; mean follow 
up, 89 months; range, 2-272 months) underwent tumor resecƟon and segmental nerve reconstrucƟon, including 11 
bone sarcomas (osteosarcoma, 6; Ewing’s sarcoma, 2; chondrosarcoma, 2; hemangioendothelioma, 1) and 18 soŌ 
Ɵssue tumors (synovial sarcoma, 6; peripheral nerve sheath tumor, 6; myxofibrosarcoma, 2; pleomorphic sarcoma, 
2; liposarcoma, 1; leiomyosarcoma, 1). Sixteen out of 29 paƟents had precedent surgery outside our insƟtuƟon: 
8 paƟents had previous inadequate resecƟons, 6 paƟents had open biopsies, and 2 paƟents had local recurrence 
aŌer iniƟal adequate resecƟon. One paƟent received neo-adjuvant radiaƟon and 9 paƟents had neo-adjuvant 
chemotherapy.
Results: Tumor resecƟons included 22 tumor resecƟons - 3 of them with endoprostheƟc reconstrucƟon (1 total 
humerus, 1 proximal humerus, 1 proximal femur) - 6 resecƟon-replantaƟons of the upper extremity, and 1 rotaƟon 
plasty of the hip with saddle prosthesis. Seven paƟents had more than one nerve reconstrucƟon. For these, 23 
sural autologeous nerve graŌs and 15 reconstrucƟons without a transplant were used. ReconstrucƟons included the 
peroneal nerve in 9, the ulnar nerve in 7, the radial nerve in 6, the median nerve in 6, the femoral nerve in 2, the 
sciaƟc nerve in 2, the Ɵbial, musculocutaneus, suprascapularis and C6 nerve root in 1 case, each. The average sural 
graŌ length was 14cm (range, 5-23cm). AddiƟonal reconstrucƟve procedures included 8 vascular reconstrucƟons, 
6 muscle flaps and 5 mesh skin graŌs. Secondary reconstrucƟve procedures were performed in 5 paƟents. FiŌeen 
paƟents received post-operaƟve radiaƟon and 29 had chemotherapy.  The grade of postoperaƟve muscle strength 
for the re-innervated muscle groups was available in 18 paƟents with a mean of M3 (M0 - M4). Seven paƟents 
developed complicaƟons requiring revision surgery, including 2 soŌ Ɵssue break-downs, 2 mechanical failures, 1 
arterial spasm, 1 neuroma, and 1 infecƟon. PaƟents with sural nerve autograŌs did not complain about pain or 
discomfort at the donor site. Local recurrence occurred in 4 paƟents aŌer a mean of 45 months and 6 paƟents 
developed metastastases aŌer a mean of 28 months. The 5 year survival rate of all paƟents was 76 percent. 
Conclusion: Nerval reconstrucƟon is a most valuable method in limb salvage surgery, providing parƟal restoraƟon of 
funcƟon in most of the paƟents and a low complicaƟon rate.
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Y9 MONTHS FOLLOWͳUP OF KYPHOͳIORT
Schmidt R., Sperk E., Reis T., Bludau F., Wenz F., Obertacke U.
1Department of Orthopedics and Traumatology, University Medical Center Mannheim, Germany
2Department of RadiaƟon Oncology, University Medical Center Mannheim, Germany
ObjecƟves: The new technique of combined kyphoplasty and intraoperaƟve radiaƟon (Kypho-IORT) has shown its 
clinical feasibility and short term safety which allowed further evaluaƟon of the technique. However, theoreƟcally 
Kypho-IORT could also enable higher local radiaƟon doses due to the steep dose fall oﬀ of the radiaƟon source. 
Intermediate prospecƟve follow-up can give first informaƟon especially by the rate of local tumor control. Therefore 
we present the first 9 months follow-up aŌer Kypho-IORT. 
Materials and Methods: All paƟents who underwent Kypho-IORT and finished the 4th follow-up appointment aŌer 
around 9 month were included. Acquired basic data were gender, age at surgery, tumor enƟty, treated vertebral 
level.  ProspecƟve collected data were pain measure by visual analogue scale (VAS) preoperaƟve and at follow-up, 
Karnofsky Index, local metastasis control in the treated vertebra and general progression of metastases by CT or 
MRI. 
Results: 8 paƟents (5 females, 3 males) with an average age of 60 years were included. 4 paƟents had breast cancer 
and one each with prostate, lung, ovarian and sigmoid cancer. 9 vertebrae from Th5 to L1 were treated with an 
average surgical Ɵme of 83 minutes. The Ɵme from surgery to latest follow-up was in average 293 days. The Karnofsky 
index was constant with 88 preoperaƟve versus 86 at follow-up. The VAS average decreased from 5 preoperaƟve to 2 
postoperaƟve and 1.5 at final follow-up. 1 paƟent had a local progress which needed open revision surgery, whereas 
4 had a general tumor progress. No secondary fractures of the treated vertebrae occurred.
Conclusions: Kypho-IORT can lead to fast postoperaƟve pain reducƟon, immediate stabilizaƟon and prevenƟon of 
secondary fractures in the treated vertebra by kyphoplasty which could be confirmed in this small cohort. VAS 
decreased postoperaƟve and this level was maintained during follow-up. Local tumor control by intraoperaƟve 
radiaƟon could be achieved in 87% over the 9 months period, which seems to be beƩer than single fracƟon radiaƟon 
schedules and at least comparable to mulƟple fracƟon schedules of  convenƟonal radiaƟon. These results warrant 
further evaluaƟon of this technique by a dose escalaƟon and a mulƟcenter study, which is currently under way. 
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Y PREOPERATIVE CHEMOͳRADIATION THERAPY MAY OFFSET 
THE NEGATIVE PROGNOSTIC IMPACT OF CLOSE/POSITIVE 
SURGICAL MARGINS ON OUTCOME: AN EXPLORATORY 
ANALYSIS FROM A PHASE III RANDOMIZED TRIAL BY ITALIAN SARCOMA 
GROUP AND SPANISH SARCOMA GROUP.
Alessandro Gronchi, Paolo Verderio, Andrea Ferraro, ViƩorio Quagliuolo, Antonino De Paoli, Claudia Sangalli, Javier MarƟn, 
Antonio Lopez-Pousa, Franco Gherlinzoni, Piero Picci, and Paolo G. Casali
Background: The impact of surgical margins on outcome in soŌ Ɵssue sarcoma has long been debated. On the 
one hand some retrospecƟve series on large number of paƟents have shown a negaƟve impact of posiƟve surgical 
margins on local and distant recurrence and disease specific survival. On the other hand some other have only found 
a negaƟve impact on local control, without any eﬀect on distant outcome or survival. Since radiaƟon therapy (RT) 
and also chemotherapy (CT) have been shown to play a role in local control, we decided to explore the correlaƟon 
between quality of surgery and outcome in a homogeneous populaƟon of high-risk STS treated within a phase III 
randomized trial by preoperaƟve CT or CT-RT. 
Methods: PaƟents were randomized either to receive 3 cycles of preoperaƟve CT with Epirubicin 120 mg/m2 and 
Ifosfamide 9 g/m2 and G-CSF (Arm A) or to receive the same 3 cycles of preoperaƟve CT followed by 2 further cycles 
of post-operaƟve CT (Arm B). Radiotherapy could be either delivered in the preoperaƟve or in the post-operaƟve 
seƫng. CorrelaƟon between surgical margins and outcome (overall survival, local recurrence and distant metastases) 
was studied by mulƟvariable analysis.
Results: Between January 2002 and April 2007, 328 paƟents were recruited, 164 in each arm. 160 paƟents received 
preoperaƟve radiaƟon therapy, 78 in Arm A and 82 in Arm B. Median tumor size was 10 cm. Microscopic status of 
surgical margins was negaƟve in 84.8% of cases, posiƟve in 8.8%, and missing in 6.4% of cases. Primary amputaƟon 
rate was 8%.
At a median follow-up of 60 months (IQR 47-74 months), 5-year OS was 0.70 for the enƟre group of paƟents, 0.69 
and 0.71 in arm A and B, respecƟvely. 20 paƟents developed local recurrence (LR) aŌer surgery (11 in arm A and 9 in 
arm B) as primary event, while 102 paƟents developed DM (50 in arm A and 52 in arm B).
Overall cumulaƟve incidence of LR at 5 yrs was 0.062 (SE ± 0.014), 0.065 (SE ± 0.020) in arm A and 0.059 (SE  ± 0.019) 
in arm B. Overall cumulaƟve incidence of DM at 5 yrs was 0.326 (SE ± 0.027), 0.321 (SE ± 0.039) in arm A and 0.033 
(SE ± 0.038) in arm B.
On mulƟvariable analysis, posiƟve microscopic margins significantly aﬀected LR (HR 4.23, 95% CI 1.48-12.12), without 
any impact on DM (HR 0.95, 95% CI 0.46-1.98) and OS (HR 0.96, 95% CI 0.46-2.00)
Conclusions: In this seƫng of high-risk STS treated by neoadjuvant  CT or CT-RT, the negaƟve impact of posiƟve 
margins on outcome seems limited. When close margins can be anƟcipated on cross secƟonal imaging, a preoperaƟve 
therapy may be of help to maximize the chance of cure at a beƩer funcƟonal prize.
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YRADIATION THERAPY INCREASED LOCAL CONTROL IN 
SURGERY OF SOFT TISSUE SARCOMAS OF THE EXTREMITIES 
BUT INCREASED WOUND COMPLICATION RATE
T. KLUBA, A. MATZ, B. KUNZE, I. IPACH
University of Tübingen, Orthopaedic Surgery, Germany
Purpose: As treatment results for soŌ-Ɵssue sarcoma sƟll have to be improved, treatment intensificaƟon is warranted. 
We performed a retrospecƟve analysis to compare the diﬀerent treatment opƟons of radiaƟon treatment in the 
perioperaƟve seƫng concerning influence of radiaƟon treatment on local control and wound healing complicaƟons 
aŌer soŌ Ɵssue sarcoma (STS) resecƟons at the extremiƟes.
Methods and Materials: Between 1990 and 2010, 406 paƟents were surgically treated for STS of the extremiƟes 
at our insƟtuƟon. 142 paƟents of these were transferred with a local recurrence aŌer primary therapy abroad. 36 
paƟents had to be excluded because of incomplete documentaƟon. The remaining 228 paƟents (115 f, 113m) were 
analysed with regard to wound healing complicaƟons related to the Ɵme of radiaƟon therapy. The mean age at 
surgery was 56.6 (±15.5) years. The indicaƟon for radiaƟon therapy was discussed individually in the tumour board 
considering the diﬀerent prognosƟc factors (grade, resecƟon status, size, histology, locaƟon). The mean follow-up 
Ɵme was 40 months.
Results: Liposarcomas (n=52), NOS (n=41) and myxofibrosarcoma (n=38) were the most common histological enƟƟes. 
The tumors were graded 1 (29%), 2 (31%) and 3 (40%). 90 paƟents received no radiaƟon therapy (RT), 37 paƟents 
neoadjuvant treatment with radiosensiƟzaƟon (ifosfomide) and / or local hyperthermia and 98 paƟent were treated 
with adjuvant radiaƟon.
Wound complicaƟons with prolonged local treatment were recorded in 18.9% of paƟents without radiaƟon, 35.1% 
with neoadjuvant therapy and 31.6 % with adjuvant radiaƟon respecƟvely. Surgical revisions were required in 7 
paƟents (7.8%) without RT, 10 paƟents (27%) aŌer neoadjuvant and 19 (19.4%) aŌer adjuvant radiaƟon therapy. 
Discussion: As in previous publicaƟons, radiaƟon therapy is a negaƟve prognosƟcator for wound complicaƟons aŌer 
STS surgery. Our data suggest that radiosensiƟzing with ifosfamide and / or locoregional hyperthermia in combinaƟon 
with neoadjuvant radiotherapy has a significantly higher complicaƟon rate (revision surgeries) in comparison to the 
adjuvant treatment. This has to be discussed with the paƟent, bearing in mind the possible funcƟonal advantage in 
the long term.
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Y HIGH DOSE RATE BRACHYTHERAPY IN THE MULTIMODALITY 
TREATMENT OF SOFT TISSUE 
Maccauro G1, Graci C1, Maƫucci GC2, ManƟni G2, Spinelli MS1, Perisano C1, Di Giacomo G1, Valenzi E1, Fabbriciani C1
1Department of Orthopaedics and Traumatology, University Hospital AgosƟno Gemelli, Catholic University of the Sacred Heart 
School of Medicine, Rome, Italy
2RadiaƟon Oncology Service, Bioimages and Radiological Science Department, Catholic University, Rome, Italy
ObjecƟve: ConservaƟve treatment of soŌ Ɵssue sarcomas usually required a combinaƟon of surgery and External 
Beam IrradiaƟon, that is considered an useful adjuvant to surgery: in parƟcular Low Dose Rate Brachytherapy is 
indicated in intermediate and high grade sarcomas and in recurrence to allow addiƟonal local dose in areas at risk 
for local failure.
The aim of this work is to analyze feasibility, methods, advantages and limits of using High Dose Rate (HDR) 
Brachytherapy Remote AŌer Loading associated to External Radiotherapy, an interesƟng perspecƟve in the mulƟ 
modal treatment soŌ Ɵssue sarcomas.
PaƟents and Methods: At surgical Ɵme total irradiaƟon volume is based on preoperaƟve imaging and hystotype. 
The irradiaƟon area is defined by markers. AŌer tumour resecƟon catheters are placed parallel at 1.5 cm of distance 
perpendicular to the scar. Seven days aŌer surgery catheters will be loaded to avoid the risk of scar problems. 
The aŌerloading catheters can remain in situ for several days to allow the feasibility of fracƟonated perioperaƟve 
HDR brachytherapy. The fracƟon size depends on residual desease. AŌer 2 weeks external beam irradiaƟon is 
administered.
In this paper, we present the results obtained from the applicaƟon oh HDR Brachytherapy, since 2003, at the InsƟtute 
of Orthopaedics University of the Sacred Heart in the mulƟmodality treatment of soŌ Ɵssue sarcoma of the limbs. 
On a total populaƟon of 62 cases of paƟents with soŌ Ɵssue sarcoma of the limbs, were selected 12 paƟents foe 
treatment with wide or marginal surgical excision and treatment with brachytherapy (HDR), followed by external 
beam radiaƟon therapy. All lesions treated were large (>5cm).
Results: To date, in our series there was no case of death. In the cases examined did not occur the presence of 
any distant metastases, except for a case with lung metastases at diagnosis. In two of the cases examined, there 
were local recurrence of disease aŌer treatment. In both cases, the lesion was a malignant fibrous hisƟocytoma 
pleomorphic high grade. We recorded only one case of severe fibrosis. We had no cases of neurotoxicity.
Conclusion: The limb-salvage surgery, HDR Brachytherapy an external beam radiotherapy has been shown, in 
literature and in our study, posiƟve in lesions with high histological grade of malignancy with resecƟon margins 
posiƟve or marginal. Although in the literature brachytherapy is used in high-grade lesions, we believe that such 
treatment, having a low rate of major complicaƟons, may be indicated even in low-grade lesions that, for large or for 
their proximity vascular and/or nervous structures, are diﬃcult resectable with wide margins.
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SARCOMAS:  EXPERIENCE OF ORTHOPAEDIC ONCOLOGY 
DEPARTMENT OF FLORENCE
Beltrami G., Caﬀ G., Frenos F., ScoccianƟ G., Matera D., Campanacci D., Capanna R.
Department Orthopaedic Oncology and ReconstrucƟve Surgery, CTO, AOUC, Florence (Italy)
IntroducƟon: RadiaƟon therapy (RT) has an essenƟal role in treatment of soŌ Ɵssue sarcomas (STS) together with 
surgery and chemotherapy. STS show significant pathological responses to radiaƟon therapy in the form of hyaline 
fibrosis, necrosis and granulaƟon Ɵssue; despite the regression of the tumor, many side eﬀects involving bone, soŌ 
Ɵssue, wound, nerves, vessels, and lymphaƟc are associated with RT . We reviewed our cases of STS treated in our 
Center on the last twenty year and subjected to radiaƟon therapy focusing on the eventual complicaƟons.
Materials and Methods: At Department of Orthopaedic Oncology of CTO - Florence, we have treated, from January 
1989 to December 2009, 1055 paƟents aﬀected by STS of limbs and superficial trunks. All the paƟents have been 
operated and followed by the same equip of surgeons, radiotherapist, micro-surgeons and pathologists, everybody 
pracƟce in soŌ Ɵssue sarcoma cases.
Adjuvant protocols of RT was associated to surgery in 477 cases (45,2%): 87 were low grade sarcoma and 390 were 
high grade. Chemotherapy was also associated in 180 (37,7%) paƟents: 8 low grade and 172 high grade. The RT 
medium dose was 60 GY (range 50 to 75 GY).
Side eﬀects aŌer RadiaƟon Therapy have been analysed on the overall group and a staƟsƟcal analysis have been 
performed. All minor or major complicaƟon related to RT were considered and in parƟcular a free event survival 
curve regarding the two most common complicaƟons (fracture and wound dehiscence) have been performed.
Results: At an average follow up of 7 years (1-20 yy), 78 complicaƟons occurred in the whole group (16,3%): 17 in 
paƟents aﬀected by a low grade STS and 61 by an high grade. The most frequent complicaƟons were: 17 cases of 
fractures (21,8%), 27 wound dehiscences (34,6%), 7 necrosis (8,9%) (interesƟng the bone in 4 cases and the flap 
in 3 cases ), 6 neuro palsy (7,6%), 4 lymphedemas (5,1%) and 1 major infecƟon. 7 paƟents were amputated for 
complicaƟon of RT.
Conclusion: Even though the important complicaƟons’ rate, RadiaƟon therapy plays an essenƟal role in treatment 
of soŌ Ɵssue sarcoma as well as adjuvant or neo adjuvant to surgery. A mulƟdisciplinary approach composed by 
specialists with pracƟce is always necessary to select paƟents aﬀected by a STS for a possible radiaƟon therapy.
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Y RETROSPECTIVE ANALYSIS OF TREATMENT RELATED TOXICITIES 
IN EWING SARCOMA PATIENTS RECEIVING RADIOTHERAPY IN 
COMBINATION WITH OR WITHOUT ACTINOMYCIN D
U. Dirksen2, V. SchüƩler2,  S. Amler1, A. RanŌ 2, H. Jürgens2 
1Pediatric Hematology and Oncology, University Hospital, Münster, Germany
2InsƟtute of BiostaƟsƟcs and Clinical Research, Wesƞalian- Wihelms University of Muenster, Germany
Background/ObjecƟves: AcƟnomycin D (actD) was the first agent described in associaƟon with recall dermaƟƟs 
in 1959 by D` Angio et al.. Recall dermaƟƟs is an inflammatory reacƟon of previously irradiated skin ranging from 
sun- burn like redness to desquamaƟng ulceraƟve lesions. RadiaƟon recall phenomena may not be restricted to the 
skin but have also been described as aﬀecƟng the mucosa or lung Ɵssue. Ewing sarcoma paƟents treated within 
the EURO-E.W.I.N.G.99 (EE99) trial received mulƟmodal treatment consisƟng of chemotherapy, radiotherapy and/or 
surgery. Maintenance chemotherapy in paƟents with localized disease or with pulmonary metastases only included 
actD. It was recommended to avoid actD parallel to radiotherapy in order to prevent severe inflammatory reacƟons. 
However, in 34 paƟents treated within the protocol, actD was not paused parallel to or aŌer radiotherapy. We 
analysed toxicity and outcome in these paƟents compared to paƟents who received no actD parallel to radiotherapy 
in a matched pair analysis.  
Methods: A total number of 34 Ewing-sarcoma paƟents (pts) who underwent chemotherapy with actD parallel 
to radiotherapy were extracted from the EE99 trial database of the German Society of Pediatric Oncology and 
Hematology. AddiƟonally, we idenƟfied the same number of a suitable control cohort without the use of acƟnomycinD 
by means of matched pair analyses, to adjust for risk factors age, tumor origin and total dose of radiaƟon. Toxicity 
was analyzed according to modified CTC toxicity grade scales of the EE99 protocol.
Results: Among the paƟents who received actD (male: 67.7%; female: 32.3%) 20 pts, 58,8% presented with localized 
disease, 10 pts with pulmonary metastases (R2pulm; 29.4%) and 3 pts with primary mainly skeletal disseminaƟon 
(R3; 8.8%), in one paƟent staging informaƟon was missing. The control group was distributed as follows: male: 52.9%; 
female: 47.1%; localized disease (25; 73.5%; pulmonary metastases 8; 23.5%; disseminated disease: 1; 2.9%).
Grade 3 and 4 toxicity was reported in 69 of 693 incidents (10.0%) receiving radiotherapy without actD, and in 70 
of 626 incidents (11.2%) receiving radiotherapy and actD. The majority of toxiciƟes were hematological with no 
diﬀerence in both groups (123 cases; about 50% of pts per group; p=0.617). Major diﬀerences with a clinical relevant 
increase of approximately 10% in dichotomous scales were observed in the actD group regarding: granulocytes (with 
actD: 77.8% vs. without actD: 60.0%; p=0.168) and platelets (40.6% vs. 31.3%; p=0.603). The three year- overall 
survival was 0.71; SE=0.09 in both groups.  Skin toxiciƟes were reported in three pts who received actD parallel to 
radiotherapy and in two pts in the control group (p= 0.667). StomaƟƟs and mucosiƟs were reported in one paƟent 
each. In none of the pts the mucosa toxicity was related to the radiaƟon field. Reversible liver toxicity with ALT/AST 
elevaƟon was reported in one paƟent each in both groups and bilirubin elevaƟon was reported only in the control 
group. In none of the pts the liver was in the radiaƟon field. Adjusted for risk group (R1/R2loc; R2pulm; R3) the OS 
risk raƟo for actD vs. no actD was 0.78 (95%CI 0.29-2.08).
Conclusion: A number of chemotherapeuƟcs have been associated with radiaƟon recall dermaƟƟs. Case reports and 
small series are published for actD, bleomycin, doxorubicin, edatrexate, etoposide, hydroxyurea, melphalan, paclitaxel, 
tamoxifen and vinca alcaloids 2. Our results show no diﬀerences in toxiciƟes in pts who received radiotherapy and 
actD. This may be contributed to more precise techniques in the field of radiotherapy. There may be an individual 
pharmacogenomic suscepƟbility to chemo-radiaƟon – induced dermaƟƟs. Further evaluaƟon is required to clarify 
which agent is a risk and who as an individual person is at risk. 
References:
1.D’Angio GJ, Farber S, Maddock CL. PotenƟaƟon of x-ray Eﬀects by AcƟnomycin D. Radiology. 1959;73:175-177
2. Camidge R, Price A. CharacterizaƟon the phenomenon of radiaƟon recall dermaƟƟs. Radiotherapy and Oncology. 
2001. 59:237-245
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ISEXPRESSION OF  CYCLIN D1 AND BETAͳCATENIN  IN GIANT 
CELL TUMOR OF BONE AS A  POSSIBLE  MARKER OF  WNT 
PATHWAY IN TUMORIGENESIS
J. Sopta*, N. Lujic**, Z. Vucinic**,  D. RisƟc***, J. Bokun***, L. Paripovic***, V. Mijucic***
*InsƟtute for Pathology, Faculty of Medicine, University of Belgrade, Serbia
**InsƟtute for Surgical and Orthopedic Diseases “Banjica”, Belgrade, Serbia
*** InsƟtute for Oncology and Radiology, Belgrade, Serbia
ObjecƟves staƟng concisely why the study was conducted
Aberrant acƟvaƟon of the Wnt signaling pathway is known to contribute to tumorigenesis of a wide range of tumors 
including some mesenchymal proliferaƟons including giant cell tumor of bone (GCTB). The Wnt signaling pathway 
is regulated by many components such as β-catenin. Recent studies have shown that cyclin D1 are important target 
genes induced by β-catenin. 
Materials and Methods: RepresentaƟve formalin-fixed, paraﬃn-embedded materials for immunohistochemical 
studies (cyclin D1 and β-catenin) were available in  25 primary and recurrent cases  of GCTB  diagnosed at the InsƟtute 
of Pathology, Faculty of Medicine. We compared nuclear labeling index (LI) in primary and  recurrent tumors. 
Results: Nuclei of  giant cells (GC) were posiƟve for both (cyclin D1 and β-catenin)  primary anƟbodies. Nuclei of 
stromal cells (SC) showed ImmunoreacƟvity  only  for  β-catenin. Cyclin D1 LI in nuclei of GC (75.9 vs. 80,4%, p=0.314) 
were not higher in recurrent tumors than in primary tumors. In opposite, recurrent tumors showed  higher   nuclear 
beta-catenin labeling index (LI)  in both cell types: SC (62.8 vs. 43.1%, p=0.064) and GC (49.1 vs. 22.5%, p=0.087).
Conclusions: This study suggested that cyclin D1 immunoreacƟvity may be a characterisƟc immunophenotype of 
GCTB and nuclear beta-catenin staining level might be associated with tumor recurrence in GCTB. According that we 
postulated  that cyclin D1 may be upregulated through an acƟvated Wnt/β-catenin pathway in GCTB.
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IS DEACETYLASE SIRT1 LINKS TUMOR SUPPRESSIVE NOTCH 
SIGNALLING TO P53 IN EWING´S SARCOMA 
Jozef Ban1, Argyro Fourtouna1, Dave N.T. Aryee1, Isidro Machado2, Max Kauer1, Gunhild Jug1, Antonio Llombart-Bosch2, Heinrich 
Kovar1. 
1Children´s Cancer Research InsƟtute, St. Anna Kinderkrebsforschung, Vienna, Austria, AT-1090; 2 Department of Pathology, 
University of Valencia, Valencia, Spain
ObjecƟves: Besides its important role in organismal development, NOTCH receptor signaling exerts Ɵssue specific 
proliferaƟve or anƟproliferaƟve funcƟons. While the oncogenic role of NOTCH has been extensively invesƟgated due 
to its consƟtuƟve acƟvaƟon in T-cell leukemias and several epithelial cancers, liƩle is known about NOTCH mediated 
tumor suppression. We have previously reported that in Ewing´s sarcoma, a pediatric bone tumor driven by the 
chimeric ETS oncogene EWS-FLI1, auto-sƟmulatory NOTCH signaling is suppressed and that reacƟvaƟon results in 
p53 and consequently growth inhibitory p21 inducƟon via acƟvaƟon of the NOTCH eﬀector HEY1. This study was 
performed to idenƟfy the mechanism by which HEY1 regulates p53 in Ewing´s sarcoma. 
Materials and Methods: EWS-FLI1 and HEY1 regulated p53 candidate modulators were idenƟfied by gene 
expression profiling, and validated by ectopic overexpression, chemical inhibiƟon, reporter gene assays, and 
immunohistochemical analyses of primary tumors.
Results: We now demonstrate that HEY1-mediated p53 sƟmulaƟon is accompanied by C-terminal p53 acetylaƟon as 
a consequence of downregulaƟon of the deacetylase sirtuin 1 (SIRT1). We found that both EWS-FLI1 and HEY1 bind 
to the SIRT1 promoter with opposite transcripƟonal consequences. Thus, knockdown of EWS-FLI1 and ectopic HEY1 
expression resulted in similar SIRT1 modulaƟon and p53 acetylaƟon which could be reversed by ectopically expressed 
SIRT1. Immunohistochemical invesƟagaƟon of a large series of diagnosƟc primary Ewing´s sarcoma samples revealed 
a marked heterogenity of SIRT1 expression. Of note, tumors with high SIRT1 expression posiƟvely correlated with 
EWS-FLI1 proliferaƟve acƟvaƟon signature suggesƟng feed-back regulaƟon between EWS-FLI1 and SIRT1.
Consistent with these results, treatment of Ewing´s sarcoma cells with the sirtuin inhibitor Tenovin 6 resulted in 
massive cell death. 
Conclusions: EWS-FLI1 acƟvates SIRT1 expression by suppressing NOTCH signalling. High SIRT1 suppresses p53 and 
supports EWS-FLI1 proliferaƟon promoƟng funcƟons. The cytotoxic eﬀect of SIRT1 inhibitor Tenovin 6 suggests SIRT1 
as a candidate therapeuƟc target in Ewing´s sarcoma. 
Support: This study was supported by grants from the Austrian Science Fund (P22328-B09) and the European 
Comission (EU-FP7 STREP 259348).
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ISmiRNA ͵ DEREGULATION AS A CRITICAL MILESTONE ON 
THE ROAD TO OSTEOSARCOMA DEVELOPMENT AND 
METASTASIS?
Stephanie Zillmer1,3,§ , Kathrin Poos2,§,  Daniel Baumhoer1, 9, KrisƟan Unger4, Michael Rosemann5, Michael J. Atkinson5, MarƟn 
Irmler6, Johannes Beckers6,7, Gernot Jundt9, Eberhard Korsching2#, Jan Smida1,8# and Michaela Nathrath1,3,8#
1Clinical CooperaƟon Group Osteosarcoma, Helmholtz Zentrum Muenchen- NaƟonal Research Centre for Environment and 
Health, Germany,
2InsƟtute of BioinformaƟcs, Wesƞälische-Wilhelms Universität Münster,  Münster, Germany
3Department of Pediatric Oncology, Klinikum Kassel, Germany, 4Research Unit of RadiaƟon CytogeneƟcs, Helmholtz Zentrum 
Muenchen - NaƟonal Research Centre for Environment and Health, Germany; 5InsƟtute of RadiaƟon Biology, Helmholtz Zentrum 
Muenchen- NaƟonal Research Centre for Environment and Health, Germany; 6InsƟtute of Experimental GeneƟcs, Helmholtz 
Zentrum Muenchen- NaƟonal Research Centre for Environment and Health, Germany; 7Chair of Experimental GeneƟcs, Technische 
Universitaet Muenchen, Centre of Life and Food Science Weihenstephan, Germany;  8Department of Pediatrics, Technische 
Universitaet Muenchen and Pediatric Oncology Center, Germany
9Bone Tumor Reference Center at the InsƟtute of Pathology, University Hospital Basel, Switzerland
§ The authors contributed equally to this work # Shared senior authorship
Corresponding author: Stephanie Zillmer, Department of Pediatric Oncology, Klinikum Kassel, Germany; Phone: +49-17620326245, 
Fax: +49-561-9806851, E-Mail: stephie.zillmer@gmx.de
Although comprehensive studies have demonstrated the complex paƩern of chromosomal and molecular changes in 
osteosarcoma, the mechanisms finally leading to osteosarcoma development are not completely understood. 
MicroRNA-expression profiling has been established as a method to unravel the impact of miRNA-involvement 
in malignancies in general. Several studies have been describing deregulated miRNA to aﬀect osteosarcoma 
pathogenesis, influencing basic pathological cellular processes like cell growth or migraƟon. 
Our approach was to examine 6 well-established OS cell lines (MG-63, MNNG/HOS, SJSA-01, SaOS, HOS-58, U2-OS) 
regarding these biologic processes in vitro, essaying each cell lines’ potenƟal to migrate, invade cell membranes and 
proliferate.  Cultured osteoblasts (hFOB 1.19) and mesenchymal stem cells (L87/4) were used for normalizaƟon.
Based on their disƟnct microarray expression paƩerns, we were able to idenƟfy certain miRNA (mir-181a and let7) 
significantly correlaƟng with the cell lines proliferaƟon, migraƟon and invasion potenƟal, respecƟvely. 
By integraƟon of these miRNA expression levels with expression paƩerns of their target genes we were able to 
detect biologically acƟve miRNA that seem to funcƟon as tumor suppressors or oncogenes in Osteosarcoma. 
Our findings indicate that the deregulaƟon of miRNAs play a crucial role in migraƟon and cell growth of osteosarcomas 
and therefore in their potenƟal to metastasize. 
In order to evaluate their funcƟonal meaning in vivo we are now starƟng to analyze the expression profiles of the 
miRNAs of interest in osteosarcoma biopsy samples.  
The goal is to idenƟfy candidate miRNA that can be used as biomarkers reflecƟng the metastaƟc potenƟal in 
osteosarcoma. 
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IS CD99 AND P53ͳACTIVATING DRUGS IN EWING SARCOMA
Guerzoni Clara1,2, Mario Terracciano1, Maria CrisƟna Manara1, Giusy Di Conza3, Selena Ventura1, Fabiola Moreƫ3, Piero Picci1 
and KaƟa Scotlandi1,2,4.
1Laboratorio di Oncologia Sperimentale, IsƟtuto Ortopedico Rizzoli, Bologna, 40136 Italy; 2Laboratorio PROMETEO, STB, 
DiparƟmento RIT, IsƟtuto Ortopedico Rizzoli, Bologna, 40136 Italy; 3InsƟtute of Cell Biology and Neurobiology, CNR, Roma 64-
00143, Italy; 4CRS Development of Biomolecular Therapies, IsƟtuto Ortopedico Rizzoli, Bologna, 40136 Italy.
ObjecƟve of the proposed research:  Ewing sarcoma (EWS) is the second most common tumor of bone in pediatric 
ages. Current therapeuƟc opƟons involve surgery and highly intensive chemo- and/or radiaƟon therapies frequently 
associated to relevant short and long term side eﬀects, due to the young age of paƟents. IdenƟficaƟon of new 
targeted therapies for EWS treatment might improve the cure rate and the side eﬀects arising from employment of 
chemotherapeuƟc agents. To idenƟfy potenƟal eﬀecƟve targets in EWS treatment we evaluated both monoclonal 
anƟbody anƟ-CD99, which triggers massive and rapid cell death of EWS cells in vitro and in vivo, and small molecules 
able to acƟvate the p53 oncosuppressor protein.
Materials and Methods: To define sensiƟvity and molecular mechanisms underlying acƟvaƟon of specific signaling 
pathways aŌer CD99 or p53 triggering we evaluated cell death in a panel of EWS cell lines. Involvement of specific 
targets was confirmed by western bloƫng. Combined treatment with chemotherapeuƟc agents and the p53-MDM2 
inhibitor Nutlin-3 was also performed to evaluate potenƟal synergic eﬀects.
Results: The monoclonal anƟbody 0662 is raised against CD99, a transmembrane 32 KDa protein, whose expression 
is constantly associated to EWS. As pointed out by array studies and subsequent western bloƫng validaƟons, 
upon 0662 treatment, the oncosuppressor protein p53 appears to be readily acƟvated by phosphorylaƟon on 
serine 15, thus resulƟng in modulaƟon of p53 canonical targets (p21, BAX, cyclin D1, Gadd45α). P53 acƟvaƟon is 
favored by rapid and strong repression of MDM2, an ubiquiƟn ligase responsible for p53 proteasome dependent 
degradaƟon. TP53 gene is rarely mutated in EWS and qualifies therefore as potenƟal target. InteresƟngly, the most 
CD99-responsive EWS cells have either wild type or transcripƟonal acƟve P53, though mutated, and greatly benefit 
from MDM2 degradaƟon. Moreover MDM2 repression may account for increased IGF1R and sustained RAS levels 
measured aŌer treatment with anƟ-CD99 anƟbody. Despite p53 involvement usually commits to cell cycle block or 
apoptosis, CD99 signaling proceeds without release of cytochrome C from mitochondria and caspase involvement, 
suggesƟng that cell death recruits mulƟple pathways with diﬀerent outcomes, likely involving sustained RAS acƟvity 
and massive cytoplasmic hypervacuolizaƟon (autophagosomes and micropinosomes). InteresƟngly, since both p53 
and IGF1-Rß are targeted by the ubiquiƟne ligase MDM2 for degradaƟon, employment of small molecules inhibiƟng 
MDM2 binding and/or acƟvity, may represent another valid therapeuƟc opƟon. Therefore, we evaluated the eﬃcacy 
of MDM2 inhibitors such as Nutlin and RITA in Ewing sarcoma cells. Surprisingly RITA is highly eﬀecƟve in reducing 
growth and tumorigenic potenƟal both in wt-p53 as well as in p53-mutant or truncated Ewing’s sarcoma cell lines, 
suggesƟng that other targets may be aﬀected by MDM2 regulaƟon. Consistently combined treatment with Nutlin 
plus convenƟonal chemiotherapeuƟc agents have synergic eﬀects also in p53 truncated cell lines.
Conclusions: Due to the low rate of P53 inacƟvaƟng mutaƟons in EWS paƟents, these findings sustain p53 and/or 
CD99-targeƟng either to directly kill EWS cells or to increase sensiƟvity to chemotherapy. Small inhibitors aﬀecƟng 
MDM2 acƟvity are eﬀecƟve in reducing EWS cell proliferaƟon alone or combined to chemotherapy. CD99, which 
is easily druggable with monoclonal anƟbodies, recruits not only p53 but also RAS, thus delivering a signal which 
exceeds that of drugs designed to reacƟvate only p53. (grants from Italian Ministry of Health and Italian AssociaƟon 
for Cancer Research).
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SURGICAL TREATMENT; A SINGLE INSTITUTION EXPERIENCE 
OF 359 CASES
L Li1, P Chawla2, P Gikas1, J Jagiello1, W Aston1, R Pollock1, J Skinner1, F Amary1, T Briggs1, A Flanagan2
1 The Sarcoma Unit, Royal NaƟonal Orthopaedic Hospital, 2 Department of Histopathology, Royal NaƟonal Orthopaedic Hospital, 
London, UK.
IntroducƟon: Giant cell tumour (GCT) is one of the most controversial and discussed bone tumours. Biological 
behaviour can be unpredictable and there is currently no consensus as to the best treatment for these theoreƟcally 
benign lesions. Surgical treatment opƟons include intralesional excision or segmental resecƟon. CureƩage has a 
higher recurrence rate than resecƟon but does preserve adjacent joint funcƟon. AŌer cureƩage, the use of adjuvant 
therapies is sƟll controversial.
Aim: We evaluated (1) clinical and histopathological features of paƟents with GCT, (2) the recurrence rate and 
recurrence-free Kaplan-Meier survival funcƟon post-resecƟon or cureƩage, (3) Musculoskeletal Tumour Society 
(MSTS) funcƟonal score (1993 version), and (4) complicaƟons aŌer treatment.
Methods: We conducted a retrospecƟve review of 359 paƟents (males and females) with GCT of bone presenƟng to 
the Royal NaƟonal Orthopaedic Hospital to evaluate oncological and funcƟonal results. 
Results: The paƟents were followed up for at least 12 months. The average age of the paƟents was 36.9 years 
(range 1-89 years). Tumours were treated with extensive cureƩage, local adjuvant therapy (e.g. phenol), cement 
reconstrucƟon or wide resecƟon +/- use of endoprostheses. The recurrence rates, Kaplan-Meier recurrence-free 
survival curves, and MSTS funcƟonal scores were recorded and correlated to the clinical and histopathological 
features of these tumours using staƟsƟcal analysis.
Conclusion: This is the largest reported series of giant cell tumours of bone to date and by correlaƟng clinical and 
histopathological features to outcome post-treatment serves to elucidate the unpredictable behaviour of these 
tumours, evaluate current surgical treatment opƟons and guide future therapeuƟc approaches.
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* InsƟtute for Orthopedic Surgery “Banjica”, Belgrade, Serbia
** InsƟtute for Pathology, Faculty of Medicine, University of Belgrade, Serbia
*** Clinic for orthopedic surgery, University of Belgrade, Clinical centre, Belgrade, Serbia
**** InsƟtute for Oncology and Radiology, Belgrade, Serbia
ObjecƟves staƟng concisely why the study was conducted: The study presents the results of the treatment GCTB 
over 50 years, specifically, what is the importance of recurrence / residual tumor and its histologic grade, undertaken 
in relaƟon to the previous operaƟon was performed, jusƟficaƟon for certain surgical procedures in relaƟon to the 
nature of the tumor and finally completes the current treatment protocol algorithm. 
Materials and Methods: The study is a retrospecƟve analysis for the period 1963-2005 year, used all available 
documentaƟon Register for Bone Tumors “BANJICA”. Histopathologic analysis was performed at the InsƟtute of 
Pathology, Medical Faculty in Belgrade. The study included 196 paƟents, treated GCTB. All apaƟnets were divided 
into 3 Ɵme interval , I group, 1964 – 1983. 76 paƟents; II group, 1984-1993, 40 paƟents; III group, 1994-2005, 48 
paƟents.
 
Results: We analyzed the oncologic and funcƟonal results, average follow up Ɵme was 8.6 years . The average age 
was  34 ±29 years and it can be concluded that the shiŌ to older ages. Slightly dominated by females (f:m=54%:46%).
The predominant localizaƟon was femur (36,72%), folowed by Ɵbia (17,5%). According it histological characterisƟc 
GCTB was classified as: grade me (29, 7 %), grade II (64, 58%), and grade III (6, 25%). The main treatment was 
aggressive cureƩage, and recurrrence was registered in I group (35,5%), II group (40%), III group (12,5%) and the 
number treated adjuvants (phenol sol.)  was only 14, but without recurrence (since 2000 to 2003 year). The analysis 
shows a clear improvement in surgical technique and more determined approach to treatment. It turned out that 
it’s Ɵme to recurrence is not completely predictable, but that usually occur during the first three years, a number 
decreased significantly (X²=10,078, p<0,05), over the years and in the last decade there were only 4 recurrences, and 
the occurrence of malignancies is staƟsƟcally insignificant. We recorded only two cases of pulmonary metastasis, 
which is a proven their benign nature. Rare aƩributes characterized by a large number of pathological fractures, and 
only 3 cases of mulƟcentric. Appearance of major complicaƟon, recurrence, clearly indicates a significant increase 
successful treatment, parƟcularly using adjuvants. 
Conclusions: And aŌer 50 years, we can not clear predict recurrence, we also, can not predict  biological behavior of 
GCTB. But we can postulate benign behavior of  GCTB, the occurrence of lung metastases is not a sign of malignancy 
GCTB.  However, decreases the number of complicaƟons, in despite the diﬃcult condiƟons at Ɵmes when it was very 
diﬃcult to meet the demands of the modern approach in the treatment GCTB. 
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TREATMENT AFTER CURETTAGE IN GIANT CELL TUMOR OF 
BONE
L van der Heijden MSc1, ICM van der Geest MD PhD2, HWB Schreuder MD PhD2, RPH Veth MD PhD2, MAJ van de Sande MD PhD1, 
PDS Dijkstra MD PhD1
Department of Orthopedic Surgery, Leiden University Medical Center, Leiden, the Netherlands1. 
Department of Orthopedic Surgery, University Medical Center St. Radboud, Nijmegen, the Netherlands2. 
ObjecƟves: CureƩage with local adjuvants has become standard of care in most Giant Cell Tumors of Bone (GCTB). 
However, main problem in the surgical management of GCTB is the high local recurrence risk aŌer intralesional 
treatment. Over the last three decades, orthopedic surgeons have experimented with diﬀerent combinaƟons of 
phenol, liquid nitrogen and polymethylmetacrylate (PMMA) to improve oncological outcomes, but preferable 
local adjuvant treatment remains controversial. Aim of the present study is to determine the opƟmal local 
adjuvant treatment regarding clinical outcomes of intralesional cureƩage in GCTB.
Methods: From a total of 167 evaluated paƟents, 120 paƟents treated for GCTB between 1989 and 2009 were 
included in this bi-center retrospecƟve study. PaƟents referred to these centers with a local recurrence, primarily 
treated diﬀerently or with GCTB of the axial skeleton and small bones (n=47) were excluded. Mean follow-
up was 82 months (range 24-236). PaƟents from one center were treated with cureƩage, liquid nitrogen and 
bonegraŌing (n=21) or cureƩage, liquid nitrogen and PMMA (n=26) and paƟents from the other center with 
cureƩage, phenol and PMMA (n=73). We evaluated local recurrence and complicaƟon rates in all groups. 
Treatment groups matched for age, gender, soŌ Ɵssue extension and pathologic fractures.
Results: 
Oncologic outcome: Overall recurrence rate was 29% (35/120). Local recurrence rates for diﬀerent local adjuvants 
were as follows: liquid nitrogen and bonegraŌing 38% (8/21); phenol and PMMA 29% (21/73); and liquid nitrogen 
and PMMA 23% (6/26). Diﬀerences between local adjuvant groups were not significant (Log Rank; p=0.526). 
Mean Ɵme to local recurrence was 23 months (range 4-78).
Surgical outcome: ComplicaƟon rates for diﬀerent local adjuvants were as follows: liquid nitrogen and bonegraŌing 
24% (5/21), liquid nitrogen and PMMA 19% (5/26) and phenol and PMMA 10% (7/73). ComplicaƟons aŌer the 
use of liquid nitrogen and bonegraŌing included transient nerve palsy (n=2), infecƟon (n=1), arthrosis (n=1) 
and fracture (n=1); aŌer liquid nitrogen and PMMA arthrosis (n=2), infecƟon (n=2) and fracture (n=1) and aŌer 
phenol and PMMA arthrosis (n=2), infecƟon (n=1), chronic pain due to cement remnants (n=4) and fracture 
(n=1). ComplicaƟon rates did not diﬀer significantly between local adjuvant groups (Log Rank; p=0.107).
Conclusions: No significant diﬀerences were found between local adjuvant groups regarding local recurrence and 
complicaƟon rates. Treatment including PMMA resulted in lower recurrence rates, possibly indicaƟng that PMMA 
is the superior of the invesƟgated local adjuvants in this study. PMMA provides for more rigorous cureƩage, in 
part because of the necroƟzing eﬀect on the tumor cavity walls and also through its reconstrucƟve properƟes. 
Therefore, adequate cureƩage should include at least PMMA as local adjuvant and cavity fill-up. 
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D.P. Neophytou, J. Jagiello, M. D.  Sewell, S. NgManSun, J. Skinner, R. Pollock, W. Aston, T. W. Briggs
The Bone and Tumor Unit, Royal NaƟonal Orthopaedic Hospital, Stanmore, UK
Purpose: The purpose of this study is to review all paƟents with chondroblastoma that were treated in our hospital 
from1980 unƟl 2012 in an aƩempt to evaluate the funcƟonal outcome and to idenƟfy possible factors related to 
increased risk of recurrence.
PaƟents and Methods: 96 paƟents, 68 male and 28 female, with mean age 27.7 years (range 9-60 years) with 
histologically proven chondroblastoma were treated in our Hospital. We retrospecƟvely reviewed these paƟents 
using our histopathological database, medical records, radiological imaging, and paƟents were followed up using 
convenƟonal funcƟonal outcome measures.
The mean follow up was 7.25 years (range 2- 18 years). The presenƟng symptom was pain and the treatment 
in the majority of the paƟents included intralesional cureƩage and graŌing (autograŌ or allograŌ) or the use of 
polymethylmethacrylate.
FuncƟonal outcome was measured with MSTS score system and their general health condiƟon was demonstrated 
by the SF-12 quesƟonnaire.
There was a wide distribuƟon of the lesions across the skeleton but the most frequently involved sites were the 
epiphyses or apophyses of the long bones, especially proximal Ɵbia, proximal humerus and distal femur.
Results: The mean MSTS sore was 26.4 (13-30) and the mean SF-12 score was 31.37 (25-37).  11 paƟents (11.3%) had 
a histological confirmed local recurrence that was treated with further procedures and one of these paƟents had an 
elbow replacement aŌer aggressive recurrence. No paƟents developed metastases.
Conclusion: Chondroblastoma is a rare benign bone  tumor commonly presenƟng in adolescents and young adults 
that can be successfully treated with intralesional cureƩage and reconstrucƟon with graŌing. This study illustrates 
that we can achieve excellent funcƟonal outcomes, ensuring a high chance of joint preservaƟon and a low rate of 
recurrence. 
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RSBONE ANGIOSARCOMA: A RETROSPECTIVE ANALYSIS OF 60 PATIENTS FROM TWO REFERRAL CENTRES
E. Palmerini M.D.1, E. L. Staals M.D.2, M. Alberghini M.D.3, R. G. Maki M.D. Ph.D4, CrisƟna Antonescu MD5, L. Zanella M.D.3, C. 
Ferrari MSc4, P. Ruggieri2, P Picci M.D.4, S. Ferrari M.D.1 
1Chemotherapy, 2Orthopaedic Surgery, 3Surgical Pathology, Laboratory4, Musculoskeletal Oncology Department, IsƟtuto 
Ortopedico Rizzoli, Bologna, Italy; Departments of 4Medicine and 5Pathology, Memorial Sloan-KeƩering Cancer Center, New 
York, NY, USA.
BACKGROUND: Angiosarcoma is a high-grade malignant vascular tumor that can occur in soŌ Ɵssue and bone (2002 
WHO classificaƟon). Data on bone angiosarcoma are extremely scarce. The main treatment for primary disease is 
surgical intervenƟon. The role of chemotherapy is undefined. Survival rates of malignant vascular tumors of bone 
are unknown.
PATIENTS AND METHODS: PaƟents with a diagnosis of bone angiosarcoma in the Bone Tumors Database of Rizzoli 
InsƟtute (1980-2009) and in the Pathology Department database of MSKCC (1996-2009) were idenƟfied and clinical 
charts were reviewed.
RESULTS: Data of 60 paƟents were analyzed: median age 54 years (range 18-82); 38 males: 22 females; site of 
primary lesion: femur (37%), pelvis (23%), Ɵbia (12%), humerus (10%); sacrum (7%), other (11%); size of primary 
lesion > 10 cm: 57%; 36 (60%) paƟents with localized disease and 24 (40%) with metastaƟc disease at presentaƟon. 
72% of paƟents underwent surgery, with 50% of paƟents achieving surgical complete remission (SCR). Radiotherapy 
(RT) was administered to 29% of paƟents, and chemotherapy (CT) to 67% of metastaƟc paƟents and 37% of localized 
paƟents. 
With a median follow-up of 10 years (range 1-25), the 5-year overall survival rate (OS) was 20%(95%CI 9-30%): 
33%(95%CI 17-50%) for paƟents with localized disease and 0 for paƟents with metastaƟc disease, P<0.0001; 
40%(95%CI 22-58%) in paƟents with SCR, and 0 for those with no SCR, P<0.0001. 5-year OS in localized paƟents: 
males 40%(95%CI 20-61%), females 20%(95%CI 0-44%), P<0.3; age < 26: 50%(95%CI 0-100),  age 26-65: 36%(95%CI 
17-56%), age >65: 17%(95%CI 0-46%), P=0.5); adjuvant CT: 49% (95%CI 20-78), no adjuvant CT: 39% (95%CI 15-
63), P=0.15. RT was only adopted in 5 paƟents with localized disease (4 of them with inadequate margins); none 
of them was alive at 5 years. PaƟents with metastaƟc disease received diﬀerent CT regimens, most of them based 
on doxorubicin/cisplaƟn (73%) and paclitaxel (27%). In 13 of the 16 paƟents evaluable for response 2 PR were 
documented: 1 with PEGylated liposomal doxorubicin, and 1 with paclitaxel.
CONCLUSIONS: MetastaƟc bone angiosarcoma is invariably fatal. SCR is key factor for survival. It is possible that 
gender influences prognosis as well. A trend towards a survival advantage for the use of adjuvant CT was shown.  
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Robert Nakayama1 robert@a2.keio.jp, Kazutaka Kikuta2, Michiro Susa1, Itsuo Watanabe1, Keisuke Horiuchi1, Yoshihisa Suzuki2, 
Ukei Anazawa3 , Hiroo Yabe1, Yoshiaki Toyama1, Hideo Morioka1
1) Department of Orthopaedic Surgery, School of Medicine, Keio University, Tokyo, Japan
2) Department of Orthopaedics, Kyosai Tachikawa Hospital, Tokyo, Japan
3) Department of Orthopaedic Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan
ObjecƟves: Myxofibrosarcoma (MFS), previously called myxoid malignant fibrous hisƟocytoma, is a soŌ Ɵssue 
sarcoma that typically aﬀects the extremiƟes and the trunk of the elderly. The number of paƟents diagnosed with 
MFS has been increasing in Japan’s aging society, and now it is one of the most common tumors among the diverse 
soŌ Ɵssue sarcomas. In order to find the prognosƟc factors that may aﬀect the clinical outcome, we retrospecƟvely 
analyzed the clinical data of paƟents with MFS with emphasis on the locaƟon of the tumor at presentaƟon.
Materials and Methods: Since 1999, there were 38 cases of MFS, including recurrent tumors, in our database. 
InvesƟgaƟve factors included age, gender, locaƟon of the tumor at presentaƟon (deep or subcutaneous, 
extremiƟes or trunk), and surgical margin. 
Results: There were 24 males and 14 females, and the age at diagnosis ranged from 38 to 88 years old (avg. 64.4). 
The follow-up period ranged from 5 to 210 months (avg. 62.1). Nine paƟents (23.7%) had the tumor in the trunk, 
whereas 29 paƟents (76.3%) did in the extremiƟes,(6 (15.8%) in the upper limb and 23 (60.5%) in the lower limb). 
25 cases (65.8%) arose in the subcutaneous fat layer with or without fascial involvement and they were more likely 
to undergo unplanned surgery before referral to our service than those which arose beneath the fascia (P=0.0021). 
13 paƟents (34%) developed local recurrence, and the interval between iniƟal surgery and the first local recurrence 
ranged from 10 to 147 months (avg. 38.7). The 5-year tumor free survival was only 54%, and seven paƟents 
(18.4%) underwent amputaƟon during their clinical course. Oncological outcomes were 24 CDF, 6 NED, 4 AWD, 3 
DOD, and 1 DOOD. Although seven paƟents (18.4%) developed distant metastases, only one case died of disease 
due to the metastaƟc lesion, whereas the remaining three died due to failure in local control. 
Conclusions: MFS is infamous for its extreme invasiveness and this study highlighted the diﬃculty in management 
of local control. For improvement of the clinical outcome, novel methods need to be established to evaluate the 
infiltrated area in both histological and radiological ways to determine the adequate surgical margin. Furthermore, 
novel mulƟdisciplinary treatment is needed to reduce the recurrence as well as to treat the recurrent tumors.
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Frederique Larousserie, Jennifer Kreshak, Marco Alberghini, Stefano Boriani, Joseph Mirra, Daniel Vanel
All authors are aﬃliated with the IsƟtuto Ortopedico Rizzoli, Bologna, Italy
ObjecƟves: Notochordal remnants have been documented in the intervertebral disk and as small soŌ Ɵssue masses 
found extraosseously in the craniosacral spine. More recently, notochordal-like lesions in the vertebrae have been 
beƩer characterized and controversy exists as to whether they may be precursors to chordoma. Various terms have 
been used, including giant notochordal rest and benign notochordal cell tumor (BNCT).  They have been described as 
having morphological features disƟnct from fetal notochordal cells, notochordal cells found in disks, and chordomas. 
This study was conducted to idenƟfy BNCTs that might have previously been diagnosed as chordoma and to beƩer 
delineate any possible relaƟonship between these two enƟƟes.
Materials and Methods: All cases of chordoma without significant soŌ Ɵssue masses diagnosed at our insƟtuƟon 
prior to the recogniƟon of BNCT were re-reviewed. Three of these chordomas included areas of BNCT.  All three 
cases underwent vertebrectomy for the diagnosis of chordoma, ensuring adequate sample size for evaluaƟon.
Results: Two lesions were found to have disƟnct areas of both chordoma and BNCT, as well as atypical areas that do 
not definiƟvely meet the criteria for BNCT or chordoma.  The third case did not have any clear areas of chordoma but 
consisted of what would now called BNCT according to published criteria, however, a small atypical area was seen 
inside the lesion.  This case ulƟmately recurred as a chordoma.  All cases were posiƟve for brachyury in all areas of 
the lesion.
Conclusions: While BNCT is now a well-recognized enƟty, its origin and relaƟonship to chordoma conƟnues to be 
controversial.  BNCT appears to have all the characterisƟcs of a benign lesion, is more prevalent than chordoma, and 
has been documented in several cases to be stable over long periods of Ɵme, however, chordomas have been found 
immediately adjacent to some BNCTs.  These three cases indicate progressive change from benign to malignant 
within the same lesion, providing further evidence for a link between the two and the possibility for transformaƟon 
of BNCT.  Under the best of circumstances, histopathologic discriminaƟon between these enƟƟes can be challenging; 
these cases highlight the need for adequate, accurate biopsy and close clinical follow-up.  
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Segura, F. 1, Delgado, M.A.2, Sarrión, P.3, Azar, N.2, Zecchini L.4, Bistué Millón, M.B.2
Chiesa, M.5; Robledo, H.5; Dodelson de Kremer, R. 2; Ballcels, S 3; Grinberg, D.3; Asteggiano, CG. 2,6,7.
(1) Cátedra de Ortopedia y Traumatología. Universidad Nacional de Córdoba. ArgenƟna
(2) CEMECO (Centro de Estudio de las Metabolopaơas Congénitas), Facultad de Ciencias Médicas, Universidad Nacional de 
Córdoba, Hospital de Niños S.T., Córdoba, ArgenƟna; (3) Departamento de GenéƟca, Facultad de Biología, Universidad de 
Barcelona, España; (4) Servicio de Traumatología, Hospital de Niños S.T., Córdoba, ArgenƟna; (5) Servicio de Bioimágenes, 
Hospital de Niños S.T., Córdoba, ArgenƟna. (6) Cátedra Química Biológica, Facultad de Medicina, Universidad Católica de 
Córdoba, ArgenƟna; (7) Consejo Nacional de InvesƟgaciones Cienơficas y Técnicas (CONICET), ArgenƟna.
MulƟple Hereditary Exostoses (MHE) is an autosomal dominant disorder characterized by the formaƟon of 
carƟlaginous bone tumors (osteochondromas) at mulƟple sites. The most severe complicaƟon is malignant 
transformaƟon to chondrosarcoma. Defects result from mutaƟons in EXT1(8q24) or EXT2(11p11.2) genes, which 
encode glycosyltransferases necessary for the synthesis of heparin sulfate proteoglycans (HSPGs). This study 
represents the first invesƟgaƟon of the genotype-phenotype correlaƟon in LaƟn American paƟents. We have studied 
25 MHE paƟents with ages ranging from 2 to 50 years old. PCR and direct sequencing of both genes were performed 
aŌer the wriƩen consents. Clinical assessments and funcƟonal raƟng were analyzed (Musculoskeletal Tumor Society 
Scale).
A total of 10 exonic changes were idenƟfied. Six were novel mutaƟons in EXT1 (p.Leu251Stop/p.Leu283Stop/p.
Arg346Thr/p.Lys126AsnfsX62/p.Lys306Stop/p.Leu264Pro) and two in EXT2 (p.Trp393Stop/p.Asp307ValVfsX45). 
Two mutaƟon were previously described in EXT1 (p.Leu490ArgfsX9 and p.Val78ArgfsX111) (hƩp://medgen.ua.ac.
be/LOVD/home.ph). Missense novel mutaƟons were analyzed by predicƟon programs. Clinical study: 8 paƟents 
presented a severe phenotype ranging from IS to IVS and 2 a mild one. A novel mutaƟon p.Leu283Stop was associated 
with a malignant transformaƟon to chondrosarcoma. We could not find a correlaƟon between EXT1 and EXT2 
genes with the grade of severity. Our results idenƟfied novel mutaƟons in a first cohort of LaƟn American paƟents. 
Preliminary analysis indicated that mutaƟons on the first EXT1 exons correlate with a more severe phenotype. This 
interdisciplinary study represents the first genotype-phenotype invesƟgaƟon in ArgenƟna and its progression will 
provide a wider vision of this pathology in our country and LaƟn America. CONICET/FONCYT-PICT2350/UCC.
EXT1:
p.Leu251Stop;
p.Leu283Stop;
p.Arg346Thr;
p.Lys126AsnfsX62;
p.Lys306Stop;
p.Leu264Pro;
p.Leu490ArgfsX9;
p.Val78ArgfsX111
EXT2:
p.Trp393X;
p.Asp307ValVfsX45
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SCAN CONTRASTͳENHANCED ULTRA SONOGRAPHY ΈCEUSΉ 
DISTINGUISH BENIGN FROM MALIGNANT SOFTͳTISSUE 
MASSES? PRELIMIRARY RESULTS
Armanda De Marchi, Simona Pozza, *Elena Brach del Prever, **Alessandra Linari, , Paola De Petro, Federica Guneƫ, ***Raimondo 
Piana, ***Gian Carlo Gino, Carlo Faleƫ.
Department of Radiology, AO CTO/Maria Adelaide of Turin, Italy
*Department of Traumatology, Orthopaedics and Health Medicine, University of Turin, Italy
**Department of Pathology, AO OIRM-S.Anna of Turin, Italy
***Department of Oncological Orthopaedics and ReconstrucƟve Surgery, AO CTO/Maria Adelaide of Turin, Italy
Backgruond: Malignant masses are characterized by anarchic vascularisaƟon related with neoangiogenesis. The 
evaluaƟon of presence/absence of  vascularisaƟon could be an easy and early method to idenƟfy masses potenƟally 
malignant. Power Doppler study idenƟfy only major vassels, but is unable to visualize the diﬀuse vascular pathological 
network. We hypothesized that vascular enhancement idenƟfied by contrast-enhanced ultra sonography (CEUS) 
could be useful to discriminate between benign and malignant lesions.
Materials and methods: A retrospecƟve cohort series of 207 paƟents from January 2009 to December 2010 
with soŌ Ɵssue masses of limbs and trunk were studied by US, PD and CEUS: the intravenous contrast agent was 
SonoVue® (Bracco, Milan, Italy). All paƟents gave their informed consent. Each lesion was scored on the following 
characterisƟc: presence or absence of vascularisaƟon, homogenous or inhomogenous enhancement with avascular 
areas, peripheric enhancement, spare intralesion vessels and lesion’s vascular Ɵme. In all cases the histological 
diagnosis was done on surgical definiƟve specimens or on biopsy. The CEUS vascular paƩerns were compared with 
the histological results.
Results: 88 benign and 117 malignant lesions were diagnosed by histology. In all masses, seven diﬀerent CEUS 
paƩerns were observed and three diﬀerent vascular Ɵming. 90% of the malignant lesions (105/117) show a rapid 
early Ɵme of vascularisaƟon (arterial phase) and  60% (70/117) an inhomogenous enhancement paƩern with 
avascular areas.  Only 20% of benign lesions (11/88) shows a paƩern similar to malignant lesions and 50% (44/88) 
showed a rapid Ɵme vascularisaƟon: histologically, these last arterial paƩern was characterisƟc of arterio-venous 
malformaƟon and hemangioma.
Conclusions: The inhomogenous CEUS enhancement paƩern with avascular areas and the rapid vascular flow can 
be related with malignancy; other CEUS paƩern are more frequent in benign lesions; rapid arterial flow in benign 
masses are present when hemangioma or artero-venous malformaƟon are present. These preliminary results 
suggest that CEUS can facilitate a rapid and easy idenƟficaƟon of masses potenƟally malignant, therefore CEUS could 
be considered as a first  level exam, before more complex and expensive imaging. If core needle biopsy is indicated, 
CEUS study could increase the sensiƟvity and sensibility (De Marchi et Al. Eur Rad 2010). Further invesƟgaƟons with 
a larger cohort of paƟents is mandatory. 
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S PROGNOSTIC RELEVANCE OF 18FͳFDG UPTAKE IN PATIENTS 
WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA OF THE 
EXTREMITIES UNDERGOING NEOADJUVANT TREATMENT
D. Andreou1, H. Boldt2, B. Jobke3, M. Werner4, D. Pink5, M. Niethard1, F. Traub1, P. Reichardt5, P.U. Tunn1 
1 Department of Orthopedic Oncology, Helios Klinikum Berlin-Buch, Sarcoma Center Berlin-Brandenburg, Berlin, Germany; 2 
Department of Nuclear Medicine, Helios Klinikum Berlin-Buch, Berlin, Germany; 3 Department of Radiology, Helios Klinikum 
Berlin-Buch, Berlin, Germany; 4 Department of Pathology, Helios Klinikum Emil von Behring, Sarcoma Center Berlin-Brandenburg, 
Berlin, Germany; 5 Department of Hematology, Oncology and PalliaƟve Care, Helios Klinikum Bad Saarow, Sarcoma Center Berlin-
Brandenburg, Bad Saarow, Germany
ObjecƟves: The management of locally advanced soŌ Ɵssue sarcomas of the extremiƟes can be challenging and 
neoadjuvant treatments are oŌen needed to improve local control and disease outcome. The objecƟve of this study 
was to evaluate in a prospecƟve seƫng whether 18F-FDG-PET can accurately predict prognosis in paƟents with 
locally advanced soŌ Ɵssue sarcoma of the extremiƟes undergoing neoadjuvant isolated limb perfusion (ILP) with 
TNFa and melphalan.
Materials and methods: 33 consecuƟve paƟents with locally advanced non-metastaƟc high-grade soŌ Ɵssue 
sarcoma of the lower (n=26) and upper (n=7) extremity underwent 18F-FDG-PET or PET/CT prior to and 6 weeks 
aŌer neoadjuvant ILP between 2006 and 2009. 24 paƟents presented with a primary tumor and 9 paƟents with 
a local recurrence. Mean follow-up amounted to 28 months. Non-parametric analyses were performed with the 
Mann-Whitney U test. Survival curves were calculated with the Kaplan-Meier method and compared with the log-
rank test.
Results: The mean and median maximum standardized uptake value (SUVmax) amounted to 9.3 and 6.3 prior to 
treatment (SUVmax1), compared to 5.7 and 3.1 aŌer 6 weeks (SUVmax2), respecƟvely. 9 paƟents developed regional 
or distant metastases aŌer a mean of 8.8 months, 3 of whom died of their disease. PaƟents who did not develop 
metastases had a mean SUVmax1 of 8.6 (range, 1.5 – 27.1) and a mean SUVmax2 of 5.4 (range, 1.0 – 30.6). PaƟents 
who developed metastaƟc disease had a mean SUVmax1 of 11.2 (range, 3.6 – 35.5) and a mean SUVmax2 of 6.6 
(range, 2.0 – 12.2). These diﬀerences were not staƟsƟcally significant (p = 0.505 for SUVmax1 and p = 0.109 for 
SUVmax2). PaƟents with a SUVmax1 > 6.3 had a metastasis-free survival of 67.4% aŌer 2 years, compared to 72.2% 
for paƟents with a SUVmax1 of ≤ 6.3 (p = 0.530). However, paƟents with a SUVmax2 of > 3.1 had a metastasis-free 
survival of 50.8% aŌer 2 years, compared to 86.7% for paƟents with a SUVmax2 of ≤ 3.1 (p = 0.05). 
Conclusions: SUVmax prior to treatment does not appear to correlate with prognosis in paƟents with locally advanced 
non-metastaƟc high-grade soŌ Ɵssue sarcomas of the extremiƟes. However, a low SUVmax 6 weeks following ILP was 
associated with an improved metastasis-free survival in this study. These results need to be validated in larger studies 
with longer follow-up, before definiƟve conclusions on the role of 18F-FDG-PET in this seƫng can be drawn.
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TOMOGRAPHY ΈPETΉ OF VALUE IN THE MANAGEMENT 
OF PATIENTS WITH CRANIOFACIAL BONE SARCOMAS 
UNDERGOING NEOADJUVANT TREATMENT? A SINGLE INSTITUTION 
EXPERIENCE.
Anna Maria Frezza, Tim Beale, Jamshed Bomanji, Amrita Jay, Simon Morley,  Nicholas Kalavrezos, Palma Dileo, Jeremy Whelan, 
Sandra Strauss 
The London Sarcoma Service, University College of London Hospital - London, England
ObjecƟves: We evaluated the role of PET/CT used to assess response to preoperaƟve chemotherapy in paƟents with 
primary craniofacial bone sarcomas.
PaƟents and methods: Thirteen paƟents with craniofacial sarcomas (12 paƟents with osteosarcoma) presenƟng 
between 2005 and 2011 were retrospecƟvely evaluated. All paƟents received up to 6 cycles of standard preoperaƟve 
chemotherapy followed by the resecƟon of the primary tumour. Response to treatment was assessed using MRI 
(evaluated according to RECIST criteria) and PET/CT (evaluated according to EORTC guidelines), performed at least at 
baseline, aŌer 2 to 3 cycles of treatment and pre-operaƟvely. 
Results: The median baseline PET SUV value was 10 (range 0-41); in 2 paƟents no uptake was detected.  The 
preoperaƟve PET, compared with the baseline, proved a PMR in 6 paƟents (55%), a CMR in 2 (18%) and SMD in 3 
(27%). Conversely, only one paƟent achieved a RECIST response on MRI: 12 (92%) had SD. One paƟent underwent 
early resecƟon due to clinical progression aŌer an iniƟal response to treatment. This was confirmed by PET (SUV 
from 21 to 42) but not on MRI.  Eleven of 13 paƟents (85%) had <90% histological necrosis the in resected tumour. 
With a median follow-up 23 months, 10 paƟents (77%) remain disease free, two had metastaƟc progression (15%) 
and 1 relapsed locally (8%). The overall median DFS was 17 months. For those paƟents who achieved a response 
to preoperaƟve PET the median DFS was 18 months compared with 3 months in those who did not (p= 0.003). 
Conversely, the median DFS did not diﬀer according to histological response (19 versus 17 months, >90% versus 
<90% necrosis). ResecƟon margins were also found not to correlate with survival (18.5 months for R0 versus 17.5 
months for R1, p= 0.20).
Conclusion: PET/CT appears more reliable than standard imaging in evaluaƟng response to neaodjuvant chemotherapy 
in craniofacial bone sarcomas, changed management in one paƟent, and in this small retrospecƟve series, correlated 
beƩer with paƟent outcome than histological response and resecƟon margins.
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METASTASIS OF SOFT TISSUE SARCOMAS
Casanova, José; Fonseca, Ruben; Simões, Pedro; Lapa, Paula; Ruivo, Catarina; Tavares, Paulo; Laranjo, António and Freitas, 
João.
Coimbra University Hospital – Coimbra - Portugal
ObjecƟves: Ganglionar metastases in soŌ Ɵssue sarcomas are not common, but when present are associated to a 
worse prognosis. CT was used for the detecƟon of ganglionar involvement is soŌ Ɵssue sarcomas, but since 2005 
PET-CT was included as a diagnosƟc tool for this specific diagnosis. The objecƟve of the present study is to compare 
both imaging techniques in a group of paƟents also submiƩed to surgery of ganglionar resecƟon based on the 
presumpƟve diagnosis obtained with the referred imaging studies.
Material and methods: between 2005 and 2011, 52 soŌ Ɵssue sarcoma paƟents were diagnosed also with metastaƟc 
ganglionar involvement, and submiƩed to surgery that included ganglionar resecƟon, and their surgical specimens 
were studied for specific detecƟon of ganglionar metastasis. 31 paƟents were female, 21 were male, with a median 
age of 53,6y. LocaƟons of the primary lesions were axial in 24 paƟents and extremiƟes in 28. The most frequent 
diagnosis was lipossarcoma, synovial cell sarcoma and soŌ Ɵssue Ewing sarcoma. 40 paƟents (76,9%) were submiƩed 
in the same week to both exams, and 12 paƟents have the exams done with an interval superior to 3 weeks, and 
their results were excluded because of the Ɵme frame diﬀerence. A staƟsƟcal analysis was performed using SPSS-19 
version, and a Fisher exact test was use to compare results. 
Results: The Fisher exact test was staƟsƟcally significant when comparing the results of both imaging techniques 
(p<0,010), not staƟsƟcally significant (p<0,472) when comparing the detected presence of ganglionar involvement 
in CT with the respecƟve posiƟvity in the surgical specimens, and staƟsƟcally significant (p<0,006) when comparing 
PET-CT results with the posiƟvity in the surgical specimens. CT specificity was of 40% and sensiƟvity of 75% and 
a posiƟve predicƟve value in 75% and a negaƟve predicƟve value of 40%. PET-CT specificity was of 83,3% with a 
sensiƟvity of 86,7%, and a posiƟve predicƟve value of 92,8% and a negaƟve predicƟve value of 71,4%.
Conclusions: PET-CT has a significant posiƟve predicƟve value, and higher specificity and sensibility  in detecƟon of 
ganglionar metastasis in soŌ Ɵssue sarcomas.
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SCONTRAST AGENT ENHANCED T1 MAPPING OF CHONDROGENIC 
TUMOURS IN THE KNEE AT 3 TESLA: A FEASIBILITY STUDY
Wanke-Jellinek E1, Domayer S1, Apprich S2, Nöbauer I2, Dominkus M1, Windhager R1, Funovics P1, TraƩnig S2
1 Medical University of Vienna - Department of Orthopaedic Surgery - Vienna General Hospital - Austria
2 Medical University of Vienna - Department of Radiology - Vienna General Hospital - Austria
ObjecƟves: As the histological enƟty of a chondroid lesion strongly influences the type of surgical intervenƟon, pre-
operaƟve diagnosƟc procedures aim to clearly disƟnguish between chondroma, low-grade chondrosarcoma and high-
grade chondrosarcoma before therapy is iniƟated. However, benign and malignant chondrogenic tumours concur 
in some clinical and imaging features. In recent literature the need for more precise tools for the comprehensive 
evaluaƟon of chondrosarcomas was postulated. The aim of this feasibility study was to evaluate the applicaƟon of 
quanƟtaƟve MR mapping technology at 3T in the assessment of chondrogenic tumours. We hypothesized that T1 
values of chondroma show a similar behavior to those of normal carƟlage, implicaƟng that the uptake of contrast 
agent is quanƟtaƟvely depictable. Furthermore we presumed that chondrosarcoma showed a diﬀerent paƩern 
concerning the kinemaƟcs of the contrast medium.
Materials and Methods: 6 consecuƟve paƟents (1 male; 5 female; mean age 53 years, range 33 - 71 years) with 
chondroid tumors around the knee were selected to enter the study. All MRI examinaƟons were performed on a 
3.0 Tesla whole body Magnetom TimTrio scanner (Siemens Healthcare, Erlangen, Germany). PaƟents first obtained 
a non-contrast baseline measurement including the morphologic sequences and the T1 mapping sequence. The 
contrast agent was given intravenously in double dose (0.2mmol/kg body weight; Magnevist, Berlex-Schering, 
Berlin, Germany), and the T1 mapping protocol was repeaƟng under maintenance of the posiƟoning and field-of-
view planning at 30, 60 and 90 minutes. A region of interest (ROI) was manually defined on naƟve T1 map images. 
Analysis was performed on 3 consecuƟve slices in which the lesion was depicted at its largest diameter and consisted 
of a global area (surrounding the whole lesion), a central area (represenƟng the central part of the lesion) and a 
circumferenƟal area (global minus central area). Subsequently, the mean signal intensity (in ms) of the ROI was 
measured and evaluated over Ɵme for each paƟent. Central and peripheral T1 values were compared for all Ɵme 
points (before contrast, 30, 60 and 90 minutes).
Results: Histological evaluaƟon of the retrieved specimens revealed 4 chondromas and 2 chondrosarcomas (grade 
2). The mean T1 value for chondromas was 1596ms in the central, and 1728ms in the circumferenƟal areas before 
applicaƟon of contrast agent. At 30, 60 and 90 minutes aŌer applicaƟon the central values were 591ms, 628ms 
and 672ms, and 620ms, 651ms and 719ms in cirumferenƟal areas. There was no significant diﬀerence between the 
central and circumferenƟal areas (p< 0.001).
Before the applicaƟon of contrast agent mean T1 values in chondrosarcomas were 2435ms centrally and 2001ms 
circumferenƟally. AŌer 30, 60 and 90 minutes the values were 2623ms, 2069ms and 1550ms in the central parts, and 
840ms, 735ms and 734ms in the circumferenƟal parts. Consequently there was a diﬀerence in contrast agent uptake 
between chondromas and chondrosarcomas.
Conclusion: Albeit we cannot draw conclusions to contrast agent kinemaƟcs in chondroid tumours in general, an 
addiƟonal diagnosƟc modality arises out of the applicaƟon from validated and well-established T1 algorithms to 
evaluate dignity of chondroid lesions. Further studies and larger case series will be needed in order to opƟmize MR-
algorithm and evaluate clinical applicability.
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TISSUE LESIONS IN SARCOMA CENTER
Olga Zaikova, Ingeborg Taksdal, Sigmund Skjeldal, Ole-Jacob Norum, Simen Sellevold, Joackim Torkildsen, Kirsten Sundby-Hall
Norwegian Radium Hospital, Oslo University Hospital, Norway
ObjecƟves: PaƟents with soŌ Ɵssue sarcomas (STS) should be referred to sarcoma centers without previous biopsy 
or surgery. However, most paƟents with soŌ Ɵssue lesions (lumps and clumps) have benign diagnosis. The challenge 
in organizing a sarcoma service is to idenƟfy STS paƟents without delay and to minimize resources used on paƟents 
who do not need treatment at the sarcoma center. MRI is becoming a widely used diagnosƟc tool in paƟents with 
soŌ Ɵssue lesions. The aim of the present study was to evaluate the role of MRI when selecƟng paƟents with soŌ 
Ɵssue lesions for invesƟgaƟon and treatment in sarcoma center.
Materials and Methods: During 2010, 746 paƟents older than 15y.o. with soŌ Ɵssue lesions in extremiƟes and 
trunk wall were referred to our center. 634 (85%) of the referrals had MRI enclosed. All MRI were re-evaluated 
by dedicated sarcoma radiologists, described and then discussed in a mulƟdisciplinary team. The preliminary 
radiological diagnosis were divided into following categories: (1) subcutaneous lipoma; (2) deep lipoma or low-
grade liposarcoma; (3) not neoplasƟc or benign lesion without need of biopsy;(4) most probably benign lesion, but 
biopsy need for confirmaƟon; (5) sarcoma; (6) other malignancy. The mulƟdisciplinary team worked out a plan for 
further diagnosƟcs and treatment for each paƟent. For the purpose of this study the paƟents´ medical records were 
retrospecƟvely reviewed and preliminary diagnoses suggested by radiologists at referral were compared with the 
final diagnoses. Follow-up Ɵme was one year or longer for all paƟents.
Results: The suggested radiological diagnoses were: (1) subcutaneous lipoma in 144 (23%) paƟents, surgery at local 
hospital was recommended, non of these paƟents had malignant diagnosis aŌer one-year follow-up; (2) deep lipoma 
or low-grade liposarcoma in 149 (24%) paƟents, surgery without biopsy was recommended, 8 paƟents in this group 
had histopathological diagnoses low grade liposarcoma; (3) not neoplasƟc or benign lesion without need of biopsy 
in 70 (11%) paƟents, non of these paƟents have got  diagnosis converted to malignant; (4) most probably benign 
lesion, but biopsy need for confirmaƟon in 185 (29%) paƟents, 7 of these paƟents had sarcoma, 4 paƟents had 
other malignancy, 161 had benign lesion and in 13 the biopsy was not performed; (5) sarcoma in 72 (11% )paƟents, 
of these paƟents  33 had STS while 11 and 28 paƟents had other malignancy and benign lesion respecƟvely ; (6) 
other malignancy in 14 (2%) paƟents, in 12 of these paƟents other malignancy was confirmed by histopathology. 
Consequently, based on MRI the biopsy could be omiƩed in 363 of 746 (48%) referred paƟents.
Conclusions: MRI alone cannot separate between benign and malignant lesions (except lipomas and a subgroup of 
other soŌ Ɵssue lesions of non-neoplasƟc appearance).  However, MRI is a safe method for selecƟng of paƟents who 
do not need to aƩend the sarcoma center in person and in priority of resources at sarcoma center.  
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SIMAGING IN LIPOSARCOMAS: THE ROLE OF CT AND MRI FOR 
HISTOLOGIC DIAGNOSIS. A RETROSPECTIVE STUDY
Boﬀano Michele1, AlberƟni Ugo1, Marone Stefano1, Boux Elena1, Robba Tiziana2, Faleƫ Carlo2, Gino Gian Carlo1, Brach del Prever 
Elena1, Piana Raimondo1
1 Oncologic and ReconstrucƟve Orthopaedics – AO CTO/Maria Adelaide Torino, Italy
2 Imaging Department – AO CTO/Maria Adelaide Torino, Italy
ObjecƟves: Lipomatous tumours are the commonest soŌ Ɵssue lesions. The aim of the study is to evaluate whether 
a correct Imaging study can drive to a ‘histologic diagnosis’ and when a biopsy is sƟll needed.
Materials and Methods: We retrospecƟvely reviewed all the lipomatous tumours treated in the Oncological 
and ReconstrucƟve Orthopaedics Department of the AO CTO/M. Adelaide in Torino (Italy) from January 2003 to 
December 2009. Imaging studies (either MR or CT) underwent an accurate analysis from a blinded radiologist with 
experƟse in musculoskeletal oncology and aŌerwards compared with final histologic reports. The accuracy of the 
sequences obtained, the contrast medium enhancement, the dimensions of the lesion, the percentage of fat Ɵssue, 
the characterisƟcs of septa and margins were considered as parameters. Exclusion criteria were: subcutaneous 
lipoma, lipoma of small dimensions (greater dimension<10cm), incomplete Imaging study.
Results: Sixty-six individuals were included in the study. The histologic diagnosis based on Imaging and compared 
with the pathologic report was correct in 73%. In 4 cases it was not possible to idenƟfy a subtype of liposarcoma, 2 
cases were downstaged from pleomorphic to myxoid, 3 cases were upstaged from pleomorphic to myxoid and from 
myxoid to atypical lipomatous tumour (ALT). The commonest mistake was to mismatch lipoma and ALT (in 8 cases 
out of 9 the lesion was erroneously considered an ALT instead of a lipoma).
Conclusions: The surgical treatment of ALT and lipomas (deep to the fascia, at least 1 dimension>10cm) is the 
‘shelling-out’ of the lesion in both cases. Excluding the cases of mismatch between ALT and lipoma, the mistakes 
were only 13.6%. We suggest that the biopsy should always be performed in low grade and higher grades lesions 
because they can benefit from adjuvant therapies. In this point of view no mistake could have aﬀected the treatment 
and the prognosis. Imaging studies can drive to a ‘histologic diagnosis’ in a high number of cases, further studies are 
necessary to define specific paƩerns of lesion.
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WHY AND WHAT IS THE OUTCOME?
Amit Kotecha, Paul Fenton, L Jeys, A Abudu, S Carter, R Tillman, R Grimer
Royal Orthopaedic Hospital, Birmingham, UK
ObjecƟves: Surgical resecƟon margins are important for the prognosis and outcome in bone sarcomas. The aim of 
the study was to find out the rate, causaƟve factors and outcomes of intralesional margins on bone tumour from a 
large series of primary bone tumour.
Methods: We idenƟfied 3514 bone sarcoma paƟents were reviewed in our unit from 1970 and 2011. There were 
2780 that were newly diagnosed bone sarcomas. The inclusion criteria for this study were; a) Detailed knowledge of 
size of surgical and pathological margins. b) Details of surgical procedures performed available, leaving 1955 paƟents 
in the study group. Demographic details, prognosƟc factors and outcomes were analysed.
Results: Mean age at diagnosis was 29 years (range 1 year to 100 years), with the most common diagnosis was 
osteosarcoma (n=1057), Chondrosarcoma (n=355) and Ewing’s sarcoma (n=263).The most common sites were femur 
(n=882), Ɵbia (n=388), humerus (n=226) and Pelvis (n=222). The mean size of the sarcoma was 10.6 cm. 
The rate of intralesional margins significantly varied by diagnosis with AdamanƟnoma 31%, chondrosarcoma 28%, 
chondrosarcoma 25%, chordoma 19%, de diﬀerenƟal ewings 9%, osteosarcoma 8%, other 15%. It was significantly 
lower in tumour where chemotherapy was used and out of all Intralesional margin of resecƟon 70 % of cases 
were observed in cases with poor tumour necrosis (less than 90% tumor necrosis, p= 0.04). The rate also varied by 
operaƟon type with AmputaƟon 7%, EPR 16%, Excision alone 25%.
There were 343 cases of local recurrence. The frequency of local recurrence as increased with narrower margins 
(Intralesional 35%, Marginal 21%, Wide 12%, wide contaminated 32%, p=0.0001). Of those paƟents who had 
intralesional margins further surgery was undertaken with AmputaƟon 15%, CureƩage 0.4%, EPR 11%, Excision 16%, 
None 58%.  The 5 year survival following wide contaminated margin 32%, intralesional resecƟon was 49%, marginal 
54%, and wide 70%.
Conclusions: Intralesional margins represent a poor independent prognosƟc factor for survival and local recurrence. 
Some tumour types and poor response to chemotherapy also contribute to the rate of intralesional margins. 
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Rob Grimer and Lee Jeys
Aim: Staging of any paƟent with a newly diagnosed cancer is essenƟal. Both the Enneking staging system and the 
TNM are in common use. We wished to idenƟfy which was more helpful in idenƟfying prognosis.
Method: PaƟents with data stored in a prospecƟve database were grouped according to both the Enneking and the 
TNM systems and their outcomes in terms of survival were compared. 
Results:  3838 paƟents had both Enneking and TNM stages of whom 1583 had a bone sarcoma and 2255 a STS. 
For both bone and STS the presence of metastases at diagnosis was the worst prognosƟc factor (HR >3).  For bone 
sarcomas the most important prognosƟc factors were  increasing age (HR 1.013), high grade (HR 2.56), size >8cm 
(HR 1.86), extra compartment spread (2.86) (all p<0.0001) and sex (female HR 0.87). On mulƟvariate analysis 
(excluding those with metastases at diagnosis)  size, age and grade remained  highly significant (p<0.001) whilst 
extracompartmental spread was slightly less so (p=0.0085).  For STS the most important prognosƟc factors were 
increasing age (HR 1.016), high grade (HR 5.0), size >5cm (HR 2.11), extra compartment spread (1.69), depth (HR = 2) 
(all p<0.0001) and extracompartmental spread (p=0.0085). On mulƟvariate analysis (excluding those with metastases 
at diagnosis)  size, age, depth  and grade remained  highly significant (p<0.001) whilst extracompartmental spread 
was slightly less so (p=0.001).
Conclusion: TNM staging proved slightly beƩer and provided a wider range of survival with clear diﬀerences between 
the groups. It should supersede the Enneking stage.
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H THE NURSE ROLE AND COMPETENCIES IN ONCOLOGY CLINICAL 
RESEARCH
E. Marchesi (IsƟtuto Ortopedico Rizzoli, Bologna, Italy)
Clinical trials are essenƟal for the idenƟficaƟon of new therapy especially in oncology.
ScienƟfic rigourousness and integrity are the basis for the compliance of clinical trial regulaƟon and data validaƟon. 
The eﬀecƟve conduct of oncology trials requires involvement of a variety of personnel. Clinical research nurses are 
a key collaboraƟon in the implementa of  clinical research and play an important and strategic role acƟng as link 
between paƟent and the clinical staﬀ.
In this scenario, diﬀerent skills and competencies are needed to fulfill this requirement.
Clinical trial nurse compentencies in oncology include fundamental knowledge and experƟse to manage paƟent 
parƟcipaƟon in a clinical trial, to ensure paƟent data protecƟon and scienƟfic integrity and reliability to regulatory 
mandates, as well as protocol and ethical compliance, clinical related communicaƟon, site coordinaƟon and data 
collecƟng skills.
Although the specific job profile of a Clinical Research Nurse is not implemented in all countries, all nurses dealing 
with oncology trials should make an eﬀord to deveolop specific competencies in Clinical Trial management in order 
to provide a beƩer and more focused service to paƟents and clinical research.
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TSUSER INVOLVEMENT IN THE LONDON SARCOMA SERVICE
Julie Woodford, Macmillan Nurse Consultant, Royal NaƟonal Orthopaedic Hospital, Stanmore. Lin Russell, Nurse Consultant 
Royal Orthopaedic Hospital, Birmingham
Royal Orthopaedic Hospital, Birmingham and the Royal NaƟonal Orthopaedic Hospital, Stanmore  
Contact: Lin Russell, Nurse Consultant Royal Orthopaedic Hospital, Birmingham
There has been increasing evidence within the UK that paƟents with rarer cancers and in parƟcular, those paƟents 
with sarcoma have a worse experience throughout their cancer journey when compared to paƟents with more 
common cancers and oŌen, informaƟon needs are not met. 
This paper will present a project undertaken in collaboraƟon by the UK NaƟonal Commissioned Bone Sarcoma 
Centres.   The project aimed to ensure that all paƟents (and their carers) who are diagnosed with a bone sarcoma 
within the UK will be oﬀered high quality, appropriate and Ɵmely informaƟon to support face to face communicaƟon 
throughout their cancer journey.   
The project has involved undertaking a scoping exercise to complete a baseline review of the available informaƟon 
resources for bone sarcoma. PaƟent and carer workshops have been held across the UK and one-to-one interviews 
have been undertaken to evaluate the current paƟent literature. 
The result is to have a universal informaƟon resource for all UK bone sarcoma paƟents that is current and up-to-
date, that contains appropriate informaƟon that can also be accessed electronically in addiƟon to being provided 
from specialist centres. The use of the PaƟent InformaƟon PrescripƟon tool will also provide a paƟent record of 
informaƟon provision and assist with peer review monitoring. 
This project encompasses other conƟnuing naƟonal iniƟaƟves to improve the paƟent experience from the point of a 
suspected cancer diagnosis, to treatment and throughout survivorship and possible relapse and advanced disease. 
These include embracing user involvement, implemenƟng advanced communicaƟon skills training for professionals 
and undertaking holisƟc needs assessments for paƟents. 
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ROOM IN SACRAL RESECTIONS FOR BONE TUMORS.
Macchia N, Mazza E, Rocchegiani L
OperaƟng Room Service and Orthopedic Oncology Department, IsƟtuto Rizzoli, Bologna, Italy.
IntroducƟon: Primary tumors of the sacrum are rare; most frequent are  giant cell tumor and chordoma. Surgery of 
giant cell tumors is  intralesional excision, chordomas require resecƟon of the sacrum. Sacral resecƟons are complex 
and require careful preparaƟon and conƟnuous assistance from the all team, including anestesiologic and surgical 
team, in the operaƟng room.The aim of our study was to review the experience of the IV Department of Orthopedics 
with sacral resecƟons, trying to analyze the crucial steps for preoperaƟve preparaƟon, intraoperaƟve assistance, 
complicaƟons and results.
Material and Methods: From 1976 to 2010 71 paƟents underwent a sacral resecƟon for chordoma, 42 males and 
29 fenales, with  mean age 54 years. Fortyeight resecƟons were proximal to S3, while 23 distal to S3. Most of the 
proximal  resecƟons had a combined anterior and posterior approach, all the distal had only posterior approach. 
Details of posiƟoning of the paƟents and anestesiologic preparaƟon were analized and oncologic results, surgical 
and anestesiological complicaƟons were reviewed, at a mean follow up of 9.5 years.
PreoperaƟve anestesiologic preparaƟon:  the paƟent preparaƟon starts at the anaestheƟc room and strictly follow 
the anaestheƟcal issues: once the anaestheƟc technique is defined, the vital funcƟons monitoring is carried out, it 
is a non-invasive procedure and shows: ECG, FC, NBP, SPO2, ETCO2 and the posiƟon of intravenous accesses. Most 
importance must be given to IBP (Invasive Blood Pressure) which gives a constant measurement of blood pressure 
and allows the fulfilment of the Blood Gas Analysis. A central venous catheter and a urinary catheter are inserted, 
the body temperature is monitored through a esophageal temperature probe, it prevents risks of hypothermia. In 
the end it is important to recommend the use of the CARDIOQ or VIGILEO monitoring for the visualizaƟon of the 
cardiac funcƟon.
PaƟents posiƟoning: The choice of the operaƟng table is crucial for correct posiƟoning; for the anterior approach 
a supine posiƟon with moderate Trendelemburg is preferable, while the posterior approach requires the prone 
posiƟoning of the paƟent with complete abducƟon of the lower limbs, moderate flexion of the knees, careful 
protecƟon against skin pressure and nerve pressure complicaƟons and monitoring of the distal vascularizaƟon.
IntraoperaƟve assistance: requires experience with the instruments used in the two diﬀerent phases of the procedure, 
including the use of some new devices to minimize bleeding, such as AcquamanƟs or Ultracision, and some new 
threadwire saws for lateral osteotomies of the sacrum. Monitoring of the anestesiologic parameters is conƟnuously 
needed, in view of possible massive bleeding occurring acutely or cardio-vascular intraoperaƟve complicaƟons.
Results: Surgical Ɵme ranged from 3 to 26 hours; blood loss ranged from 2000 to 26000 mls.
Th eintroducƟon of the modified Osaka technique  using threadwire saw dramaƟcally decreased both blood loss and 
surgical Ɵme. IntraoperaƟve complicaƟons occurred in 9 paƟens, including massive bleeding and vascular lesions. 
Early postoperaƟve complicaƟons were 35, most of these wound infecƟons related to the proximity of the bowel 
and the prolonged surgical Ɵme.Actuarial overall survival was 67% at 10 years and local recurrence rate was about 
33% with wide margins.
Conclusions: Favorable outcome can be achieved in paƟents with sacral chordomas with resecƟon of the sacrum 
with wide margins. This type of surgery is complex and requires a team approach with careful pre and intraoperaƟve 
assistance to minimize risks and complicaƟons.
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TSDRINKING RESTRICTIONS FOR PATIENTS WITH OSTEOGENT 
SARCOMA RECIEVING HIGH DOSE METHOTREXATE ΈMTXΉ Έ12 
G/M²Ή
CharloƩ Våde, Sissel Gjengedal, Svein Rian, KjersƟ Stokke.
Oslo University Hospital – The Norwegian Radiumhospital
Oslo, Norway
Background: During 2009 and 2010 the auther has maped rouƟnes for drinking restricƟons at hospitals in Scandinavia 
treaƟng paƟents with Osteogent sarcoma recieving high dose MTX. The results showed that drinking rouƟnes varies 
a lot. With this background we decided to invesƟgate literature to find out if drinking restricƟons is requested for 
this group of paƟents.
Method: SystemaƟc search in literature of rouƟnes for drinking restricƟons to paƟents recieving high dose MTX and 
relaƟon between MTX-values and prognosis. 
Results: Many studies indicates a correlaƟon between MTX plasma values, tumor response and survival. Several 
studies finds a correlaƟon between peak values more than 1000 μmol/L and increased survival. Some studies do not 
find this correlaƟon. 
Three studies finds a correlaƟon between good histological response and 24 hour MTX value. One study correlates 
48 hour MTX value with good histological response.
Several studies concludes that hydraƟon is important for MTX value. If hydraƟon means intravenous fluid or includes 
oral intake are oŌen unknown.
One study finds a correlaƟon between MTX value (three courses) over 1500 μmol/L and poor histological response.
Conclusion: RouƟnes for paƟents recieving high dose MTX varies a lot in Scandinavia. Literature shows that drinking 
resƟcƟons are important for paƟents recieving high dose MTX. We found no evidence that paƟents should drink less 
than 600 ml/24 hour and our recommandaƟons are:
Drinking per os:
1.day 600 ml (1 – 24 hour)
2.day 1000 ml (24 – 48 hour)
3.day 1000 ml (48 – 72 hour)
Delayed secreƟon of MTX : Free drinking
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TS USE OF POLYURETHANE FOAM INSIDE PLASTER CASTS TO 
PREVENT THE ONSET OF HEEL SORES IN THE POPULATION AT 
RISK. A CONTROLLED CLINICAL STUDY 
Rossana Genco1,CrisƟana Forni,1 LoreƩa Loro,1 Morena Tremosini,1 Sandra Mini,1 EleƩra Pignoƫ, 2 OmbreƩa Bigoni,3 Giuseppe 
Guzzo,3 Laura Bellini,3 Carmela Trofa,3 Anna Maria Di Cataldo,3 Marilena Guzzi.3 
1Research Nurses, 2StaƟsƟcian, 3Plaster cast nurses
Aim: The aim of this study was to test the eﬀecƟveness of polyurethane foam in contact with the heel inside a plaster 
cast to decrease the rate of pressure sores in the populaƟon at most risk.
Background: The rate of pressure sores caused by the plaster cast is reported to be 14-15% in the paediatric 
populaƟon, 33.3% in paƟents having undergone chemotherapy for bone tumours, and 43% in orthopaedic paƟents 
who already have sore skin when the cast is applied (grade 1 lesion) to the heel.
Materials and methods: From November 2007 to January 2009, all consecuƟve subjects requiring lower limb casts 
having undergone chemotherapy and/or presenƟng heel soreness received polyurethane foam in contact with the 
skin of the heel before applying the cast. The results were compared with those of paƟents with the same risk factors 
but were not administered the foam and were enrolled from May 2005 to August 2006.
Results: All together 156 paƟents were enrolled, 85 in the control group and 71 in the experimental group. In the 
experimental group 2 of the 56 paƟents (3.6%) paƟents with sore skin developed a pressure sore compared with 21 
out of 49 (42.9%) of the control group without polyurethane foam (P<0.0005). In the experimental group 1 of the 24 
paƟents (4.2%) paƟents undergoing chemotherapy developed a pressure sore compared with 18 out of 54 (33.3%) 
of the control group (P= 0.005). 
Conclusions: Placing polyurethane foam in contact with the skin of the heel inside a plaster cast prevents the 
formaƟon of pressure sores.
Importance for clinical pracƟce: This study provides evidence that using polyurethane foam to prevent sores even 
inside plaster casts in populaƟons at most risk is a simple and cost eﬀecƟve strategy, and  decreases the discomfort, 
pain and risks in these paƟents. 
Key words: plaster casts, pressure sores, heel, polyurethane foam.
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TSCOHORT STUDY OF PERIPHERAL CATHETER RELATED 
COMPLICATIONS AND IDENTIFICATION OF PREDICTIVE 
FACTORS IN A POPULATION OF ONCOLOGYͳORTHOPEDIC 
PATIENTS 
Fabio D’Alessandro RN, IsƟtuto Ortopedico Rizzoli, Bologna Italy
IntroducƟon: Peripheral venous catheters (PVC) may cause complicaƟons, specifically local.
Their management varies across health care workers and wards, and guidelines recommendaƟons are oŌen weak 
and based on experts’ opinion. 
Aim: To measure the incidence of PVCs phlebiƟs, occlusions, accidental removal and infiltraƟons and their predicƟve 
factors in an orthopaedic and oncology-orthopaedic  populaƟon. 
Methods: From may 4 2009 to 30, in an orthopedic hospital, data on paƟents to whom a PVC was inserted were 
collected: paƟent’s and PVC characterisƟcs, management and securing strategies, unƟl one of the following outcomes: 
phlebiƟs, occlusion, accidental removal, infiltraƟon or end of treatment. 
Results: Overall, 873 paƟents were recruited and 139 PVCs. The following complicaƟons occurred: phlebiƟs 10.9%; 
occlusions 16.8%; accidental removals 5.8%, local infiltraƟons 14.4%; 648 PVCs (46.5%) were removed without 
complicaƟons. The risk for all complicaƟons (mulƟvariate analysis) increased with  age and for the other complicaƟons 
also with the administraƟon of blood transfusions thorough PVC, irritant drugs and use >3 Ɵmes/day for phlebiƟs; 
small gauge, not using PVC and surgical site infecƟons for occlusions; posiƟoning the PVC in the hand and fixing the 
PVC with the Chevron method for accidental removals; and female sex, transfusions and thromboembolic therapy 
for infiltraƟons. 
Conclusions: The incidence of phlebiƟs is high compared to the gold standard of 5%. Knowing the incidence of 
main complicaƟons is a requirement for any improvement strategy and may favor the abandonment of useless or 
dangerous pracƟces.
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TS EFFECTIVENESS OF THE TRANSPARENT STERILE DRESSING TO 
FIX THE PERIPHERAL VENOUS CATHETER ΈPVCΉ ON THE RATE 
OF PHLEBITIS COMPARED TO THE STANDARD DRESSING. A 
RANDOMIZED CONTROLLED TRIAL
Laura Rocheggiani RN, IsƟtuto Ortopedico Rizzoli, italy 
IntroducƟon: There are studies that indicate the types of dressing that can contribute to the rate of phlebiƟs, 
infiltraƟon and accidental removal  but the results are contrasƟng and, in some cases, samples are too small to be 
meaningful.
Aim: To check whether the rate of the phlebiƟs due to peripheral venous catheter (PVC) changes by using a 
transparent sterile dressing made of polyurethane film to cover the inserƟon point of the PVC (experimental dressing) 
compared to a sƟcking plaster already in use in current pracƟce but which does not have sterile properƟes (standard 
dressing). 
Design Randomized controlled trial
ParƟcipants. 1061 PVCs (703 paƟents) both adults and children at a research orthopedic hospital in the north of Italy. 
540 PVCs allocated to receive the experimental dressing and 521 the standard dressing.
Results: 96 PVCs were excluded because they caused phlebiƟs, 48 (9.6%) in the experimental group and 48 (10.1%) 
in the control group. The relaƟve risk was 0.96 (CI. 0.697 to 1.335). Accidental removal of the PVC was greater with 
the sterile dressing (9.6% vs 6.3%) but the catheter removal rate at the end of treatment without complicaƟons was 
greater in the standard dressing group (48.9% vs 54.9% P= 0.0503). It was necessary to replace 85 PVCs because the 
dressing detached: 50 with sterile dressing (9.2%) and 35 with standard dressing (6.7%). The cheapest transparent 
sterile dressing, used in the present study, costs 32 cents each, whereas the standard one costs 9 cents.
Conclusions: Using sƟcking plasters without sterile properƟes (standard dressing) is not influenƟal on the rate of 
phlebiƟs and ensures an good fix of the PVC to the skin compared with the transparent sterile dressing made of 
polyurethane film (experimental dressing).
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TSNURSING PREOPERATIVE VISIT FOR HOSPITALIZED PATIENT 
COMPLIANCE: VERIFICATION OF THE EFFECTIVENESS. A PILOT 
STUDY
Giovanna Gabusi 
IsƟtuto Ortopedico Rizzoli Bologna Italy
Is widely known that in common imagery the unexpected or planned hospitalizaƟon in ICU (Intensive Care Unit), 
generates in the user and in his family a consistence emoƟon impact. 
Feelings of anxiety, fear and stress are common manifested expression of the paƟent in ICU. These condiƟons, 
frequently, induce weak compliance with the assistenƟal terapeuƟc project. 
An assistance driven to response to the needs of single people, in order to be eﬀecƟve and eﬃcient, cannot, or 
beƩer, must not neglect these aspects. 
The complexity of inpaƟent care in the ICU is not always evaluated on the basis of the stability/instability of the clinic, 
oŌen, other variables can have a significant and substanƟal weight, such as emoƟonal instability, relaƟonal aspects 
or even ethical, religious and cultural factors.
The instrument used for tesƟng the eﬀecƟveness of the Nursing preoperaƟve Visit for hospitalized paƟent compliance 
is the interview.
The aŌernoon before the operaƟon, a nurse of Intensive Care Unit, aŌer Ɵmes agreed by telephone and the opƟmal 
Ɵme to start the interview, will visit the unit operaƟonal of the paƟent.
The purpose of this study is to demonstrate that the interview is a useful tool to facilitate the path to intensive care, 
alleviate the trauma of hospitalizaƟon, enable eﬀecƟve care planning and measuring adherence to therapeuƟc plan 
of care.
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TS LOW LEVEL LASER THERAPY IN THE TREATMENT OF ORAL 
MUCOSITIS ON A PAEDIATRIC HAEMATO ͳ ONCOLOGY AND 
STEM CELL TRANSPLANTATION UNIT.  
V. Van de Velde 1,  J. De Porre 1, Y.Benoit 1 ,C. Dhooge 1, R. Cauwels ²
1: Dept. of Paediatric Haemato-oncology, Ghent University Hospital, Ghent, Belgium
²: Dept. of Paediatric Densitry & Special Care, PaeCaMed-research, Dental school, Ghent University, Ghent, Belgium
OBJECTIVE: Despite the implementaƟon of evidence based mouthcare guidelines, oral mucosiƟs (OM) remains a 
frequently encountered and painful complicaƟon of chemotherapy.
There is an increasing evidence that low level laser irradiaƟon can reduce the severity and duraƟon of mucosiƟs.
The objecƟve of this study was to assess the eﬀecƟveness, quanƟtaƟvely and qualitaƟvely, of low level laser therapy 
(LLLT) for the treatment of chemotherapy induced OM in pediatric paƟents.
METHOD: When mucosiƟs occurred, paƟents were treated using AlGaAs diode laser every two days unƟl complete 
healing of the mucosiƟs. PaƟents were evaluated for pain severity by the visual analogue scale or the faces pain scale 
before and immediately aŌer LLLT. OM grade (WHO-criteria) as well as funcƟonal impairment were evaluated. Both 
nurses and denƟsts were trained to assess OM and to administer LLLT in an idenƟcal way. Data is analyzed using SPSS 
version 17. 
RESULTS: From  May 2009 Ɵll December 2011, 122 children, mostly with diagnosis of leukemia, lymphoma, 
osteosarcoma or Ewing sarcoma, treated with chemotherapy and suﬀering from chemotherapy-induced mucosiƟs, 
were treated with LLLT.  Out of these 122 paƟents, 23 had undergone a hematopoieƟc stem cell transplantaƟon. Age 
ranged from 1 to17 years.
During 300 mucosiƟs episodes, 846 treatments with LLLT were done and 3124 lesions were treated.  
DistribuƟon of mucosiƟs grade was : grade 0 (n=59), grade 1 (n=1181), grade 2 (n=1228), grade 3 (n=438), grade 4 
(n=98) and unknown (n= 120).
Cheeks (n=828), tongue (n=640), lips (n=521), pallatum (n=259) and gums (n=233) were the most frequent sites 
aﬀected.
A mean of 4 to 5 treatments were necessary to heal mucosiƟs and to obtain overall pain relief.
For 1301 lesions there was an immediate pain relief and in 692 cases the pain remains the same. In 799 cases pain 
scores were missing due to noncooperaƟon or young age of the paƟents or invalid scores. 
CONCLUSION: These results demonstrate that LLLT, in addiƟon to standard oral care can reduce pain. Four low level 
laser treatments per mucosiƟs episode seem to be a realisƟc approach.  Further research and controlled randomized 
trials are necessary to confirm the eﬃcacy of LLLT and to develop more general guidelines.
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CAROL HUGHES
Royal Orthopaedic Hospital FoundaƟon Trust, Department :Oncology, Bristol Rd South, Northfield, Birmingham
The incidence of phantom limb pain (PLP) is variously esƟmated at about 70%.  It is even higher when pre-amputaƟon 
pain is present, so represents a significant problem in orthopaedic oncology.  ConvenƟonal treatment for neuropathic 
pain is with the gamma-aminobutyric acid analogue (eg GabapenƟn).  Mirror Box Therapy can be helpful in some 
cases.  It is thought to work by providing arƟficial visual feedback which “tricks” the brain into thinking it is possible 
to “move” the phantom limb, and to unclench it from potenƟally painful posiƟons.   The author will present the 
raƟonale for uƟlising the power of the imaginaƟon to create helpful feedback and illustrate with a case history. 
Could this be a useful adjuncƟve therapy to manage PLP?  
122
84
13
th
 S
ym
po
si
um
 E
M
SO
S 
N
ur
se
 G
ro
up
PA
IN
 IN
 S
AR
CO
M
A 
PA
TI
EN
TS THE PROBLEM OF PAIN IN ORTHOPEDIC INTERVENTIONAL 
RADIOLOGY DURING CTͳGUIDED NEEDLE BIOPSY OF BONE 
LoreƩa Loro RN,1 CrisƟana Forni RN,1 Gelsomina Volpa RN,1; EleƩra Pignoƫ PhD,2 Eugenio Rimondi MD3
1Research Nurse, 2StaƟsƟcian, 3Doctor of Medicine
Aim: To record the levels of pain perceived before, during and immediately aŌer the procedure of CT-guided needle 
biopsy of bone, with respect to pain therapy, the harvesƟng site and the paƟent’s characterisƟcs.
Background: There has been a rapid increase in intervenƟonal radiology procedures in recent years but there are sƟll 
few studies about pain control during these operaƟons. 
Design: ProspecƟve Cohort Study
Material and Methods: From January 2008 to July 2010  all paƟents admiƩed to intervenƟonal radiology for CT-
guided needle biopsy of bone were asked to give their consent to the collecƟon of data with regards to the extent 
of pain before, during and immediately aŌer this diagnosƟc procedure. The level of pain perceived was recorded by 
the Numeric RaƟng Scale.
Results: 282 paƟents were assessed. The mean level of pain before the procedure was 2.4 (SD 2.94). During the 
procedure the mean pain level was 6.5 (SD 3.19). The level of pain perceived 15 minutes aŌer the procedure was 3 
(SD 2.99). Comparing the pain perceived before and aŌer the procedure, there was a mean diﬀerence of 1.27 (SD 
3.20) on the scale, which is staƟsƟcally significant (p<0.0005). The change in the level of pain before and during the 
procedure was not sensiƟve to the diﬀerent sites where the CT-guided needle was placed, or the paƟent’s gender or 
even the type of anestheƟc used (local or systemic), but was significantly correlated with age (P< 0.0005).
Conclusion: The problem of pain in intervenƟonal radiology is an important one. It is urgent to establish pain therapy/
sedaƟon protocols in paƟents undergoing CT-guided needle biopsy of bone regardless of the biopsy site.
Importance for clinical pracƟce: All paƟents undergoing CT-guided needle biopsy of bone must receive eﬀecƟve 
prevenƟve pain therapy for the test regardless of the anatomical site of the procedure.
Key words: Radiology, IntervenƟonal; procedure pain; Risk Factors
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TSLIMB AMPUTATION AS A MEANS OF “TAKING LIFE BACK”.
Lev Shula R.N.B.A., coordinator nurse, 
The Nathional Unit of Orthopedic Oncology
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Background: Osteosarcoma of soŌ Ɵssues is a malignant disease that is more common among children and teenagers 
than adults.
These tumors are customarily treated with neoadjuvant chemotherapy followed by excisional surgery (amputaƟon) 
that involves replacement of the damaged bone with an arƟficial implant. On the other hand, limb-sparing procedures 
are associated with numerous side eﬀects of chemotherapy and radiaƟon. This becomes within Ɵme, to chronic .
Pediatric osteosarcoma paƟents are likely to develop chronic osteomyeliƟs requiring frequent hospitalizaƟon and 
mulƟple surgical procedures, which might cause physical and emoƟonal disability. As a result, these paƟents do not 
experience the normaƟve development processes of healthy teenagers and young adults.
A 27-year-old woman who had been diagnosed as having osteosarcoma of the hip at the age of 10 years, had been 
hospitalized 20 Ɵmes over the ensuing 17 years for surgical purposes or prolonged intravenous anƟbioƟc treatment. 
She also underwent chemotherapy 10 Ɵmes during the same period of Ɵme.
AŌer many years of refusing surgery in order to improve her quality of life, she now decided to undergo the 
procedure following many talks with the aƩending physician and the nurse coordinator. The planned surgery was a 
hip disarƟculaƟon amputaƟon.
The surgical results were excellent, and she was opƟmisƟc and free of pain almost immediately aŌerwards. She 
is currently in a rehabilitaƟon facility where she is undergoing treatment at an unexpectedly rapid pace She is a 
candidate for a place in an independent apartment community.
Limb amputaƟon is generally considered as being an aggressive medical intervenƟon that causes severe disability. In 
this case, the amputaƟon of her limb enabled a young woman to shed a lifestyle and self-image of disability to one 
of posiƟvity and strong moƟvaƟon to live life to the fullest. 
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TS ASSESSMENT OF EARLY AMBULATION IN MUSCULOSKELETAL 
ONCOLOGY  IN PATIENTS WITH LOWER LIMB AMPUTATION 
AND PREDICTIVE FACTORS.
Barbieri M, Boneƫ E, Bortoloƫ R, Merli L, Rossi M.
IntroducƟon: The survival rate of paƟents with bone cancer treated with amputaƟon has been 
increasing over the years, determining the demand of greater aƩenƟon to the needs of autonomy 
and quality of life of the paƟents. An early rehabilitaƟon approach is necessary to reach an opƟmal 
motor performances overƟme. The aim of this retrospecƟve study is to idenƟfy the number of days 
required to aƩain autonomy for early ambulaƟon in paƟents operated for lower limb amputaƟon. 
 
Materials and methods: Data collecƟon at the IsƟtuto Ortopedico Rizzoli (IOR) was eﬀected using Rizzoli Computer 
System (SIR) and the records from StruƩura Complessa di Medicina Fisica e RiabilitaƟva (SCMFR). Subjects were selected 
between the hospitalized at the IVth Clinic who received amputaƟon of foot, leg, thigh or abdominopelvic from January 
2001 to July 2011. Beginning of the physiotherapic treatment and aƩaining of early ambulaƟon Ɵmes have been recorded. 
 
Results: A group of 318 subjects was idenƟfied. PaƟents were operated for lower limb amputaƟon of the 
musculoskeletal system for oncologic diseases and for 280 of them rehabilitaƟon was required 173 men (62%)e 107 
women (38%), average age 54 years-old.
Mean Ɵmes for clinical admiƩance from surgery corresponds to 3,8 days (average ± 3), while mean Ɵmes for 
ambulaƟon corresponds to 6,1 days (average ± 4). Comparing the second five-year period (2006-2011) with the first 
one (2001-2005), is it possible to observe a reducƟon of the mean Ɵme of ambulaƟon that changes from 6,5 days 
(average 5) to 5,7 days (average 4). At the same Ɵme a reducƟon regarding the beginning of the rehabilitaƟon was 
recorded, from 4,5 days (average 4) to 3,4 days (average 3).
Conclusions: In the post operaƟve phase, the rehabilitaƟon process of paƟents who received amputaƟon should 
focus on improving their level of independence, with special regard upon the autonomy of the paƟent movements. 
An early beginning of rehabilitaƟon has proved to enhance an anƟcipaƟon of the autonomy of movements of the 
paƟents.
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TSTHE EFFECT OF INPATIENT PHYSIOTHERAPY ON FUNCTION 
FOLLOWING TUMOUR RESECTION AND RECONSTRUCTION
Mrs K Grant, Mr P Cool, Miss G Cribb
The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS FoundaƟon Trust
IntroducƟon: This is a prospecƟve study analysing the eﬀect of inpaƟent physiotherapy for paƟents who had tumour 
resecƟon and surgical reconstrucƟon.
Methods: Eleven subsequent paƟents who had a surgical reconstrucƟon following tumour resecƟon were admiƩed 
for inpaƟent physiotherapy 6 – 24 weeks aŌer surgery (average 10 weeks). 
The average age was 46 years (21 – 72 years). Nine paƟents had lower limb surgery and two paƟents had surgery to 
the upper limb. Four paƟents had metastaƟc bone disease and seven had a primary bone tumour. Ten paƟents had 
surgical reconstrucƟon with an endoprostheƟc replacement. The remaining paƟent had soŌ Ɵssue reconstrucƟon 
following excision of a malignant primary shoulder tumour.  All paƟents had a TESS score on admission and 
discharge.
Results: Before physiotherapy admission, the average TESS score was 47% (14 – 73 %). Following inpaƟent 
physiotherapy the TESS score was 68% (20 – 90%). Only one paƟent failed to have a significant improvement in 
funcƟon. The average increase in score was 21% (0 - 49%). StaƟsƟcal analysis using a Mann-Whitney-Wilcoxon test 
confirmed a significant diﬀerence at p=0.2%.
Discussion: We strongly recommend inpaƟent physiotherapy following tumour surgery with surgical 
reconstrucƟon.
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TS QUALITY OF LIFE AND FUNCTIONAL ABILITY IN CHILDREN AND 
YOUNG ADULTS AFTER MALIGNANT BONE CANCER SURGERY 
OF THE LEG.
WP Bekkering, TPM. Vliet Vlieland, HM Koopman, GR Schaap, A Beishuizen , H.W. Bart Schreuder, Paul C. JuƩe, RGHH Nelissen, 
AHM Taminiau.
Leiden University Medical Centre, Academic Medical Centre University of Amsterdam, Erasmus MC University Medical Centre - 
Sophia Children’s Hospital, RoƩerdam, Radboud University Nijmegen Medical Centre, University Medical Center Groningen, The 
Netherlands.
BACKGROUND: A great majority of osteosarcoma and Ewing-sarcoma occurs in young people under the age of 
20 years However, the average age at evaluaƟon in most studies is 20 years or older and include mainly paƟents 
several years aŌer their diagnosis and surgical treatment. This approach fails to address the specific issues that aﬀect 
children and young people following limb ablaƟon or salvage surgery and liƩle is known about the impact of surgery 
over Ɵme or in the period immediately aŌer the intervenƟon. 
Therefore, aim of the present study was to evaluate paƟents’ quality of life (QoL) and funcƟonal ability; prospecƟvely 
during a 2-year postoperaƟve period and cross-secƟonal within 5 years aŌer the surgery for lower-extremity bone 
cancer.
METHODS: The prospecƟve study and a cross-secƟonal study were conducted in five university medical centres in 
the Netherlands. QoL was measured with the TNO-AZL Children’s or Adult’s Quality of Life QuesƟonnaires (TACQOL 
and TAAQOL), the Short Form-36 (SF-36) and Bone tumour (Bt)-DUX; funcƟonal ability with the Toronto Extremity 
Salvage Scale (TESS), the 6-minutes walk test (6MWT) and four funcƟonal performance tests.
RESULTS: Forty-four paƟents with an average age of 14.9 (SD 4.8) years were included into the prospecƟve study. 
PaƟents showed significant improvement on the physical dimension of QoL and funcƟonal ability. These improvements 
were especially seen in the first 12 months aŌer surgery. 
Eighty-one paƟents with a mean age of 16.9 yrs (SD 4.2) were included into the cross-secƟonal study. In 
comparison with healthy controls, paƟents had significantly poorer QoL 
Apart from significantly beƩer scores for funcƟonal ability tests in the limb-salvage group, nearly no significant 
diﬀerences were seen for any of the outcome measures between limb ablaƟon and salvage surgery and between 
male and female paƟents.
CONCLUSIONS: In the first year aŌer bone tumour surgery, QoL and funcƟonal ability improvements are most evident. 
In comparison with healthy peers, paƟents report significantly poorer QoL. Diﬀerences at QoL and funcƟonal ability 
with respect to the type of surgical intervenƟon were small.
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TSFOLLOWͳUP OF BONE TUMOURS: WHAT’S THE POINT?  
Veldman P.I., Schreuder H.W.B., Geest van der I.C.M.
Department of Orthopedic Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands.
IntroducƟon: The incidence of malignant primary bone tumours in the Netherlands is about 150 per year. The most 
common malignant bone tumours are osteosarcoma (35%), chondrosarcoma (30%) and Ewing´s sarcoma (16%). 
AŌer iniƟal treatment paƟents are evaluated for many years in a protocolized follow-up program. The purpose of this 
follow-up program is to detect and treat local recurrence and metastasis. ExisƟng guidelines for follow-up of paƟents 
aŌer iniƟal treatment of malignant bone tumours are mostly based on expert opinions. 
ObjecƟves /  aim of the study: invesƟgate when and how a local recurrence or metastasis has been detected in 
paƟents aŌer iniƟal treatment of osteosarcoma, Ewing´s sarcoma or chondrosarcoma. QuesƟons are: 
What is the Ɵme elapsed between the end of the iniƟal treatment and the emergence of the local recurrence and/or 
metastasis? Is it detected by new complaints of the paƟent or did it reveal during the standard follow-up program? 
With the results of de study a more evidence based follow-up program may be proposed.
Materials and Method: To answer these quesƟons a quanƟtaƟve research has been implemented through 
retrospecƟve data analysis by using a digital database, containing data of paƟents treated for osteosarcoma, Ewing´s 
sarcoma or chondrosarcoma in the Radboud University Medical Centre, supplemented with research from the 
medical file. 
Results and Conclusions: As research takes place up unƟl April 2012, results and conclusions cannot be shown in this 
abstract but will be presented at the 13th symposium of the EMSOS Nurses Group.
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A APPLYING OF HYPERTHERMIA IN LIMB SALVAGE SURGERY 
FOR BONE TUMOR OF EXTREMITIES
Qing-Yu fan, Ma Boan, Zhou Yong, Zhang Minhua, Shen Wanan, Li Zhao
PresenƟng Author: Qing-Yu Fan
Department of Orthopedic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi’an, China, 710038 - E-mail: 
bonetm@fmmu.edu.cn
The limb salvage process sƟll has many unsolved problems, which remain severely limiƟng the long-term funcƟon 
of the preserved limbs. The asepƟc loosening at a specified future date is a main concern. The inherent problems 
are related to the materials used. The anchorage of metallic parts to bone and to soŌ Ɵssues is especially a poorly 
solved problem. For young paƟents, the implantaƟon of arƟficial material will have to stand wear and tear for 
decades.
The advent of the ablaƟon in situ has gained significant interest due to the appeal of durability of the implants.
In medicine, ablaƟon is defined as the removal of a part of biological Ɵssue, or killing cancerous cells by any 
kind of physical, chemical or other method (such as microwave, liquid nitrogen, x-ray radiaƟon, and irreversible 
electroporaƟon) . 
The microwave devitalized bone was proved to have a very good potenƟal of osteogenesis. Instead of en-bloc 
resecƟon of tumor- bearing bone, only dissect it from surrounding normal Ɵssues, then devitalize the bone 
segment by microwave induced hyperthermia in situ through the antenna array which are properly distributed in 
the tumor bulk, and finally  re-strengthen the dead bone through autograŌ, or allograŌ plus prophylacƟc fixaƟon 
of plate and screws, making its mechanical property strong enough to support the weight bearing. In this way, the 
structures of the adjacent natural joint were salvaged well. The funcƟon was greatly improved.
Between July 1992 to March 2009, 719 paƟents with malignant bone tumors of the extremiƟes were treated using 
hyperthermia at the authors’ insƟtuƟon as follows: 
629 cases with high grade malignant sarcoma of extremiƟes (mainly is osteosarcoma, second and third diagnosis 
are MFH, Ewing’s sarcoma), 62 cases with low grade sarcomas (chondrosarcoma 42cases, adamanƟnoblastoma 16 
cases), and 28cases with metastaƟc lesion. DistribuƟon among the diﬀerent ages, sexs, and places are not special 
compared with the reports in the literature. Before surgery, three courses of chemotherapy were given.
Results: The beyond 3 years survival rate was 59.1% for high-grade malignancy. Unlike carcinoma, sarcoma 
commonly suﬀered the young persons, and the metastasis appeared in lung at the period of mean 18 months aŌer 
operaƟon. (13) The life tables of event-free survival have stable plateaus beyond 3-4 years, and relapses aŌer 3 
years are infrequent. The majority of paƟents surviving 3 years without evidence of recurrence are probably cured. 
(14) The beyond 3 years survival rate was 88.7% for low-grade malignancy. For the metastaƟc lesions, the aim of 
the surgery is to relieve symptoms. 
ComplicaƟons: Local recurrence rate is 8.5%, Fracture rate is 5%. It was worse in the early stage of the study. 
AutograŌ of the fibula (even vascularized) and wearing of parƟal-weight bearing brace diminished the fracture 
rate. No one had amputaƟon due to fracture.
Deep infecƟon rate is 1.8%.
In majority of the paƟents alive, cosmeƟc and useful limbs were preserved. Once healing is occurred, it is durable 
without any further concern of the loosening. Average funcƟonal score is about 90%. Even though it is not every 
case that has been uniformly saƟsfactory, suﬃcient success has been achieved. 
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Typical cases:
Osteosarcoma in distal femur1. 
             1.1                          1.2                                        1.3               
              1.4                             1.5                                    1.6                                               1 .7    
               1.8                                           1.9                       1.10
          1.11                               1.12   
    
Fig 1: Typical procedure for osteosarcoma at distal femur.
     1.1-1.2: Image data shows an osteosarcoma of distal femur
     1.3: Dissect the tumor-bearing bone from surrounding normal Ɵssues with a safe margin.
     1.4-1.5: Microwave generator and antenna
     1.6: Introduce electromagneƟc energy into tumor bone 
     1.7: Remove or cureƩage the soŌen tumor mass
     1.8: Fibular bone allograŌ
     1.9: The mixture material of bone chips and bone cement
     1.20: Restore the normal shape of the femur and give a prophylacƟc fixaƟon
     1.11: X-ray film aŌer surgery
     1.12: FuncƟon is perfect aŌer 11 years
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A BORDERLINE CARTILAGINOUS TUMORS: BIOLOGIC POTENTIAL 
AND PROGNOSTIC FACTORS.
Irena Boulytcheva M.D.Ph.D., Allexandr Bondarev M.D.,  professor Nikolay Kushlinskiy., professor Anatolyi Machson.
N.N. Blokhin Cancer Research Centre, Hospital #62 -  Moscow - Russia.
The aggressive behavior of borderline carƟlaginous tumors and chondrosarcoma varies from slowly growing, 
nonmetatastasizing tumors to highly aggressive sarcomas. The modern classificaƟon idenƟfies low grade 
chondrosarcomas and chondromas. Is there anything in between? Is it safe to introduce intralesional cureƩage for 
borderline lesions without compromising paƟent outcome?   What is the best diagnosƟc aproach  and weight of 
morphology and immunohistochemistry in making a decision?
Methods: We retrospecƟvely reviewed 350 paƟents with chondrosarcomas of diﬀerent grades  and 50 paƟents 
with chondromas from 2000 through 2011. The mean age of the paƟents was 38 years (range, 24-72 years) with 
a  predilecƟon for men (198/152) in chondrosarcomas and women (31/19) in chondromas.  The minimum follow-
up was 0,6 year. All paƟents underwent modern surgical treatrment in N.N. Blokhin Cancer Research Centre and 
Hospital # 62, Moscow, Russia with incorporaƟon of CT and MRI for details before and aŌer the operaƟon. To perform 
immunohistochemical study  (MMP-1,-2,-9, Bcl-2, COX-2, Bax, estrogen receptors) we chose 65 cases of grade 1 
chondrosarcomas and 32 borderline chondromas with aggressive radiographic, or morphologic behavior. 
Results: The overall disease-free survival rates were similar between so called “atypical chondromas” and grade 1 
chondrosarcomas. Local recurrence and metastases were rare in long bones and  more common in axial skeleton. The 
prognosƟc factors, that determine the outcome were related to anatomic site, tumor size, adequacy of treatment. 
MulƟdisciplinary approach in diagnoses is mandatory.  Overexpression of Bax, MMP-1 and MMP-9 ≥40% is a marker 
for altered cell phenotype and more aggressive behavior of the tumor. 
Conclusions: Local recurrence and potenƟal metastasis are low in the group of agressive (atypical ) chondromas 
and low grade (grade 1) chondrosarcomas. To beƩer classify these lesions mulƟdisciplinary approach is nessesary. 
Radiografic criteria, morphology and immunohistochemistry helps to tailor less aggressive surgical procedure without 
compromising the results of the treatment.
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ACHONDROSARCOMA OF BONE IN CHILDREN AND 
ADOLESCENTS
D. Andreou1, A. Frings2, P.U. Tunn1, A. Leithner2
1 Department of Orthopedic Oncology, Helios Klinikum Berlin-Buch, Sarcoma Center Berlin-Brandenburg, Berlin, Germany; 2 
Department of Orthopedics and Orthopedic Surgery, Medical University of Graz, Graz, Austria
ObjecƟves: Chondrosarcoma of bone rarely aﬀects children and adolescents and there are only a few data about its 
course in this subgroup of paƟents in the literature. The objecƟve of this study was to examine the clinical course and 
outcome of chondrosarcoma of bone in children and adolescents.
Materials and methods: 13 children and adolescents, 9 female and 4 male, with a chondrosarcoma of the pelvis 
(n=4), the humerus (n=3), the femur (n=2), the phalanges of the hand (n=2), the Ɵbia (n=1) and the thoracic wall 
(n=1) underwent operaƟve treatment at our insƟtuƟons between 1978 and 2011. Mean paƟent age at diagnosis 
amounted to 15.2 years (range, 11 – 18 years), mean follow-up was 10.3 years (range, 0.33 – 21.25 years). 
Results: 8 paƟents presented with a grade 1, 4 paƟents with a grade 2 and 1 paƟent with a grade 3 tumor. 4 paƟents 
underwent an intralesional and 9 paƟents a wide resecƟon, according to the Enneking classificaƟon. No paƟents 
received chemotherapy; adjuvant radiotherapy was performed in 1 paƟent. 5 paƟents developed a local recurrence 
aŌer a mean of 2.6 years (range, 0.6 – 6.5 years), following an intralesional resecƟon in 3 cases and a wide resecƟon in 
the remaining 2 paƟents. All 5 local recurrences were treated operaƟvely. 1 paƟent with a grade 3 tumor developed 
lung metastases 4 years aŌer iniƟal diagnosis, which were also treated operaƟvely. No paƟent has died of disease in 
follow-up.
Conclusions: Chondrosarcoma of bone in children and adolescents appears to have an excellent prognosis. Surgical 
resecƟon without adjuvant treatment appears to be suﬃcient both for primary and recurrent tumors. 
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A INTERMEDIATE GRADE OSTEOSARCOMA AND LOW GRADE 
CHONDROSARCOMA ARISING IN THE SAME PATIENT: AN 
EXTRAORDINARY CASE IN MULTIPLE EXOSTOSIS
Zoccali C.1, Prencipe U.1, Marolda G.1, Favale L.1, Covello R2.,  Ferraresi V.3, Biagini R.1
1Division of Orthopedics, 2Division of Pathology,  3Division of Medical Oncology A, 
Regina Elena NaƟonal Cancer InsƟtute
Rome - ITALY
Background: Hereditary mulƟple exostosis is an autosomal dominant skeletal disorder characterized by the 
development of mulƟple osteochondromas that can result in orthopedic deformiƟes. In the major of cases a posiƟve 
familiar history is present but several cases are ex novo. The most serious complicaƟon of HME is the transformaƟon 
of an osteochondroma in chondrosarcoma that is of peripheral type in 95% of the cases. The frequency of malignant 
transformaƟon is reported to vary from 1% to 25%, being non consensus in literature. Osteosarcoma presents 
a prevalence of about 2-3 cases/million populaƟon/year. No case of associaƟon between osteosarcoma and 
chondrosarcoma are found in literature.
Case report: A 50 years old Caucasian lady, aﬀected by hereditary mulƟple exostosis, showed up at our department 
because of the presence of a mulƟnodular recurrence of a low chondrosarcoma in the posterior aspect of the sacrum 
arisen two years aŌer a intralesional resecƟon. A sacral resecƟon was scheduled but an apparently not significant 
uptake of 2 cm in diameter was found at preoperaƟve CT-PET into the vertebral body of D12. The CT guided biopsy 
revealed a diagnosis of a intermediate grade osteosarcoma. Taking into account the concomitant presence of the 
two tumors, it was decided to first treat the major aggressive OS; neoadjuvant chemotherapy was excluded basing 
on the intermediate grade of the OS and the necessity to avoid a long delay before the treatment of the mulƟnodular 
recurrence of the sacral chondrosarcoma. An en bloc vertebrectomy was performed. Histopathology on the vertebral 
specimen evidenced a low grade OS so any other systemic therapy was considered not useful. Sacral resecƟon was 
done three months later when the paƟent was suﬃciently healthy to undergo to a second important operaƟon. A 
mulƟnodular recurrence of a low grade chondrosarcoma was found in the sacrum.  At one year of follow-up she is 
alive and without evidence of disease.   
Conclusion: The clinical case we presented is apparently the first reported in literature of a paƟent simultaneously 
aﬀected by a chondrosarcoma and an Osteosarcoma. When a hereditary syndrome is present every suspected finding 
has to be invesƟgated to exclude further concomitant tumors.
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AEXTRASKELETAL MIXOID CHONDROSARCOMA OF THE LIMBS: 
THE EXPERIENCE OF DEPARTMENT ORTHOPEDIC ONCOLOGY 
OF FLORENCE
Beltrami G, Frenos F, Franchi A*, ScoccianƟ G,  Matera D, Caﬀ G, Campanacci DA,Capanna R 
Orthopaedic Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, CTO Largo Palagi 1, 50139 Firenze, Italy
* Department of Human Pathology and Oncology, University of Florence Medical School, Florence, Italy.
BACKGROUND: Extraskeletal myxoid chondrosarcoma is a rare soŌ Ɵssue neoplasm,  high grade and aﬀecƟng young 
adults. The dial of our paper is to analyze the biological characterisƟcs and clinical behavior of our cases.
METHODS: From the overall data base of 1210 soŌ Ɵssue sarcoma cases treated at Department of Orthopedic 
Oncology of Florence we analyzed all the extraskeletal myxoid chondrosarcoma cases. They were 15 paƟents (10 
males and five females), treated from 2001 to 2011, with an average follow-up  of 47 months (range 6-153). The 
mean age at diagnosis was 62 years (range 37-83), lower limb was involved in 11 cases (73%, 5 thighes and 5 legs, 1 
pelvic girdle), upper limb in four cases (one girdle and three distal of the elbow). According to WHO, any histological 
grading system was applied, but all the cases were rated as “atypical” high grade. 
All the paƟents have been reviewed, considering histological, clinical, oncological and funcƟonal results.
RESULTS: All paƟents but one were treated by limb sparing surgery; one was primarily amputated due to local extra-
compartmental extension. Surgical margins were rated as wide in 10 paƟents, marginal in three, radical in two. In 
three cases adjuvant radiaƟon therapy was associated, while chemotherapy was employed only in one case. Three 
main complicaƟons were found: one deep venous thrombosis and two complicaƟon related to radiaƟontherapy 
(one scar slough with secondary infecƟon and one late bone fracture). At follow up, no secondary amputaƟon were 
performed and no paƟent developed local recurrence or metastases.
CONCLUSIONS: In our experience, extraskeletal mixoid chondrosarcomas are locally aggressive tumors and 
conservaƟve surgery with wide margins is recommended, while adjuvant radiaƟontherapy has to be considered 
if marginal excision is proved.  In our cases with average four years follow up, no systemic progression have been 
observed, but a longer follow up is necessary because late pulmonary metastasis have been described.
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A DETECTION OF HEY1ͳNCOA2 FUSION BY FLUORESCENCE 
IN SITU HYBRIDIZATION IN FORMALINͳFIXED, PARAFFINͳ
EMBEDDED TISSUES AS A POSSIBLE DEFINING DIAGNOSTIC 
TOOL IN MESENCHYMAL CHONDROSARCOMA
Robert Nakayama  1 robert@a2.keio.jp - Jiro Ogino  3 - Michiro Susa 1 - Itsuo Watanabe 1 - Keisuke Horiuchi  1 - Ukei Anazawa  
4 - Yoshiaki Toyama  1 - Hideo Morioka  1 - Makio Mukai  2 - Tadashi Hasegawa  3
1Department of Orthopaedic Surgery and 2Department of Pathology, School of Medicine, Keio University, Tokyo, Japan
3Department of Surgical Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan
4 Department of Orthopaedic Surgery, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan
ObjecƟves: Mesenchymal chondrosarcoma is an extremely rare subtype of chondrosarcoma. It typically shows a 
mixture of Ewing-like small round cell area and islands of chondroid matrix, however, histological diagnosis of this 
tumor is oŌen diﬃcult since the proporƟon of the two components vary in each case. Recently a tumor specific 
fusion gene, HEY1-NCOA2, has been idenƟfied by Wang et al. (Genes Chromosomes Cancer. 2012), and this finding 
should improve the pathological diagnosis and promote understanding of mechanisms underlying pathogenesis of 
this tumor. In order to validate the eﬃcacy of the Fluorescence In Situ HybridizaƟon (FISH) detecƟng HEY1-NCOA2, 
eight cases of mesenchymal chondrosarcomas were analyzed.
Materials and Methods: A query of our database yielded eight cases histologically diagnosed as mesenchymal 
chondrosarcoma. Formalin-fixed paraﬃn-embedded (FFPE) secƟons were pretreated and dual-color FISH was 
performed using two probes detecƟng both HEY1 and NCOA2 .
Results: There were four males and four females, and the age at diagnosis ranged from 14 to 42years old (average 
26.9). Four paƟents developed their disease in the bone, ((axis (n=2), rib (n=1), fibula (n=1)), while four paƟents 
had them in the soŌ Ɵssue (lower limb (n=2), sacral meninx (n=1), abdominal wall (n=1)). Fusion signals were 
detected in all six tumors in which the FISH signals were posiƟve. There were two cases negaƟve of FISH signal, one 
due to decalcificaƟon of the tumor, and the other one due to inadequate volume of tumor in the specimen.
Conclusions: We were able to validate the eﬃcacy of the molecular diagnosis by FISH detecƟng HEY1-NCOA2 
in diagnosis of mesenchymal chondrosarcoma. In addiƟon to the results by Wang et al, the sensiƟvity of FISH 
detecƟng HEY1-NCOA2 is 100% in tumors with a definiƟve diagnosis and adequate specimen showing posiƟve FISH 
signals. This tool should be useful especially when the tumor has liƩle chondroid matrix presenƟng as a pure round 
cell sarcoma. Since mesenchymal chondrosarcoma usually present as a hard calcified mass, tumor sampling for 
FISH before decalcificaƟon should be considered when this rare sarcoma is suspected.
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ACHEST WALL CHONDROSARCOMA: DIAGNOSIS AND SURGICAL 
STRATEGY
M. Rocca, M. Salone, °P. Ruggieri, °A. Angelini, A.  Briccoli
General Surgery and °Orthopaedic Oncology – Rizzoli Orthopaedic Insitute – Bologna, Italy
ObjecƟves: To present our experience in the diagnosis and surgical treatment of chest wall chondrosarcoma (CS) 
which, although a rare enƟty, is the most common malignant tumor of the chest wall. 
Materials and Methods: Over the last 20 years, 34 paƟents with CS of the chest wall were surgically treated at the 
Rizzoli Orthopaedic InsƟtute in Bologna. There were 25 men and 9 women ranging in age from 23 to 74 years. The 
median follow-up period was 44 months. The tumor was located in ribs only in 20 paƟents, in the sternum and ribs 
in 9, in sternum only in 4, and in the ribs and spine in one. The most frequent histological variety was central with 27 
observaƟons. 28 out of 34 were high grade CS, 5 of them had been previously submiƩed to surgery in other hospital 
and developed a local recurrence. CT scan with intravenous contrast is the gold standard study for diagnosis. An 
ultrasound study of the tumor was performed to analyze the superficial surgical margins and to idenƟfy the presence 
of micronodules in recurred cases.
Results: ReconstrucƟon using cadaveric fascia lata or Marlex mesh was combined with mouldable metal plates to 
prevent flail chest in 19 paƟents, resecƟon alone was performed in 8 paƟents, and a muscular flap was used in 7 
paƟents. Five-year overall and disease-free survivals were 83% and 67%, respecƟvely. One operaƟve death occurred, 
another required temporary tracheostomy, one paƟent developed a fistula during post-operaƟve chemotherapy 
(the only case of dediﬀerenƟated CS). Survival was staƟsƟcally higher in paƟents primarily treated at our insƟtuƟon 
than paƟents treated for recurrence. In 18 paƟents treated with wide excision and reconstrucƟon of the chest wall, 
the postoperaƟve respiratory funcƟon test result (at 6 months) was 10% less than the preoperaƟve one.
Conclusions: Surgical treatment involving wide exeresis is mandatory. In wide excisions, the reconstrucƟon method 
with fascia lata or marlex associated to metal plates is a reliable and reproducible surgical technique.
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A RESULTS OF THE TREATMENT OF PEDIATRIC 
CHONDROSARCOMA
D.B. Khestanov, A.Z. Dzampaev, N.M. Ivanova, M.D. Aliev
InsƟtute Pediatric Oncology and Hematology Russian Cancer Research Center, Moscow
Purpose: To invesƟgate prognosƟc factors, biological behavior of tumors and individual features of pediatric paƟents 
with chondrosarcoma (CS). To improve survival of the children with CS by using of PHT and surgery.
Materials and methods: In our study were included 77 children. Median age was 12 years (range, 3 to 17) with CS 
treated in IPOH RCRC from February 1981 to February 2010. Boys were 38 (49,4%), girls — 39 (50,6%). Male-female 
raƟo was 1:1. Localized disease was in 62 (80,5%) pts, metastaƟc — 15 (19,5%). Lung metastasis were observed in 
13 (16,9%) cases, combined metastasis — 2 (2,6%). We used combined approach in the treatment of CS grade (G) 
II and III: aggressive PHT with  doxorubicin, CDDP, ifosfamide, etoposide, HD MTX and surgery. PaƟents with CS GI 
treated with surgery only.
Results: Use of aggressive PHT improve limb salvage rate from 30% to 48,4%, advance 5-year overall survival from 
63,4% to 75,1%, 5-year DFS from 50,6% to 74,4%, improve radiological response rate (PR+CR)  from 57,2% to 87,5%. 
Two-years DFS in pts treated with surgery was 80,5% compared with 23,8% in pts without surgery (p<0,05). Five-year 
DFS in pts with histological response GIV was 100%, GIII— 88,4%, GII  — 52,5%, GI— 48% (p<0,05).
Conclusion: Use of aggressive PHT in children with CS GIII and GII improve 5-y DFS to 74,4%. Main prognosƟc factors 
were duraƟon of anamnesis, primary site, grade of tumor, radiological and histological response.
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ASYNOVIAL CHONDROSARCOMA ARISING IN SYNOVIAL 
CHONDROMATOSIS: A TERTIARY CENTRE EXPERIENCE. 
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Ms S. Chaudhry1 MBChB MRCS. SpR Trauma and Orthopaedics
Mr M. Boﬀano1. Senior Tumour Fellow 
Mr L. Jeys FRCS (Tr+Orth)1. Consultant Orthopaedic Surgeon
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Mr R. Grimer FRCS (Tr+Orth)1. Consultant Orthopaedic Surgeon
1 Royal Orthopaedic Hospital, Birmingham, Birmingham, UK.
Lead author: Mr. ScoƩ Evans.
Email: drscoƩevans@yahoo.co.uk
Royal Orthopaedic Hospital, Birmingham
Aim: IdenƟfy paƟents treated at our centre with synovial chondromatosis that subsequently developed into a 
synovial chondrosarcoma.
Methods: RetrospecƟve review of a prospecƟvely collected database. PaƟent demographics recorded along with 
site of primary synovial chondromatosis. From this, details of those paƟents who subsequently developed synovial 
chondrosarcoma were collected. 
Results: 77 paƟents idenƟfied. 45 male, 32 female. Mean age at presentaƟon with synovial chondromatosis 49.3 
years. All referred to our unit with pain, swelling or loss of funcƟon to the aﬀected area; 30 knees, 21 hips, 6 
shoulders, 5 fingers, 5 feet, 5 elbows, 2 hands, 2 wrists, 1 ankle.  Of the 77 paƟents, 4 (5.2%) went on to develop 
synovial chondrosarcoma; 3 around the hip, 1 around the knee. The median Ɵme from original diagnosis of synovial 
chondromatosis to malignant transformaƟon was 11 years (range 2-41). The single knee paƟent was managed with 
an above knee amputaƟon, but developed lung metastases 32 months aŌer the amputaƟon and died 18 months later. 
Of the 3 hip paƟents, 1 was managed with a hind-quarter amputaƟon and at last follow-up, 12 years post-surgery, was 
doing well with no local recurrence or lung metastases. Unfortunately, the 2 other paƟents who developed synovial 
chondrosarcoma around the hip had large, aggressive tumours. Both had debulking and total hip arthroplasty prior 
to developing lung metastases within 18 months of these palliaƟve procedures.
Discussion: Chondrosarcoma arising in synovial chondromatosis is extremely rare with most paƟents having had a 
prolonged history of synovial chondromatosis. In both condiƟons (synovial chondromatosis and chondrosarcoma 
arising in synovial chondromatosis) the clinical presentaƟon is similar, namely pain, swelling, loss of range of moƟon, 
and mulƟple previous surgical procedures. The diagnosis should be based on the histologic findings. Reports suggest 
a 5% prevalence of malignant transformaƟon in synovial chondromatosis and our study would confirm this.  
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A DELAYED DIAGNOSIS OF CLEAR CELL CHONDROSARCOMA 
AFTER TOTAL HIP REPLACEMENT ͳ A RARE ENTITY 
ENCOUNTERED IN COMMON SURGERY
LISKA Franz
University Hospital Rechts der Isar Munich
Clear cell chondrosarcoma (CCCS) is a rare subtype of chondrosarcoma. Besides mesenchymal, myxoid and 
dediﬀerenƟated types of chondrosarcoma the CCCS can be found in less than 10 percent of the heterogenous 
group of chondrosarcomas in addiƟon to central, peripheral and periosteal/juxtacorƟcal chondrosarcomas. Clear 
cell chondrosarcoma accounts for approximately 2% of all chondrosarcoma and is a rare low-grade variant of this 
enƟty. Nevertheless, marginal or incomplete excisions are associated with a 70 percent or higher recurrence rate. 
Metastases may develop and the overall mortality rate is up to 15 percent.
We report the case of a young female paƟent who received a total hip replacement due to pain in her leŌ hip 
joint that was diagnosed as degeneraƟve arthriƟs. A CCCS in the femoral head had not been detected at that Ɵme. 
Subsequently a periprostheƟc relapse of CCCS close to the former femoral osteotomy occurred. Although a biopsy 
of the periprostheƟc tumor had been taken for histologic analysis, the recurrence of CCCS remained misdiagnosed 
for a long Ɵme due to the rare histopathologic morphology. Finally revision surgery with wide tumor resecƟon 
and reconstrucƟon using a modular megaimplant (proximal femur replacement) had to be performed. We report 
the case of a periprostheƟc CCCS of the proximal femur. Relevant facts of this rare enƟty regarding pathogenesis, 
treatment and diﬀerenƟal diagnoses will be discussed.
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ADIAGNOSTIC UTILITY OF MOLECULAR INVESTIGATION IN 
EXTRASKELETAL MYXOID CHONDROSARCOMA: THE RIZZOLI 
EXPERIENCE.
Benini S.*, Cocchi S.*, Gamberi G.*, Magagnoli G. §, Picci P. §, Ruggieri P.°, Gambaroƫ M.*, Alberghini M.*
* Department of Pathology, IsƟtuto Ortopedico Rizzoli, Bologna, Italy § Department of Experimental Oncology, IsƟtuto Ortopedico 
Rizzoli, Bologna, Italy, °Department of Orthopaedic Oncology, IsƟtuto Ortopedico Rizzoli, Bologna, Italy.
INTRODUCTION: Extraskeletal myxoid chondrosarcoma (EMC) is a malignant neoplasm histologically characterized 
by an abundant myxoid matrix and malignant chondroblast-like cells arranged in cords or clusters with eosinophilic 
cytoplasm. It is a rare mesenchymal tumor occurring in soŌ Ɵssues and rarely in the bone accounƟng for less than 
3% of soŌ Ɵssue sarcomas. Most cases of EMC harbor the reciprocal chromosomal translocaƟon t(9;22)(q22;q12) 
and the resultant fused gene EWSR1-NR4A3. A second, less common, cytogeneƟc subgroup of EMC is characterized 
by the presence of a t(9;17)(q22;q11) involving the fusion between gene NR4A3 and TAF2N. Other less frequent 
fusion variants of the NR4A3 gene, TCF12-NR4A3 and TFG-NR4A3 idenƟfied in a single case each, are associated with 
t(9;15)(q22;q21) and t(9;3)(q22;q12) respecƟvely.
METHODS: The samples from paƟents with EMC were examined for the presence of EWSR1-NR4A3, NR4A3-TAF2N 
and TCF12-NR4A3 transcripts by using Reverse Transcriptase-Polymerase Chain ReacƟon (RT-PCR) on frozen and 
paraﬃn embedded Ɵssues. Fluorescence in Situ HybridizaƟon (FISH) was performed to analyze the EWSR1 gene 
rearrangement on paraﬃn embedded Ɵssue in all that samples negaƟve for the fusion transcripts detected. 
RESULTS: A total of thirty-eight paƟents with a diagnosis of EMC were characterized by molecular analyses. 
Chromosomal aberraƟon was found in thirty-two samples (84% of all samples), five (13%) were negaƟve and one was 
considered not evaluable. The fusion transcripts were detected in twenty-five samples by RT-PCR of which nineteen 
resulted posiƟve for EWSR1-NR4A3 and seven for NR4A3-TAF2N. The presence of EWSR1 gene rearrangement was 
detected by FISH in seven samples resulƟng negaƟve for all fusion transcripts detected by RT-PCR.
CONCLUSIONS: The combinaƟon of RT-PCR and FISH on frozen and paraﬃn embedded Ɵssue is a sensiƟve and 
specific method for molecular detecƟon of recurrent translocaƟons and is an important ancillary method to establish 
the diagnosis of EMC.
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A PERIPHERAL CHONDROSARCOMA ΈPCSΉ:DIAGNOSIS AND 
TREAMENT OF 91 CONSECUTIVE CASES. 
The experience of the G.Pini Orthopaedic InsƟtute in Milan from 1957 to 2010
*S.Mapelli, P.A.Daolio, F.Lazzaro, R.Zorzi, P.Zacconi, S.Bastoni,                         
^E.Armiraglio, “E.Ferri, °F.Giardina, °M.S.Bartoli.                                                                    
*Orthopaedic Oncology Department; ^ Pathology Department;  “Radiology Department.
Gaetano Pini Orthopaedic InsƟtute – Milan – Italy.                                                      
°Course of SpecializaƟon in Orthopaedics - University of Milan.
ObjecƟve: PCS is a rare malignant neoplasm that require a very long follow-up for prognosƟc evaluaƟon. For this 
reason there are few good and reliable studies in the literature. The purpose of the Authors is to give their contribuƟon 
to these studies revising the complete consecuƟve series of the 91 PCS that occurred in the Orthopaedic Oncology 
Unit Ɵll now. Materials and methods. The pathological, radiological and surgical files of the paƟents that were 
registered in the Unit for a PCS from 1957 to 1984  were already  revised by a team including a surgeon, a radiologist 
and a pathologist; the data were  presented in the naƟonal congress of the S.I.O.T. in 1988. The files of the successive 
paƟents, from 1985 to 2010, are now revised and analyzed, for a total number of 91 cases.                                           
Results: The second, third and fourth decades of life are the most aﬀected; the raƟo male:female is 2:1; the most 
frequent site of localizaƟon is the pelvis followed by the proximal femur and proximal humerus but also proximal 
Ɵbia, spine, scapula and ribs are aﬀected. In 80% of the cases there is an evident  mass while pain is present in 2/3 of 
the paƟents and ¼ of them have a funcƟonal impairment. The mean duraƟon of symptoms is 4 years. The preexisƟng 
exostosis was evident radiologically in the 70% of the cases, macroscopically in the 36% and histologically in the 17%. 
All the paƟents had a surgical treatment; 9 had an amputaƟon, 39 a simple resecƟon without reconstrucƟon and 
43 a resecƟon-reconstrucƟon with bone graŌs (37) or prosthesis (6). The oncological results prove 54 paƟents NED 
and CDF, 11 NED2, 2 AWD, 18 DOD and 6 LOST. The recurrences occurred in 1/3 of the paƟents for a total number 
of 50 operaƟons because some paƟent had 2 or more recurrences. Progression in malignancy was found in 10 cases 
(30%). The analysis of the complicaƟons show 5 deep infecƟons, 4 mechanical failures, 3 neurological palsy and 2 
vascular damages.                                                              
Conclusions: PCS is a rare tumor generally secondary to a preexisƟng exostosis; the malignant transformaƟon of 
an exostosis is rare (about 1%); PCS is generally a low grade tumor and grade I PCS does not metastaƟze without 
upgrade in malignancy; wide resecƟon is a standard indicaƟon for all cases but it can be very diﬃcult to perform in 
wide lesions; the incidence of the recurrences is related to correct surgical margins more than  histological grading, 
marginal margins has an high risk of local recurrence; recurrence can be very late and very long follow-up is required; 
the complete resecƟon of the recurrences can allow very long free survival; recurrences in the trunk can become 
inoperable and cause death; metastases are rare. 
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AVEGF EXPRESSION IN BENIGN AND MALIGNANT 
CARTILAGINOUS TUMORS
Spinelli MS1, Graci C1, Perisano C1, Fadda G2, Rossi ED2, Valenzi E1, Di Giacomo G1, Ricciardella ML1, Falcone G3, Rosa MA4, 
Maccauro G1.
1Department of Orthopaedics and Traumatology, University Hospital AgosƟno Gemelli, Catholic University of the Sacred Heart 
School of Medicine, Rome, Italy
2Division of Anatomic Pathology and Histology, University Hospital AgosƟno Gemelli, Catholic University of the Sacred Heart 
School of Medicine, Rome, Italy
3Villa Valeria Clinic, Rome, Italy
4Department of Orthopaeics and Traumatology, Messina, Italy
ObjecƟve: In contrast to normal carƟlage, which is avascular, angiogenesis is characterisƟc of carƟlage tumors. 
The goal of this study was to evaluate the diagnosƟc relevance of the expression of growth factors in carƟlaginous 
tumors and to invesƟgate on the possible correlaƟon with grade, local recurrence, metastaƟc potenƟal, and 
survival. 
Material and Methods: Expression of VEGF, PDGF, FGF1, TFGbeta2, TNFalpha, Ki-67, and p53 was analyzed in 29 cases 
of benign and malignant carƟlaginous tumors, including 8 cases of hand tumors,  using radiographic, histological and 
immunohistochemical studies. 
Results: Immunohistochemistry revealed a high correlaƟon between grading and VEGF-posiƟve staining (P=0.001). 
In addiƟon, a correlaƟon with local recurrence was found in cases with a posiƟve expression of Ki-67 (P=0.035), 
TGFbeta (P=0.007), PDGF (P=0.007), and p53 (P=0.0455), with a Ɵme-related associaƟon. These data suggest a 
progressive modificaƟon in the biologic behavior of malignant carƟlaginous tumors. 
Conclusion: VEGF could be used as a marker in the preoperaƟve surgical assessment of chondrosarcoma. New 
therapeuƟc strategies could be considered for VEGF-posiƟve cases. The evidence in caƟlagineus tumor of the hand 
shows a specific model of tumour progression in which VEGF expression should be the first stadium of the tumour 
aggressiveness, and the following PDGF, TGF 2 expression should be accompanied with a morphological outline 
worsening. It is important to remember that the cellular polymorphism typical of the carƟlaginous tumours does not 
allow the applicaƟon of an only oncogenesis model.
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A DYNAMIC CONTRASTͳENHANCED MAGNETIC RESONANCE 
IMAGING ΈDCE MRIΉ IN CHONDRAL BONE TUMOURS 
Tiziana Robba, Maurizio StraƩa, Valeria ClemenƟ*, Alessandra Gallo, Guido Regis, Raimondo Piana**, Gian Carlo Gino**, 
Alessandra Linari***, Carlo Faleƫ
* GE Health Care Medical System
** Chirurgia Oncologica e Ricostruƫva, AO C.T.O-M.Adelaide di Torino
*** Servizio di Anatomia Patologica, AO OIRM-S.Anna di TorinoObjecƟve: to invesƟgate the role of Dynamic Contrast-Enhanced 
MagneƟc Resonance Imaging (DCE MRI) in bone tumours with chondral matrix.
Materials  and Methods: in the period December 2010-September 2011 we performed DCE MRI in 14 paƟents with 
a chondral tumour of the bone. The contrast-media (gadobenate dimeglumine 0.5 M) was injected with flow 2.5 ml/
ml by automaƟc injector, during mulƟphase acquisiƟon of Liver AcquisiƟon with Volume AcquisiƟon (LAVA) or SPoiled 
Gradient Recall (SPGR) sequences (temporal resoluƟon: 5’’) depending on the coil used. Signal-intensity curves were 
obtained puƫng a Region Of Interest (ROI) on the largest areas of contrast-enhancement of each tumour. The start 
of tumoral enhancement was measured and classified into early (within 10’’ aŌer arterial enhancement), delayed ( 
between 10’’-2 ‘) and late (aŌer 2’). The results were correlated with the pathological data. 
Results: in two enchondroma the start of tumoral enhancement  was late, while in one osteochondroma was delayed. 
It  was late in a case of uncertain diagnosis (enchondroma/chondrosarcoma G1). In case of G1/G2 chondral tumours 
the start of tumoral enhancement was early in three paƟents  and delayed in one case. In the remaining cases of G2 
and G3 tumours the STE was always early. 
Conclusions: the biggest limitaƟon of our study is the small number of paƟents, especially of enchondroma. When 
the start of tumoral enhancement is late, a chondrosarcoma should be excluded, whilst an early start of tumoral 
enhancement  should be indicaƟve for malignancy. However in our study the start of tumoral enhancement seems 
to be not useful  to predict the grading of the chondrosarcoma.
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ATHE OUTCOME OF INTRALESIONAL CURETTAGE FOR LOWͳ
GRADE CHONDROSARCOMA OF LONG BONES
Y. Khan, S.A. Hanna, P. Whiƫngham-Jones , M.D. Sewell , R.C. Pollock , J.A. Skinner, A. Saifuddin, A. Flanagan, S.R. Cannon , T.W.R. 
Briggs 
Keywords: Chondrosarcoma; Intralesional cureƩage; Polymethylmethacrylate cement e PMMA; Musculoskeletal Tumour Society 
Score e MSTS; Local recurrence
IntroducƟon: Chondrosarcoma is the second most commonly occurring primary malignant bone tumour, with a 
peak incidence between the fourth and seventh decades of life. These tumors were first described as a separate 
enƟty by Phemister in 1930. In adults, the pelvis, ribs, shoulder girdle, femur, and humerus are mainly aﬀected, while 
in children, facial bones and the knee region are the main sites. Authors link the prognosis to tumor size, anatomical 
locaƟon, and most importantly, histological grade. In this paper, we examine the oncological and funcƟonal outcomes 
of intralesional cureƩage and cementaƟon as a treatment strategy low-grade chondrosarcoma of long bones.
Background: Diﬀerent treatment strategies for low-grade chondrosarcomas are reported in the literature with 
variable outcomes. The aim of this study was to assess the oncological and funcƟonal outcomes associated with 
intralesional cureƩage and cementaƟon of the lesion as a treatment strategy.
PaƟents and methods: We performed a retrospecƟve review of 39 consecuƟve paƟents with intramedullary low-
grade chondrosarcoma of long bones treated by intralesional cureƩage and cementaƟon at our insƟtuƟon between 
1999 and 2005.
Results: There were 10 males and 29 females with a mean age of 55.5 years and a mean follow-up of 5.1 years Local 
recurrence occurred in two paƟents (5%) within the first two years following index surgery. Both were treated by re-
cureƩage and cementaƟon of the resultant defects. A second local recurrence developed a year later in one of these 
two paƟents, for which a further cureƩage followed by local liquid nitrogen treatment was performed. Overall, there 
were no cases of post-operaƟve complicaƟons or metastases. The paƟents were assessed using the Musculoskeletal 
Tumour Society scoring system (MSTS) to determine limb funcƟon. The average score achieved was 94%.
Conclusion: Intralesional cureƩage is an eﬀecƟve treatment strategy for low-grade intramedullary chondrosarcoma 
of long bones, with excellent oncological and funcƟonal results. Careful case selecƟon with stringent clinical and 
radiographic follow-up is recommended.
References:
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oncology. Oxford University Press; 1995. p. 1977e8.
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5. Leerapun T, Hugate RR, Inwards C, et al. Surgical management of convenƟonal grade I chondrosarcoma of long 
bones. Clin Orthop Relat Res 2007;463:166–72.
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years of age. Am J Surg Pathol 1987 Dec;11(12):930–42.
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A TREATMENT RESULTS  OF MESENCHYMAL 
CHONDROSARCOMA
Diedkov A.G., Klymnyuk G.I.
NaƟonal Cancer InsƟtute, Kiev, Ukraine
IntroducƟon: Mesenchymal chondrosarcoma (MC) diﬀers from classical chondrosarcoma uncommon, aggressive 
clinical course , a penchant for late recurrence and lung metastasis and occurs usually in young paƟents. Histologically 
characterized by occurrence to changeable amount of diﬀerenƟated carƟlaginous matrix mixed with undiﬀerenƟated 
small round cells. Although at the present moment there is no standart treatment of MC, most surgeons use a radical 
tumor resecƟon. EﬀecƟve of adjuvant chemotherapy or radiaƟon therapy as an adjunct to surgical treatment at the 
present Ɵme is also not defined.
 Purpose: Show the treatment results in comparison with the MC complex treatment and only surgical treatment.
Materials and Methods:Treatment result of 29 paƟents with MC of bones. The tumor localised in the pelvis - 4, in 
the long bones of the lower limb - 22, in the humerus - 3 paƟent treated at the insƟtute from 1999 to 2010. Mean 
age - 31.1 years. Depending on the method of treatment, paƟents were divided into 2 groups: a group with complex 
treatment (treatment protocol ISG/SSG I and SSG XIV for osteosarcomas) to 11 paƟents and a group with only 
surgery treatment, 18 paƟents. Medium follow-up term was 54.2 and 68.4 months. Tumor response to neoadjuvant 
treatment was esƟmated decrease in tumor size and degree of tumor necrosis according to Huvos. All pelvic 
localizaƟon used in the neoadjuvant mode intraarterial cisplaƟn. Survival was studied by Kaplan-Maier.
Results: Surgical treatment in the form of general radical resecƟon was performed in 27 paƟents, including 
the reconstrucƟon of the defect endoprosthesis - 25, resecƟon without reconstrucƟon of the pelvis (internal 
hemipelvectomia type-1) -2. Two paƟents with pelvic localizaƟon refused surgical treatment, they completed 
radiaƟon therapy at a dose of 55 Gy. Of the 11 paƟents with complex treatment of clinical tumor response to 
neoadjuvant therapy was observed in all paƟents in the form of reduced pain and stabilizaƟon of tumor size. Medical 
pathomorphosis was in 2 paƟents (18.2%) as 3-rd degree to Huvos (greater than 90% necrosis), the rest - 1st and 
2-nd degree. ReducƟon of the tumor were observed in any of the paƟents with complex treatment. In this group of 
paƟents with local recurrence was detected in 1 (9.1%) paƟents and in 3 (27.3%) – lungs metastases. In the group 
with surgical treatment of local recurrence was in 1 (5.5%) and metastasis in 8 (44.4%) paƟents. Total deaths 7 
(24.13%) paƟents: 3 - in the group with complex treatment, 4 - with surgery treatment, on the progression of the 
disease. Relapse-free survival value in the group with complex treatment was higher - 56.8% compared with surgical 
treatment of -39,2% (p> 0,05), though, no significant diﬀerences.
Conclusions: The chemotherapy in the treatment of MC in combinaƟon with surgery can achieve beƩer results of 
survival, but the main treatment is surgical. Further progress in the treatment of MC is development of criteria for 
individualizing treatment strategy, depending on prognosƟc factors.
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ACHONDROSARCOMA OF THE HAND & FEET
Lesenský J., Matějovský, Z., Kofránek I.
Orthopedic Clinic 1st Medical School, Charles University, Teaching Hospital Bulovka, Prague, Czech Republic 
IntroducƟon/objecƟve: Even though solitary enchondromas (ECH) a rather frequent bone hamartomas, that 
account for the most benign tumors of the hand, their malignant counterpart in these locaƟons is a surprisingly rare 
occurrence. They account only for approximately 2% of all condrosarcomas (CHSA) of the body. Diﬀerences between 
central and acral (hand and feet) CHSA are well known. However the the biological behaviour of the laƩer is sƟll 
somewhat unclear and its metastaƟc potenƟal is oŌen doubted. Hence is oŌen treated with intralaesional cureƩage 
with liƩle or no concern for distant metastases. We therefore concluded a comprehensive retrospecƟve study with 
emphasis on posƟng a solid recommendaƟons on how to treat these condiƟons.
Materials & methods: We reviewed charts of all paƟents operated in our clinic form 1965 Ɵll today and found total 
no. of 42 paƟents treated for acral CHSa. We primarily excluded all paƟents with incomplete charts and history 
less than 2years so that a suﬃcient follow-up can be part of a standard. Tumors originated in distal forearm or 
lower leg with extension to periphery were not included as well as CHSa arising from soŌ Ɵssue. Also paƟents with 
mesenchymal, dediﬀerenƟated and clear cell chondrosarcomas were not included as they have a diﬀerent biological 
behaviour. We included only paƟents with diagnosis of classical GI-GIII CHSa according to classificaƟon system by 
Evans.
Results: For 31 paƟents all demographic data, clinical history, histology, surgery protocols and outpaƟent clinic visits 
were available. Of these paƟents 22 had tumor in hand and 8 bellow  the ankle. Most common locaƟon was the 
3rd and 5th ray of the hand. Men and female were equally aﬀected. PaƟents were elderly in general – mean age at 
the Ɵme of diagnosis was 50,1 years (6y to 87y) with peak incidence in 7th decade. The most common presenƟng 
symptom was a bulge (n=21), that was enlarging for a relaƟvely long Ɵme (40,7 months in average) before the 
paƟents seeked medical aƩenƟon. One paƟent had a history of a slowly growing deformity for over 25 years (case 
17). Pain was an inconsistent symptom that occurred only in 5 paƟents with the bulge and 2 paƟents had pain only. 
Few cases manifested as a pathological fracture (n=5). Tumors in the foot were more likely to be HG (75% were 
either GII or GIII), than those in the hand. Wast majority of CHSa in our series were secondary. The most frequent 
underlying condiƟon was enchondroma (ECH): n=20 (in 5 cases associated with Olliere disease and in 1 case with 
Maﬀucci sy.), followed by osteochondroma (OCH): n=3, and synovial chondromatosis (SCH) in 1 case.  Only 5 paƟents 
suﬀered from primary chondrosarcoma. The treatment was always surgical. Four paƟents (13,8%) developed distant 
pulmonary metastases that were fatal for two of them, one paƟent died of unrelated causes and one paƟent is alive 
with disease.
The staƟsƟcal analysis suggested that only 2 groups of CHSA should be disƟnguished in these seƫngs : low grade (LG) 
group for GI CHSA and high grade (HG) group  for the rest (GII,GIII). PaƟents with LG CHSA tend to be younger (40,6y 
vs 58,2y) and, except for one paƟent, were all primarily treated by intralaesional surgery (91,7%). Nine of these 
paƟents (81%) suﬀered local recurrence (LR) (4 of them mulƟple) at an average of 131 months since primary surgery. 
Seven of them underwent ablaƟve surgery later on and only two of them were cured aŌer addiƟonal intralaesional 
surgery. All of our four cases with mulƟple LR relapsed in a higher grade then the primary tumor - up to GIII in three 
cases. Two of these paƟents developed distant pulmonary metastases.
On the other hand 63,15% of paƟents with HG CHSa had an ablaƟve surgery as a primary treatment. Only four of them 
had an intralaesional surgery, which was always followed by LR at an average of 5,75 months. We did not encouter a 
single LR aŌer primary ablaƟve surgery, nevertheles two paƟents developed distant pulmonary metastases despite 
good local control.
Discussion: Our study shows, that the behaviour of acral CHSA is not as benign as generally believed and successful 
treatment requires careful planning. For LG CHSa of the hand an feet, intralesional surgery is widely accepted and 
despite the high rate of LR in our series, we believe this is sƟll a treatment of choice. Especially because it is also 
rather diﬃcult to diﬀer GI lesion form an acƟve enchondroma and the diagnosis is oŌen done only retrospecƟvely. 
However in case of a LR, more aggressive approach should be taken in consideraƟon as the risk of having a HG CHSa 
raises with every recurrence. 
For GII-III CHSa on the other hand, intralaesional surgery is to be avoided. In these cases LR  is constant and the 
potenƟal of evolving into a fatal metastaƟc disease is substanƟal. For such tumors we recommend primarily block 
resecƟon with structural autograŌ reconstrucƟon wherever possible. The funcƟonal result aŌer such reconstrucƟon 
can be acceptable even in extreme cases as will be presented in case reports. The temptaƟon of performing an IL 
surgery in an eﬀort to achieve a beƩer funcƟonal result should be resisted. As a maƩer of fact, usually an even more 
aggressive surgery is later needed to treat the recurrent tumor.
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The fact, that most of these tumors in our series were secondary to a previously benign condiƟon suggests that 
chondromatous lesions should be followed more carefully with respect to this. Also the higher age of paƟents with 
GII-III CHSa supports the idea, that the chondromatous tumors have a potenƟal to progress slowly into higher grades. 
Therefore in case of any clinical suspicion, an early acƟve approach is advocated. Feet were more likely to harbour a 
HG CHSa probably because in this locaƟon they can grow longer unnoƟced. 
Distant metastases developed only in paƟents with HG lesions, nevertheless one paƟent with Olliere disease had 
already been treated for CHSa of the femur and the source of these metastases is more likely to orign from there.
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AEXTREME CHONDROSARCOMA ͵ IS PALIATIVE TREATMENT 
JUSTIFIED
Matějovský, Z., Lesenský J., Kofránek I.
Orthopedic Clinic 1st Medical School, Charles University, Teaching Hospital Bulovka, Prague, Czech Republic 
Materials and methods: We show three paƟents with extreme large secondary chondrosarcomas that were 
presented late with already spread disease. Radiological evaluaƟon of these paƟents is presented together with the 
results of controversial treatment that surprisingly showed benefit.
Results: First paƟent was a bed ridden male with huge chondrosarcomas of the pelvic as well as shoulder girdle. 
Interthoracoscapular amputaƟon and hemipelvectomy on the ipsilateral side were carried out. AŌer the surgery he 
started to ambulate in a wheelchair and was able to move around at home. He died two years aŌer surgery on lung 
metastases with an only minimally symptomaƟc pelvic local recurrence.
Second paƟent is a female with mulƟple enchondromatoses presented with a large chondrosarcomas on the anterior 
part of the proximal femur growing from the lesser trochanter anteriorly. A wide resecƟon was planed with a tumor 
endoprostheses. Nevertheless further enchondromas showed radiological signs of malignisaƟons. Due to this only 
an marginal resecƟon of the extraoseal part with resecƟon of the lesser trochanter were performed and the hip was 
preserved. She achieved immediate full range of moƟon in the hip and had a quick recovery into normal life.
The third paƟent is a female with a history of over 30 years growing mass from the chest wall starƟng below the 
diaphragm on the right side pushing the liver high up into the chest wall. It started to grow also caudally into the 
pelvis. Surprisingly the women refused to go to see a doctor with the growing mass, but first visited the orthopedic 
specialist because she could not sit properly due to a limited flexion in the hip from the growing pelvic mass. The tumor 
exulcerated in the dorsal thoracic part and general as well as chest surgeons so far refused surgical intervenƟon.
Conclusion: Secondary chondrosarcoma is an, at first only slowly growing tumor that some paƟents accept as 
part of their normal life and refuse treatment unƟl other problems occur. In such large tumors that are at least 
potenƟally mulƟfocal, it is always diﬃcult to choose between overtreatment and undertreatment. The paƟent has 
to be evaluated individually and someƟmes we can see a surprisingly great improvement in life quality even aŌer 
a muƟlaƟng surgical procedure even if only for a limited period of Ɵme. In such cases an intralesional procedure 
can be jusƟfied taking into advantage the fact, that chondrosarcomas are hypovascular tumors and that repeated 
exƟrpaƟons can be performed for the residual or relapsed tumor.
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S EVOLUTION OF EXTRA ABDOMINAL AGGRESSIVE 
FIBROMATOSIS : ANALYSIS BASED ON A “WAIT AND SEE” 
POLICY. 
F. Gouin, P. Anract, O. Barbier, G. Odri, E. Bompas, S. Briand
University Hospital of Nantes, France
Bone tumor Research Laboratory, UMR 957 Inserm, University of Nantes, France
University Hospital of Cochin-Port Royal, Paris, France
West InsƟtut of Cancer, Nantes-Angers, France
IntroducƟon: Extra-abdominal aggressive fibromatosis (EAAF) are benign soŌ Ɵssue tumors with a potenƟal of local 
aggressive behaviour due to a clonal fibroblasƟc proliferaƟon. The mainstay of treatment has been wide surgical 
resecƟon for decades, leading to high rate of local recurrence and frequent severe funcƟonal impairment. For these 
reasons, and the unpredictable outcome of this disease, the benefit of surgery is currently quesƟonable. Thus, “wait 
and see” (W&S) policy (no aggressive surgical or irradiaƟon treatment) can lead to stabilizaƟon of the disease in a 
subset of paƟents. The aim of this study is to describe course of naƟve or recurrent EAAF based on the retrospecƟve 
study of 48 paƟents. 
PaƟents and methods: Forty eight paƟents (2 bone and soŌ Ɵssue tumor referent centers) with histologically proved 
EAAF were involved in the study. The W&S policy was proposed aŌer a mulƟdisciplinary decision that  relied on 
arbitrary criterias at the diagnosis (paƟent and tumor status, site, size) and was the first line approach for all paƟents 
during the past 5 years. All paƟents were followed up every 6 months during the tumor progression period (clinical 
and MRI assessements) and then every year. The stability of the tumor was decided when no progression was seen 
between two successive MRI.
Results: Twenty five paƟents were treated with this conservaƟve approach aŌer biopsy and 13 aŌer 1 or several local 
recurrences. Medical a treatment was proposed for symptomaƟc paƟents, including  painkillers and nonsteroid anƟ-
inflammatory drugs. Tamoxifen has been proposed in some growing tumors and chemotherapy in one case.
In 47 of the 48 paƟents, the tumors stopped their progression (with 5 cases of total regression 10%). The median 
duraƟon of progression was 9 months for naƟve tumors and 14 months for recurrent tumors. The mean follow-up 
aŌer stabilisaƟon was 71 months (2- 258). Only one tumor had had a progression period of more than 36 months 
(49 months). For two paƟents, aŌer growth arrest, a second step of progression was observed during one year, and 
they are now stable since more than 2 years for each. 
Only one paƟent had a worrying progression of  a chest wall tumor, despite chemotherapy and radiotherapy : she 
was operated aŌer 3 years of progression, with no recurrence at 5 years of follow-up. 
Pain and funcƟon impairment were in all cases stable or improved. 
Conclusion: This study confirms that W&S conservaƟve approach for naƟve or recurrent EAAD can lead to long 
lasƟng stabilizaƟon of the tumor. In our hands, the first 3 years aŌer diagnosƟc is the most criƟcal period as no tumor 
except one had progressed aŌer 36 months. SymptomaƟc treatment and psychological approach are necessary for 
the paƟent during this period, especially when the tumor is close to neurovascular bundles. Despite this approach is 
our nowadays first line treatment, the methodology of this study is unable to idenƟfy prognosƟc factors to choose 
which paƟent is eligible for this conservaƟve approach and literature is very poor on that topic. 
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SVIRTUAL RECONSTRUCTION OF PELVIC TUMOR DEFECTS 
BASED ON A STATISTICAL SHAPE MODEL
Zdzislaw Krol1, Pawel Skadlubowicz2, Fritz HeŌi1, Andreas H. Krieg1
1Paediatric Orthopaedic Department, Children’s University Hospital Basel (UKBB) Spitalstrasse 33, 4056 Basel, Switzerland
2 Department of Biomedical Computer Systems, InsƟtute of Computer Science, Faculty of Computer Science and Materials Science, 
University of Silesia, 41-205 Sosnowiec, Poland 
Background: Bone tumor in the pelvis region usually causes its deformaƟon and destrucƟon. PreservaƟon of the 
biomechanical characterisƟcs of the pelvis aŌer a large periacetabular resecƟon due to a malignant pelvic tumor 
is challenging. The reconstrucƟon of the resected osseous structures around the acetabulum using allogenous 
transplants or arƟficial implants is not saƟsfying and the orthopedic surgeons try to design and apply ever more 
oŌen paƟent-specific implants. Because the original anatomy of the pelvis cannot be adequately assessed at the 
tumor site, methods for its reconstrucƟon are required. The widely used strategy for planning the reconstrucƟon of 
the resected part of the pelvis is the mirroring of the contralateral side. We propose a novel planning method for 
reconstrucƟon of pelvis defects.
Method: Our approach uƟlizes pelvic staƟsƟcal shape models to generate paƟent-specific implant geometries. This 
parametric pelvic model can be manipulated to opƟmally match a paƟent’s pelvic anatomy. The main objecƟves of 
this study were to present and evaluate the virtual anatomical reconstrucƟon of eight tumor-damaged pelvic bones 
using the pelvic staƟsƟcal shape model. This included also a comparison with the mirroring method. The collected 
and segmented CT datasets were subdivided into male (n=50) and female (n=50) pelvises, and a gender-specific 
staƟsƟcal shape model was generated from each dataset collecƟon. 
Results: We achieved an overall mean deviaƟon distance of 0.89 mm (for the intact area) and 1.26 mm for the 
reconstrucƟon of the equivalent defect in the healthy hemipelvis (for the whole hemipelvis area). The comparison 
with the mirroring of the contralateral side approach shows the same reconstrucƟon quality level. 
Conclusion: In the clinical case applicaƟon both virtual reconstrucƟon approaches the mirroring and the SSM-based 
one reconstruct the defect at the same clinically acceptable accuracy level. Clinically speaking, a surface deviaƟon 
error in the range of 1 mm is a very good result. This study demonstrates that the presented model can be a valuable 
tool for the planning of pelvic reconstrucƟve surgery and implant design.
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S SORAFENIB AND DACARBAZINE IN SOFT TISSUE SARCOMA: A 
SINGLE INSTITUTION EXPERIENCE
Vincenzi B1, SilleƩa M1, Schiavon G2, Frezza AM1, Del Vescovo R1, Dei Tos AP3, Zobel BB1, SanƟni D1, Tonini G1.
1University Campus Bio Medico, Rome, Italy
2 Department of Medical Oncology, Erasmus University Medical Center - Daniel den Hoed Cancer Center, RoƩerdam, The 
Netherlands
3Azienda ULSS 9 Treviso, Treviso, Italy 
Background: To report on the anƟtumor acƟvity and toxicity of sorafenib combined with dacarbazine in paƟents 
with pre-treated advanced soŌ Ɵssue sarcoma (STS).
Method: Our phase II study enrolled 17 consecuƟve paƟents (..men/..women) aﬀected by STS with a performance 
status ≤2 and measurable disease, who failed two or more previous regimen of chemotherapy, from November 2009 
to December 2010. All the paƟents received conƟnuous dosing of sorafenib 400 mg twice daily and dacarbazine 300 
mg/m2 for 3 consecuƟve days every 21 days unƟl disease progression (PD) or intolerable toxicity. 
Results: A total of 14 paƟents were evaluable for response, having 3  paƟents stopped treatment early due to 
death for non-disease related reasons and rapid clinical deterioraƟon (1 and 2 paƟents, respecƟvely). No complete 
responses were observed. As by RECIST, parƟal responses (PR) were recorded in 3 paƟents (21%), stable disease 
(SD) in 6 paƟents (43%), and PD in 5 paƟents (36%), with a clinical benefit (PR+SD>6 mos) of 64%. The median 
progression-free survival was 20 weeks (range: 9-34) and the median overall survival was 43.5 weeks (range: 17-
65). The main recorded toxiciƟes were: neutropenia (36%), thrombocytopenia (36%), hypertension (36%), faƟgue 
(50%), and skin reacƟons (57%). Five paƟents required dose reducƟons (both drugs) for toxicity and 3 paƟents 
required only sorafenib reducƟon due to skin reacƟons. One paƟent went oﬀ-study because of severe sorafenib-
related dermatologic toxicity.
Conclusions: Sorafenib and dacarbazine combinaƟon seems to be an acƟve and safe regimen in pre-treated STSs. A 
phase II study is currently ongoing in paƟents aﬀected by selected sarcoma subtypes.
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SMETALLOTHIONEINS ͳ NEW DIAGNOSTIC MARKER IN 
OSTEOSARCOMA AND OTHER SOLID CHILD TUMOR 
Kruseova J.(1), Krizkova L.(2), Bunesova M.(3), Hynek D.(2), Adam V.(2), Kizek R.(2), Eckschlager T.(1) 
1. Department of Paediatric Haematology and Oncology, Motol Hospital, Prague.
2. Department of Chemistry and Biochemistry, Faculty of agronomy, Mendel University, Brno. 
3. Department of Clinical biochemistry and Pathobiochemistry, Motol Hospital, Prague.
IntroducƟon: Metallothioneins (MTs) are low molecular (cca 6kDa) cystein rich proteins, which have naturally 
occurring Zn2+ in both binding sites. MTs parƟcipate in the carcinogenic process, but their use as a tumor marker or 
predicƟve marker remains controversial. MTs are necesseary for metal transport and protecƟon against metal and 
ROS toxicity, what can influence chemotherapy eﬀecƟvness. 
ObjecƟves: to understand relaƟonship between MTs serum levels and diﬀerent treatment and posƩreatment period 
with correlaƟon to tumor acƟvity and chemotherapy side eﬀects. 
Materials and methods: prospecƟve observaƟonal study involving a sample of 194 paƟents with child solid tumors 
treated from 2008 – 2011. Median age of paƟents was 10,09 years. Examined were 756 serum samples.  MTs were 
determined in blood serum using diﬀerenƟal pulse voltammetry - Brdicka reacƟon. 
Results: The average level of MTs was 3,4 umol/l. There was correlaƟon between MTs level and increased creaƟninine 
p‹ 0,002 in all solid tumor. Diﬀerent level of MTs between complete remission and acƟvive disesase was found only 
in osteosarcoma p‹ 0,016 and germ cell tumors p‹ 0,007. The last two diagnosis had highest amount of paƟents with 
increased creaƟnine level caused by plaƟnium based chemotherapy. 
Conclusions: we found new correlaƟon between kidney funcƟon and MTs level. Our results support hypothesis that 
MTs  involve chemotherapy eﬀecƟvness.
5 key references: serum metallothione in levels, diﬀerenƟal pulse voltammetry, solid tumors, kidney funcƟon, 
chemotherapy
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S PRELIMINARY DATA OF HIFͳ1Α EXPRESSION IN 50 CHORDOMA 
SPECIMENS: A POTENTIAL ADJUVANT THERAPEUTIC 
TARGET?
E.V. Froehlich1, S. Scheipl1, C. Wibmer1, P. P. Varga2, A. Lazáry2, F. Quehenberger3, B. Liegl4, A. Leithner1.
1 Department of Orthopaedics and Orthopaedic Surgery, Medical University Graz, Austria
2 NaƟonal Centre for Spinal Disorders, Budapest, Hungary
3 InsƟtute of Medical InformaƟcs, StaƟsƟcs and DocumentaƟon, Medical University of Graz, Austria
4 InsƟtue of Pathology, Medical University of Graz, Austria 
.
ObjecƟves: Chordomas are known as intermediate-grade malignant tumors that show a slow but destrucƟve 
growth. To date standard treatment consists of surgery and radiotherapy, oŌen ending in recurrent disease. An 
explanaƟon for the high recurrence rates might be the involvement of HIF-1α (Hypoxia-inducable factor) in the 
tumor progression, such as angiogenesis, metabolism, cellular growth, metastasis, and apoptosis. Therefore, the aim 
of the present study was to invesƟgate the expression of HIF-1α in chordomas by immunohistochemistry. 
Materials and Methods: The study-group included 50 Brachyury-verified chordoma specimens (34 primary, 16 
recurrent tumours), obtained from 27 males and 17 females. At Ɵme of diagnosis the paƟents’ age ranged from 24 
to 90 (mean 53.9 ys.). Tumours were located in the skull, the sacrum/coccyx and the spinal column in 11, 20, and 
13 cases, respecƟvely. Tumour-volume ranged from 0.6 to 2720cm3 (mean 324.6cm3). Follow-up, available in 39 
cases, ranged from 2 to 234 months (mean 68 months). Immunohistochemistry was performed with monoclonal 
anƟbodies against HIF-1α. Staining-paƩern and posiƟve tumour-cells were evaluated. 
Results: HIF-1α expression was obtained in 26/34 (76.5%) of the primary chordomas and in 15/16 (93.7%) of the 
recurrent cases. The staining-paƩern was cytoplasmic in 19 and cytoplasmic/nuclear in 22 cases. Nine cases were 
negaƟve. Of the primary lesions 5 showed 1+ staining (0-49% of chordoma cells reacƟve), 21 cases 2+ staining (50-
100% of chordoma cells reacƟve). Recurrent chordomas showed a 1+ staining in 4 cases and 2+ staining in 11 tumors, 
respecƟvely.
Conclusion: Enbloc resecƟon with tumor-free margins is seldom feasible, parƟcularly in the sacrum. Intralesional 
excisions mostly end in early local recurrence; therefore, the demand for further treatment opƟons is frequently 
posed. Recently published studies on solid malignancies have shown that an enhanced sensiƟvity towards radio- 
but also chemotherapy can be achieved by the selecƟve suppression of HIF-1α. Thus our results may indicate that a 
specific HIF-1α targeƟng in chordomas could be a future adjuvant therapy strategy to increase the respond to radio- 
and especially chemotherapy in these tumors.
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STUMOUR GRAFTS DERIVED FROM SARCOMA PATIENTS MIMIC 
TUMOUR PATHOLOGY, VIABILITY AND INVASION IN THE CHICK 
CHORIOALLANTOIC MEMBRANE MODEL
Gwen Sys°, Ramses Forsyth°°, Ian Peeters, Mieke Van Bockstal°°, Maurice Balke**, Bart Poﬀyn°, Dirk UyƩendaele°, Marc Bracke*, 
Olivier De Wever*.
Gwen Sys, MD
°Department of Orthopaedic Surgery and Traumatology
Ghent University Hospital
De Pintelaan 185 - B – 9000 Ghent, Belgium
*Department of RadiaƟon Oncology and Experimental Cancer Research
Ghent University
°°M. GhoormaghƟgh InsƟtute of Pathology
Ghent University Hospital
** Department of Trauma and Orthopaedic Surgery
WiƩen/Herdecke University, Faculty of Health - School of Medicine
Cologne Merheim Medical Center - D-51109 Cologne, Germany
Sarcomas, or tumours of the musculoskeletal system, are very rare. In this study, fresh tumour samples were used 
to establish whether the chick chorioallantoic membrane (CAM) assay can be used to evaluate the viability of these 
tumours and to examine their migraƟonal, invasive and angiogeneƟc behaviour. 
Material and methods: Fresh tumour material was obtained from 28 consecuƟve paƟents with an aggressive benign 
or malignant bone or soŌ-Ɵssue tumour. Digital images were used to score angiogenesis according to the Ausprunk 
classificaƟon. Histological evaluaƟon and scoring of graŌ (viability, necrosis, infiltraƟon) and host (vascular ingrowth, 
bleeding and CAM hyperplasia) behaviour was performed by three observers according to protocol.
Results: Correct histological diagnosis remained possible aŌer harvesƟng of the CAM. Less than half of the tumour 
samples proved to be viable, with marked diﬀerences between paƟents. Chemotherapy had an adverse eﬀect on 
tumour invasiveness. MetastaƟc lesions proved to be very viable and showed marked vascular ingrowth. InfiltraƟon 
of fibroblasts from the CAM into the tumour samples is thought to herald vascular ingrowth. Macroscopic vascular 
reacƟon did not correlate with microscopic vascular ingrowth. 
Conclusion: The CAM assay can be used to study fresh material derived from tumours of the musculoskeletal system 
and proved to be a useful tool for the evaluaƟon of tumour sample viability and its locally invasive behaviour. We 
suggest using the xenograŌ CAM assay to generate a sarcoma study populaƟon that could be profiled for biomarker 
assessment and randomized for prospecƟve treatment with targeted agents.
Key words: CAM assay, sarcoma, targeted agents, xenograŌ model, angiogenesis
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S THE USE OF TOTAL CT IN DETECTING DISTANT METASTASES 
OF BONE SARCOMAS.
Kobys V.L.1, Ternitskaya Y.P.4, Konovalenko V.F.2., Klusov A.N.1, Repinа N.V.3, Matyushok O.F.1 
1 Kyiv City Oncology Hospital. 2 “Fresenius” RepresentaƟon in Ukraine.3 Oberig Clinic, Kiev. 4Center of RadiodiagnosƟcs, Academy 
of Sciences of Ukraine
IntroducƟon: According to the ESMO 2009 recommendaƟons for examinaƟon of paƟents with bone sarcomas, it 
is necessary to study the primary lesion, two adjacent joints, the chest, and perform bone scan. Our observaƟon 
indicates this amount of research for the staging of the disease to be inadequate.
Materials and Methods: In the children’s department in the period from May 2010 to February 2012 for staging 
the disease, a total spiral computed tomography was performed in addiƟon to the standard study. We examined 16 
children aged 8 to 18, 5 with Ewing’s sarcoma and 9 with osteogenic sarcoma. The study was conducted on a 64-slice 
General Electric computer tomograph, Light Speed  VCT model, 1.25 mm slice thickness, 2.5 mm pitch, with further 
slice reconstrucƟon 0.625 mm. Contrast enhancement was not performed.
Results: In 2 of 16 paƟents (12.5%  of paƟents) individual lesions were revealed that were not detected by bone scan. 
They were located in the medullary canal of the humerus in a paƟent with a lesion of the radius of the same limb and 
in the medullary canal of the diaphysis of the femur of the opposite limb.
Conclusions: Total computed tomography using modern devices in paƟents with bone sarcomas may be an alternaƟve 
to total magneƟc resonance imaging in the examinaƟon of paƟents.
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STREATMENT OF KNEE ONCOENDOPROSTHESIS INFECTIONS.
Kobys V.L.1, Konovalenko V.F.2., Klusov A.N.1, Repinа N.V.3, Dolinsky F.S.1, Zaharycheva E.V. 4 , Matyushok O.F.1 
1 Kyiv City Oncology Hospital. 2 “Fresenius” RepresentaƟon in Ukraine.3 Oberig Clinic, Kiev.4Kyiv City Children’s Hospital No. 7.
IntroducƟon: Late infecƟon of oncoendoprostheis is a threatening complicaƟon that can ulƟmately lead to amputaƟon. 
ExisƟng approaches in the treatment of this pathology (removal of the festering endoprosthesis, installaƟon of a 
temporary cement spacer impregnated with anƟbioƟcs, long-term anƟbioƟc therapy, repeated reconstrucƟve 
surgery) cannot ensure recovery of all paƟents.
Materials and Methods: In a group of three paƟents aged 19-22 years who received knee endoprosthesis in 2004, 
2005, 2006 due to distal femur osteosarcoma, endoprosthesis infecƟon occurred 3-4 years aŌer surgery. The reasons 
were: tooth infecƟon, lengthening of the implant, unknown reason. Staphylococcus aureus was plated in 2 paƟents, 
Staphylococcus epidermidis in 1 paƟent. Treatment consisted of removal of the endoprosthesis, installaƟons of the 
spacer (from 2 to 5 Ɵmes in one paƟent), prolonged anƟbioƟc therapy for about two years. The extremiƟes were 
not bent at the knee joint. AŌer 3-4 months, spacer re-infecƟon was observed. It was decided to perform complete 
removal of the spacer in all paƟents, install a rod apparatus for external fixaƟon of bone fragments. AŌer 4-5 months, 
reimplantaƟon of endoprosthesis impregnated with silver was performed.
Results: In all paƟents an excellent funcƟonal result was received: the flexion funcƟon of the knee is fully recovered; 
there is no evidence of infecƟon from 9 months to 1 year aŌer surgery. One paƟent is pregnant, another one returned 
to her job, and the third one is preparing for enrollment at a university.
Conclusions: Treatment of infecƟons of oncologic prostheses should be more aggressive with the removal of foreign 
bodies in contrast to the treatment of infecƟons of orthopedic endoprotheses. .
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S LONG TERM RESULTS OF MINIMALLY INVASIVE 
ENDOPROSTHETIC REPLACEMENTS IN CHILDREN
V Neelapala, R Grimer, S Carter, R Tillman, A Abudu, L Jeys 
Royal Orthopaedic Hospital, Birmingham
Aim: To assess the outcomes in terms of prostheƟc survival and complicaƟons of children who underwent a minimally 
invasive Stanmore growing prosthesis. 
Method: RetrospecƟve review of all paƟents treated idenƟfying complicaƟons and outcomes.
Results: 140 children between the ages of 2 and 16 had a minimally invasive prosthesis inserted between 1992 
and 2011. All were for bone tumours, 99 being osteosarcoma and 35 Ewing’s sarcoma. There were 59 distal femur, 
25 proximal humerus, 34 proximal Ɵbia, 15 proximal femur, 3 midshaŌ femur, 2 total femur, 2 total humerus 
prostheses. 
48 paƟents have died, 2 aŌer renal failure the rest from metastases. Survival is 69% at ten years. There were 18 local 
recurrences, 9 of these paƟents have died. 
12 paƟents had an amputaƟon of which 8 were for local recurrence and 4 infecƟon. 74 of the paƟents had one 
or more lengthening (average 3.6). 15 paƟents had a problem with lengthening (either shortening, spontaneous 
lengthening or failure) and five needed revision for problems with this. There were three infecƟons aŌer a lengthening 
(1.1% risk). 37 of the implants needed revision of which 30 were done as single stage procedure and 5 were done 
as two stage revision for infecƟon. Survival of the implant without revision or amputaƟon was 52% at 5 years and 
42% at ten years but all paƟents had undergone a revision by 15 years. There was no obvious diﬀerence in survival 
of the implants when split by site, age at Ɵme of inserƟon or diagnosis. Most surviving children had a limb length 
discrepancy of less than 2cm. 
Conclusion: The minimally invasive extendable prosthesis has proved eﬀecƟve and safer than anƟcipated. The rate 
of infecƟon despite repeated lengthenings is under 4% but revision appears to be inevitable within 15 years. 
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SHAS ASEPTIC LOOSENING IN DISTAL FEMORAL 
ENDOPROSTHETIC REPLACEMENT BEEN ABOLISHED BY THE 
INTRODUCTION OF THE HYDROXYAPATITE COLLAR?
JRW Glanville, AE Simpson, RJ Grimer
Royal Orthopaedic Hospital NHS FoundaƟon Trust, Orthopaedic Oncology Department, Bristol Road South, Northfield, 
Birmingham, B31 2AP, UK.
Aim: AsepƟc loosening has been one of the main causes of failure of joint replacements. This is a parƟcular problem 
following bone tumour resecƟons and reconstrucƟon with endoprostheƟc replacement (EPR), as the paƟents are 
oŌen young and acƟve. The introducƟon of a hydroxyapaƟte (HA) collar seemed to have significantly decreased this 
problem at medium term follow up. We have reviewed the 19 year experience of prosthesis failure in paƟents with 
a distal femur EPR incorporaƟng the HA collar.
Method: Survival informaƟon was collected from a prospecƟve database for all paƟents who underwent a custom 
made distal femoral EPR with an HA collar between September 1991 and December 2011. Outcomes were recorded 
in terms of paƟent death (implant in situ), survival of implant, failure of implant, or amputaƟon and were split by 
whether the procedure was primary or secondary. 
Results: Over the past 19 years, 362 distal femoral EPRs with an HA collar have been inserted, 261 as primary cases 
and 101 as secondary procedures.  54 paƟents required further revision due to: infecƟon (n=24), asepƟc loosening 
(n=10), implant fracture/failure (n=17) or metal allergy (n=3). There were 20 amputaƟons (local recurrence n=13; 
infecƟon n=7). Using Kaplan-Meier survivorship analysis, at 19 years there was a 7% chance of asepƟc loosening and 
11% risk of infecƟon.  The risk of further major surgery (amputaƟon or revision for any cause) was 37.7% at 19 years. 
There was no significant diﬀerence in the incidence of asepƟc loosening or infecƟon between primary and revision 
prostheses, even when the revision was done for a previous failed EPR. 
Conclusions: AsepƟc loosening has been markedly reduced since the introducƟon of the HA collar with rotaƟng 
hinge. There is no greater risk of implant failure in terms of asepƟc loosening in paƟents requiring revision surgery 
as opposed to primary. 
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S PROLIFERATION OF OSTEOSARCOMA CELLS TARGETED BY 
SMALL MOLECULES IN A HIGHͳTHROUGHPUT APPROACH
Doris M. Seiler1,2, Jan Smida1,2, Stephanie Zillmer1,3, Ina Rothenaigner4, Kenji Schorpp4, Kamyar Hadian4, Daniel Baumhoer1,5, and 
Michaela Nathrath1,2
1 Clinical CooperaƟon Group Osteosarcoma, Helmholtz Zentrum München – NaƟonal Research Centre for Environment and 
Health, Neuherberg, Germany
2 Department of Pediatrics, Technische Universität München and Pediatric Oncology Center, Munich, Germany
3 Department of Pediatric Oncology, Klinikum Kassel, Kassel, Germany
4 InsƟtute of Toxicology, Helmholtz Zentrum München – NaƟonal Research Centre for Environment and Health, Neuherberg, 
Germany
5 Bone Tumor Reference Center at the InsƟtute of Pathology, University Hospital Basel, Basel, Switzerland
Tumor malignancy is correlated to tumor progression and invasiveness into surrounding Ɵssues. ComparaƟve 
analysis of various osteosarcoma (OS) cell lines showed diﬀerent behavior of OS cells in proliferaƟon, invasiveness 
and migraƟon in vitro. These phenotypes were associated with diﬀerenƟal expression of specific miRNA, indicaƟng 
that miRNA deregulaƟon influences cell migraƟon and proliferaƟon.
Here we present a strategy for screening in a high-throughput manner of biological acƟve compounds that might 
aﬀect the proliferaƟve behavior of OS cells. We established an automated pipeƫng system and subsequent 
quanƟtaƟve measure of cell proliferaƟon and apoptosis for screening of the eﬀect of a large set of small, non-toxic 
compounds (>10.000) on our set of OS cell lines. First experiments show that cell viability and apoptosis can be 
robustly determined using the high-throughput approach. We currently invesƟgate the eﬀect of specific miRNA 
inhibiƟon and mimic, respecƟvely, on cell proliferaƟon in comparison to treatment with small molecule inhibitors 
and other known proliferaƟon inhibitors.
The compounds are oŌen used for inhibiƟon of target molecules and for idenƟficaƟon of specific pathways that are 
represented by a specific cell phenotype. Thus, we plan to mimic miRNA eﬀects on cell proliferaƟon using these 
compounds and to finally idenƟfy targets and pathways involved in osteosarcoma progression. Taken together, 
regulaƟve mechanisms, such as miRNA regulaƟon might be targeted by small molecules to influence the metastaƟc 
potenƟal of osteosarcoma cells and improve prognosƟc and individual therapeuƟc strategies. 
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SPREͳCLINICAL VALIDATION OF APPROACHES TARGETING 
PROTEIN KINASES IN OSTEOSARCOMA.
Elisa TavanƟ, Valeria Sero, Serena Vella, Francesca Michelacci, Marilù Fanelli, Claudia Haƫnger, Maria CrisƟna Manara, Lorena 
Landuzzi, Piero Picci, Massimo Serra
Laboratory of Experimental Oncology, Orthopaedic Rizzoli InsƟtute , Bologna, Italy
ObjecƟves: In order to improve the survival rate of osteosarcoma paƟents, it is necessary developing novel therapies. 
Although osteosarcoma has not been studied as well as other types of cancer, diﬀerent kinases have been indicated 
to be involved in its pathogenesis and progression. Deepening the role of specific protein kinases in osteosarcoma 
may therefore indicate new candidate therapeuƟc markers, which can be targeted by specific inhibitor drugs that 
have emerged as aƩracƟve compounds for development of targeted treatments in other human tumours.
ObjecƟve of this study was the preclinical validaƟon of protein kinases and kinase inhibitors of possible clinical usefulness 
in osteosarcoma.
Materials and Methods: By mining genome-wide expression profiling data obtained from 21 osteosarcoma clinical 
samples, the following five protein kinases emerged as the most relevant for the osteosarcoma biology: AURKA, 
AURKB, CDK2, PIK3CA, PLK-1. These five kinases received the highest priority from the in silico analyses on the basis of 
their expression paƩern and because they are: 1) drugable, 2) frequently over-expressed in osteosarcoma at clinical 
onset, 3) associated with highly malignant features, and 4) expressed at higher levels in osteosarcomas compared to 
normal musculoskeletal Ɵssues. Analysis of the osteosarcoma cell dependency from these kinases by RNA interference 
(RNAi) revealed that Aurora kinase A (AURKA) and Aurora kinase B (AURKB) were the most relevant for osteosarcoma 
cell lines growth and survival. We therefore invesƟgated the eﬃcacy of the two Aurora kinases inhibitors VX-680 
and ZM-447439, which have already been included in clinical trials for other tumors. ChemosensiƟvity against VX-
680 and ZM-447439 was invesƟgated on four drug-sensiƟve and six drug-resistant human osteosarcoma cell lines 
and the in vitro eﬃcay of each drug was esƟmated in terms of cell growth inhibiƟon, cell cycle perturbaƟons and 
apoptosis inducƟon. The impact of each drug on the malignant phenotype of osteosarcoma cells was assessed by 
evaluaƟng its eﬀects on the in vitro cell moƟlity and on the cloning eﬃciency in nonadherent condiƟons (soŌ-agar). 
Finally, VX-680 and ZM-447439 acƟvity was analysed in combinaƟon with convenƟonal chemotherapeuƟc agents 
(doxorubicin, methotrexate or cisplaƟn). 
Results: The sensiƟvity to VX-680 and ZM-447439 was quanƟfied by evaluaƟng the IC50 value of each cell line (Tables 
1-2). 
In terms of cell growth inhibiƟon, all cell lines proved to be more sensiƟve to VX680 than to ZM447439. Cell growth 
inhibiƟon was caused by a remarkable phase S accumulaƟon more than an apotosis inducƟon, suggesƟng that these 
drugs have cytostaƟc rather than cytotoxic eﬀects on osteosarcoma cell lines. A decrease of drug sensiƟvity was 
observed in doxorubicin-resistant cell lines (which are characterized by a high expression of ABCB1), indicaƟng that 
VX680 and ZM-447439 are most probably ABCB1 substrates. VX680 also decreased moƟlity and soŌ-agar colony 
formaƟon ability of human osteosarcoma cells. 
Drug associaƟon experiments showed that VX680 posiƟvely interacts with all convenƟonal chemotherapeuƟcs, 
indicaƟng that it can be used in combinaƟon with the drugs included in osteosarcoma treatment protocols. Of 
parƟcular relevance was the observaƟon of a synergisƟc interacƟon between VX680 and cisplaƟn (CDDP) in CDDP-
resistant cell lines, a result that supports the Aurora kinases involvement in CDDP resistance, as described for other 
tumours.
Conclusions: These results indicate that Aurora kinases might represent new candidate therapeuƟc targets for 
osteosarcoma, being frequently highly expressed and playing an important role in osteosarcoma cell growth. In vitro 
analysis of two Aurora kinase inhibitors in vitro acƟvity indicated in VX680 a new promising candidate drug of potenƟal 
clinical usefulness to target these molecules.  
Table 1.
VX-680 Mean μM s.d.
U-2OS 0,376 0,16
Saos-2 0,365 0,168
IOR/OS18 2,210 0,480
IOR/OS9 0,220 0,149
U-2OS/MTX300 0,58 0,03
Saos-2/MTX300 0,28 0,17
U-2OS/DX580 52,77 6,44
Saos-2/DX580 16,3 2,53
U-2OS/CDDP4 μg 15,16 1,24
Saos-2/CDDP6 μg 8,4 2,59
143
Table 2.
ZM-447439 Mean μM s.d.
U-2OS 2,67 0,12
Saos-2 2,63 0,29
IOR/OS18 5,5 1,2
IOR/OS9 0,67 0,17
U-2OS/MTX300 4,3 0,38
Saos-2/MTX300 0,6 0,17
U-2OS/DX580 11,23 2,28
Saos-2/DX580 13,82 2,33
U-2OS/CDDP4 μg 4,43 1,04
Saos-2/CDDP6 μg 2,75 0,82
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S 160PALLIATIVE TREATMENT OF SOFT TISSUE SARCOMA WITH 
TRABECTEDIN
Joana Godinho1; Filipa Carneiro1; Rosa Vallinoto1; Ana Ferreira1; José Dinis1; Marta Soares1; Mariana Afonso2; Jorge Guimarães3.
1 – Department of Medical Oncology; 2 – Department of Pathology; 3 – Head of the Sarcoma Unit.
Portuguese InsƟtute of Oncology, Oporto, Portugal.
Background: SoŌ Ɵssue sarcomas (STS) are a rare and heterogeneous group of tumours that derive from 
mesenchymal cells and include a variety of histological subtypes. Despite treatment of the primary tumour, 50% of 
paƟents ulƟmately develop metastases or local recurrence. MetastaƟc disease treatment frequently depends on 
chemotherapy and median survival ranges from 6 to 12 months. Standard chemotherapy regimens usually include 
Doxorubicin and Ifosfamide either in combinaƟon or monotherapy. Trabectedin has shown to improve response 
rate and overall survival in STS that has progressed aŌer the use of those agents and whenever they are contra-
indicated. 
ObjecƟves: Our purpose was to assess the eﬀecƟveness of Trabectedin in a cohort of metastaƟc STS paƟents.
Material and Methods: RetrospecƟve cohort study, in a Portuguese cancer centre, of all STS paƟents treated with 
Trabectedin. Comorbidity was assessed by Charlson’s index. Toxicity was evaluated using Common Terminology 
Criteria for Adverse Events (CTCAE) version 3. Eﬃcacy was evaluated by Ɵme to progression and overall survival using 
Kaplan-Meier’s method. A 95% confidence interval was used.
Results: From July 2009 Ɵll February 2012, 13 STS paƟents were treated with Trabectedin. Median age was 55 (range 
24-79; 15,4% > 65 years), 69,2% were female, all had ECOG performance status ≤1 and 61,5% had a Charlson’s 
comorbidity index of 0. The most common histological subtypes were Leiomyosarcoma (38,5%), Liposarcoma 
(23,1%) and Synovial sarcoma (15,4%). Over 80% of paƟents had previously been submiƩed to chemotherapy with 
Doxorubicin and Ifosfamide. Six or more cycles were accomplished by 46% of paƟents and a relaƟve dose-intensity 
≥ 80% was achieved in 54% of pts. Grade 3 or 4 adverse events occurred in 61,5% of paƟents and the most common 
were neutropenia (30,8%) and infecƟon (23,1%). Two paƟents died due to treatment toxicity. Stable disease was 
achieved in 50% of paƟents and 20% had parƟal response. Median duraƟon of response was 5 months [95CI, 2,4 – 
7,6]. Median Ɵme to progression was 9 months [95 CI, 3,5 – 14,5] and 61% of paƟents were alive at 24 months of 
follow-up aŌer the start of Trabectedin.
Conclusions: Our results strengthen the benefit of Trabectedin’s use in the treatment of metastaƟc soŌ Ɵssue 
sarcomas. Its toxicity profile presents a challenge to the selecƟon and management of paƟents during treatment. 
The small sample size is a limitaƟon of this study.  
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SSEX AND OSTEOSARCOMA: STILL A RIDDLE TO BE SOLVED
Leithner A, Pirker-Fruehauf U, Friesenbichler J, Wibmer C
Department of Orthopaedic Surgery, Medical University of Graz – Graz - Austria
ObjecƟves Female gender has been reported as an independent factor for survival in osteosarcoma paƟents. 
Furthermore male gender seems to be at higher risk for osteosarcoma development.The aim of the study was to 
accumulate recent and sex-specific data on incidence and mortality of osteosarcoma paƟents.
Materials and Methods: We used the cumulaƟve osteosarcoma incidence rate from the CDC Wonder database 
for 1999-2008, which provides incidence data for nearly the whole U.S. populaƟon, including 8803 paƟents with 
osteosarcoma. Sex-specific data were obtained for six 5-year age groups between 1 and 39 years including 5970 
paƟents. For mortality data a PubMed search was conducted for comparison of major treatment studies published 
aŌer 2000.
Results: For the age group between 1 and 40 years the annual incidence for female osteosarcoma paƟents was 3,4 
per 1.000.000, while the incidence for male paƟents was 4,3 per 1.000.000 (1:1,33; p<0,001). Mortality data favored 
female gender in nearly all studies although diﬀerences exist if sex can be regarded as an independent factor.
Conclusions: While the causes for the higher incidence for male osteosarcoma paƟents remain totally unclear, there 
are at least some possible explanaƟons for worse male survival. The presented staƟsƟcal data from the U.S. confirm 
the previously reported later peak in the male group (female 10-14 yrs; male 15-19 yrs) and therefore a possible 
decreased suscepƟbility to chemotherapy. If an addiƟonal gender-specific approach to chemotherapy should be 
applied sƟll remains elusive.  
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S 185TREATMENT OF PRIMARY ANEURYSMAL BONE CYST ΈABCΉ 
WITH CURETTAGE AND THREE CROSSED KIRSCHNER WIRES 
ΈK/WΉ. PRESENTATION OF TWO Έ2Ή CASES. 
KonstanƟnos Tsanidis
Consultant Orthopaedic Surgeon – Sarcoma Surgeon 
Orthopaedic Dept. 
“Saint Luke” Private Hospital,
Panorama, Thessaloniki, GREECE.
Primary aneurysmal bone cyst is a benign cysƟc lesion of bone. It is an extensile cysƟc lesion and can cause extensive 
weakening of the bony structure and impinge on the surrounding Ɵssues. It is composed of blood filled spaces 
separated by connecƟve Ɵssue septa containing fibroblasts, osteoclast type giant cells and reacƟve woven bone. 
EƟology and pathophysiology remain uncertain. OŌen aﬀects individuals during their second decade of life and may 
occur in any bone in the body. The treatment of choice is intralesional cureƩage with significant rate of recurrence. 
Other surgical opƟons include en bloc resecƟon or wide excision, selecƟve arterial embolizaƟon, and cureƩage with 
locally applied adjuvants such as liquid nitrogen or phenol. 
It presented a method of treatment consisted in cureƩage and the use of three (3) crossed K/W. Two boys paƟents (A 
& B), 4 and 14 y.o., respecƟvely, were treated with this method on 2009 and on 2010. In both paƟents the symptoms 
were pain, swelling and discomfort of the adjacent joint. To the paƟent A the aﬀected site was the right distal radius, 
very close to the growth plate and to the paƟent B the 2nd right metatarsal bone.  The imaging, x-ray and MRI, reveled 
a cysƟc, extensile lesion with increased weakening of the cortex. The CT guided needle biopsy confirmed in both the 
diagnosis of the primary ABC. The choice of intralesional cureƩage and the use of 3 K/W was adopted because the 
parents were not so enthusiasƟc with the idea of taken auto graŌs from the iliac bone or with the use of syntheƟc 
graŌs. The first paƟent (A) operated with this method on 2009 and the second (B) on 2010.The follow-up showed 
healing of the ABC without any recurrence and with progressive restoraƟon of the aﬀected bone. 
The K/W were removed aŌer the compleƟon of a year aŌer surgery. The latest 
x-rays control revealed remarkable healing without any trace of the pre-exisƟng lesion. The role of the 3 K/W 
remains obscure but in the past were used less and more K/W without success and with formaƟon of abnormal or 
hypertrophic bone. 
The K/W plays a role of scaﬀold and there is a correlaƟon to the pressure – electric phenomenon and to the Wolf’s 
law for the orientaƟon of the bony lacunae but the answer why only the 3 K/W oﬀers the ideal result in bone 
reorientaƟon remain uncertain and under study. 
The two paƟents, today, clinically and imaginarily present no evidence of disease or recurrence.
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SISOLATED LIMB PERFUSION IN TREATMENT OF ADVANCED 
EXTREMITY MELANOMA AND SOFT TISSUE SARCOMAS.
KharaƟshvili TK, Martynkov DV, Buydenok YV, Narkevich BJ, Fedenko AA, Petrachenko NS, Dolgushin BI, Aliev MD
FGBU N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Moscow, Russian FederaƟon
ObjecƟve: To esƟmate the eﬀecƟveness of using the technique of  isolated limb perfusion in the RCRC RAMS
Materials and methods: In the treatment of locally advanced forms of melanoma and soŌ Ɵssue sarcomas using 
new methods of local treatment. Isolated regional chemotherapeuƟc perfusion, according to internaƟonal studies, is 
an eﬀecƟve method in the aﬀected limb. In Russian Cancer Research Center in 2010-2012 were treated 13 paƟents 
(13 ILP`s). Female - 10 (77%), male - 3 (23%), mean age 51 ± 17,5 years, range 21-79 years. PaƟents underwent ILP 
via the femoral (n = 12) and axillary (n = 1) approach. The distribuƟon by histological type of tumor: melanoma - 8 
cases (stage IIIB, IIIC), soŌ Ɵssue sarcoma - 5 cases (large, recurrent or mulƟple). Control of leakage from the isolated 
limb in the general blood circulaƟon system was carried out by the dynamic radiometry with 99mTc-red blood cells 
(labeling in vivo) and precordial scinƟllaƟon probe. Leakage was <6% (mean 1-2%). Perfusion was performed at mild 
hyperthermia.
Results: Overall response was recorded in 12 (92.3%) paƟents, CR - 3 (23.1%), PR - 9 (69.2%), SD - 1 paƟent. Limb 
salvage rate was 92,3%. One paƟent with large tumor had PR, but the tumor was sƟll unresectable. Median follow-
up - 12 months (range 2 to 25 months).
The local toxicity was slight (Wieberdink II). None of the paƟents had severe systemic toxicity.
Conclusion: ILP is a high eﬃciency and safe treatment modality (up to 92.3% of overall responses). ImplementaƟon 
of high regional chemotherapy is possible without significant local and systemic side eﬀects.
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S 215PRECLINICAL MODELS OF TUMORͳSPECIFIC CYTOTOXIC T 
LYMPHOCYTES IN SARCOMA PATIENTS 
Elena Signorino, Michela Muraro, Laura Castello, Sara CasƟglia, Ivana Ferrero, Monica Guneƫ, Alessandra Mandese, KaƟa 
Mareschi,  Deborah RusƟchelli, Fiorella Sanavio, Franca Fagioli
Stem Cell TransplantaƟon and Cellular Therapy Unit, Pediatric Onco-Hematology Division, Regina Margherita Children’s Hospital, 
Turin, Italy.
ObjecƟves staƟng concisely why the study was conducted: Osteosarcomas and other sarcoma tumors are the most 
frequent bone tumors in adolescents and young adults. Progress has been made over the past 30 years in improving 
the outcome of high-risk sarcomas paƟents, but the 5-year overall survival rate remains at 20% or less for metastaƟc 
sarcomas. Although there are new experimental therapeuƟc strategies they have failed to significantly improve 
survival in this subset of paƟents.
The integraƟon of adopƟve immunotherapy strategies with chemotherapy and/or targeted therapies represent a 
reasonable and appealing innovaƟve approach that has to be explored. Some recent clinical trials have confirmed 
the possibility of using autologous anƟtumor CTLs to control tumor growth.
The main aim of our study was to invesƟgate the possibility of generaƟng an in vitro tumor-specific targeted 
immunotherapy for bone sarcomas.
Materials and Methods: We isolated primary tumor cells from surgical biopsy, that were mechanically desegregated, 
maintained in culture and expanded in vitro.
We generated tumor specific CTLs through two sƟmulaƟon dependent anƟgens, using the whole tumor cells as 
an anƟgen source. In parƟcular, the irradiated tumor cells, were co-cultured with autologous dendriƟc cells, thus 
exploiƟng the capability of anƟgen presentaƟon.
Subsequently, the CTLs were expanded in a anƟgen independent way with recombinant human IL-2 and anƟ-CD3 
and a pool of irradiated PBMCs from three donors as a proliferaƟve sƟmulaƟon of CTLs. CTLs were expandend in 
vitro for several weeks.
Results: Sarcoma cells express specific MSCs markers: CD90, CD73, CD44 and CD105, and low levels of hematopoieƟc 
markers. Sarcoma cells express MHC I and maintain it aŌer various culture passages and can thus be used as a target 
in in vitro tests to analyse CTL specificity.
The immunophenotype analysis of the subpopulaƟon aŌer CTL generaƟon showed that CTLs were about 50% CD4 
and CD8, less than 10% NK.
CTLs from sarcoma paƟents specifically kill autologous tumor cells.
This specificity was also seen with the ELISpot assay for INF-gamma release. This assay confirmed cytotoxic results: 
the release was higher using autologous cells as the target, and lower using commercial lines and allogeneic PB.
The fold increase of CTL expansion was good. This allowed us to expect a good number of cells in a clinical protocol 
of immunotherapy for sarcoma paƟents.
Conclusions: We managed to establish culture condiƟons from the surgical biopsy to generate and maintain sarcoma 
paƟents primary cells in culture
We generated eﬃcient CTLs that are specific against those cells that were a source of anƟgens.
We had saƟsfactory in vitro expansion that provided a suﬃcient number of CTLs for clinical infusion.
Our findings are encouraging and support the design of adopƟve immunotherapy clinical trials with autologous CTLs 
for sarcoma paƟents.
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SPRECLINICAL EFFECTIVENESS OF  METFORMIN IN EWING 
SARCOMA
Cecilia Garofalo,1, 2,Caterina Mancarella1, 2,,  Maria CrisƟna Manara1, 2,, Chiara Donadei1, 2,,Maria Serena Benassi, 1 Giordano 
Nicoleƫ,1Lorena Landuzzi, 1 Pier-Luigi Lollini, 3 Piero Picci, 1 and KaƟa Scotlandi1, 2
1Experimental Oncology Lab , Orthopaedic Rizzoli InsƟtute, Bologna, Italy, 2 CRS Development of Biomolecular Therapies, 
Orthopaedic Rizzoli InsƟtute, Bologna, Italy, 3 Department of Hematology and Oncologic Sciences ‘‘L. e A. Seragnoli’’, University 
of Bologna, Bologna, Italy. 
Background: The IGF system has an important role in growth, tumorigenesis and cancer progression. In addiƟon 
to the well-known role of IGF-1R, recent evidences have clearly demonstrated the importance of insulin and its 
receptor (IR) in  both animal models and clinical studies. The isoform A of IR, which is usually overexpressed in cancer 
cells, may be sƟmulated by increased level of circulaƟng insulin as well as IGF-2 and mediates non-metabolic eﬀects, 
such as cell survival, proliferaƟon, and migraƟon. In addiƟon, high levels of insulin, obesity and Type 2 diabetes are 
associated with increased risk for various malignancies. In this context, drugs aimed at reducing  circulaƟng insulin 
levels, such as meƞormin, have received aƩenƟon as potenƟal anƟ-cancer agents. Here we evaluated eﬃcacy of 
meƞormin in Ewing sarcoma  cells.
Materials and Methods: Eﬀects on cell growth were evaluated by MTT assay.  Eﬀects on glucose up-take were 
assessed  in the Ewing sarcoma TC-71 and SKNMC cell lines aŌer treatments  with meƞormin (10mM)  and evaluaƟon 
of fluorescent glucose up-take by microscopy. The anƟtumor acƟvity of meƞormin was evaluated also in combinaƟon 
with convenƟonal drugs doxorubicine, vincrisƟne, acƟnomycin D and ifosfamide, which are the main drugs in the 
treatment of Ewing sarcoma.
Results: In vitro, meƞormin exhibited anƟ-proliferaƟve acƟvity, with IC50 values ranging from 6 to 21 mM. TC-71 cell 
line appeared the most sensiƟve to treatment, while 6647 and RD-ES cell lines were the most resistant ones. Time-
dependent acƟvaƟon of AMPK, with subsequent variaƟons in phosphorylaƟon of the S6 protein and/or glucose 
uptake, indicated that convenƟonal targets of meƞormin are aﬀected. However, the variable eﬃcacy of meƞormin 
in the diﬀerent cell lines did not appear to be related to diﬀerences in these pathways, suggesƟng other sƟll poorly 
defined mechanisms of acƟon. Inhibitory growth eﬀects were amplified when cells were grown in anchorage 
independent condiƟons. In addiƟon, combined treatments of meƞormin with convenƟonal chemotherapeuƟc drugs 
showed synergisƟc or addiƟve eﬀects, depending on drugs
Conclusions: These preclinical findings display a potenƟal  eﬃcacy of meƞormin against Ewing sarcoma, parƟcularly 
when combined with convenƟonal drugs, thus supporƟng its possible use as adjuvant drug.  (Grants: AIRC IG10452 
to KS, AIRC to CG; MINSAN Finalizzata 2009)
.
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S 244PROPOSAL ON UTILIZING LAUTENBACH SUCTION INSTILLATION 
SYSTEM TO PREVENT INFECTION IN MEGA PROSTHESES.
Dr’s Richard Kyte & Franz Snyman 
Division of Orthopaedic Surgery - University of the Witwatersrand - Johannesburg - South Africa
The infecƟon rate in MegaprosteƟc replacements varies between 7 and 25% in diﬀerent series, and for allograŌ 
reconstrucƟons can be as high as 30-40%. We have been uƟlizing the Lautenbach sucƟon insƟllaƟon system in 
treatment of Bony and ProstheƟc infecƟons, by insƟlling high concentraƟons of anƟbioƟc therapy into the wound 
bed, and combining the internal sucƟon dressing eﬀect. The purpose of this study was to compare our early infecƟon 
rates, with the profilacƟc uƟlizaƟon of the Lautenbach system, to published infecƟon rates.
We had 90 megaprostheƟc reconstrucƟon and musculoskeletal tumour paƟents, and 65 complex musculoskeletal 
trauma paƟents in the study, that was treated between 2004 and 2011, with profilacƟc Lautenbach irrigaƟon.
Our infecƟon rate in this study in the 44 paƟents with megaprostheƟc, allograŌ and allograŌ prostheƟc prosthesis 
composite reconstrucƟon; were no early infecƟons in the megaprostheƟc category, and one each in the bulk allograŌ 
and allograŌ prostheƟc composite category, amounƟng to 1,14%. No infecƟons occurred in the 19 paƟents in the large 
soŌ Ɵssue sarcoma category. (14 unrelated deaths) Our early results for infecƟon prevenƟon in these complex cases 
therefore compares very well to recent studies of between 7,7% (Roggieri 2008) and 47,8% (Cummings 2010). 
The Lautenbach system was also uƟlized in complex musculoskeletal trauma paƟents with one infecƟon in a grade 
3 B open fracture, in the cohort of 65 paƟents, amounƟng to 1,5%. This again compares favourably to other studies 
where infecƟon rates of 9-55% are reported.
Therefore the early results of our small inhomogenous cohort seem to support the uƟlisaƟon of the Lautenbach 
sucƟon insƟllaƟon system as a profillacƟc measure to prevent deep infecƟon in these complex cases.
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SPROGNOSTIC VALUE OF MIRͳ34A EXPRESSION IN EWING 
SARCOMA
Maria Teresa Marino1,2, Maria CrisƟna Manara1, 2, Andrea Grilli1,2, Massimo Serra1, Alessandra Carè3, Gianfranco Maƫa3, 
Federica Sella1, Marco Alberghini,4 Piero Picci1, Stefano Ferrari4, and KaƟa Scotlandi1,2
1Laboratory of Experimental Oncology, 2 CRS Development of Biomolecular Therapies,  Orthopaedic Rizzoli InsƟtute, Bologna, 
Italy; 3 Dept. of Hematology, Oncology and Molecular Medicine, IsƟtuto Superiore Sanità, Rome, Italy; 
4 Pathology SecƟon, 
Musculoskeletal Tumors Chemotherapy SecƟon Rizzoli InsƟtute, Bologna, Italy
IntroducƟon: MicroRNAs (miRNAs) are a class of small, non-coding RNA molecules whose role as molecular 
biomarkers have been confirmed in several types of tumors.  Recently, we have invesƟgated miRNA expression profile 
in Ewing sarcoma defining a signature of miRNAs that was associated with a diﬀerenƟal risk to disease progression. 
Of parƟcular prognosƟc relevance appeared the expression of miR-34a and miR490-3p.  In this study, we extended 
the analysis of miR34a expression in a larger cohort of paƟents homogeneously treated.
Methods: quanƟtaƟve RT-PCR was performed by using Taqman Micro RNA Assay kit (Applied Biosystems) in 64 
primary tumors of EFT (31 primary biopsy, 33 primary resecƟon).  Human normal stromal stem cells were used as 
calibrator. All tumor samples referred to Rizzoli InsƟtute and were treated with high-dose chemotherapy according 
to ISG/SGIII protocol. Log rank raƟon, Kaplan-Meier survival curves and Cox mulƟvariate analyses were used as 
staƟsƟcal methods
Results: Expression profile of miR-34a was found to be significantly related to either EFS (p-value = 0.0165) or OS 
(p-value = 0.0136);  PaƟents with the highest  expression of the miR-34a had an event-free as well as a survival 
rate that was superior than 90%; on the contrary paƟents with the lowest level of expression had very high risk of 
progression. MulƟvariate analysis showed that miR-34a expression is as independent prognosƟc factor. FuncƟonal 
studies are on-going to establish its relaƟonship with p53 signaling.
Conclusions: miR-34a expression was confirmed to be a strong predictor of outcome in EWS. Its rouƟnely evaluaƟon 
is strongly suggested to straƟfy paƟents according to risk,  so sparing excessive long-term toxicity to EWS paƟents 
with good prognosis. (Grants: AIRC IG-10452 to KS, MinSan bando 2009; FS is a recipient of a fellowship from the 
Onlus Il pensatore: MaƩeo Amitrano per la ricerca su tumori ossei infanƟli)
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S 264EFFECT OF THE ONCOLYTIC ADENOVIRUS DELTAͳ24ͳRGD IN 
AN IN VITRO AND IN VIVO OSTEOSARCOMA MODEL
1Mikel San-Julián, 1Blanca Vazquez-García, 2Marta M. Alonso, 3Lucía Marrodán, 4Patricia Jauregui, 2Enric Xipell, 4Leire Urquiza, 
3Luis Sierrasesúmaga, 4Fernando Lecanda, 3Marta Zalacain, 3Ana PaƟño-García.
University Clinic of Navarra, 1Dpt. of Orthopaedic Surgery, 2Dpt. of Oncology, 3Dpt. of Pediatrics; 4Center for Applied Medical 
Research, CIMA – Pamplona - Spain
ObjecƟves and Background: The condiƟonally replicaƟve oncolyƟc adenovirus Ad5-Delta24RGD achieves tumor 
selecƟvity through a mutaƟon in the Rb-binding CR2 region of E1A and presents enhanced tropism trough integrin 
infecƟon (RGD-4C modificaƟon of the fiber HI loop). Autophagic cell death is a type of programmed cell death 
that is an alternaƟve to apoptosis; so that the development of autophagy-inducing treatments could be criƟcal to 
improving the therapy for pediatric osteosarcoma. This study was designed to ascertain whether the combinaƟon of 
the oncolyƟc adenovirus Delta-24-RGD with cisplaƟn (CDDP) would result in an enhanced anƟsarcoma eﬀect in vitro 
and in vivo in an in-house murine ortothopic osteosarcoma model. 
Materials/methods and results: We performed in vitro studies using osteosarcoma cell lines that have been 
established from 4 of our osteosarcoma paƟents with metastaƟc disease: 531MII, 678R, 588M, and 598M. 
InfecƟvity studies showed that all the cell lines were suscepƟble to the Delta-24-RGD infecƟon ranging from 60 to 
100% of infected cells at 25 MOI. Delta-24-RGD showed cytopathic eﬀect and replicaƟon capacity in all cell lines. 
Viability assays showed that CDDP anƟtumoral acƟvity was synergisƟcally enhanced by combinaƟon with Delta-24-
RGD, lowering the IC50 for each of the drug in at least two logs of concentraƟon. Treatment with CDDP resulted in 
G2-M cell cycle arrest that was overcome by the combinaƟon with Delta-24-RGD, indicaƟng that addiƟon of the 
virus sensiƟzes these cells to the drug anƟtumor eﬀect. Of importance, combinaƟon treatment of Delta-24-RGD with 
CDDP resulted in autophagic cell death as shown by the electron microscopy and several autophagic biochemical 
markers such as LC3 conversion.
Orthotopic injecƟon of 250.000 531MII cells in the Ɵbial tuberosity resulted in development of tumors in >80% of 
Common gamma (γc)/Rag2/B10 animals. AŌer tumor development, animals were randomized as +/controls (no 
treatment), treated with CDDP (2 mg/Kg x 3 days/wk x 4 wk, i.p.), Delta-24-RGD (3.8x107 pfu once a wk x 3 wk, i.t.) 
or CDDP+Delta-24-RGD. Animals were followed with X-ray and at day 45 FDG-PET was performed, the animals were 
sacrified and the tumoral lesions were analyzed by H&E staining, necrosis evaluaƟon and IHC for diﬀerent histologic 
and viral markers. Our preliminary data indicate that the virus has an important onclyƟc acƟvity in the tumoral 
lesions, which are significantly reduced compared to those from untreated mice. 
Conclusions: CombinaƟon of the oncolyƟc adenovirus Delta-24-RGD with CDDP results in synergisƟc cytotoxicity 
through autophagic cell death. Our preliminary data suggest that exploiƟng autophagic cell death could provide new 
approaches to anƟsarcoma therapies. We have developed a valid ortothopic osteosarcoma model which we have 
used to validate the in vivo oncolyƟc acƟvity of Delta-24-RGD.
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SA NEW APPROACH IN THE CONSERVATIVE TREATMENT 
USING  DAPTOMYCIN IN INFECTION CASES OF 
ENDOPROSTHESIS IN EAST EUROPEAN SARCOMA GROUP
Nisichenko D.V., Grigorievskaya Z.V., Sokolovskiy V.A., Kubirov M.S., Sergeev P.S., Dmitrieva N.V., Aliev M.D.
N. N. Blokhin Russian Cancer Research Center, Moscow, Russian FederaƟon
The aim:  to evaluate the possibility of daptomycin in children and adults when performing operaƟons endoprosthesis 
in bone tumors. 
In accordance with the results of studies that were presented at the Annual Conference on AnƟmicrobial Resistance 
(2008 Annual Conference on AnƟmicrobial Resistance), daptomycin was eﬀecƟve in infecƟons of the skin and soŌ 
Ɵssues, caused by both MSSA, and MRSA strains of Staphylococcus aureus. Criteria for the applicaƟon daptomycin 
with infecƟons associated with the steel structure (stent) is not fully defined.
Materials: The invesƟgaƟon  included 15 paƟents with cancer of bone, who underwent primary or repeat hip 
replacement, for the period from 03/2010 to 11/2010 in the Department of General Oncology NN Blokhin Research 
InsƟtute. Min. age 10, max. 48 years (mean 18.6 years). Children under 12 used a dose 250mg/day; to 14 years 
350mg/day. Adults 500mg/day. DuraƟon of the course in prevenƟon of infecƟon (due to the high risk of infecƟon 
implant bed) varied introducƟon of 8 to 26. In the treatment of infecƟon rate ranged from 14 days to 36. At high 
risk of infecƟon, we mean: the paƟents with resecƟon of the proximal Ɵbia, with a deficit of soŌ Ɵssue to cover 
the endoprosthesis, an extensive skin necrosis in the postoperaƟve scar, reimplantaƟon. At 1/15 (6.5%) paƟent 
developed an allergic reacƟon in the form of urƟcaria.
For the treatment infecƟon of the endoprosthesis bed daptomycin was used in 5 paƟents. In 3 out of 5 MRSE flora 
was detected in 2 out of 5 - MSSA. IneﬀecƟveness of daptomycin revealed only one out of five paƟents - 20% with 
the agent of MSSA. In this paƟent during surgery revealed osteomyeliƟs-spoke - MSSA, for a long Ɵme to receive 
prevenƟve therapy daptomycin 500mg/day - without eﬀect, the paƟent was removed implant, the defect is replaced 
by a spacer from the bone cement with gentamicin - pus from the wound conƟnues to stand out; bacteriological 
crops - without any flora.
Results: In 10/15 (66%) cases, paƟents received a prevenƟve daptomycin prevenƟon of infecƟon 
implant bed. None of the paƟents the infecƟon was not detected during the observaƟon period. 
Conclusion: The use of the drug daptomycin in children and adults aŌer using of tumor endoprosthesis, as a prevenƟve 
anƟbioƟc treatment is jusƟfied only for a group of paƟents at high risk of possible complicaƟons. Treatment of 
infecƟons implant bed with daptomycin - eﬀecƟve, but requires further careful observaƟon and analysis.
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TUMOURS ͵ SEARCHING FOR A SYNDROME: A CASE REPORT
A. Frings*, J.Geigl+, B. Liegl-Atzwanger+++, A. Leithner+
+Department of Orthopaedics and Orthopaedic Surgery, Medical University of Graz, Auenbruggerplatz 5, 8036 Graz, Austria
++InsƟtute of Medical Biology and Human GeneƟcs, Medical University of Graz, Harrachgasse 21/8, 8010 Graz, Austria
+++InsƟtute of Pathology, Medical University of Graz, Auenbruggerplatz 25, 8036 Graz, Austria
Medical family history is an important risk factor for various cancers and therefore further invesƟgaƟons needs to be 
done if a familial aggregaƟon of cancer is observed. To address the hypothesized diagnosis Li-Fraumeni syndrome, 
we set out to invesƟgate the case presented herein by molecular geneƟc analysis of the TP53 gene.
A 76-year-old Caucasian female was admiƩed to our department due to a tumour confined to her leŌ proximal 
femur. The histologic examinaƟon confirmed grade 2 dediﬀerenƟated chondrosarcoma. In the same year, the paƟent 
was diagnosed with a clear cell renal cell carcinoma. Medical family history revealed that her youngest brother 
started suﬀering from an invasive medium- to low-diﬀerenƟated urothelial carcinoma of the bladder when he was 
67 years old and finally died of an osteoblasƟc osteosarcoma (leŌ femur) at age 69. Their mother had become ill 
due to renal cell carcinoma, as well, when she was 65 years old. Regarding the tumour spectrum presented herein, 
Li-Fraumeni syndrome was strongly considered as diﬀerenƟal diagnosis. However, molecular tesƟng did not reveal 
any pathologic alteraƟons of the TP53 gene.
Based on current data, some minor changes found in the DNA sequence could be classified as polymorphism without 
pathologic significance, however, current data may be subject to changes. A geneƟc predisposiƟon, perhaps due to 
other, currently unknown factors may sƟll not be excluded. Regarding medical family history, the empirical risk for 
tumours has increased.
As the case herein reported implies, families with highly suspicious medical family history should be closely monitored 
to minimize disease-related morbidity. Clinicians should be aware of geneƟc syndromes like Li-Fraumeni syndrome 
as diﬀerenƟal diagnosis – even if only to exclude the diagnosis.
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MODALITIES
G. Ulrich Exner1, MD, Charles E. Dumont1, MD, PhD, Pascal Schai2, MD
1Orthopaedie Zentrum Zurich ozz and 
2KS Luzern Wolhusen, Switzerland
IntroducƟon: The advances of imaging modaliƟes have importantly contributed to the improved outcome and 
survival of paƟents with malignant solid tumors. BeƩer definiƟon of resecƟon planes and  margins has allowed to 
replace amputaƟon. 
ObjecƟve: Having large experience in the CT-guided  treatment of Osteoid-osteomas  we have applied CT-based 
direcƟon of resecƟon margins in three diﬀerent modaliƟes.
Methods and Results:
1°. PreoperaƟve CT-guided inserƟon of K-wires to be used for orientaƟon and as guides for the resecƟon planes 
during definiƟve surgery (‚convenƟonal CT method’)
the day before or on the day of definiƟve surgery in the CT K-wires are inserted according to the planned resecƟon 
planes. They are either leŌ per- or subcutaneously. The cuts are performed by saw or osteotomy at the K-wire side 
averted to the tumor and guided by the K-wires 
2°. PreoperaƟve CT-scan to be used for electronic navigaƟon during surgery (neurosurgical MedtronicR system applied 
for tumor surgery, ‚advanced CT-method’).
a CT scan of the region is performed with 4 stable marks inserted before surgery. While the paƟent is transferred to 
the operaƟng theatre the CT data are loaded to the navigaƟon system. When the paƟent is prepared for surgery the 
4 inserted marks are used to synchronise the CT data in the navigaƟon system with the paƟent. The ‚navigaƟon star’ 
is calibrated and then used in the way tradiƟonally used for navigaƟon in joint replacement 
3°. IntraoperaƟve use of a mobile CT combined with digital navigaƟonal (MedtronicR O-Arm, ‚real Ɵme CT-
method’)) 
The mobile CT-scanner is used as an image intensifier in combinaƟon with digital navigaƟon during surgery. This is 
the ‚easiest’ applicaƟon, but because of the cost of the O-Arm in the near future sƟll unavailable in most set-ups.
With these techniques precision of the planned resecƟons has been reached in the order of a maximum deviaƟon 
of 1 mm.
Conclusion: Computer assisted navigaƟon is of great value in tumor surgery especially around the pelvis and around 
growth plates, when joint preservaƟon is the goal.
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AND IMPLANTATION OF A PARTIAL PELVIC REPLACEMENT.
Juergen BRUNS*, Georg DEURETZBACHER**
*   Dpt. of Orthop. Surgery, AGAPLESION Diakonieklinikum Hamburg, Germany
** Laboratory for biomechanics, Dept. of Orthop. Surgery, University Hospital, Hamburg, Germany.  
The analysis had been done in the laboratory for biomechanics.
ParƟal pelvic resecƟon and implantaƟon of a parƫel pelvic replacement (PPR) is one of the surgical procedures to 
cure a pelvic sarcoma. 
In order to analyse the postop. gait with reproducable techniques, we performed as a pilot study a gait analysis in 6 
paƟents suﬀering from a osseous pelvic tumor located in the P2-region.
Material & methods: For gait analysis the VICOM-system using video cameras and surface reflecƟon markers had 
been used. Synchroneously we recorded the ground reacƟon forces (GRF) and the surface-EMG data. Results from 
the paƟents treated side were compared with from the contralateral side and with those from healthy volunteers.
Results: We analysed 6 paƟents, 5 suﬀering from a primary bone sarcoma and one suﬀering from a loosened PPR. 
All received a parƟal pelvic replacement aŌer tumor (P2-resecƟon) resecƟon or removal of the loosened PPR. The 
clinical Enneking score correlated well with the clinical gait and the data of the gait analysis.
The best paƟent (Enneking-score 28/30) did not show severe changes in the GRF, gait data, kinemaƟcs and EMG. 
PaƟents with a medium result (Enneking-score 24-26/30) exhibited parƟcularly in the kinemaƟcs of the pelvis and 
hip joint and in the EMG disƟnct changes compared to contralateral and volunteers.
The paƟent with the worst clinical score (Enneking-score 16/30) using a cane contralaterally) exhibited massive 
changes in all criteria.
Discussion: These pilot study demonstrates in concordance with the clinical score excellent results in paƟents with a 
good Enneking-score. Most of the paƟents (4) exhibited slight to moderate changes in all gait criteria. The worst gait 
data were seen in the paƟent with the worst Enneking-score. 
Compared to a gait analysis in paƟents who had received a megaprosthesis into the distal femur those paƟents with 
a PPR demonstrated less changes in the knee and ankle joint and more changes in the hip and pelvic gait data. 
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OBJECTIVES AND PURPOSE OF STUDY: To present our results of the surgical management of symptomaƟc 
periacetabular metastases and develop an algorithm to guide management.
MATERIALS AND METHODS: ProspecƟve study idenƟfied 81 paƟents, from 30,000 referrals between 1987 and 2010, 
with hip pain from metastases where periacetabular surgery was undertaken. 
The diagnosis, lesion size, pelvic conƟnuity, reconstrucƟon type, WHO performance status, the Ɵme alive, pain, 
mobility and complicaƟons including implant failure were recorded.
RESULTS: The most common diagnosis was metastaƟc breast carcinoma (26 paƟents) followed by renal carcinoma 
(25 paƟents).  The median survival of all metastases was 14 months, with no significant diﬀerence between categories 
(breast, renal, other, p=0.87).
OperaƟons performed with number in brackets; Total hip replacement (THR) with a ‘Harrington type’ acetabular 
reconstrucƟon (32), Cemented THR (32), ice cream cone hemipelvic replacement (11), cureƩage and cementaƟon 
(7), excision without reconstrucƟon (6), tumour endoprostheƟc replacement (1), THR with reconstrucƟon with a ring 
or cement augmentaƟon (9) and one paƟent required a palliaƟve hindquarter amputaƟon due to severe neurological 
pain.
There were significant diﬀerences between the longevity of reconstrucƟon (Chi2, p=0.01) with 5 failures of 
reconstrucƟon which all occurred where cement supplementaƟon was used to reconstruct the defect without 
reinforcement. There were no failures with reconstrucƟons with tumour implants (EPR or coned hemipelvis 
placements).
ComplicaƟons were hardware failure (8), dislocaƟons (4), infecƟon (2) & neurological injury (2), significant intra-
operaƟve haemorrhage (1), >2cm leg length inequality (1) and above knee DVT (2).
We present an algorithm for the treatment of periacetabular metastases.
CONCLUSIONS: Periacetabular metasƟc lesions are challenging surgically, however, advanced techniques are more 
durable and likely to remain viable for the paƟents survival. We recommend an ice cream cone for pelvic disconƟnuity 
and Harrington rod reconstrucƟon for severe bone loss. Smaller defects can be safely managed in a non tumour 
seƫng with standard revision hip techniques.
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PERIACETABULAR RESECTION.
Delépine G1., Delépine F2., Alkhalaf S1., Cornille H. 1
1Oncologic pediatric unit Raymond Poincaré Hospital  Garches France
2Clinique du parc impérial 28boulevard du tzarevitch06045 Nice France
ObjecƟves:  Internal hemipelvectomy followed by acetabulum reconstrucƟon is a very demanding procedure and 
5 year life expectancy of the paƟents rarely exceeds 50%. For these reasons few reports give long term results of 
reconstrucƟve procedures. We want present here the results of paƟents with hand on innominate prosthesis with 
total hip prosthesis. 
Materials and methods: The hand on innominate prosthesis described in 2003 (Sarcoma  2003 7,19-27) is made of 
a Ɵtanium cup, a set of long Ɵtanium screws and 2 or 3 packs of anƟbioƟcs loaded cement. 
Between 1990 and 2007, 84 paƟents with for peri acetabular bone sarcoma (40) or metastases (44) have been 
treated by internal hemipelvectomy followed by this reconstrucƟve procedure.   Only 23 survivors (20/40 sarcoma 
and 3/44 metastases) could be followed more than 5 years. ). The histology of tumors  of these 23 paƟents 
included chondrosarcoma in 8 paƟents, osteosarcoma in 5, Ewing’s in 5, , MFH in 1, anaplasic sarcoma in 1,  renal 
cell carcinoma in 2, thyroid in 1,.  ResecƟon included 4 zone 2, 6 zone 2+3, 9 zones 2+1, 3 zones 2+1+4, and 1 zones 
1+2+3. 
Results: The mean follow up of these paƟents is 13,5 years (range 63 to 240 months). A lot of postoperaƟve 
complicaƟons have been observed; 1 deep infecƟon, 6 hip prosthesis dislocaƟon (26%), neurologic palsy (2). Late 
complicaƟons included 2 deep infecƟon, 6 polyethylene wear and 7 loosening (5 iliac, 2 femoral). 10 paƟents (43 
%) had to be re operated. The rate of orthopedic complicaƟons is significantly correlated with the topography of 
the resecƟon : loosening of the iliac reconstrucƟon was observed only aŌer resecƟon of zone 1
To evaluate the funcƟon, we used the musculoskeletal tumor society system derived from Ennecking. For overall 
evaluaƟon numerical raƟng was used for beƩer comparison of alternaƟve method. Each of these seventh variables 
was assessed on a five point scale, giving a maximum score of 35 points which was recorded as 100 %. As the aim 
of the study was to evaluate the orthopaedic result of the implants we take in account the last score of paƟent with 
local control. The mean  funcƟonal  result,  rated according modified Ennecking’s grading system, was  80%.This 
result is similar to those described in the literature for custom made innominate prosthesis and beƩer than those of 
published alternaƟve reconstrucƟve procedures. 
Conclusions: The immediate advantages and the durability of such procedure plea for using it extensively aŌer 
acetabulum resecƟon of zone 2 and 3 where we did not observed loosening of the iliac reconstrucƟon. Such a 
procedure can also be used aŌer total iliac wing resecƟon even when including zone 4. but in this locaƟon loosening 
is frequent and pleas  for reinforcing the reconstrucƟon with the head and neck of femur when there are free of 
tumor.
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Department of Trauma Surgery and spinal chord injuries, University Hospital Bergmannsheil Bochum, Buerkle-de-la-Camp-2) 
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Department of Orthopaedics and Trauma Surgery, University Hospital of Bonn, Sigmund-Freud-Strasse 25, D-53105 Bonn4) 
ObjecƟve: Up unƟl now, no consensus has been reached whether there is a need for reconstrucƟon in 
supraacetabular defects or not. As a result, no universal procedure has been established yet.  This retrospecƟve 
study was iniƟated to analyse clinical and funcƟonal outcome of pelvic ring reconstrucƟon using a tradiƟonal 
biological reconstrucƟon versus a new material combinaƟon. 
Material and methods: This study retrospecƟvely evaluates 39 (w=20/m=19) paƟents with a mean age of 
30,5 years (8,2y to 78,9y), who had undergone supraacetabular tumor resecƟon (pIb and pIc according to 
Enneking). IndicaƟons for surgery where as follows: Ewing sarcoma n=25, ostosarcoma n=4, chondrosarcoma 
n=5, other n=5. The pelvic ring was reconstructed biologically (n= 11; allograŌ n=3, autograŌ n=8) or by a 
combinaƟon of polyaxial screws and Ɵtanium rods augmented with PMMA (n= 28).
Results: The mean follow-up was 48,8 month (3 to 139,5). The mean operaƟon Ɵme was 244 min(biological) 
versus 269 min (mechanical). Mean Ɵme to mobilisaƟon with weight bearing was 27,8  weeks (biological) 
versus 3,7 weeks (mechanical). The paƟent 5-year overall survival rate was 77.2%. The 5-year survival rate 
based on the type of reconstrucƟon was 69.3% (biological) and 79.6% (mechanical), respecƟvely.
Wound healing problems where observed in 9 cases (biological n=1, mechanical n=8), deep infecƟon in 5 cases 
(biological n=2, mechanical n=3). Local recurrence was observed in 4 cases (biological n=3, mechanical n=1). 
The biological reconstrucƟon needed to be revised in 4 cases (36.4%), the mechanical reconstrucƟon also in 
4 cases (14.3%). The mean MSTS-score was 70.0% (biological=69.3%, mechanical=70.3%).  
Conclusion: Both types of reconstrucƟon presented here show an adequate funcƟonal outcome with relaƟve 
low complicaƟon rates. Main advantage of the non-biological reconstrucƟon is the potenƟally early 
mobilisaƟon. 
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WITH THE AID OF CRYOSURGERY FOR BLOOD SPARING AND 
ADJUVANT EFFECT 
Guido ScoccianƟ, Domenico Andrea Campanacci, Giovanni Beltrami, Filippo Frenos, Rodolfo Capanna
Department of Orthopaedic Oncology, AOU Careggi, Firenze, Italy
OBJECTIVES: Intralesional cureƩage of benign aggressive tumors or metastaƟc lesions in the pelvis and sacrum 
can be a challenging procedure when dealing with wide lesions or with tumors at high risk for massive bleeding. 
To reduce bleeding and to obtain an anƟtumoral eﬀect on surgical margins, we began to use cryosurgery as an 
aid during removal of the lesion, which is progressively freezed and cureƩed, and as an adjuvant treatment aŌer 
cureƩage on the remaining walls of the cavity.  A retrospecƟve evaluaƟon of 10 cases treated with this technique 
was performed to verify its eﬃcacy and safeness.
MATERIALS AND METHODS: In the last five years we performed 10 surgical procedures of intralesional excision of 
bone tumors in the sacrum and pelvis with the intraoperaƟve aid of cryosurgery.
Histology of the tumor was: metastaƟc lesion from renal cell adenocarcinoma in 4 cases, metastaƟc lesion from 
hemangiopericytoma in 1, giant cell tumor in 1, aneurysmal bone cyst in 1, schwannoma in 1, chondrosarcoma in 2 
cases. LocaƟon of the tumor was: sacrum in 3 cases, sacroiliac area in 2, periacetabular in 3, ileopubic ramus in 1, 
ischium in 1.
Age of the paƟents ranged from 19 to 77 years (average 56). Freezing was performed using cryoprobes reaching a 
temperature of -150°C. Size and number of probes varied according to size and locaƟon of the lesion. According to 
locaƟon and characterisƟc of the lesion, the defect was filled with cement or leŌ empty.
RESULTS: Average duraƟon of surgery was 3.6 hours (2.15 – 6). CumulaƟve number (intraoperaƟve and postoperaƟve) 
of blood transfusions per paƟent ranged from 0 to 15 (average 3.8). In one paƟent control of bleeding was parƟcularly 
diﬃcult and the paƟent received 15 blood units; in the remaining 9 paƟents average number of blood transfusions 
was 2.5. In these cases, at intraoperaƟve haemogasanalysis and postoperaƟve blood exams, HGB value never fell 
under 7 g/dL.
No skin necrosis was encountered. No deep infecƟon and no neurovascular damage occurred.
Follow-up ranged from 0 to 47 months (average 19.5). Two paƟents aﬀected by metastaƟc disease died 14 and 15 
months aŌer surgery for systemic disease. In the 7 paƟents with follow-up longer than 1 year no local recurrence or 
progression (in the case of schwannoma a parƟal cureƩage was performed) was observed, 
CONCLUSIONS: Cryosurgery as an aid during cureƩage of bone tumors of the sacrum and pelvis is a useful tool to 
decrease bleeding in a high-risk surgery. Use of cryoprobes to freeze tumoral Ɵssue resulted in limited bleeding. 
The absence of complicaƟons showed the safeness of the technique. Eﬀect of cryosurgery on surgical margins in 
intralesional excisions need a longer follow-up and wider series to be evaluated.
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ALLOGRAFT RECONSTRUCTION AFTER TYPE IIͳIII PELVIC 
RESECTION WITH CUSTOM MADE PROSTHESIS:  A CASE 
REPORT
M. Ayvaz, S. Bekmez, M. Tokgozoglu (Ankara, Turkey)
ReconstrucƟon of defects aŌer plevic sarcoma resecƟon with massive structural allograŌs is the choice of treatment 
in young paƟents with high funcƟonal demands. High risk of infecƟon is one of the most important factors aﬀecƟng 
the outcome of  massive allograŌ reconstrucƟon. Revison aŌersepƟc failure is a challange for surgeon  and even 
amputaƟon may be an opƟon.
Case Report: A 29 y.o. male paƟent, with complaints of pain and a mass in his thigh, in an outcenter clinic, had a 
diagnosis of chondrosarcoma aŌer biopsy. Tumor excision had been performed for two Ɵmes, aŌerwards, he had 
been referred to our clinic because of recurrence of  the tumor.  AŌer clinic and radiographic evaluaƟon, Type II + 
III hemipelvectomy and reconstrucƟon with massive structural pelvic allograŌ was performed, five years ago, with 
the diagnosis of recurrent chondrosarcoma. AllograŌ resorpƟon and drainage from the incision was found in the 
fourth year follow-up.  MulƟple debridements, spacer with anƟbioƟc loaded cement and Vacuum assisted closure 
implementaƟons was performed. In deep cultures, Klebsiella pneumonia was isolated, so parenteral anƟbioƟcs 
was admiƩed for 6 weeks, parenterally. AŌer improvement of clinic and serologic markers, reconstrucƟon with 
custom-made pelvic prosthesis  was performed, fiŌeen months ago. Resultant soŌ Ɵssue defect is closed with rectus 
abdominis local flap by plasƟc surgeons. AŌer one year follow-up, infecƟon markers were normal and MSTS score 
was 20 (good). 
Higher rates of mechanical insuﬃciency and infecƟon (up to 50% in the literature) has been reported aŌer 
reconstrucƟon with structural bone allograŌs in the treatment of pelvic sarcoma. In case of failure of reconstrucƟon 
with allograŌs,two stage revision with custom made pelvic prosthesis can be a good opƟon
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IN 14 PATIENTS AFTER INTRALESIONAL EXCISION
L. van der Heijden MSc1, A.P. van Noort-Suijdendorp MD2, M.A.J. van de Sande MD PhD1, A.H.M. Taminiau MD PhD1, B.J. van 
Royen MD PhD3, P.D.S. Dijkstra MD PhD1
Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, the Netherlands1. 
Department of Orthopaedic Surgery, Vlietland Hospital, Schiedam, the Netherlands2. 
Department of Orthopaedic Surgery, VU University Medical Center, Amsterdam, the Netherlands3. 
ObjecƟves: Surgical management of giant cell tumors of the sacrum (2-8% of all GCT) is challenging because of 
(usual) late discovery, large size, sacral nerve root involvement and spinal instability. Only small case series on 
intralesionally treated sacral GCT have been published thus far; opƟmal treatment for sacral GCT remains subject 
of debate. The purpose of the present study was to evaluate mid-term clinical outcomes aŌer intralesional 
excision of sacral GCT.
Methods: From 146 consecuƟve paƟents treated for GCT between 1994 and 2009 at a terƟary referral center, we 
retrospecƟvely evaluated all 15 paƟents with sacral GCT. One paƟent was excluded due to inoperability (extensive 
presacral soŌ Ɵssue involvement). Thus, 14 paƟents (6 male, 8 female, mean age 38 years, range 14-66) were 
included; 12 paƟents underwent primary surgery and two were referred for treatment of local recurrence. Mean 
follow-up was 88 (5-209) months; no paƟents were lost to follow-up. 
Results: PreoperaƟve complaints were pain (n=14), sensory impairment (n=3), bladder dysfuncƟon (n=2), 
rectal dysfuncƟon (n=2) and progressive neurologic deficits (n=2). All paƟents underwent selecƟve arterial 
embolizaƟon and cureƩage. Three paƟents had addiƟonal parƟal excision of the anterior sacral wall. ResecƟon 
was not indicated since the lesion was localized in S1 and lower segments (12 paƟents) and distal from S2 (2 
paƟents). ReconstrucƟon was performed through bonegraŌing in 6 paƟents and posterior spinopelvic fusion in 2 
paƟents (1 with bonegraŌing); no reconstrucƟon was needed in 6 paƟents. Three paƟents received neoadjuvant 
interferon-α and one bisphosphonates. 
Oncological outcome: Seven paƟents (50%) developed a local recurrence aŌer a median of seven months 
(range 3-139). Increasing the surgical margin by parƟal excision of the anterior sacral wall showed a reduced 
recurrence risk (1/3). Recurrence rate was also lower aŌer neoadjuvant IFN-α (1/3). Recurrences were treated 
with a combinaƟon of re-cureƩage (n=6), addiƟonal parƟal excision (n=2), adjuvant radiaƟon therapy (n=3), 
bisphosphonates (n=1) and radiofrequency ablaƟon (n=1). ReconstrucƟon was performed through posterior 
spinopelvic fusion and bonegraŌing in three and bonegraŌing alone in one paƟent; no reconstrucƟon was 
needed in three paƟents. Three paƟents developed a second recurrence. Two paƟents died from extensive tumor 
growth and distant metastases at 5 and 41 months aŌer iniƟal surgery; one developed mulƟple recurrences. 
Surgical outcome: PostoperaƟvely, complaints of pain resolved in eight paƟents; rectal dysfuncƟon resolved in two; 
and bladder dysfuncƟon remained in two. Sensory impairment was improved in two paƟents and remained in 
one. Four paƟents developed a (parƟal) cauda syndrome which eventually resolved in two. Other postoperaƟve 
complicaƟons were delayed wound healing (n=1), wound infecƟon (n=1), failure of instrumentaƟon (n=1) and 
radiaƟon induced menopause (n=1). 
FuncƟonal outcome: Mean Musculoskeletal Tumor Society (MSTS) score was 25 (15-29) at final follow-up. MSTS 
scores were highest for 6 paƟents without local recurrences (21-29) and lowest for 3 paƟents with cauda equina 
syndrome (15-21). Walking distance was normal in 10 paƟents and limited in one. One paƟent is wheelchair 
bound. Two paƟents had progressive neurological deficits and deteriorated funcƟon shortly before death.
Conclusions: Overall local recurrence rate aŌer intralesional excision was high (7/14). This was notably higher aŌer 
cureƩage alone (5/7), suggesƟng that adjuvant treatment may be desired to obtain immediate local control of 
sacral GCT. This could result in less complicaƟons and superior funcƟonal outcome, as was demonstrated in 
paƟents without local recurrences. Local recurrence risk may be reduced by wider surgical margins (e.g. anterior 
wall excision), neoadjuvant IFN-α or external beam radiaƟon for residual or recurrent disease.
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Department of Orthopaedics
Centro Hospitalar do Porto – Hospital Geral de Santo António
Oporto, Portugal
www.chporto.pt
IntroducƟon and ObjecƟves
Giant cell tumor of bone is the sixth most common primary osseous neoplasm accounƟng for about 5 percent of 
all primary bone tumors. It has a peak incidence in the third decade of life and, although being considered a benign 
lesion, this type of tumor is locally aggressive and tends to recur aŌer resecƟon. Giant cell tumors typically presents 
as an eccentric lyƟc lesion with ill-defined borders and in the absence of perilesional sclerosis.
More than 75 percent of giant cell tumors are located at the arƟcular ends of long bones. Indeed, pelvic involvement, 
with the excepƟon of the sacrum, is rare, and parƟcularly the involvement of the ischium represents only 0.5 percent 
of all giant cell bone tumors.
Treatment opƟons include cureƩage alone, wide resecƟon or excision-cureƩage, with or without radiotherapy, and 
depend on the stage of the disease, its locaƟon and expectaƟons of the paƟent.
The purpose of this presentaƟon is to report a rare case of a giant cell tumor of the ischium.
Case Report: The authors present an interesƟng case of a 30 year-old male with complaints of persistent hip pain 
aŌer trauma during sport acƟvity. Physical examinaƟon and laboratory data were not remarkable but the radiographs 
showed an ill-defined expansible and lyƟc lesion of the leŌ ischium, extending into the acetabulum. 
AddiƟonal studies with CT-scan and MRI confirmed a destrucƟve, lyƟc lesion with origin in the leŌ ischium extending 
into the posterior pillar of the acetabulum and involving the adjacent soŌ Ɵssues, with exuberant vascularizaƟon. CT-
guided biopsy revealed a giant cell tumor and the paƟent underwent surgery aŌer previous angiography for selecƟve 
arterial embolizaƟon in order to reduce tumoral vascularizaƟon. An excision-cureƩage procedure was chosen with 
resecƟon of the enƟre soŌ Ɵssue component and the leŌ ischium. In the acetabular extension of the tumor it 
was performed an extensive cureƩage followed by phenolizaƟon and cement-filling of the cavity. The paƟent also 
received adjuvant radiotherapy.
Histologic review of the excised lesion confirmed the diagnosis of giant cell tumor.
One year aŌer treatment he remains asymptomaƟc and without evidence of recurrent disease.
Discussion: Giant cell tumor of the ischium is rare and oŌen of diﬃcult diagnosis because the clinical presentaƟon 
may be easily confused with low-back pain or muscle strain.
Due to its locaƟon there is usually some delay in the appearance of symptoms. This fact allows them to reach quite 
large dimensions unƟl the Ɵme the diagnosis is made.
In the reported case the authors were dealing with a stage 3 tumor, as it was described by Enneking, because 
it involved the surrounding soŌ Ɵssue and threatened the integrity of the acetabulum. These features required 
the ressecƟon of the enƟre soŌ Ɵssue component as well as of the leŌ ischium associated with cureƩage and 
cementaƟon of the acetabular extension. This was done to avoid endangering the stability of the hip and because of 
the potenƟal comorbidity associated with supplementary reconstrucƟon procedures. Radiotherapy was also used as 
a way to decrease the risk of local recurrence.
In conclusion, it must be stressed out that a clinician must maintain at all Ɵmes a certain degree of suspicion when 
a young paƟent has pain that does not resolve. Furthermore, because of the potenƟal problems that pelvic giant 
cell tumors impose, one should keep in mind that treatment must be individualized, depending on the stage of the 
disease, its locaƟon, and the expectaƟons of the paƟent.
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LARGE INTRAOSSEOUS PORTION IN THE ILIAC BONE
C. Wibmer, MD1, B., E. Fröhlich-Sorger,  MD1, P. Sovinz, MD3, W. Maurer-Ertl, MD1, A. Leithner, MD1 B. Liegl2.
1Dept. of Orthopaedics and orthopaedic Surgery, 2InsƟtute of Pathology, 3Division of Paediatric Haemato-Oncology, Medical 
University of Graz, Austria
ObjecƟves: Clear cell sarcoma (CCS), also called malignant melanoma of the soŌ Ɵssue, is a rare enƟty (1% of all soŌ 
Ɵssue sarcomas) with a predilecƟon of tendons and aponeuroses, an incidence peak around the 3rd decade, and an 
oŌen fatal prognosis due to lymphaƟc metastases and lack of eﬀecƟve systemic therapy. Recent studies discuss the 
similariƟes between EWSR1-rearrangement posiƟve (EWSR1+) and negaƟve (EWSR1-) CCS and metastaƟc malignant 
melanoma, and possible future therapy-opƟons with the same mulƟkinase or tyrosinekinase inhibitors. We present 
the rare case of a CCS with a large intraosseous porƟon in the pelvic bone.
Case report: A 18-year-old female presented at the authors department in January 2012 with a tender, fast-growing 
mass in the right gluteal region. MRI and convenƟonal radiographs revealed an osteodestrucƟve process of max. 
3 cm in the iliac bone and a soŌ Ɵssue mass measuring 7.5 cm, with contrast enhancement and central necrosis. 
The radiologic diﬀerenƟal diagnoses were Ewing´s sarcoma, osteosarcoma or soŌ Ɵssue sarcoma. Staging (CT-
scan) revealed local lymphnode metastases, but no distant metastases. Biopsy sampling showed round to oval 
spindle cells arranged in nodules, in between rough collagen bands, posiƟve for S-100 and VimenƟn, negaƟve for 
PancytoceraƟn, EMA, SMA, Desmin, CD99. Only few, isolated cells showed posiƟvity for Melan A. FISH analysis 
revealed a rearrangement 22q12 confirming the diagnosis of a clear cell sarcoma of soŌ Ɵssue. A wide resecƟon, 
including parƟal pelvic resecƟon, as well as lymphnode resecƟon was performed. ReconstrucƟon included arthrodesis 
of the remaining sacroiliac joint with cancellous bone graŌ and canulated screws.
Histopathology revealed a malignant mesenchymal tumor arranged in nests and fascicles. The tumor cells were 
polygonal/epitheloid and spindle cell shaped with abundant eosinophilic to clear cytoplasm. The nuclei were vesicular 
with prominent nucleoli. The nests were partly surrounded by fibrous septa with wreath-like mulƟnucleated giant 
cells. An area contained melanin pigment.  NecroƟc areas and up to 9 mitoses per 10 HPF were seen.
Immunohistochemistry showed a significant posiƟve reacƟon with AB against S100, HMB 45 and Melan A. MutaƟonal 
analysis did not demonstrate a BFAF V600E  mutaƟon nor other mutaƟons in EXONS 11 and 15 of the BRAF gene. 
A resecƟon with clear margins was confirmed but 4 out of 7 of the resected iliac lymphnodes revealed metastaƟc 
disease. The interdisciplinary tumorboard decided for adjuvant local irradiaƟon including the lymph drainage region 
and adjuvant systemic therapy with a tyrosine-kinase-inhibitor.
Conclusions: An osteolyƟc lesion in the iliac bone in combinaƟon with a soŌ Ɵssue mass in an adolescent, would 
lead to other, more frequent diﬀerenƟal diagnoses than CCS. In this case of CCS a possible origin in the bone may be 
discussed, although the radiology displayed the main part of the mass in the soŌ Ɵssues. 
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POROUS TANTALUM IMPLANTS AFTER PELVIC RADIATION 
THERAPY 
N. FABBRI, G. Bianchi, M. De Paolis, P. Ruggieri, M. Mercuri
IsƟtuto Ortopedico Rizzoli, Bologna, ITALY
ObjecƟves: Durable acetabular fixaƟon is a challenging problem aŌer radiotherapy for pelvic malignancy. Acrylic 
cement is a short-term saƟsfactory soluƟon but is associated with significant risk of failure at follow-up longer than 
5 years. Porous tantalum has been successfully used during the last decade in complex joint revision surgery and 
its great potenƟal for osseointegraƟon makes it an ideal material for use in biomechanically diﬃcult situaƟons such 
as radiaƟon-induced osteonecrosis. Goal of this study is to analyse the results obtained using a porous tantalum 
cementless acetabular component in paƟents undergoing total hip replacement aŌer radiaƟon therapy.  
Materials e Methods: It is a retrospecive study of 8 paƟents managed using an uncemented porous tantalum 
acetabular component for primary implant (6 cases) or revision surgery of a previously failed total hip arthroplasty (2 
cases) aŌer radiaƟon therapy; 5 females and 3 males, average age 49 years (26-76 yrs). The cause for radiaƟon therapy 
was a primary musculoskeletal neoplasm of the pelvis in 5 cases and an hematologic condiƟon /metastaƟc cancer in 
3 cases. At the Ɵme of surgery, none of the paƟents presented evidence of clinical acƟvity of the underlying disease 
at a minimum follow-up of 2 years (2-12 years). The 2 revision cases consisted of one case of asepƟc loosening and 
one case of deep infecƟon, at 3 years and 1 year respecƟvely from previous surgery. Deep infecƟon has been treated 
by staged revision. In 2 cases, the porous tantalum acetabular component has been associated with an “augment” 
to fill a segmental periacetabular defect and support the cup. Minimum follow-up aŌer implantaƟon of the porous 
tantalum socket is 2 years.in all the cases, mean follow-up is 3 years (2-5.5 yrs). 
Results: In none of the cases there was local recurrence. There has been 1 case of  recurrent hip dislocaƟon requiring 
further surgical management. There is no clinical nor radiographic evidence of acetabular or femoral loosening at the 
most recent follow-up. Implant is well funcƟoning and stable in all cases. These results are very promising and are 
related to the great potenƟal for osseointegraƟon of porous tantalum. 
Conclusions: Porous tantalum has been very saƟsfactory at short term follow-up, demonstraƟng reliable capability 
to obtain biologic fixaƟon aŌer radiaƟon therapy. A longer follow-up is necessary to idenƟfy later potenƟal failures.
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AROUND THE PELVIS. COMPLICATIONS REPORT
GALLI SERRA MARCOS
Background: Limb-sparing surgery for tumors around the pelvis is complex and associated with a high morbidity 
(20 to 80 %). The extended sacroiliofemoral or ilioinguinofemoral (triradiate) approach is frequently used in these 
complex surgeries in spite of the high incidence of local complicaƟons reported.  The aim of the following study was 
to develop an alternaƟve to this classic approach, (i.e. a variant of surgical exposure) described as an inverted “U” 
with a distal base over the iliac crest, and to report the incidence of local complicaƟons.
The hypothesis is that this surgical exposure preserves the skin vascularity in the above menƟoned region thus 
reducing local wound complicaƟons.
Methods: From 2004 to 2008 we performed eight hemipelvectomies for diﬀerent musculoskeletal tumors (four 
chondrosarcomas, five metastaƟc lesions, two from myelomas one from thyroid adenocarcinoma, and 1 dysplasia 
epiphysealis hemimelica. We describe the surgical technique.
Results: The margins obtained were classified as “wide”. The length stay at the hospital in average was 7.1 (10-4) 
days. With this approach we had no wound dehiscence or superficial infecƟons. One paƟent presented a complicaƟon 
(parƟal necrosis of the wound) requiring an irrigaƟon and debridement procedure.
Conclusions: The inverted U approach appears as an alternaƟve in selected cases to the classical extended 
sacroiliofemoral or ilioinguinofemoral (triradiate) approach for hemipelvectomies. The incidence of local complicaƟons 
is lower and allows for a correct exposure of the pelvis without compromising the resecƟon margins.
KEY WORDS: Approach. Pelvis. ComplicaƟons. Inverted U. Limb salvage. triradiate approach.
145
PO
ST
ER
PE
LV
IC
 T
U
M
O
RSRESECTION OF MALIGNANT PELVIC TUMORS USING A MOBILE 
MULTIDIMENSIONAL IMAGING AND COMPUTERͳASSISTED 
NAVIGATION SYSTEMS 
Yang-Guk Chung, Yong-Koo Kang, Won-Jong Bahk, An-Hi Lee*, Jung-Mi Park**, Chan-Kwon Chung*
Department of Orthopedic Surgery, Clinical Pathology*, Radiology**, College of Medicine, The Catholic University of Korea, 
Seoul, Korea  
ObjecƟves: Surgical treatment of malignant pelvic bone tumors is a diﬃcult problem due to complex anatomy, delayed 
presentaƟon and limited imaging informaƟon even with various preoperaƟve imaging studies and intraoperaƟve 
fluoroscopy. A computer-assisted navigaƟon system may be helpful especially in juxta-acetabular or juxtasacral 
tumor resecƟon for preserving hip joint or neural structure, which will provide funcƟonal excellence. We evaluated 
the result of our early experience of pelvic tumor resecƟon using computer-assisted navigaƟon system.
Materials and methods: Four paƟents with juxta-acetabular malignant bone tumor and one paƟent with posterior 
iliac bone tumor underwent surgical resecƟon with the aid of computer-assisted navigaƟon system. There were 
one high grade chondrosarcoma, four metastaƟc carcinomas from thyroid follicular adenocarcinoma, laryngeal ca 
or malignant peripheral nerve sheath tumor. AŌer histologic diagnosis, the resecƟon plans were set with through 
analysis of all preoperaƟve imaging studies. The nearest distances from tumor margins to acetabulum or sacral 
foramen were 12-20 mm. Tumor resecƟon were carried out with the guidance of three plane localizaƟons of cuƫng 
points provided by computer-assisted navigaƟon with a mobile mulƟdimensional imaging system (O-arm, Medtronic 
co.) The achieved surgical margin and evidence of local recurrence were evaluated. The mean follow up periods was 
19.2 months (12-28 months)
Results: Minimum 5 mm surgical margins were obtained in four juxta-acetabular malignant pelvic bone tumors (5-11 
mm). There was no evidence of local recurrence in four paƟents with 13-28 month follow up. One latest paƟent with 
metastaƟc malignant peripheral nerve sheath tumors involving right posterior iliac bone and SI joints revealed 4 mm 
clear margin with the preserved lumbosacral plexus funcƟon postoperaƟvely. However, one new metastaƟc focus 
was developed near the resecƟon margin of posterior ilium 4 month aŌer iniƟal operaƟon. 
Conclusion: Precision of tumor resecƟon with narrow surgical margin using Computer-assisted navigaƟon system 
allowed joint preserving surgery in four juxta-acetabular malignant bone tumors and preservaƟon of neural structures 
in one juxta-sacral malignant bone tumor. 
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LYMPHOMA IN A 15ͳYEAR OLD MALE PATIENT BORN IN A 
FAMILY WITH HIGH TUMOR BURDEN
Woltsche N1, Friesenbichler J1, Maurer-Ertl W1, Urban C2, Müller E2, Leithner A1
1  Department of Orthopedic Surgery, Medical University of Graz, Austria
2  Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, 
Austria
IntroducƟon: The coincidence of malignant lymphoma and osteosarcoma with or without geneƟc background 
is rarely observed. Li-Fraumeni syndrome is a cancer predisposiƟon syndrome associated with a diversity of 
malignancies including sarcomas and also hematopoieƟc malignancies like lymphomas. Two manifestaƟons can be 
disƟnguished: classic Li-Fraumeni syndrome and Li-Fraumeni-like syndrome, which does not share all characterisƟcs 
listed for classic Li-Fraumeni syndrome. Only 8 to 22% of paƟents suﬀering from Li-Fraumeni-like syndrome show a 
detectable p53 mutaƟon.
Case presentaƟon: We present a 15-year old male paƟent, who was diagnosed a nodular-sclerosing Hodgkin’s 
lymphoma at the beginning of 2011. Under the iniƟated polychemotherapy (OEPA/VEPA) a complete remission could 
be achieved. Within a reuptake examinaƟon for progression of the chemotherapy’s second block in April, the paƟent 
reported pain in his leŌ knee dependent on acƟvity. Plain radiographs and magneƟc resonance imaging revealed 
an osteodestrucƟon in the leŌ distal femur. A biopsy was inconclusive. Three months later, a progression of the 
osteodestrucƟon was shown by imaging procedures and an open re-biopsy revealed an osteoblasƟc osteosarcoma. 
His relaƟons in first and second degree increasingly developed solid tumors, for instance leukemia, cervical carcinoma, 
colon carcinoma and bronchial carcinoma. A Lynch syndrome was excluded by immunohistochemical detecƟon of 
the DNA repair enzymes MLH-1, MSH-2, MSH-6 and PMS-2. A loss of acƟvity of these enzymes could not be shown 
in the extracted Ɵssue. A p53 mutaƟon associated with Li-Fraumeni syndrome was excluded by geneƟc analysis of a 
blood sample.  
Discussion: In the past, the development of osteosarcoma as second malignancy aŌer childhood malignancies was 
aƩributed to the carcinogenic eﬀects of treatment. The synchronous diagnosis and the family’s high tumor burden 
in this case suggest a geneƟc predisposiƟon – however, evidence has not yet been provided. In consideraƟon of his 
family’s background the paƟent could suﬀer from Li Fraumeni-like syndrome. 
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EFFECTIVE  TOOL IN  THE CLASSIFICATION OF METASTATIC 
BONE DISEASE 
J. Sopta*, J. Vasiljevic** N. Lujic***, G. Tulica****, D. RisƟc*****, J. Bokun*****, V. Mijucic***** 
*InsƟtute for Pathology, Faculty of Medicine, University of Belgrade, Serbia
** InsƟtute “Mihajlo Pupin”, University of Belgrade
***InsƟtute for Surgical and Orthopaedic Diseases “Banjica”, Belgrade, Serbia
**** Clinic for orthopaedic surgery, University of Belgrade, Clinical centre, Belgrade, Serbia
***** InsƟtute for  Oncology and Radiology, Belgrade, Serbia
ObjecƟves staƟng concisely why the study was conducted: In this study an image classificaƟon method based 
on the mulƟfractal analysis (MF) is described. This method can be applied as an addiƟonal and objecƟve tool in 
idenƟficaƟon of primary cancer in cases of metastaƟc bone disease, as well as in decreasing of the subjecƟve factor 
and error probability. This research was directed to find diﬀerences in parameters  ofmulƟfractals analysis between 
three types of primary cancer  which produce bone metastases:  renal cell ,  breast carcinoma  and lung carcinoma.
Materials and Methods: The method is tested on a  1050 cases of  metastaƟc  carcinoma into the bone who were 
diagnosed on the InsƟtute of Pathology. MF analysis can be applied to gray-level images, in general. The shape of 
segmented objects within an image can be described by analyzing binary images (black and white).
Results: This study shows that parameters of MF are significantly diﬀerent for all three invesƟgated groups of Ɵssue 
images. The accuracy of all three types of  cancer was higher than 73%.The highest accuracy (78.38%) and the highist 
specificity (85.71%) were confirmed in MF predicƟon for lung carcinoma. The most sensiƟve MF ( sensiƟvity 68.29% ) 
was in cases of breast carcinoma.  Importance of parameters in classificaƟon of metastaƟc cancers was also clasified: 
αfmax100.000, f(α)max 81.129.
Conclusions: The accuracy of all three types of  cancer was higher than 73%. According to that we can conclude that 
using this method we can postulate primary localisaƟon of metastaƟc bone carcinoma. 
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POLYMORPHISMS ASSOCIATED WITH OSTEOSARCOMA IN A 
GROUP OF PATIENTS WITH VARIOUS BONE TUMORS
1Naumov V.A., 1Generozov E.V., 2Kushlinskiy N.E.
1 Research InsƟtute of Physico-Chemical Medicine MBA RF
2 Russian N.N.Blokhin Cancer Research Center RAMS 
ObjecƟves: Osteosarcoma (OS) is a bone malignancy occurring primarily in adolescents and young adults. With 
the excepƟon of rare syndromes, liƩle is known about geneƟc predisposiƟon to sporadic form of OS and other 
bone malignancies. One of the recent large scale studies [Mirabello et al., BMC Cancer 11:209, 2011] demonstrated 
significant associaƟon between OS and single nucleoƟde polymorphisms (SNPs) in genes involved in the regulaƟon 
of bone growth and DNA repair. PracƟcally no data are available about possible associaƟon of SNPs with other types 
of bone tumors.
Methods: 66 bone tumor paƟents (35 males, 31 females, age 16 - 74) receiving treatment in the Russian N.N.Blokhin 
Cancer Research Center RAMS: 26 OS, 23 chondrosarcoma, 12 giant cell tumor, 4 Ewing’s sarcoma, 1 malignant fibrous 
hisƟocytoma, 1 schwannoma and 1 enchondroma cases - were enclosed in this study. 96 age- and sex- matched 
cancer-free healthy individuals were comprised a control group. Genomic DNA was extracted from peripheral blood. 
Genotyping of 5 candidate SNP’s located in genes involved in bone formaƟon: growth hormone 1 (GH1) gene (rs7921), 
insulin-like growth factor 1 (IGF1) gene (rs7956547), gonadotropin-releasing hormone 2 (GNRH2) gene (rs3761243), 
fibroblast growth factor 2 (FGF2) gene (rs11737764), fibroblast growth factor receptor 3 (FGFR3) gene (rs6599400), 
and one SNP located in p53 binding protein homolog (MDM2) gene (rs1690916) was performed using custom assay 
based on single-base primer extension with subsequent MALDI-TOF mass-spectrometry measuring.
Results: 2 of 6 polymorphisms showed significant associaƟon with bone tumor formaƟon: rs1690916 – MDM2 
(protecƟve allele A, OR=0.39 [0.19-0.78], p=0.007482) involved in apoptosis, and rs6599400 - FGFR3 (risk allele A, 
OR=2.15 [1.06-4.34], p=0.03005) involved in proliferaƟon regulaƟon. 
Conclusion: Significant geneƟc associaƟon of candidate OS-associated SNPs with various types of bone tumors in 
clinically heterogeneous group may suggest a possible common mechanism of their pathogenesis. Thus, our results 
confirm previous findings concerning associaƟon between certain SNPs and OS and open a new perspecƟve in 
geneƟc analysis of predisposiƟon to various histological types of bone tumors. Larger studies are required to confirm 
this hypothesis.
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OF EXPRESSION ARRAY ΈGENES AND MICRORNAΉ: 
OSTEOSARCOMA CELLS AND CD99 TRANSFECTANTS IN 
COMPARISON
Marika Sciandra1,2, Andrea Grilli1,2, Maria Teresa Marino1,2, Maria CrisƟna Manara1,2, Piero Picci1, and KaƟa Scotlandi1
1 Laboratory of Experimental Oncology – 2 CRS Development of Biomolecular Therapies,  Orthopaedic Rizzoli InsƟtute, Bologna, 
Italy
IntroducƟon and aims: osteosarcoma (OS) is the most common bone tumor which aﬀects children and young adults. 
Emerging evidence suggests this neoplasm as a diﬀerenƟaƟon disease in which geneƟc and epigeneƟc abnormaliƟes 
could interrupt the process that osteoblast precursors face to become mature cells. The CD99 molecule, down-
regulated in OS, acts as a tumor suppressor in this tumor and it is expressed in the normal counterpart, in osteoblasts 
and mesenchymal stem cells. It seems to emerge as a new mediator in osteoblasƟc diﬀerenƟaƟon, being able to 
overcome the impaired osteoblastogenesis that characterizes osteosarcoma cells. In this study we  invesƟgate the 
molecular aspects responsible for CD99-induced phenotype.
Materials and Methods:  we examined an OS cell line and CD99 stable transfectants in basal condiƟons and addressed 
to diﬀerenƟate into osteoblasƟc lineage aŌer 7 and 14 days of treatment.  Microarray analyses of gene expression 
(Aﬀymetrix plaƞorm) and microRNA profiling (Agilent plaƞorm) were performed. The relaƟonship between the two 
plaƞorms was explored both following correlaƟon studies and using database predicƟons for miRNA targets.
Results:  Cells with forced expression of CD99 were found to be characterized by a  sustained down-regulaƟon in 
gene expression. This led us to explore microRNA profiling of these cells, considering their role in the epigeneƟc 
regulaƟon of gene expression. We found significant up-regulaƟon of some miRNAs when we directly compared 
CD99 overexpressing cells and parental cell line in basal (t0) and during osteoblasƟc diﬀerenƟaƟon (t7; t14). Since 
miRNAs are generally associated with gene expression repression, this suggests miRNA as possible mediators of 
general gene expression silencing that characterizes CD99 overexpressing cells. Among the up-regulated miRNAs, 
miR-34a, up-regulated at  t0 and t7, aƩracted our aƩenƟon due to its funcƟonal relaƟonship with p53 signalling and 
cell cycle regulators. qPCR validaƟon confirmed up-regulaƟon of miR34a in cells overexpressing CD99 either in basal 
and in diﬀerenƟaƟve condiƟons. This is in line with a recent report on Ewing sarcoma (Nakatani F. et at., 2012) and 
with the general oncosuppressor role of this miRNA in cancer. BioinformaƟc analysis of the cross-talk between gene 
expression and miRNA profile of these cell indicated involvement of TGFβ signalling, with AKT1 and SMAD2 and 4 
among the leading modulated targets. FuncƟonal studies are on-going.
Conclusions:  The data obtained in this study support the role of CD99 as a tumor suppressor  that mediates 
mechanisms of transcripƟonal repression likely associated to changes in miRNA  expression. Up-regulaƟon of miR34a 
as well as regulaƟon of TGFβ signalling appears to be crucial mediators that deserve further invesƟgaƟon. 
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PIGMENTET VILLONODULAR SYNOVITIS
Schauwecker, J. 1; Horn, C. 2, Rudert, M. 2, von Eisenhart-Rothe, R. 1
1Department of Orthopedic Surgery, Klinikum rechts der Isar, Technical University of Munich, Germany
2Department of Orthopedic Surgery, Koenig-Ludwig-Haus, University of Wuerzburg, Germany
ObjecƟves: Pigmented villonodular synoviƟs (PVNS) also called tenosynovial giant cell tumor is a rare tumor-like 
lesion causing local destrucƟon of the joint. Along with its semimalignant histology tumor recurrence is the main 
complicaƟon aŌer resecƟon. Thus the following retrospecƟve study should clarify the adequate surgical method and 
the indicaƟon for addiƟonal irradiaƟon therapy depending on surgical method and type of PVNS.
Materials and Methods: Between 1997 and 2007 43 paƟents undervent surgery for PVNS of the hip (6), the knee 
(33), and ankle (3). 24 paƟents were showing a diﬀuse type, 19 a localized type of PVN’S. 39 paƟents following 
arthroscopical (7) or open (32) treatment were included in a retrospecƟve study with a mean follow-up of 37.2 
months. Tumor recurrence according type of PVNS and surgical method have been analyzed staƟsƟcally.
Results: 6 paƟents (86%) following arthroscopical treatment showed recurrence of PVNS aŌer 36.3 (5.9-66.6) 
months. 8 (25%) paƟents following open surgical treatment showed recurrence of PVNS aŌer 85.1 (69.2-101) months. 
Thereby 12 paƟents (50%) with diﬀuse type developed recurrence aŌer 63.6 (44.2-83) months and 2 paƟents (13%) 
with localized type aŌer 103.5 (73.5-133.3) months. Arthroscopical treatment of diﬀuse PVNS was always (100%) 
leading to recurrence whereas open surgical treatment showed a recurrence rate of 36.8%.
Conclusions: The present study demonstrates that arthrosocpical treatment of PVNS is a possible surgical method 
only in case of localized type and should be avoided in diﬀuse type. In summary we suggest, that addiƟonal 
radiotherapy should be performed aŌer first recurrence of diﬀuse type PVNS. AŌer first resecƟon of diﬀuse type 
PVNS radiotherapy might reduce tumor recurrence and should be discussed with the paƟent.
Keywords: Pigmented Villonodular SynoviƟs, Tenosynovial Giant Cell Tumor, Radiotherapy, Recurrence
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AFTER ENDOPROSTHETIC REPLACEMENT FOR EWING 
SARCOMA.
M Boﬀano, C Gaston, R Grimer, S Carter, R Tillman, A Abudu, L Jeys
Royal Orthopaedic Hospital, Birmingham (UK). 
ObjecƟves: EndoprostheƟc replacements are commonly used following resecƟon of Ewing sarcoma in the limbs. If 
there is either a poor response to chemotherapy or a posiƟve margin, radiotherapy (RT) is usually recommended. We 
have invesƟgated the oncological and prostheƟc outcomes for paƟents to see what the advantages and disadvantages 
of radiotherapy have been in this group of paƟents.
Methods: RetrospecƟve review of prospecƟve database.
Results: 187 paƟents have had an endoprostheses for Ewing sarcoma with an age range from 2 to 67yrs. There were 
57 proximal femur replacements, 35 proximal Ɵbia, 25 proximal humerus, 24 distal femur and 6 total femur. 49 were 
extendible replacements in children. 136 paƟents had wide margins with 51 having marginal or intralesional margins. 
104 had >90% necrosis and 83 had <90% necrosis. According to current protocols 82 paƟents would not have needed 
RT (ie good margin and >90% necrosis) but 105 should have had RT – although in fact only 38 did have RT. 
The local recurrence (LR) rate for the ‘good’ group was 6% but was 10% for the ‘bad’ group who did have RT and 
15% for the ‘bad’ group who did not have RT. Overall survival was predicted by chemotherapy response, not by the 
use of RT.  In the paƟents who had RT the infecƟon rate of the prostheses was 26%, compared to 13% in those who 
did not have RT. The infecƟon rate was doubled in children with growing prostheses so that a child with a growing 
prosthesis and radiotherapy had a 44% chance of geƫng it infected compared to a 11% risk for an adult not having 
radiotherapy. 
Conclusions: Although radiotherapy decreases the risk of local recurrence it doubles the risk of infecƟon around a 
prosthesis. PaƟents need carefully informing of the risks and benefits of RT around EPRs. 
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Ivone Ribeiro1, Joana Gonçalves1, Margarida Caldas2, Flávio Videira3, Augusto Moreira3, Marta Soares4, Mariana Afonso2, Jorge 
Guimarães3, Sofia Conde1
Radiotherapy1, Pathology2, Surgery3 and Medical Oncology4 Departments, Portuguese Oncology InsƟtute -Oporto, Portugal.
IntroducƟon: Surgery and adjuvant radiotherapy have been the standard treatment for most deep-seated sarcomas. 
The subgroup of myxoid lipossarcoma (MLS), the second most common type of liposarcoma, has been reported to 
be more radiosensiƟve compared with other soŌ Ɵssue sarcomas.  Thus, radiotherapy may be used in neoadjuvant 
seƫng, to induce downsizing and promote resectability.
ObjecƟve: To demonstrate the clinical and histologic response of three paƟents with MLS to neoadjuvant 
radiotherapy.
Material and Methods: We have retrospecƟvely analyzed three paƟents diagnosed as MLS in biopsies and were 
submiƩed to neoadjuvant radiotherapy. We have analyzed clinical, radiologic and pathologic responses as well as 
acute toxicity to neoadjuvant radiotherapy.
Results: Neoadjuvant radiotherapy has been well tolerated. All paƟents had a good clinical response with some 
reducƟon of tumor volume. Pre-operaƟve MagneƟc Ressonance Image (MRI) also showed some degree of tumor 
volume reducƟon, however without any imagiologic morphologic change compare with iniƟal images. Histologic 
examinaƟon revealed an almost   complete pathologic response in all cases.
Conclusion: These three cases suport the idea that MLS tumors show significant response to the treatment with 
neoadjuvant radiotherapy, with a near-complete pathologic response, despite the absence of an accurate correlaƟon 
with pre-operaƟve imaging studies.
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PATIENT WITH NONͳSMALL CELL LUNG CANCER. 
Vasileios Kontogeorgakos1, Maria Aggeliki Kalogeridi2, Ioannis Gioulbasanis3, Ioannou Maria4
Department of Orthopaedic Surgery, University Hospital of Thessalia, Larissa, Greece  1. 
Department of RadiaƟon Oncology, University Hospital of Thessalia, Larissa, Greece2. 
Medical Oncology Department, University Hospital of Thessalia, Larissa, Greece3. 
Pathology Department, University of Thessalia, Larissa, Greece4. 
IntroducƟon: RadiaƟon recall phenomenon is an inflammatory reacƟon appearing to previously irradiated areas. 
AnƟcancer agents including doxorubicin, taxanes and anƟmetabolites such as gemcitabine have been reported 
to trigger this phenomenon when administered aŌer radiaƟon therapy. The frequency of this poorly understood 
phenomenon may have been underesƟmated in the past. Timely diagnosis is of paramount importance for the 
appropriate management of associated symptoms. 
Material - Aim: We present a case of a 56 year-old man with a poorly diﬀerenƟated, non- small cell cancer of 
the right upper lung lobe originally presented with stage cT3N2Mx (IIIb). The paƟent was referred for definite 
chemoradiotherapy. He received the first  chemotherapy cycle with the combinaƟon of CisplaƟn 75mg/m2 (D1) 
2 
and Gemcitabine on 1000mg/m2 (D1, 8) and then he was planned for concomitant chemoradiotherapy with 33 daily 
fracƟons to a total dose of 66Gy concurrently with weekly CisplaƟn (40mg/m2). Finally, he was planned to receive 5 
addiƟonal cycles of CisplaƟn - Gemcitabine. During the fourth cycle of his post-radiaƟon chemotherapy the paƟent 
complained about a newly presented pain of his right shoulder.  The pain became constant and severe within a week, 
aggravated by shoulder moƟon. During physical examinaƟon a very painful nodule was palpated in the subscapularis 
muscle. No skin reacƟon was present. MRI of the shoulder revealed a fusiform swelling of subscapularis muscle, 
within the radiotherapy portal. He was oﬀered a diagnosƟc biopsy and histology revealed inflammatory cells within 
the muscle. 
Results: The diagnosis of myosiƟs as a radiaƟon recall phenomenon was first in line. Treatment consisted of steroid 
im to the involved muscle and per-os therapy. Immediate relief of pain was noƟced. This report joins a small number 
or radiaƟon recall events related to Gemcitabine exposure. However, radiaƟon myosiƟs in the absence of cutaneous 
involvement, as in this case, has rarely been described in the literature. 
Conclusion: MyosiƟs should be kept in mind as a radiaƟon recall phenomenon whenever a paƟent presents with 
pain within a previous irradiaƟon field during exposure to certain chemotherapeuƟc regimens. 
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EXPERIENCE ON 52 CASES
Elisa Pala, MD; Giuseppe Bianchi, MD; Andreas F. Mavrogenis, MD; Carlo Romagnoli, MD; Giovanni Guerra, MD; Pietro Ruggieri, 
MD, PhD;
IV Department of Orthopaedics, University of Bologna, IsƟtuto Ortopedico Rizzoli, Bologna, Italy 
ObjecƟves: Radio induced sarcomas are rare. We report our experience about incidence, treatment and outcome 
of fiŌy-two paƟents followed at long term. We retrospecƟvely reviewed our experience to characterize prevalence, 
treatment, relapse and survivorship at long term follow up of this rare disease.
Material and Methods: FiŌy-two paƟents aged from 14 to 83 years (mean 49 years), were treated from 1980 to 
2008. Lesions aﬀected the femur (16), pelvis (11),  Ɵbia (6),clavicle(6),scapula (4),spine (3) humerus (3),  skull(2) 
and sacrum (1). The mean radiaƟon exposure dose for the paƟent was 33 Gy (range from 25 to 50 Gy) with a 
mean interval from radiaƟon of 15.1 years (range 5-30 years). Forty-five paƟents had post-radiaƟon bone sarcoma, 
seven had post–radiaƟon soŌ-Ɵssue sarcoma. There were thirty-five secondary osteosarcomas, sixteen secondary 
high grade spindle cell sarcomas and one case of secondary angiosarcoma. Limb salvage surgery was performed 
in 24 cases, amputaƟon in 15 cases. Thirty-two paƟents were treated with neoadjuvant chemotherapy according 
to diﬀerent protocols, twelve paƟents had surgery as first treatment, one paƟent underwent embolizaƟon, five 
had chemotherapy only, two paƟents received palliaƟve care. StaƟsƟcal analysis with Kaplan Meier curves and Cox 
regression mulƟvariate analysis were performed.
Results: At a mean follow up of 4 years twenty-one paƟents were disease-free, seven were alive with disease, 
twenty-four died with disease, six local recurrences were observed and 12 paƟents developed lung metastases. 
Kaplan Meier curves showed an overall survival of 53%, 47% and 42% respecƟvely at 2,5, 5 and 10 years. PrognosƟc 
influence of margins, neoadjuvant chemotherapy and site of tumor was evaluated at mulƟvariate staƟsƟcal analysis: 
paƟents with wide surgical margins and  neoadjuvant chemotherapy, with tumor in clavicle and in the Ɵbia  had 
beƩer survivorship, without staƟsƟcal significance. MetastaƟc disease at diagnosis influenced survivorship, without 
staƟsƟcal significance .
Conclusion: Post radiaƟon sarcoma has always had a poor prognosis, in previously reported literature. Prognosis 
improved with recent treatments, as from our analysis. A high percentage of paƟents can be treated with neoadjuvant 
chemotherapy and surgery. In most paƟents, limb sparing surgery is possible and safe, but the expectaƟon of life is 
poor.
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HIGH DOSEͳRATE BRACHYTHERAPY ΈPHDRBΉ AND 
LIMITEDͳDOSE EXTERNAL IRRADIATION ΈEBRTΉ IN NONͳ
RHABDOMYOSARCOMA PEDIATRIC SOFT TISSUE SARCOMAS ΈPSTSΉ.
1San-Julián M; 1Vázquez-García BL, 2San-Miguel I; 2Rodríguez-Ruiz M; 2Olarte A; 3Sierrasesúmaga L; 2Marơnez-Monge R
 1Department of Orthopaedic Surgery,       2 Department of RadiaƟon Therapy, 3 Department of Paediatrics. University of 
Navarra – Pamplona - Spain
OBJETIVE: To decrease radiaƟon-related long-term toxicity in paƟents with pSTS. 
PATIENTS AND METHODS: Eight paƟents (two girl, six boys) with a median age of 11 years (range 7 - 15 years) 
were treated between 2001 and 2010 with conservaƟve surgical resecƟon and PHDRB (24Gy in 6 b.i.d. treatments) 
followed by 27Gy of EBRT three weeks later. Site-appropriate chemotherapy started at the commencement of 
EBRT.
RESULTS: AŌer a median follow-up of 5 years (range, 1–8), only two paƟents had grade 1 o greater side eﬀects 
(grade 2 fibrosis in a forearm pSTS and grade 2-3 cosmesis/atrophy in a perimandibular sarcoma). Two paƟents 
with metastaƟc disease at diagnosis died of disease without evidence of locoregional failure at 1 and 1.3 years, 
respecƟvely. The remaining 6 paƟents are alive and without evidence of disease.
CONCLUSION: PHDRB of 24Gy combined with 27Gy of EBRT is highly eﬃcacious in pSTS and preserves organ 
funcƟon and cosmesis in the majority of the paƟents. Further refinement is needed to minimize long-term 
morbidity.
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NONRHABDOMYOSARCOMA IN CHILDREN ͳ SINGLE CENTER 
EXPERIENCE 
J. Bokun1 , Paripović L1, V. Ilić1, J.Sopta 2, Z. Vučinić3, N. Lujic3, Z.Bekic1, M. Nikitovic1
1 InsƟtute for Oncology and Radiology of Serbia, Belgrade, Serbia     
2 InsƟtute of Pathology, School of Medicine, Belgrade, Serbia
3 InsƟtute for Ortopedic surgery “Banjica”, Belgrade, Serbia
IntroducƟon: The aim of our study was to analyze the results of mulƟmodal therapy and the role of radiotherapy 
in children and adolescents with adult type nonrhabdomyosarcoma  soŌ Ɵssue sarcoma (NRSTS) treated at the 
InsƟtute for Oncology and Radilogy of Serbia.
Materials and methods: Between 1996 and 2010, 17 children (11 male, 6 female)  with adult type of NRSTS were 
treated. Median age at diagnosis was 12 years ( range 3 to 18 yrs.). There was 7/17 (41.1%)) paƟents with malignant 
peripheral nerve sheath  tumour (MPNST), 2 paƟents with clear cell sarcoma, 2 with alveolar soŌ part sarcoma, 1 
with  epitheloid sarcoma, 1 neuroepithelioma, 1 liposarcoma,  1 leiomyosarcoma, 1 fibrosarcoma and 1 mesenchimal 
chondrosarcoma.  
Primary site of tumor was extremiƟes in 9, trunk and thorax  in 1,  head and neck in 3 and pelvis in 4 cases.  Most 
of them (12 pts.) had large tumor (> 5 cm).There was 2/17 (11,76%) pts with metastaƟc disease, 1 with pulmonary 
metastases and 1 with lymph node involvement. They were treated using mulƟmodality therapeuƟc approach 
including  surgery, chemotherapy and radiotherapy.
Results: Grossly complete tumor resecƟon had 8 pts. and they were classified as IRS group I. 4 pts. classified as IRS 
II, 1 pt. IRS III and 2 pts as IRS IV . Chemotherapy was administered in 16/17 pts. neoadjuvant chemotherapy in 8 
pts. The chemotherapy regimens were VACA , EVAIA and CEVAIE. Radiotherapy ( RT) was performed in 12 pts. In 10 
paƟents RT was postoperaƟve, concomitantly with chemotherapy. The total dose ranged from 4400 to 6000 cGy, in 
convenƟonal fracƟonaƟon. Daily fracƟonaƟon from 170- 200 cGy. PaliaƟve irradiaƟon was performed for 2 pts.
During the 15 to 175 months follow-up period  (Me= 65 months), overall survival rate was  73,9 %  and disease free 
survival rate was 68,1 %. 
Conclusion: Complete surgical excision is the mainstay of therapy. PostoperaƟve radiotherapy is acceptable for localized 
NRSTS with gross residual disease or microscopic residual tumor. CombinaƟon of limited surgery and RT should be 
able to achieve local control with superior funcƟonal result. PreoperaƟve RT is area of further invesƟgaƟon.    
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Kazuki
Department of Orthopaedic Surgery, Osaka City General Hospital, 2-13-22, Miyakojimahondori, Miyakojima-ku, Osaka 534-0021, 
Japan - TEL:81-6-6929-1221  FAX:81-6929-1091
Background: With advances in the treatment of lung cancer, the prognosis of paƟents with bone metastases from 
lung cancer has been improving. We aƩempted to evaluate the clinical outcomes and prognosis of paƟents with 
bone metastases from lung cancer.
PaƟents and methods: We retrospecƟvely invesƟgated the charts of 35 paƟents diagnosed with bone metastases 
from non-small cell lung cancer (NSCLC), who visited and consulted the Department of Orthpaedic Surgery at 
Osaka City General Hospital between January 2007 and April 2011. There were 18 men and 17 women, and the 
mean age at the Ɵme of first visit to our department was 64 years. We assessed their clinical outcomes by using 
the following parameters: the locaƟon of bone metastases; skeletal-related events (SREs); treatment of SREs, 
including bisphosphonates (BPs); epidermal growth factor receptor (EGFR) mutaƟon; treatment of lung cancer with 
convenƟonal cytotoxic chemotherapy and molecular target-based therapy; and prognosis.
Results: Among all 35 paƟents, there were pathological fractures in 9 cases (surgical indicaƟon in 7 cases), and bone 
biopsy was performed in 15 cases. Radiotherapy was performed in 24 cases. EGFR mutaƟon was determined in 12 
cases, and EGFR-targeted therapy was performed in 14 cases and cytotoxic chemotherapy in 20 cases. BP treatment 
was performed in 23 cases. In the follow-up period (mean, 197 days), 16 paƟents died of disease, 13 paƟents were 
alive with disease, and 6 paƟents were lost to follow-up. The median survival Ɵme was 357 days.
Conclusion: SREs cause significant loss of acƟvity of daily living and quality of life in NSCLC paƟents. It is important 
that orthopedic surgeons in cancer hospitals diagnose bone metastases from NSCLC smoothly and indicate suitable 
treatment to prevent SREs. As a consequence, these paƟents can be treated with chemotherapy for NSCLC, including 
EGFR-targeted therapy, according to the rouƟne protocol. Such therapeuƟc strategy may syntheƟcally improve the 
prognosis of NSCLC paƟents with bone metastases.
009
158
PO
ST
ER
O
N
CO
LO
GY 023PROGNOSTIC FACTORS FOR PATIENTS WITH SOLITARY BONE METASTASIS
Manabu Hoshi, Jun Takada, Naoto Oebisu, Makoto Ieguchi, Shinji Takahashi, Masanari Aono, Masatsugu Takami, Hiroaki 
Nakamura
Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 
545-8585, Japan.
ObjecƟve: The term “solitary bone metastasis” is defined in the present study as a single bone metastasis originaƟng 
from a primary cancer without visceral organ metastasis. We assessed the survival rates and prognosƟc factors in 42 
paƟents with solitary bone metastasis, and discussed the impact of diﬀerent surgical strategies on survival. 
Materials and Methods: We retrospecƟvely analyzed data from 42 paƟents who underwent treatment for solitary 
bone metastasis at a single insƟtuƟon. There were 25 men and 17 women. The median age of the paƟents was 
64.5 years (range 41–82 years). The paƟents were followed for an average period of 21.2 months (range 0.4–127.3 
months). Their clinical records were retrospecƟvely reviewed. Factors influencing survival were determined using 
univariate and mulƟvariate analyses. ParƟcular aƩenƟon was paid to the orthopedic surgery used for solitary bone 
metastasis. 
Results: The one-year survival rate was 76.5%, and the median survival period was 30.0 months. The presence of 
primary cancer and poor performance status were idenƟfied as independent prognosƟc factors using Cox regression 
mulƟvariate analysis. Tumor resecƟon and surgical margin were not significantly related to paƟent survival. 
Conclusions: The results of this analysis indicated that the prognosis for paƟents with solitary bone metastasis 
depended on the presence of primary cancer and on poor performance status.
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P Brewer, BSc, MBChB, FY2 Doctor
Z Riddell, BSc, Medical student
RJ Grimer, FRCS, Consultant Orthopaedic Surgeon
L Jeys FRCS, Consultant Orthopaedic Surgeon
The Royal Orthopaedic Hospital Oncology Service,
Bristol Road South,- Birmingham, - B31 2AP.
Whilst there are numerous studies invesƟgaƟon perioperaƟve mortality of amputaƟons performed for peripheral 
vascular disease, there are few studies exploring this in oncology paƟents. The authors have reviewed their 
experience in oncology paƟents who had had an above-knee amputaƟon (AKA), invesƟgaƟng the incidence of 
reported thromboembolic events, and death.
Method: RetrospecƟve review of data stored on a prospecƟve database.
Results: 484 paƟents were idenƟfied that had had an above-knee amputaƟon between 1980 and 2011. The 
most common diagnosis leading to amputaƟon was osteosarcoma (45%) followed by chondrosarcoma (6%). The 
majority of paƟents (301) underwent their above knee amputaƟon as a primary procedure (62%). There were two 
inpaƟent deaths soon aŌer the above knee amputaƟon (mortality 0.4%) and a further two deaths within 30 days 
of the procedure (30 day mortality 1%). Only two deaths were directly related to the procedure and were due to a 
pulmonary embolism. The incidence of nonfatal, clinically evident thromboembolic events was 0.6% in the defined 
perioperaƟve period of 30 days. The one year survival was 79% and the five year survival was 52%.
PaƟents who had an amputaƟon due to failure of reconstrucƟon were found to have a beƩer survival.
Conclusion: Above knee amputaƟons are performed mainly for vascular indicaƟons but also for bone of soŌ Ɵssue 
tumours of the lower limbs; represenƟng two completely diﬀerent paƟent groups reflected by the perioperaƟve risk, 
significantly lower in oncology paƟents (<1% vs 8 to 23%). Although a high risk group there is no consensus regarding 
thromboprophylaxis due to the increased risk of bleeding. However, due to the low complicaƟon rates of modern 
methods of prophylaxis the authors propose rouƟne prophylaxis for paƟents undergoing above knee amputaƟons.
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J. Friesenbichler1, W. Maurer-Ertl1, J. Szkandera2, P. Sadoghi1, C. Weger1, U. Pirker-Frühauf1, A. Leithner1.
1Department of Orthopaedic Surgery, Medical University of Graz, Austria.
2Department of Oncology, University Clinic of Internal Medicine, Medical University of Graz, Austria.
Purpose: The eﬀects of systemic metal ion exposure in paƟents with implants made of common prostheƟc alloys are 
sƟll a maƩer of concern. The aim of the study was to determine the measurement values of cobalt (Co), chromium (Cr) 
and molybdenum (Mo) in the serum of paediatrics and young adults following tumour resecƟon and reconstrucƟon 
of the knee using fixed hinge megaprostheses as well as the funcƟonal outcome.
Methods: Blood was taken from 10 paƟents [mean follow-up: 109 months (range, 67 to 163)] treated with fixed 
hinge megaprostheses (HMRS, Stryker, Mahwah, NJ) and analysis was carried out using electrothermal graphite 
furnace atomic absorpƟon spectrometry (ET-ASS). For funcƟonal evaluaƟon the MSTS Score, WOMAC Score and KSS 
were used.
Results: AŌer an average follow-up of 109 months the mean results for cobalt were 5,07 μg/L (range, 0,40-12,80 
μg/L), for chromium 4,20 μg/L (range, 1,48-8,91 μg/L) and for molybdenum 0,55 μg/L (range, 0,10-0,90 μg/L). The 
values for Co (normal: 0-0,50 μg/L) and Cr (normal: 0-1,90 μg/L) were tenfold and twofold, respecƟvely, increased, 
while Mo (normal: 0-1,0 μg/L) was within the limits. Overall, the funcƟonal outcome was good to excellent in all 
paƟents (means: MSTS: 28 pts (range, 22-30), WOMAC: 3 (range, 0-9), KSS Part 1: 92 (range, 80-100), KSS Part 2: 97 
(range, 80-100).
Conclusion: Determining the concentraƟons of metal ions following fixed hinge total knee arthroplasty revealed 
significant increments for Co and Cr. The authors believe there might be an addiƟonal metal ion release from 
the surface of the prosthesis although the metal-on-polyethylene arƟculaƟon. Nevertheless, long-term studies 
are required to determine adverse eﬀects of Co, Cr and Mo following total hip replacement as well as total knee 
arthroplasty.
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FIBROMATOSIS?
G. Erturan1* (Corresponding author), H. Holme2, A. Cassoni2, R. Tirabosco3, R. Pollock4, T. Briggs4, M. Michelagnoli2
1 Oxford Trauma Unit, John Radcliﬀe Hospital, Headley Way, Headington, Oxford, Oxfordshire, OX3 9DU. UK.
2  The London Sarcoma Service, University College London Hospital, 235 Euston Road, London. NW1 2BU. UK.
3 Department of Pathology, Royal NaƟonal Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, HA7 4LP. UK.
4 The London Sarcoma Service, Royal NaƟonal Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, HA7 4LP. UK.
IntroducƟon: Desmoid fibromatosis (DF) is a heterogeneous condiƟon with lack of consensus regarding therapy. 
Fatality is rare but repeated surgery prevalent. FuncƟonal assessment for this group is not well established, although 
we believe it to be an important marker of treatment success. No validated self-assessment score exists for non-
malignant limb tumours and this may explain why no previous reports exist in the literature. However, we elected 
to use the Toronto Extremity Salvage Score (TESS) developed and validated by Davis et al. for self-assessment of 
problems with daily life aŌer treatment of limb sarcoma. The TESS is a percentage score based on 30 quesƟons 
to evaluate disability, psychosocial factors, and their relaƟonship to physical disability that has shown reliability, 
validity, and responsiveness for paƟents with an extremity tumour.
ObjecƟves: The London Sarcoma Service, one of the largest centres in Europe, set out to retrospecƟvely review self-
assessed funcƟonal outcome using the TESS.
Methods: All young people (< 21 years), with a histological diagnosis of DF in an extremity, from 2003 to 2010 were 
included. Nineteen children were assessed by telephone or post using the TESS quesƟonnaire. 
Results: Median Ɵme from diagnosis to TESS was 97 months and was not correlated with score. TESS was lower in 
children who underwent surgical resecƟon compared with those who did not, although this was not significantly 
significant (p=0.12). Five children had non-surgical therapy involving chemotherapy in 3 children, 1 child had diclofenac 
alone, and a further is sƟll under observaƟon, with a median TESS of 75.5%. Median TESS of those children receiving 
cytotoxic and non-cytotoxic therapies was high (median TESS 75.5%), despite a trend towards advanced inoperable 
disease. TESS was lower in those receiving radiotherapy (median 52.5%). It happens that the TESS analysis in this 
cohort took place greater than 2 years from treatment in all children except one at 15 months. We found children 
with progressive disease, 5 or more treatment modaliƟes, or greater than 6 events had lowest outcome scores. 
Conclusions: These finding correlates with clinical experience, confirming that progressive disease or mulƟple 
treatment modaliƟes impart a funcƟonal disadvantage. AddiƟonally, while radiotherapy is a useful treatment 
modality, the consequenƟal funcƟonal impairment should not be underesƟmated and will conƟnue to limit its use in 
younger paƟents. Longitudinal data may aid opƟmisaƟon, validaƟon and development of treatment strategies. We 
suggest an annual formal objecƟve assessment of funcƟon with addiƟonal assessment prior to a new therapeuƟc 
modality. To facilitate ease of compleƟon, we propose a touch screen electronic tablet interface for paƟent input of 
quesƟonnaires while waiƟng for outpaƟent clinical review.
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Manal A. Zamzam (1) ,  Emad Ali H.Moussa (1), Ahmed El ghoneimy (2),Mohamed S. Zagloul (5),.  Hala Taha(3), Magdy El Sherbiny (2), 
Iman Goda (3), Sameera Ezzat (4) Ranin Magdy (4)
 (1)Department  of Pediatric Hematology/Oncology-The New  Children’s Cancer Hospital (2)Department of surgical Oncology 
Oncology-The new children’s cancer hospital (3) Departement of Pathology-The New Children’s Cancer Hospital                      (4) 
Departement of Research-The New Children’s Cancer Hospital (5)Departement of RadiaƟon Therapy -The New  Children’s Cancer 
Hospital .
IntroducƟon: The evaluaƟon of factors aﬀecƟng systemic and local recurrence and final outcome are extremely 
important in defining risk-adapted treatments for paƟents with non-metastaƟc osteosarcoma of the extremity. 
PaƟents and Methods: FiŌy seven (57) paƟents treated at The Children’s Cancer Hospital-Egypt between July 2007 
and December 2010, with a minimum follow up of 12 months paƟents were retrospecƟvely evaluated in relaƟon 
to gender, age, , tumor site and size, type of surgery, surgical margins, serum levels of alkaline phosphatase and 
histologic response to preoperaƟve treatment. 
Results: With a median follow-up of 23 months, the 3-year event-free survival (EFS) and overall survival rates were 
70.5% and 77.8 %, respecƟvely. Upon univariate analysis, EFS was significantly related to the age of paƟents, serum 
level of alkaline phosphatase, tumor volume, but not to histologic subtype, or histologic response to preoperaƟve 
treatment. In MulƟvariate analysis only gender and serum alkaline phosphatase were staƟsƟcally significantly 
correlated to survival. Local and systemic recurrences occurred in 12 paƟents (21%) (Ten paƟents developed 
pulmonary metastasis, one paƟent had both bone and pulmonary and only one paƟent had local recurrence). While 
median Ɵme to recurrence was 9.2 months, all paƟents with recurrences were significantly correlated with histologic 
response to preoperaƟve treatment, and serum alkaline phosphatase. 
Conclusions: The 3 years EFS, and Overall survival were 70.5% and 77.8% respecƟvely. Serum alkaline phosphatase 
and histologic response to chemotherapy, as well as age and gender to a lesser extent, can be considered proper 
tools for deciding risk-adapted treatments for osteosarcoma paƟents. 
Key Words: Osteosarcoma, PrognosƟc factors, Pathological response, Outcome
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E. Robertson , F. Maggiani, F. Pezzella, Ni. Athanasou, M. Gibbons 
Nuﬃeld Orthopaedic Centre, Oxford University Hospital NHS Trust
IntroducƟon: Primary Lymphoma rarely presents in bone.  It commonly presents as a painful soŌ Ɵssue and bony 
mass rarely with neurological symptoms.  These tumours present incidentally in specialist shoulder and upper limb 
clinics as a presumed benign condiƟon.  
Aims:
To determine the incidence of primary lymphoma of bone, treatment and survival presenƟng to the Oxford 1.
Sarcoma Service
To assess the funcƟonal outcomes following convenƟonal treatment of this disease 2.
Methods: The histopathology database was examined for primary lymphoma of bone in the upper limb between 
1994 and 2011.  External audit cases were not included in this review.  Histology was reviewed and further confirmed 
independently for the purpose of this study. 
PaƟent records were retrieved and paƟents were excluded if a prior diagnosis of diﬀuse or non-primary bone disease 
was idenƟfied.  
The surviving paƟents were contacted by telephone and clinical review asked to complete a funcƟonal scoring 
quesƟonnaires, Oxford Shoulder Score (OSS)(1).  
Results: Forty two paƟents were iniƟally idenƟfied in the study.  Nineteen paƟents were included in the study.  The 
exclusions were 23; 9 for histological confirmaƟon, 10 soŌ Ɵssue lymphomas, 2 recurrent lymphoma involving bone, 
2 unidenƟfied.  
The anatomical site of upper limb disease was scapula (4), clavicle (2), humerus (12) and olecranon (1).  Treatment 
included combined (CHOP, rCHOP, PMitCEVO) chemotherapy and radiotherapy in all cases.  
Three paƟents required surgery for fracture including two hemi-arthoplasty and one cementoplasty.  
Of 19, 9 died, 3 are lost to follow up, and 6 alive with no disease.  
Of the remaining paƟents, 4 completed final funcƟonal assessment, reporƟng near-normal funcƟon.  The OSS score 
ranged from 42 to 48, indicaƟng liƩle funcƟonal impediment.  
Discussion: Primary lymphoma in the bone is recognised in the shoulder as an incidental finding.  The treatment 
is non-surgical with a good funcƟonal outcome expected.  Even in the presence of pathological fracture a good 
funcƟonal outcome is to be expected.   
1. Dawson J, Fitzpatrick R, Carr A. A self-administered quesƟonnaire for assessment of symptoms and funcƟon of the 
shoulder. J Bone Joint Surg Am. 1998 May;80(5):766-7.
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Jun Takada, Manabu Hoshi, Naoto Oebisu, Masanari Aono, Makoto Ieguchi, Masatsugu Takami, Hiroaki Nakamura
Department of Orthopedic Surgery, Graduate School of Medicine, Osaka City University – Osaka - JAPAN
ObjecƟves:  There have been few clinical reports concerning bone metastases from hepatocellular carcinoma (HCC). 
The aim of the present study was to elucidate the clinical outcomes of HCC metastases to bone. 
Material and Methods:  The clinical records of 15 paƟents diagnosed with HCC metastases to bone were retrospecƟvely 
reviewed.  The paƟents’ mean age was 70.8 years.  Clinical features, treatments and outcomes were analyzed. 
Results:  ExtrahepaƟc metastases, except to bone, were detectable in the lymph nodes of three paƟents (20.0%), the 
lungs of two paƟents (13.3%) and the adrenal glands of two paƟents (13.3%).  RadiaƟon therapy was carried out at 
31 sites in 13 paƟents and its eﬃcacy was calculated to be 80.6%.  Orthopedic surgery was undertaken at 15 sites in 
10 paƟents.  Unexpected mortality due to sudden bleeding occurred in two paƟents soon aŌer surgery. 
Conclusions:  RadiaƟon therapy may be the first-choice palliaƟve treatment for bone metastases from HCC.  If 
the condiƟon allows for residual liver funcƟon and a coagulaƟve paƩern, surgery should be considered for the 
treatment of some severe pain and symptoms.  Surgical planning, such as preoperaƟve transarterial embolizaƟon 
or intraoperaƟve cemenƟng, may play an important role in reducing intraoperaƟve bleeding, which can lead to liver 
failure and death.
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Kunze B, Haas HP, Ipach I, Kluba T
Department of Orthopaedics, University of Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany
Aim: Due to the heterogeneity of histological subtypes of soŌ Ɵssue sarcoma as well as the diﬀerent response 
to neoadjuvant therapy, uniform conclusions about therapeuƟc concepts, survival Ɵme and the opƟmal restaging 
scheme are diﬃcult.
The established follow-up scheme “soŌ Ɵssue sarcoma” at our insƟtuƟon was reviewed and modified based on the 
study data.
Method: The study included 117 paƟents (159 operaƟons) with soŌ Ɵssue sarcoma, which had been treated surgically 
between 2006 and 2010 at our insƟtuƟon. 7 paƟents were excluded because of incomplete paƟent records. In 
addiƟon to the demographic data, the preoperaƟve and postoperaƟve follow-up imaging studies were analyzed in 
regard to the sensiƟvity to detect distant metastases and local recurrence.
Results: NOS was the most common histological enƟty (21.5%). Primary metastases were seen in 17% of the paƟents 
(GI 5%, GII 16%, GIII 78%). 67% of primary metastases were seen in the lung and the lymph nodes. Regarding the 
follow-up examinaƟons, the local MRI (89%) and the CT-chest (40%), had the highest priority for the detecƟon of 
metastases (60% aﬀecƟng the lung).
Accordantly to these data a relevant modificaƟon of the follow-up scheme was done. Radiographs of the chest and 
bone scinƟgraphy directed not significantly to the early diagnosis of metastasis.
Factors for a poor prognosis were primary metastasis, high-grade tumours and several histological enƟƟes. 
Conclusion: The importance of adequate follow-up was shown. To evaluate the individual prognosis, mulƟple factors 
have to be considered. The MRI (local recurrence) and CT (pulmonary metastases) are demanded at regular intervals 
in the follow-up. The grading of the tumour should be considered in the follow-up frequency of the lung examinaƟon 
to avoid unnecessary radiaƟon exposure and costs in paƟents with low grade tumours.
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EXTREMITY BONES.
Mirza A.Gafur-Akhunov, Khurshid G.Abdikarimov, Sundr D.Urunbayev, Djamila Sh.Polatova
NaƟonal Oncology Research Centre, Tashkent, Uzbekistan
Aim: to study the treatment results of paƟents with osteosarcoma (OS) of lower extremity with applying the diﬀerent 
conducƟng methods of no adjuvant chemotherapy.
Materials and methods: Treatment results analysis of 122 paƟents with OS of lower extremity was performed. Men-
80(65, 6%), women-42(34, 4%).Average -19, 8+0, 9.PaƟents were divided into 3 groups: I group-34 paƟents (27, 9%), 
who had been performed no adjuvant systemic chemotherapy +operaƟve intervenƟon (OP). II group-52 patents (42, 
6%), who had been performed prolonged intra-arterial regional chemotherapy (PIACT) +OP.III group-36 paƟents (29, 
5%) PIACT on the back ground of modifiers+OP have been performed. Chemotherapy was carried out by scheme of 
CAP. Local hyperthermia with temporary hyper glycemia have used as modifiers.
Results: In the I group in 2 (5,9%) paƟents  absolute eﬀect, in 13(38,2%) parƟal eﬀect, in 15(44,1%) stabilizaƟon of 
process and in 4(11,8%)paƟents progressing of tumor process was noted. In the II group the absolute eﬀect in 7(13, 
4%); parƟal in 23(44, 2%); stabilizaƟon of process in 18(34, 6%) and in 4(7, 7%) paƟents progressing of tumor process 
was marked. In the III group absolute eﬀect was in 7(19, 4%), parƟal- in18 (50%), stabilizaƟon process-in 9(25%) and 
in 2(5, 6%) paƟents progressing of tumor process have been observed.
In the I group relapse of tumor in 8 (23, 5%) paƟents, in the II group in 9(17, 3%), but in the III group in 5(13, 9%) have 
been observed. Metastasis was detected: Ɵll 9 months in the I group in 29, 4%, in the II group in 13, 5%, in the III 5, 
6% paƟents. In the period of 10-18 months 23.5%,19,2%,16,6% and in the period of 19-36months 11,8 %,7,7%,5,6% 
cases were detected correspondingly by groups. Three-year survival 35,3%, 48,1%, 72,1%, five-year  23,5%, 38,5%, 
55,6% was composed correspondingly.
Conclusion: Survival rate of paƟent is 1, 5 Ɵmes higher in the group of PIACT with modifiers than in the group with 
pure PIACT and 2, 4 Ɵmes higher than in the group of paƟents treated with tradiƟonal systemic chemotherapy. 
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Tomoki Nakamura, Adesegun Abudu, Hiroaki Murata, Robert Grimer, Simon Carter, 
Rojer Tillman, Lee Jeys 
InsƟtuƟon; Oncology Unit, The Royal Orthopaedic Hospital, Birmingham, United Kingdom
IntroducƟon: SoŌ Ɵssue sarcomas (STS) of the pelvis present one of the most challenging problems in musculoskeletal 
oncology because of the complex anatomy of the pelvis, late diagnosis and large sizes of the tumors. The aim of 
this study is to determine the outcome and prognosƟc factors for survival and local recurrence in paƟents newly 
diagnosed with STS involving the pelvic region deemed suitable for curaƟve surgical treatment. 
PaƟents and Method: The outcome of 122 consecuƟve paƟents with newly diagnosed STS involving the pelvic 
region with at least 5-year follow-up was studied. The mean age at diagnosis was 53 years. There were 62 male and 
60 female paƟents. The mean follow-up period was 72 months (range, 3-336). The mean tumor size at diagnosis was 
11 cm. 63 paƟents had histologically grade 3 sarcomas, 32 were grade 2 and 27 were grade 1. The primary tumor 
locaƟons were extra-pelvic (n=98), intra-pelvic (n=11), and combined (n=13). 
Result: Surgical treatment was excision in 116 paƟents and hindquarter amputaƟon in 6 paƟents. Overall survival in 
122 paƟents was 59.8% at 5 years. Local recurrence occurred in 21%. Development of local recurrence was related 
to surgical margin (p=0.01), and tumor locaƟon (p=0.01). Local recurrence and tumor histological grade influenced 
development of metastases and overall survival in mulƟvariate analysis (p<0.0001, p=0.003, respecƟvely). 
Conclusion: PaƟents who develop local recurrence have a poor prognosis. The PaƟents with intra-pelvic and combined 
pelvic STS represent a parƟcular group with very high risk of local recurrence even with radiotherapy. 
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Ferraresi V.1 , Zoccali C.2, Prencipe U.2, Marolda G.2, Nuzzo C.2, Anelli V.3, Salducca N.2, , Biagini R.2
1Division of Medical Oncology A, 2Division of Orthopedics, , 3Division of Radiology
Regina Elena NaƟonal Cancer InsƟtute
Rome - ITALY
Background: Ewing’s sarcoma is one of the most aggressive and recognizzed primiƟve malignant bone tumors, 
nevertheless it is of rare presentaƟon in extraosseous sites. The most frequent sites of extraskeletal Ewing’s sarcoma 
are the chest wall, lower extremiƟes, and the trunk. We report a case of intradural extramedullary Ewing’s sarcoma 
arising in L1-L4 levels and treated with exclusive chemo-radiotherapy.  
Case report: A  40 year-old female was referred to our department complaining of progressive paralysis in her lower 
extremiƟes. Due to a radiological diagnosis of suspect ependymoma, the paƟent had recently undergone a lumbar 
surgery but the  surgeon, aŌer opening the dura mater, and verifying the unusual nature of the mass, performed 
a biopsy confirming the bony origin of the tumor. The histological examinaƟons revealed a highly cellular poorly 
diﬀerenƟated malignant neoplasm composed for the most part of quite uniform rounded cells with limited amounts 
of amphophilic cytoplasm and relaƟvely bland nuclei with evenly distribuited chromaƟn. Immunostains for keraƟn, 
EMA, S-100 protein, synaptophysin, desmin and TLEI were negaƟve, but there was a diﬀuse membranous posiƟvity 
for CD99 and FLI-1 in virtually 100% of the neoplasƟc cells fiƫng to the  diagnosis of Ewing’s intradural sarcoma. 
Basing on the diagnosis of Ewing’s sarcoma, the paƟent was rapidly addressed to a neoadjuvant  chemotherapy with 
VincrisƟna, Adriamicina, Ciclofosfamide, Ifosfamide, DacƟnomicina and Etoposide. AŌer neoadjuvant treatment the 
paƟent had a subtotal recovery of her neurological funcƟon with a slight eﬀort deficit, and an almost complete 
response as documented by total body CT/PET and spine MRI. AŌer mulƟdisciplinary discussion of the case and 
considering a wide surgery not feasible, it was decided to undergo the paƟent to a definiƟve radiotherapy as local 
treatment followed by adjuvant chemotherapy employing the same agents used in neoadjuvant seƫng, the paƟent 
being evaluated as a “good responder”. The adjuvant chemotherapy treatment is sƟll ongoing. 
Conclusion: being this localizaƟon extremely rare, no guidelines are present in literature, but considering the 
aggressiveness of the tumor and its behavior probably, not being possible to obtain wide margins, chemotherapy ad 
systemic therapy and radiotherapy for local control should be the best approach. Indeed, even though some author 
sustains the importance to remove the major part possible of tumoral mass, there is no evidence in literature that 
intralesional surgery followed by radiotherapy give beƩer results.
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Centomo, H. PhD 3, Barry, J. MSc 1, St-Yves, H. 3, Rakovich, G. MD 2, Isler, M. MD 1, TurcoƩe, RE. MD 4 and MoƩard, S. MD 1.
1-Department of Orthopedic Oncology Surgery, Montreal University, Quebec, Canada.
2-Department of Thoracic Surgery, Montreal University, Quebec, Canada.
3-Faculty of medicine, Montreal University, Quebec, Canada.
4-Division of Orthopedic Surgery, McGill University, Quebec, Canada.
ObjecƟves: The main objecƟve of this study was to assess the prognosƟc factors of paƟents presenƟng with aggressive 
sarcomas (bone and soŌ Ɵssue) with early onset of pulmonary metastasis (< 3 years) . Overall survival was assess 
according to metastasis treatment.
Materials and Methods: PaƟents from an orthopedic oncology referral center, between 1992 and 2011, that were 
diagnosed with soŌ Ɵssue or bone sarcomas and developed lung metastases were retrospecƟvely reviewed.  96 
paƟents were idenƟfied  out of which 56 paƟents with complete follow-up were included in the study. Factors 
aﬀecƟng overall survival were analyzed, with special interest in metastases treatment. Average follow up was 35.8 ± 
26.5 months. Mean age at diagnosis was 48.8 ± 18.7 years. 
Results: 5 years survival was 14.3%. 75% of sarcomas were situated in lower extremiƟes and 19.6% in upper extremiƟes. 
41.1% of paƟents had metastaƟc lung disease at iniƟal presentaƟon. The primary neoplasm was mainly soŌ Ɵssue 
presentaƟon (67.9% where: 23.7% were synovial sarcoma, 13.2% were liposarcoma, 13.2% were myxofibrosarcoma, 
10.5% were leiomyosarcoma, 7.9% were epithelioid sarcoma, 5.3% were malignant fibrous hisƟocytoma (MFH) and 
26.2% were others). Bone sarcoma represent 32.1% where osteosarcoma account for 38.9%, Ewing sarcoma for 
11.1%, MFH bone for 11.1%, chondrosarcoma for 5.5% and others for 33.4%. PaƟents presenƟng with localized 
disease develop lung metastasis in a relaƟvely short period of Ɵme 9.4 ± 7.3 months aŌer the primary diagnosis. 
33.9% of paƟents underwent surgical removal of thoracic metastasis (surgical alone 17.9% and 16.1% for surgery 
combined with chemotherapy). Aggressive surgical removal of thoracic metastases (lung resecƟon and/or greater 
than 10 metastatectomies) had a trend towards longer survival period (mean follow-up 47.5 months vs 25.7 months 
for chemotherapy only and 24.0 months for palliaƟve chemotherapy). 
Conclusions: PaƟents with pulmonary metastases following primary sarcomas have poor overall survival. In this 
study, pulmonary metastases appear early aŌer primary diagnosis and paƟents showed a poor prognosis. However, 
paƟents treated with surgical removal of pulmonary metastasis have a small improvement in their overall survival, 
but are unlikely to be cured from their disease. This improvement could jusƟfy an aggressive approach in younger 
paƟents who can tolerate aggressive surgery. However, impacts on quality of life of these paƟents remain to be 
determined.
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SPINE.
Aliev M.D., Musaev E.R., Sokolovsky A.V., Sergeev P.S., Sokolovsky V.A.
Department of Bone and SoŌ Tissue Tumors, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian FederaƟon.
IntroducƟon/ObjecƟves: The aim of the current study was to determine tacƟcal choice of diﬀerent variants of 
surgical and combined treatment at paƟents with hemoblastosis lesion of spine.
Methods: A retrospecƟve analysis was conducted on 6o paƟents with a diagnosis of mulƟple myeloma and lymphoma 
of spine who were underwent with vertebroplasty and surgical treatment between January 2001 and December 
2011. In group of paƟents there were 34 (56,7%) males and 26 (43,3%) female, with a mean age of 56 (22 to 81) 
years, thus 48 (80%) was younger 65 years. Among the treated paƟents 46 were with mulƟple myeloma, 7 with 
lymphoma and 7 plasmacytoma. During the 10 years period in our clinic were executed 60 various operaƟons to 
paƟents with hemoblastosis lesion. The mean duraƟon of follow-up aŌer the operaƟon in group of paƟents with 
mulƟple myeloma, plasmacytoma was 11,2 months (1 to 63) and lymphoma 22,4 months (3 to 96). Neurological 
status was evaluated using the classificaƟon system described by Frankel, which was before the treatment “E” at 44, 
“D” at 6, “C” at 2, “B” at 1 paƟents with mulƟple myeloma, plasmacytoma and “E” at 5, “C” at 1, “B” at 1 paƟents 
with lymphoma. 
Results: Overall surviving since surgery during 3 years was 81,5%, during 5 years 68%. While common free of 
recurrence surviving during 3 years was 46,9%, during 5 years 32,1%. Progressing of the primary disease is revealed 
in 67,3 % during 5 years. The average pain score (VAS) decreased significantly from pre- (6,3) to post-treatment (2,3). 
Based at the data of the present research the was developed a new scale of choice of tacƟcs of surgical treatment 
paƟents with mulƟple myeloma and lymphoma.
Conclusion: The tacƟcal choice of treatment depends on disease prevalence and prospecƟve term of life. 
Vertebroplasty and kyphoplasty is an eﬀecƟve minimally invasive procedure for the stabilizaƟon of pathologic 
fractures and instability of vertebra caused by mulƟple myeloma and lymphoma leading to staƟcally reducƟon of 
pain status.
Key words: hemoblastosis lesion of spine, scale of choice.
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Castellanos-Toledo A1, Rivera-Luna R2, Cárdenas-Cardós R1, Figueroa-Carbajal JJ3, Leal-Cavazos CA1
1Oncology Department and 2Division of Pediatric Hem/Oncology, InsƟtuto Nacional de Pediatría, México City, MEXICO. 3 InsƟtuto 
Mexicano del Seguro Social, Cuernavaca, Morelos, MEXICO.
Background: Some others prognosƟc factors are interrelated with the well-known prognosƟc factors in high-grade 
Osteosarcoma (HGO), this can result in poor survival and should be considered for appropriate clinical decision 
making.
Aim: To inform the influence of risk factors on prognosis.
PaƟents and Methods: RetrospecƟve, longitudinal and clinical study was performed from Jan/1991-Dec/1998, 58 
paƟents younger than 18 years with extremity HGO and no prior chemotherapy treatment were included. All received 
CDDP, DOX, CFA and VP-16. PrognosƟc-factors and Cox analysis with odds-raƟo (OR) and p<0.05 were calculated. 
Outcome variables were age, histologic paƩerns (HP), primary site, tumor size (TS), metastaƟc disease, soŌ-Ɵssue 
involvement (STI), histological response (HR) assessed by Huvos-grades and disease-free survival (DFS).
Results: Median age was 12 years (5-18y) with 18 paƟents (31%) younger than 10 years. Skeletal site (SS) distribuƟon 
was 59% distal femur, 17% proximal humerus, 14% proximal Ɵbia, 7% fibula and 3% proximal femur. 18 paƟents (31%) 
had pulmonary metastases and 3 paƟents (5%) had mulƟfocal disease at diagnosis. There were 74% osteoblasƟc 
tumors, 14% osteoblasƟc and chondroblasƟc, and 5% chondroblasƟc. 15 paƟents had an amputaƟon procedure and 
33 paƟents undergoing limb salvage of which 5 paƟents (15%) had eventual local recurrence. The more significant 
associated prognosƟc factors (APF) for local recurrence were STI at diagnosis (OR=6), grade-II HR (OR=2.8), grade-
III HR (OR=10), TS (p0.0350) and chondroblasƟc-HP (p0.0089). For amputaƟon procedures were SS (p0.0018) and 
have microscopic surgical margins (MSM) p0.0075. For development of metastaƟc disease were TS (p0.0008), MSM 
(p0.000), pulmonary metastases at diagnosis (p0.000), SS (p0.000) and chondroblasƟc-HP (p0.000). For death by 
tumor acƟvity was poor in HR (p0.0013) and TS (p0.0278). 5-years DFS without APF was 68% Vs 43% with APF 
(p0.021).
Conclusions: APF play a very important roll in Osteosarcoma prognosis and should be considered for appropriate 
clinical decisions making.
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GY 118PUTTING YOUR BEST FOOT FORWARD! IS FOOT SIZE DIFFERENT AFTER ENDOPROSTHETIC REPLACEMENT IN CHILDREN?
 CL Gaston, B Vazquez, RJ Grimer
Royal Orthopaedic Hospital Birmingham, UK
IntroducƟon: Limb salvage surgery with growing endoprostheses has allowed for a near normal body image for long 
term survivors of bone sarcomas with the achievement of equal leg lengths and normal walking.  Knowledge of other 
possible deformiƟes of the limb will help paƟents accept them later on.  This study aimed to determine whether 
paƟents with bone sarcomas treated with a growing prosthesis had any discrepancy in their foot sizes at skeletal 
maturity.
Methodology: From March 2011 – February 2012, foot sizes were measured from 53 paƟents treated with 
endoprostheƟc replacements for bone sarcomas on rouƟne outpaƟent follow-up at our hospital.  35 (67%) were 
extendible prostheses.  Weightbearing foot tracings were taken measuring maximum length and width of both 
extremiƟes for comparison.
Results: There was a significant discrepancy in foot size of paƟents who underwent lengthening with an extendible 
prosthesis compared to those that did not undergo any type of lengthening.  Feet were shorter (7.8mm vs 2.8mm, 
p = 0.02) and narrower (3.4mm vs 0.8mm, p = 0.07).  Leg lengths at final follow-up were not significantly diﬀerent 
between the 2 groups.
Conclusion: Majority of children with bone sarcomas treated with a growing endoprosthesis while skeletally 
immature develop a discrepancy in foot size on reaching adulthood. 
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CL Gaston, M Boﬀano, RJ Grimer
Royal Orthopaedic Hospital Birmingham, UK
IntroducƟon: Superficial soŌ Ɵssue sarcomas (SSTS) comprise 11-32% of all soŌ Ɵssue sarcomas.  Treatment is wide 
local excision with various studies recommending margins ranging from 1cm, 2cm, or 3-5cm.  The need for adjuvant 
radiotherapy is controversial as well.  The present study was done to document current surgical pracƟces of diﬀerent 
sarcoma centres in treaƟng SSTS.
Methods: A quesƟonnaire demonstraƟng typical cases of SSTS was developed by the senior author and sent to 
42 surgeons that treated sarcomas from 34 terƟary referral centres specializing in musculoskeletal tumours in 24 
diﬀerent countries.  Responses were tabulated and presented here. 
Results: 27 surgeons (64%) from 21 centres in 14 countries responded to the quesƟonnaire.   The mean number of 
SSTS treated per centre was 21.3/year.  There was liƩle consensus between surgeons with regards to their treatment 
strategies for both primary and secondary treatment aŌer previous inadvertent surgery for SSTS.  Surgeons had 
varying definiƟons of adequate margins as evidenced by their diﬀerent treatment protocols aŌer close surgical 
margins.  For paƟents previously treated with inadvertent surgery, 50% would rouƟnely give adjuvant radiotherapy. 
40% would excise the previous surgical bed with an overlying skin ellipse of 1cm or less on either side of the scar.
Conclusions: The lack of consensus among sarcoma surgeons with regards to the treatment of superficial soŌ Ɵssue 
sarcomas reflects the scarcity of evidence in medical literature.  More clinical studies are needed to answer the 
simple quesƟon of what consƟtutes an adequate margin for SSTS and the corresponding treatment for an inadequate 
margin.
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TUMORS OF THE MUSCULOSKELETAL SYSTEM
Maxim Rykov, Yury Buydenok
InsƟtute of Pediatric Oncology and Haematology N. N. Blokhin Cancer Research Center - Moscow - Russia
ObjecƟves: Current standards of treatment of musculoskeletal tumors in children require numerous courses of 
chemotherapy (at least 10 per year). This long and important stage of treatment requires adequate vascular access, 
which should be reliable and comfortable for the paƟent. The usual approach in establishing long-term venous 
access in child paƟents is to install a central venous catheter. However, an external central venous system requires 
meƟculous care, control and maintenance, which cannot be achieved and provided while at home in between courses 
of chemotherapy. Therefore, a central catheter needs to be inserted prior to almost every course of chemotherapy. 
This procedure requires repeated anesthesia and may cause a number of serious complicaƟons, thus delaying the 
start of the next course or stage of treatment.
Implantable venous port-system are free from many of the disadvantages which are associated with the use of central 
venous catheters. In contrast to the external venous systems, port-systems are implanted once for the enƟre period 
of treatment, reducing the need for the administraƟon of general anesthesia, required when central catheterizaƟon 
is performed on a child paƟent. However, proper care and maintenance is essenƟal to the long life and funcƟon of 
venous port systems.
Our goal was to reduce the occurrence of infecƟous and thromboƟc complicaƟons in children with central venous 
systems of long-term use.
Materials and Methods: From July 2010 to March 2012 we observed 109 paƟents with tumors of the musculoskeletal 
system aged between 6 months to 17 years, for 78 of which implanted venous port systems were used and for 
31 of which tradiƟonal subclavian catheters were used. We evaluated performance against the following criteria: 
local manifestaƟons of infecƟon, the development of catheter-related bloodstream infecƟons, and cases of catheter 
thrombosis. Local infecƟous were treated with an unguent containing Chloramphenicol, and any suspected systemic 
infecƟon was addressed with anƟbioƟc therapy. In cases of port thrombosis, we injected the system with a 25,000 
IU dose of Urokinase with an exposure of 15 minutes.
Results: Of the paƟents implanted with subcutaneous venous ports, periportal Ɵssue infecƟon was noted in 3 
cases (3.8%). No catheter-related bloodstream infecƟons were noted. Port catheter thrombosis was observed in 
7 cases (8.9%), which presented as lower infusion rate and diﬃculƟes with retrograde blood flow. In paƟents with 
a tradiƟonal subclavian artery catheter, puncture site infecƟon was noted in 21 cases (67.7%). The development 
of catheter-related bloodstream infecƟons was noted in 8 cases (25.8%). Catheter thrombosis was observed in 17 
cases (54.8%). The treatment of 8 cases (47%) of the 17 occurrences of subclavian catheter thrombosis necessitated 
replacement, together with the associated need for general anesthesia and the risk of complicaƟons. To seal the 
catheter between courses of treatment, we used heparin or a soluƟon containing cyclotaurolidin (when using which 
no catheter-related bloodstream infecƟons were noted).
All venous ports worked saƟsfactorily following implantaƟon. All cases of thrombosis were successfully treated.
Conclusion: The use of a cyclotaurolidin soluƟon to close the venous system in the intervals between treatments 
prevents infecƟon. The treatment of catheter-related infecƟons is beƩer eﬀected by a combinaƟon of cyclotaurolidin 
and urokinase, which provides lysis of the microtrombs serving as a source of bacteria in both the catheter and port 
chamber. The incidence of catheter thrombosis and catheter-related bloodstream infecƟons is significantly higher in 
paƟents with subclavian catheters, the treatment of which oŌen requires replacement of the catheter, which is more 
traumaƟc and requires general anesthesia, and disrupts treatment.
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1 Department of Orthopaedics and Orthopaedic Surgery, Medical University of Graz
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ObjecƟves: PredicƟon of final height in children treated for bone tumours is needed to determine what kind of 
prostheses can be implanted. A current method for height prognosis is the mulƟplier method by Paley. Recent 
publicaƟons suggest inhibiƟng eﬀects of polychemotherapy on longitudinal growth. The aim of this retrospecƟve 
study was to invesƟgate if this formula is applicable to children who have received polychemotherapy.
PaƟents and Methods: We retrospecƟvely analysed height records of 33 children, 6 female and 27 male, who had 
polychemotherapy for osteosarcoma or Ewing’s sarcoma in our two centres. Actual adult height (Ha) was compared 
to the height predicted (Hp) by the mulƟplier method at the date of iniƟal diagnosis. The height diﬀerence (Hdiﬀ) 
Ha minus Hp was also calculated. The data was analysed with descripƟve methods and correlaƟon was tested with 
Pearson’s Coeﬃcient. A p-value of < 0.05 was regarded significant.
Results: Within one standard deviaƟon 10 children had a correct and 23 children had a false prognosis of Ha with 
Paley’s formula. The esƟmated adult height was too high in 25 and too low in 8 children. Median Hdiﬀ was -5.0 cm 
(range -17 to -0.6 cm) in children whose height was overesƟmated and 5.4 cm (range 0.5 to 8 cm) in those whose 
height was underesƟmated. Overall the Hp was 2.3 cm higher than the Ha (p = .013). The absolute error of predicƟon 
ranged from 0.5 to 17.0 cm (median 5.0 cm). We found a posiƟve correlaƟon (r = .799, p<.001) between Hp and Ha 
and a negaƟve correlaƟon between Hp and Hdiﬀ (r = -.417, p= .016). 
Conclusion: Due to the high amount of false predicƟons a reliable prognosis on adult height could not be made with 
Paley’s method in our collecƟve. In this study populaƟon tall predicted body heights were overesƟmated. In our 
dataset the majority of children reached a lower adult height than predicted. Consequently, Paley’s formula may 
have to be adjusted for paƟents undergoing polychemotherapy for osteosarcoma and Ewing’s sarcoma. 
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MUSCULOSKELETAL SYSTEM
Maxim Rykov, Yury Buydenok, Anna Shavrova, Nadegda Ivanova
InsƟtute of Pediatric Oncology and Haematology N. N. Blokhin Cancer Research Center
Moscow - Russia
ObjecƟves: The chemotherapeuƟcal treatment of musculoskeletal tumors in children requires numerous courses 
of chemotherapy (at least 10 per year). An iniƟal problem to be solved before beginning chemotherapy is therefore 
providing access into the venous system of the child. This venous access must be reliable and comfortable for the 
paƟent, should be established once for the enƟre period of treatment and should entail minimal risk of infecƟon and 
thrombosis (of both the catheter and vein). External infusion systems, peripheral catheters, and central catheters, 
including chronic Broviaka type catheters, do not saƟsfy the aforemenƟoned requirements. The best opƟon is a 
fully implantable venous port system, which in addiƟon to saƟsfying all the above criteria can significantly reduce 
the need for the repeated administraƟon of general anesthesia, required in each and any case where a tradiƟonal 
subclavian catheter is introduced in a child paƟent.
Our goal was to reduce the number of central venous catheterisaƟons, and accordingly the need for general 
anesthesia, during the treatment of children with musculoskeletal tumors, and to reduce the number of complicaƟons 
associated with central venous catheterisaƟon. We were also aiming to make the installaƟon of central venous 
systems in children safer.
Materials and Methods: From July 2010 to February 2012 78 children with tumors of the musculoskeletal system 
(aged 6 months to 17 years) underwent the implantaƟon of subcutaneous venous port-systems in order to receive 
mulƟple courses of chemotherapy. All surgeries were performed in an operaƟng theatre with the use of ultrasonic 
and X-ray scanning equipment. Children aged under 15 years underwent implantaƟon under general anesthesia. 
With child paƟents over 15 years old we used local anesthesia with sedaƟon.
Results: In light of our experience in the installaƟon of central catheters in children, we punctured the internal v. 
jugularis only aŌer preliminary ultrasonic marking, in order to reduce the risk of complicaƟons (for example haemo- 
and/or pneumo- thorax, and/or trauma to surrounding anatomical structures). We succeeded in puncturing a vein 
on our first aƩempt in 74 cases (94,8 %), and on the second aƩempt in 4 cases (5,4 %). In some complex cases (where 
the vein was thin or flexible), vein puncture was performed directly under sterile ultrasound navigaƟon. In only 3 
cases (3,8 % ) was there an accidental puncture of the adjacent caroƟd artery. Neither haemo- nor pneumo- thorax 
nor lung injury was detected. AŌer the jugular vein was punctured by the Seldinger method, a wire was introduced 
under X-ray control using a C-arm. In 59 cases (75,6 %) the wire immediately moved towards the heart in the superior 
vena cava. In 19 cases (24,3 %) there were problems with the introducƟon of the wire, whereby the wire folded or 
moved in other direcƟons, most oŌen in the distal porƟon of the jugular vein. In 4 cases (5,1 %) the migraƟon of the 
wire in the opposite subclavian vein was observed, in 9 cases (11,5 %) it migrated in the subclavian vein on the side 
of the catheterizaƟon. In all cases we managed to posiƟon the wire properly by using the introducer to introduce the 
catheter into the superior vena cava, where rapid blood flow and the large diameter of the vessel provides for the 
eﬀecƟve mixing of chemotherapeuƟc agents with the blood, and minimizes the risk of developing thrombophlebiƟs. 
Since implantaƟon, all venous port-systems have worked saƟsfactorily, providing for a volume infusion of more than 
5 liters per day.
Conclusion: The introducƟon of implantable venous port-systems for the treatment of child paƟents with tumors of 
the musculoskeletal system has significantly reduced the number of administraƟons of general anesthesia, improved 
the quality of life of the paƟents and minimized the risk of developing complicaƟons during the actual catheterizaƟon 
procedure or during subsequent use of the port-systems. The use of ultrasonic marking (both prior to the puncture 
of the internal jugular vein as well as during the puncture) permits the avoidance of injury to the adjacent anatomical 
structures (haemo- and/or pneumo- thorax) and the reducƟon of the  duraƟon of the implantaƟon surgery. The use 
of an X-ray scanner during the posiƟoning of the port catheter prevents its migraƟon into the veins of the neck and 
upper extremiƟes, which otherwise happens fairly frequently due to the anatomical peculiariƟes of children. It is 
parƟcularly important precisely to place the distal end of the catheter into the superior vena cava above the entrance 
to the right atrium, since it is excepƟonally diﬃcult to adjust the implanted system aŌer the surgery is over.
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IN AMPUTEES? PRELIMINARY RESULTS
Boﬀano M1, Giordano A2, Cicolin A2, Francese V2, Boux E1, Piana R1.
1S.C. Oncologic and ReconstrucƟve Orthopaedics Department – AO CTO/Maria Adelaide Torino - Italy
2Sleep Medicine Centre - Neuroscience Department – University of Torino Torino - Italy
ObjecƟves: The aim of the study is to assess the self body percepƟon, during wake and sleep, in paƟents aﬀected 
by bone and soŌ Ɵssue sarcomas who underwent amputaƟon to evaluate phantom limb and telescoping and to 
opƟmize the therapeuƟc protocol and the compliance in prosthesis use.
Materials and Methods: Nineteen consecuƟve outpaƟents referred to S.C. Oncologic and ReconstrucƟve 
Orthopaedics Department AO CTO/Maria Adelaide Torino (Italy) were evaluated with the collaboraƟon of the Sleep 
Medicine Centre – Neuroscience Department – University of Torino. Inclusion criteria: diagnosis of bone or soŌ 
Ɵssue sarcoma, minimum age 16 years old. Exclusion criteria: impaired cogniƟve ability, psychiatric disease, ray 
amputaƟons (or smaller), previous amputaƟon. PaƟents were divided in two groups: 1-perspecƟve group, paƟents 
evaluated within two weeks and 4 months from surgery, and 2-retrospecƟve group, less than 1 year from surgery. 
The local ethical commiƩee approved the protocol and all paƟents signed the informed consent form. PaƟents were 
assessed using quesƟonnaires and dream content diaries: Kooijman’s phantom limb quesƟonnaire [1], a weekly 
dream content diary, the West Haven-Yale MulƟdimensional Pain Inventory [2], the Body Image Concern Inventory 
[3], a clinical assessment of the body image. StaƟsƟcal analysis was performed by SPSS 17.0 (mean+/-SD, p<0,05).
Results: Ten paƟents fulfilled the criteria for the inclusion in the group 1 and nine paƟents for the group 2. Nine 
paƟents completed the protocol (7 of the perspecƟve group and 2 of the retrospecƟve group). Three of the nineteen 
eligible paƟents did not complete the study due to death (1 case) and incomplete protocol compliance. 
A preliminary result analysis shows:
phantom limb can be found in 100% of paƟents, mainly represented by somato-sensory and movement - 
percepƟons; phantom limb pain is referred only by 40% of paƟents
telescoping is present in 1/5 of paƟents, mainly in young people- 
all paƟents with telescoping do not use the prosthesis and refer pain- 
all paƟents with telescoping dream about limb (mainly without limb)- 
the prosthesis use seems to be related with the body image concern of paƟent- 
Conclusions: Although there has been much progress in the surgical treatment of bone and soŌ Ɵssue sarcomas, 
amputaƟon is unfortunately sƟll needed in 5-10% of cases [4]. Few studies have evaluated the integraƟon among 
these phenomena also related to the change of body schema in the dream content. The self-concept schema is 
influenced by the cogniƟve generalizaƟon about oneself derived from past experiences in a social context [5]. 
InformaƟon about body schema is diﬀerently interpreted by each individual also related to a potenƟally worry-some 
physical appearance [3] that can lead to cogniƟve distorƟons such as phantom limb [6] (70-100% of paƟents who 
underwent amputaƟon), phantom limb pain (from 60 to 85%) and telescoping, a phenomenon characterized by the 
gradual proximal migraƟon of the phantom limb aﬀecƟng one third of the amputees/paƟent [7]. When compared 
with literature data, our results show a lower percentage of phantom limb pain and telescoping, and a significant 
relaƟonship between telescoping and the use of prosthesis, pain and body image in dreams. If confirmed, these 
data could help to improve the rehabilitaƟon protocols opƟmizing the Ɵming of prosthesizaƟon with reference to 
the adaptaƟon of the body schema.
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APPROACH
   
Paripović L1, Bekić Z1 , Ilić V1, Pudrlja-Slović M1, Gavrilović D2, Vučinić Z3, Sopta J4, Bokun J1
1 InsƟtute for Oncology and Radiology of Serbia, Belgrade, Serbia     
2 InsƟtute for Oncology and Radiology of Serbia-Data center Belgrade, Serbia     
3 InsƟtute for Ortopedic surgery “Banjica”, Belgrade, Serbia
4InsƟtute for Pathology, Belgrade, Serbia
ObjecƟve: The aim of the study was to evaluate the choice of opƟmal therapeuƟc approach and prognosƟc factors 
in children with Nonrhabdomyosarcoma soŌ Ɵssue sarcoma (NRSTS).
PaƟents and Methods: Between 1997 and 2010, 24 paƟents with NRSTS, with the median age 15 (range 3 to 18 
years) were treated and analyzed for survival. The most common histotypes were synovial sarcoma (29,17%) and 
malignant peripheral nerve sheath tumour (29,17%). Sixty six percent were presented on the extremiƟes. We 
diagnosƟcated 8,3% of paƟents with metastaƟc disease, 1 paƟent with pulmonary metastases and 1 with lymph 
nodal involvement. Tumour size greater than 5 cm was diagnosƟcated in 75% of paƟents. PaƟents were treated by 
using of mulƟmodality therapeuƟc approach including surgery, chemotherapy and radiotherapy. Surgery was the 
mainstay of the treatments. Radiotherapy was administered to 70,8% and chemotherapy to 91,6% paƟents (45,8% 
neoadjuvant chemotherapy). 
Results: During the median follow up of 60,5 months (6 to 175 months), 5 years overall survival was 71.6% and 
the disease free survival was 57%. It was possible to perform radical resecƟon aŌer neoadjuvant therapy in 50% of 
paƟents with primary unresectable tumours.The prognosƟc factors such as tumour size ≥5cm, invasiveness, posiƟve 
microscopic margin, high-grade tumors, were not predicƟve of survival but this must be taken with certain reserves 
due to small number of paƟents in our serie.
Conclusion: Results indicate that stage, tumour size and radical surgery played the key role in treatment of NRSTS. 
ProspecƟve randomized trials are needed to quanƟfy the contribuƟon of chemotherapy and to determine the ideal 
regimen.
179
PO
ST
ER
O
N
CO
LO
GYPARTIAL LIMB LOADING CONTROL IN PATIENTS OPERATED FOR BONE TUMOURS THROUGH A PORTABLE BIOFEEDBACK 
DEVICE.
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ObjecƟves staƟng concisely why the study was conducted: In the post-surgical period, ParƟal Weight Bearing (PWB) 
is early prescribed to paƟents subjected to Limb Salvage Surgery (LSS) in order to counteract their expected reducƟon 
of physical acƟviƟes. PWB sƟmulates osteoblasts prevenƟng osteoporosis, a known collateral eﬀect that can possibly 
occur aŌer chemotherapy, and also preserves biological implants. We have conducted this pilot study in order to 
verify how much paƟents comply with verbal instrucƟons given by the physical therapist with regard to walking with 
PWB using a biofeedback device, and also to check the extent to which these instrucƟons are useful to sƟmulate the 
paƟent to follow the prescribed PWB.
Materials and Methods: The device used for the biofeedback is the Pedar Mobile System (NovelGmbH, Munich, 
Germany), which implies the use of flexible and size-adaptable insoles with 99 capaciƟve sensors. Eleven paƟents (7 
females, 4 males, mean age 26.5) with primiƟve bone tumors in the lower limbs, who received LSS were recruited. 
PWB was prescribed to them in various amounts in post-surgery rehabilitaƟon. The load actually applied on the 
aﬀected limb using the biofeedback device was measured in three condiƟons within a single experimental session: 
1) during a Free Walking phase; 2) during a CondiƟoning phase in which paƟents walked with PWB with the audio-
feedback device; 3) during Post-condiƟoning phase without audio-feedback. 
Results: During the Free Walking phase, 8 paƟents exceeded on average the prescribed PWB from a minimum of 
8,9 N up to a maximum of 144,9 N. Loads from the remaining 3 paƟents were on average lower than the prescribed 
ones from a minimum of 28,7 N to a maximum of 83,8 N. All paƟents, except two, did not exceed on average the 
prescribed PWB, the measured load being within the two thresholds during the CondiƟoning phase. During post-
condiƟoning phase, 4 out of the 8 paƟents who completed this experimental session, did not exceed on average the 
prescribed PWB, the load remaining below it and within the two thresholds. Four paƟents sƟll exceeded on average 
the prescribed PWB, though less than during Free Walking.
Conclusions: The audio-feedback device, used to sƟmulate walking with PWB, allowed more adherence between the 
load actually applied on the aﬀected limb by the paƟent and the correspondent prescribed. This adherence is also 
maintained in the short term even without the audio-feedback. This is of relevance when PWB has a clear clinical 
significance on bone remodelling or implant fixaƟon.
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RisƟc D.,Milanovic N.,Puric M.,Luic N,Sopta J.
OBJECTIVE: To examine the eﬃcacy of an intensified inducƟon regimen (vincrisƟne, ifosfamide, doxorubicin, and 
etoposide [VIDE]) in paƟents with newly diagnosed Ewing’s family of tumors (EFT) localized on head and trunk .
PATIENTS AND METHODS: Fourteen paƟents (ten male and four female paƟents) entered the study in period between 
June 2007 and July 2011. Median age was 30 years (18 to 57 years).Two paƟents had primary tumor localized on head 
(parietal bone and jaw) ,four paƟents had primary tumor of spine, five paƟents had pelvis tumor, one paƟent had 
tumor of kindney, one had rib cage and one had scapula as primary tumor localizaƟon. Three paƟents had metastaƟc 
disease, two with single lung metastases and one with breast metastasis, at the Ɵme of diagnosis . All paƟents were 
treated with VIDE (vincrisƟne 1.4 mg/m2 (maximum 2 mg) on day 1, doxorubicin 20 mg/m2, ifosfamide 3 g/m2 plus 
mesna and etoposide 150 mg/m2 on days 1 to 3) with growth factor support. Cycles were given every 21 days for up 
to six cycles. AŌer inducƟon therapy all paƟents with response were treated with radiotherapy at the tumor bed in 
CR or at residual tumor in PR.
RESULTS: Sixty eight cycles of VIDE were given. Four paƟents did not completed all six cycles (two because of 
encephalopathy ,one renal toxicity and one hematological toxicity). Response rate was 78% (95% CI 52.41-92.43) 
.Five complete remission and 6 parƟal response were registered according to RECIST criteria . Three paƟents had 
progression of  disease during therapy with development of metastaƟc disease. Median follow up  was 22 months 
(range 3-54 months) . Overall survival was 23 months (95% CI ) with six paƟents sƟll alive.
CONCLUSION: Our study suggests that VIDE is an eﬀecƟve inducƟon regimen in treatment of non resectable Ewing 
Sarcomas of trunk and head. Local control in paƟents with parƟal response to inducƟon therapy sƟll remains open 
quesƟon. 
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ObjecƟve: A retrospecƟve study to compare between the length of intra-osseous extent of Ewing sarcoma of long 
bones in the iniƟal and the pre-operaƟve MRI, and to correlate between the MRI evaluaƟon and the surgical planning, 
surgical margins and incidence of local failure. 
Material and methods: Since the year of 2007 and up to 2010, 38 cases of Ewing sarcoma of long bones were treated 
by chemotherapy and surgery, in the Children Cancer Hospital in Egypt. Two paƟents were excluded from the study: 
one was lost to follow-up and the other had no iniƟal MRI for evaluaƟon, leaving a total number of 36 paƟents to be 
evaluated. 
The iniƟal (at presentaƟon) and pre-operaƟve MRI studies were reviewed for all cases. The intra-osseous extent was 
best measured in the T1 sequence with no contrast. The operaƟve notes, surgical margins, and local relapses were 
reviewed for all cases unƟl the latest follow-up.  
Results: Twenty-two paƟents (61.1%) had their MRI measurements (intra-osseous extent) unchanged aŌer neo-
adjuvant chemotherapy. In the remaining 14 paƟents, the diﬀerence between the iniƟal and pre-operaƟve MRI was 
restricted to 1 to 1.5 cm less tumor involvement as seen in the pre-operaƟve MRI. 
The iniƟal MRI was used for pre-operaƟve planning in 8 cases and the post-chemotherapy MRI in 28 cases. The 
surgical margins were negaƟve in all cases except one case in which the marrow margin was posiƟve and the paƟent 
received post-operaƟve radiotherapy. UnƟl the latest follow-up (median follow-up period 19 months) only one 
paƟent had a local recurrence. The iniƟal surgical margins of this case were negaƟve. 
Conclusion: Following chemotherapy for Ewing sarcoma of long bones, MRI measurements of bone extent do not 
change much when comparing the iniƟal to the pre-operaƟve MRI. 
The use of the pre-operaƟve MRI in the surgical planning, did not lead to a higher incidence of posiƟve margins and 
local failure. 
Although, this study has the limitaƟon of a short follow-up period (median of 19 months), the incidence of local 
failure is highest in the first two years following surgery as reported in the literature.  
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Graci C, Perisano C, Spinelli MS, Valenzi E, Di Giacomo G, Fabbriciani C, Maccauro G
Department of Orthopaedics and Traumatology, University Hospital AgosƟno Gemelli, Catholic University of the Sacred Heart 
School of Medicine, Rome, Italy
ObjecƟve: In lung cancer paƟents, metastases to soŌ Ɵssues (STs), including the skeletal muscle, subcutaneous 
Ɵssue and skin, are rarely reported. Besides, lung cancer, primary carcinomas of the kidney and colon are the most 
commonly associated with ST metastases. The aim of the study is to determine the prevalence, clinical-pathological 
features and treatment opƟons of ST metastases originaƟng from lung carcinoma.
Materials and Methods: A literature search was performed using the following terms: lung cancer, ST metastasis, 
skeletal muscle metastasis, cutaneous metastasis, subcutaneous metastasis.
Results: Autopsy series have detected soŌ Ɵssues metastases in 0.75-9% of paƟents who died from metastaƟc 
lung carcinoma. Pain and the presence of a palpable mass are the most frequent clinical features. The biopsy is 
recommended aŌer MRI for diagnosis. Due to the infrequency of ST metastases, the diﬀerenƟal diagnosis must be 
done especially with ST primary sarcomas. The type of treatment depends on the clinical picture and prognosis and 
includes observaƟon, radiotherapy, chemotherapy and surgery.
Conclusions: In lung cancer paƟents, ST metastases are rare, but not excepƟonal. Their presence should be suspected 
in the presence of a palpable mass either painful or asymptomaƟc. Radiological and histological examinaƟons are 
required for the definite diagnosis. The choice of treatment should be based on consideraƟons related to the stage 
of the primary tumor and the paƟent’s global health status.
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Cosker T, Ohringer G, Porter C, Whitwell D, Sharpley F, Gibbons M
Of the Nuﬃeld Orthopaedic Centre, Oxford, UK
INTRODUCTION: EsƟmates from the NaƟonal Cancer Network suggest that approximately 3,000 paƟents are 
diagnosed with sarcoma annually in the UK. SoŌ Ɵssue sarcoma occurs at any age and are common in those of 
working age.  The financial impact for paƟents with a diagnosis of sarcoma is significant. Treatment is undertaken in 
specialist regional centres and paƟents may have to travel significant distances for ongoing treatment. The disease 
process and Ɵme away from work for appointments may have an adverse eﬀect on employment. 
METHODS: PaƟents aƩending the Oxford Sarcoma Service between June 2010 and June 2011 were quesƟoned about 
the distance they had had to travel to the clinic, the mode of transport they used to get there, the associated costs 
incurred whilst visiƟng the hospital (such as car parking), and any other relevant costs associated with treatment.  
They were also quesƟoned with regard their occupaƟon and the amount of Ɵme they had had to take away from 
work as a result of their diagnosis as well as whether they felt that their chances of promoƟon or career progression 
had been adversely aﬀected.
RESULTS: There were 93 paƟents, of which 45 (48%) had benign disease and 48 (52%) had malignant disease. 54 
(58%) were employed, 33 (36%) were unemployed. On average, paƟents had to make a return journey 62 miles for 
every visit to the hospital (max 188 miles). PaƟent’s employment was more likely to be aﬀected and their partners 
more likely to take Ɵme oﬀ work if they lived further away from the hospital (p =0.021 and p=0.028 respecƟvely). For 
the 75 paƟents who came to hospital by car, the mean total cost of travel was £414. This includes an average cost 
of £29.60 associated with every outpaƟent appointment. PaƟents with malignant disease experienced significantly 
higher total costs £608 vs. £205  (p<0.001) when compared with those with a benign diagnosis. The highest cost 
incurred by a single paƟent was £4364.
DISCUSSION: Whilst the treatment of bone and soŌ Ɵssue sarcoma is increasingly well understood, liƩle has been 
wriƩen on the financial impact for paƟents undergoing treatment.  This study shows that for paƟents of working 
age treatment at a specialist centre has a significant financial impact.  In addiƟon there is a significant eﬀect on 
employment and career progression. 
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NERVE : 13 YEAR RESULTS
Tom Cosker*;Stephen Gwilym;Stephen McDonnell;Nic Athanisou;Takeshi Kashima;Bass Hassan;Duncan Whitwell;Max Gibbons
Tumour Oncology, Nuﬃeld Department of Orthopaedic Surgery, Oxford, UK
IntroducƟon: Our Unit has been treaƟng large volume soŌ Ɵssue sarcomas involving the sciaƟc nerve with 
epineurectomy for over a decade. The aim of this study was to quanƟfy the funcƟonal outcome of paƟents who were 
known to have sciaƟc nerve involvement pre-operaƟvely and went on to have nerve preserving surgery uƟlising a 
planned marginal excision with epineurectomy.
Methods: 36 paƟents with soŌ Ɵssue sarcomas involving the sciaƟc nerve were studied treated between 1997 
and 2010. Nineteen underwent surgery with extended epineurectomy of the sciaƟc nerve and planned marginal 
excision. All paƟents underwent staging and follow up at our Sarcoma Clinic with funcƟonal assessment and TESS 
evaluaƟon.
Results: There were twenty six low / intermedite and ten high grade posterior thigh tumours . Two were recurrent 
and eighteen were primary. There were thirteen men and twenty three women with a mean age of 74 years. Thirty 
five paƟents underwent planned marginal excision. There was soŌ Ɵssue reconstrucƟon in three cases using fascial 
adductor or gracilis graŌ for sciaƟc nerve cover and one with superficial femoral nerve and vein resecƟon requiring 
ipsilateral saphenous reconstrucƟon. The remainder underwent direct primary reconstrucƟon. Eighteen paƟents 
underwent post operaƟve radiotherapy. There was no local recurrence of disease. There was one paƟent with post 
radiaƟon wound necrosis that resolved. Four paƟents have died of unrelated causes. 
Discussion: Planned marginal excision (PME) of low grade large volume posterior thigh sarcomas with extensive 
sciaƟc nerve involvement can be successfully treated with preservaƟon of the sciaƟc nerve without significant 
morbidity and excellent resultant limb funcƟon. Even with PME of high grade disease with adjuvant radiotherapy, 
there was no local recurrence. Whilst the procedure is technically demanding, providing strict surgical technique is 
employed, damage to the sciaƟc nerve is rare and leaves paƟents with an unimpaired future lifestyle.
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ObjecƟve: To analyse prognosƟc factors associated with local recurrence of soŌ-Ɵssue sarcomas 
Materials and methods: 228 paƟents with recurrent soŌ Ɵssue sarcomas were treated in RCRC RAMS in 2000-2010 
years. There were 112 (49,1%) male and 116 (50,9%) female, with a age of 42,9±15,3 years (range 16-77). Tumor 
size was: <5 cm – 39,5%; 5-10cm – 32%; >10 cm – 28,4%. Histological types were: malignant fibrous hisƟocytoma 
– 27,2%, liposarcoma – 19,8%, synovial sarcoma – 18,5%, malignant peripheral nerve sheath tumors – 19,8% , 
leiomiosarcoma – 7,7% and others. G3 – 69,1% of cases, G2 – 27,2% and G1 – 3,7%. Time to local recurrence: 
<6 months – 39,5% of paƟents, 6-12 months – 24,7%, 12-24 months – 18,5% and >24 months – 17,3%. Also we 
analysed surgical margin (intralesional, marginal, wide, radical), locaƟon in the anatomic compartments. The 
prognosƟc influence of clinicopathological characterisƟcs on disease-specific survival were examined by univariate 
and mulƟvariate analyses.
Results: The mean follow-up was 41,7 ranged from 2,1 to 161,2 months. The overall 5-year survival was 69%. Tumor 
size, tumor grade and short Ɵme to local recurrence (<6 months) are independent factors for disease-specific survival 
(p < 0.05) in univariate and mulƟvariate analyses.
Conclusion: PaƟents with large high-grade rapidly growing tumors require a more acƟve approach to treatment, 
with the inclusion of systemic chemotherapy. We conƟnue the clinical development of staging system for paƟents 
with isolated local recurrence for the formaƟon of subgroups of paƟents with diﬀerent survival rates and raƟonal 
treatment based on their prognosis.
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Matějovský, Z. 1, Lesenský J. 1, Kofránek I. 1, Krystlík Z. 1, Matějovská J2, Frajer L.2 Povýšil C.3
1st Medical School, Charles University, Teaching Hospital Bulovka, Prague, Czech Republic –Orthopedic Clinic1, Clinic for plasƟc 
surgery2, InsƟtute for pathologic anatomy3.
Materials and methods: We retrospecƟvely evaluated over 300 paƟents with malignant soŌ Ɵssue sarcomas 
considering the paƩerns of local and regional disease relapses together with the resecƟon margins and adjuvant 
treatment. LG liposarcomas were excluded.
Results: We had two groups with over 100 paƟents with synovial sarcomas and malignant fibrous hisƟocytomas 
(MFH). Other larger groups with over 20 paƟents were diagnosed as neurogenic tumors and leiomyosarcomas.
In synovial sarcoma located as deep tumors mainly in the foot we observed bone skip lesions. Such bone lesions 
usually progressed systemaƟcally. Superficial synovial sarcomas relapsed usually as skip lesions into subcutaneous 
Ɵssue. Such aﬀecƟons if further excised usually did not progress systemically. In deep MFH skip lesions in adjacent 
compartments were connected with bad prognosis for systemic spread and survival. On the contrary superficial 
MFH recurred repeatedly as skip lesion into the subcutaneous Ɵssue without systemic spread. This occurred first 
if the tumor skipped into deep Ɵssue. Deep dediﬀerenƟated HG liposarcomas were connected with skip lesions in 
adjacent compartments while leiomyosarcomas were connected with lymphaƟc and distal metastases, even into 
bones or distant soŌ Ɵssues. InteresƟng were 3 cases of clear cell sarcomas which all relapsed through LN further 
systemaƟcally.
Conclusion: MFH and synovial sarcomas in superficial locaƟons usually spread with skip lesions into adjacent 
subcutaneous Ɵssue which do not further progress systemaƟcally and therefore thorough controls and early 
wide excisions of such lesions are a good treatment opƟon. Once they progress into deep Ɵssue ablaƟve surgery 
should be considered.  For such primary superficial lesions we recommend wider margins of at least 3 to 5 cm with 
secondary closure with skin graŌs or flaps. If presented in deep locaƟon biopsy with preoperaƟve treatment of 
either chemotherapy or radiaƟon of the whole compartment should be considered to prevent relapse into the same 
or adjacent compartments. Even wide excisions of the whole muscle do not warranty local control as skip lesions 
into the adjacent muscles are to be expected and ablaƟve surgery should be considered in such cases if no systemic 
spread is presented. In bony involvement of synovial sarcoma ablaƟve surgery should be strongly recommended.
Metastases of leiomyosarcomas can be controlled with combined wide excision and systemic treatment and/or 
radiaƟon on lymph nodes. Nevertheless skip lesions within 5 cm around the scars were repeatedly observed in 
subcutaneous Ɵssue and therefore resecƟon of the whole skin and subcutaneous Ɵssue covering the tumor with 
reconstrucƟon of the skin defect should be preferred.
Clear cell sarcoma in our experience always showed a systemic relapse first through lymph nodes. Primary 
lymphadenectomy with radiaƟon should be therefore considered. Nevertheless histological diﬀerenƟal diagnosis of 
such tumors is very diﬃcult.
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Moscow, Russian FederaƟon
ObjecƟve: To idenƟfy the most significant prognosƟc factors in the prehospital phase for further local recurrence of 
soŌ Ɵssue sarcomas of the locomotor apparatus.
Materials and methods: We analysed 168 paƟents with extremity soŌ Ɵssue sarcomas treated in the Cancer 
Research Center in 2000-2010 years. Gender distribuƟon was as follows: 87 were male (51.2%), 83 were female 
(48.8%). Mean age 52,16 ± 18,36 years, range 22-85 years. All paƟents were iniƟally examined not in the sarcoma 
centers. The primary diagnosis at any medical facility was soŌ Ɵssue sarcoma (group A, 73 cases, 43.4%) or others 
(group B, 95 cases, 56,5%): inflammaƟon - 26 (15.5%), benign tumors - 20 (11.9%), hematoma - 13 (7.7%), venous 
thrombosis - 13 (7.7% ), hernia - 3 (1.8%), etc. PaƟents before entering the RCRC received in the group A specific 
treatment in 71 cases (42%). In the group B paƟents received symptomaƟc treatment in 64 cases (38.1%). AŌer 
reviewing all cases in the Cancer Research Center, sarcoma was founded in 100% of paƟents. DistribuƟon of 
paƟents according to tumor size and depth were: T1a - 7 paƟents (4.1%), T1b - 2 (1.1%), T2a - 5 (2.9%), T2b - 154 
(91%). The most frequent tumors were G3 - 82% of cases. The distribuƟon by histological type of tumor: malignant 
fibrous hisƟocytoma - 18.4%, liposarcoma - 17.2%, synovial sarcoma - 16.7%, rhabdomyosarcoma - 10.2% and 
others. Time from diagnosis to the treatment facility before entering the RCRC is in the range from 1 to 7 months. 
Results: Median follow-up of paƟents - 65 months. In the group B mean Ɵme to correct diagnosis was 5,5 months. 
In the group A a local recurrence rate was 16%. In the group B (with the iniƟal incorrect diagnosis) the level of local 
recurrence - 37%, and resecƟon R1 was dominated during operaƟons. The 5-year overall survival was 75% and 62% 
in group A and group B respecƟvely.
Conclusions: It was noted a significant increase in local recurrence in group B. In most of these cases have been 
diﬃculƟes with the treatment. An analysis of errors and complicaƟons in the diagnosis and iniƟal treatment of soŌ 
Ɵssue sarcomas can improve the quality of the procedures to determine the most important aspects influencing the 
subsequent recurrence.
272
188
PO
ST
ER
O
N
CO
LO
GY 280INTRABDOMINAL  METASTASIS IN OSTEOSARCOMA: EXPERIENCE OF A SINGLE CENTER
1 Kebudi Rejin, 2 Özgüven A. Aykan, 1 Görgün Ömer, 3 Yekeler Ensar , 4Bilgiç Bilge,   1 Ayan İnci, 5 Özger Harzem,
Istanbul University, 1Cerrahpaşa Medical Faculty & Oncology InsƟtute, Department of Pediatric Hematology and Oncology; 2 
Istanbul Faculty of Medicine, Department of Pediatric Hematology and Oncology, 3 Department of Radiology, 4Department of 
Pathology, 5Department of Orthopaedics
ObjecƟves: Extra-pulmonary metastasis, parƟcularly  abdominal metastasis from osteogenic sarcoma are rare and 
generally appear as a solid mass of calcificaƟon as the primary tumor. The  aim of this study is to document  the 
incidence, characterisƟcs, treatment, prognosis of  abdominal  metastasis in osteosarcomas  in a single insƟtuƟon 
and to review the literature.
Methods: From September 1989 to  December 2002, 94 children < 16 years of age with osteosarcomas were 
diagnosed and treated in the Division of Pediatric Oncology,  Oncology InsƟtute, Istanbul Unıversity. PaƟents with 
abdominal metastases were assessed. 
Results: Two girls  of 94 paƟents (2.1 %)  with osteosarcoma developed  abdominal  metastases. One had pulmonary 
metastasis at diagnosis and the other had developed lung metastasis 15 months aŌer diagnosis. They developed 
abdominal metastasis 4 and 3 years aŌer diagnosis during therapy or relapse at a median duraƟon of 16 (1-70) 
months from iniƟal diagnosis. All paƟents had metastases to various sites, mostly lung, at the Ɵme the abdominal 
metastases were detected. Treatment included surgery, and chemotherapy (CT) in 1, S in 1. Both  paƟents died at a 
median Ɵme of 2 months (2 days- 6 months) from the Ɵme of  abdominal metastasis with progressive disease. Brain 
metastasis have also been reported especially in paƟents who had lung metastasis at diagnosis and in our series the 
incidence was 1.45 % (Kebudi R et al, Neurooncology 2005).
Conclusions. Abdominal metastasis in osteosarcoma is a rare event, but the abdomen should be invesƟgated in 
case of recurrence from osteosarcoma. The outcome for these paƟents is dismal in this series and in the literature. 
Children with metastaƟc osteosarcoma who develop abdominal pain or any other gastrointesƟnal  symptom should 
be invesƟgated for possible  abdominal  metastasis. 
Key words: Osteosarcoma, abdominal metastasis
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T. Nakamura, C. Gaston, A.  Abudu, L. Jeys, R. Tillman, S. Carter, R. Grimer
InsƟtuƟon; Oncology Unit, The Royal Orthopaedic Hospital, 
Birmingham city, United Kingdom
IntroducƟon: Anaemia is a common finding in cancer paƟents. Anaemia is associated with shorter survival Ɵmes 
for many cancers. Recently, several studies demonstrated that interleukin-6 could be a mediator of cancer-related 
anaemia, which induces the producƟon of C-reacƟve protein (CRP). The aims of this study were to invesƟgate the 
relaƟonship between anaemia and CRP and to determine whether anaemia before treatment predicts the overall 
survival and disease-free survival in paƟents with newly diagnosed non metastaƟc soŌ Ɵssue sarcoma (STS).
Methods: A total of 376 primary STS paƟents treated between 2003 and 2010 were retrospecƟvely reviewed.  All 
paƟents were treated with surgery and adjuvant radiaƟon therapy when indicated. The Haemoglobin (Hb) levels 
were obtained before treatment for all paƟents.  According to World Health OrganizaƟon (WHO), we defined anaemia 
when Hb levels were less than 13g/dl for male and 12g/dl for female, respecƟvely. The mean age at diagnosis was 59 
years. There were 221 male and 155 female paƟents. The mean follow-up period was 32 months. 
Results: Anaemia was seen in 117 paƟents (31%).  The histological grade, age, tumour size, depth and pre-treatment 
CRP levels were related to anaemia.  Hb levels were strongly correlated with CRP levels (spearman’s r=-0.54, p<0.0001). 
PaƟents with anaemia had a poorer overall survival than paƟents without anaemia (p<0.0001).  The overall survival 
esƟmates at 5 years were 53.4% versus 79.6%, respecƟvely.  PaƟents with anaemia had also poorer disease-free 
survival than paƟents with normal CRP levels (p<0.0001).  The disease-free survival esƟmates at 5 years were 45.0% 
versus 66.0%, respecƟvely.  MulƟvariate analysis showed that pre-treatment anaemia was an independent predictor 
of disease-free survival (P=0.04). 
Conclusions: Pre-treatment anaemia was related to CRP levels. Anaemia was found to be a poor prognosƟc factor for 
overall survival in a univariate analysis and for disease-free survival in a mulƟvariate analysis for STS paƟents. 
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GY 291EXTENDED  EXPERIENCE WITH AN ADJUVANT SANDWICH CHEMOͳRADIOͳCHEMOͳTHERAPY CONCEPT FOR HIGHͳRISK 
ADULT SOFT TISSUE SARCOMAS
Kerkhoﬀ, S. Bröckling, R. Liersch, J. Hardes, G. Gosheger, H.-T. Eich, P. Tschanter, U. Krug, M. Pohlen, A. Hilbig, C. Pohlkamp, C. 
Schulz, R. M. Mesters, C. Müller-Tidow, T. Kessler and W. E. Berdel
Department of Medicine, Hematology and Oncology,  Department of Orthopedic Surgery and Department of RadiaƟon Oncology, 
Albert-Schweitzer-Campus 1, 48149 Muenster, Germany
Purpose: Surgery and radiaƟon therapy represent the standard treatment of localized high-risk soŌ Ɵssue sarcomas 
(STS), while the significance of adjuvant chemotherapy is discussed controversially. Our single center phase II trial 
had shown a favourable long-term survival with low distant recurrence and acceptable toxicity for paƟents treated 
with a sandwich chemo-radio-chemotherapy concept. We present our extended experience and analysed further 
paƟents treated subsequently to the study with an idenƟcal protocol. 
PaƟents and Methods: From 1997 to 2012 forty-three paƟents with localized, completely resected (R0) high risk STS 
were accrued to this analysis. Twenty-seven paƟents were analysed in our prospecƟve study, while sixteen paƟents 
were analysed subsequently. All paƟents were treated with a sequence of surgery, adjuvant chemotherapy and 
interposed radiotherapy. Within a median Ɵme of 33.9 days aŌer surgery they received a chemotherapy consisƟng 
of doxorubicin (75 mg/m² d1q 3w) and ifosfamide (5g/m²d1q3w) in 4 cycles. Between cycle 2 and 3 radiotherapy 
(total dose of 50.4 Gy fracƟonated plus boost  of 10 Gy) was administered.
The paƟents were followed up with regard to remission status and long-term toxicity. 
Results: Data of all paƟents with a minimum follow-up of 5 months from diagnosis showed an EFS of  70.7 % and an 
OS rate of  80.5 %.  Of the 27 paƟents treated in our phase II study, 81.4 % are sƟll alive and in complete remission at a 
median follow-up of  107.8 months ( 22-164 months).  There was no long term toxicity. The 16 paƟents subsequently 
treated and analysed had a median follow up of 32 months (range 5-80 months) with an OS of 87.5%. Therapy-
related toxicity was mild. 
Conclusion: Sandwich chemo-radio-chemotherapy aŌer R0 resecƟon oﬀers a promising rate of long-term remission 
by a short term combined treatment with a low toxicity profile. Future mulƟcenter studies are warranted. 
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SEARLY SYMPTOMS OF BONE AND SOFT TISSUE SARCOMAS: 
COULD THEY BE DIAGNOSED EARLIER?
A. George; R. Grimer
Royal Orthopaedic Hospital, Birmingham, UK
IntroducƟon: Delays in diagnosis are common for paƟents with bone and soŌ Ɵssue sarcoma (STS). This is despite 
referral guidelines produced by the Department of Health and NICE more than a decade ago. 
ObjecƟves: This study set out to idenƟfy the early symptoms experienced by paƟents with sarcomas and reasons for 
delays in making a definiƟve diagnosis. We proposed to evaluate symptoms experienced against current guidelines 
for referral to determine whether amendment might improve direct referral rates for paƟents.
Methods: RetrospecƟve interviews were carried out with 107 paƟents with bone sarcoma (41 paƟents) and STS (66 
paƟents) presenƟng to a specialist centre. We determined iniƟal symptoms experienced prior to definiƟve diagnosis 
and occurrence of paƟent and doctor delays in reaching specialist care.
Results: Median paƟent delay was 1 month whilst doctor delay was 3.2 months from first symptoms to diagnosis 
for all sarcomas. Forty-nine paƟents (74%) with STS iniƟally presented to their GP with at least one guideline feature 
to prompt urgent referral. Only 2 paƟents (4%), however, were referred directly to a sarcoma unit with 21 (43%) 
referred to secondary care for invesƟgaƟon. PaƟents with a lump increasing in size exhibited longer paƟent delays 
whilst doctor delay was shorter for deep lumps. Thirty-six paƟents (88%) with a bone sarcoma iniƟally presented 
with symptoms to prompt further invesƟgaƟon. However, significant delays (3.9 months) were seen in reaching 
specialist care. Only 4 paƟents (10%) were referred directly to a sarcoma unit at first presentaƟon with 21 paƟents 
(54%) referred for further invesƟgaƟon elsewhere.
Conclusions: It is evident that awareness and referral of sarcomas remains poor. We suggest specific amendment to 
current guidelines and clearer referral pathways for paƟents. Furthermore, the need for robust educaƟon strategies, 
predominantly amongst healthcare professionals is indicated in order to promote greater awareness to potenƟally 
malignant lesions.
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S 014USEFULNESS OF 18FͳFDGͳPET/CT IN DIFFERENTIATING 
BETWEEN BENIGN AND MALIGNANT SOFT TISSUE TUMORS
Manabu Hoshi, Jun Takada, Naoto Oebisu, Masanari Aono, Makoto Ieguchi, Hiroaki Nakamura
Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-Ku, Osaka 
545-8585, Japan
ObjecƟve: Integrated 2-deoxy-2-F18-fluoro-D-glucose positron emission tomography combined with computed 
tomography (18F-FDG-PET/CT) evaluates both tumor funcƟon through glucose metabolism, and morphological 
features through CT imaging. The aim of the current study was to evaluate the usefulness of 18F-FDG-PET/CT for 
preoperaƟve diﬀerenƟal diagnosis between benign and malignant soŌ Ɵssue tumors. 
Materials and Methods: The criteria for diagnosis of malignancy on 18F-FDG-PET/CT,  was defined as the soŌ Ɵssue 
tumor having a maximum standardized uptake value (SUV max) over 2.0 on PET, and the greatest diameter being 
more than 5cm measured on CT. A total of 122 paƟents with soŌ Ɵssue tumors were examined by 18F-FDG-PET/CT, 
prior to histopathological diagnosis. 18F-FDG-PET/CT, 18F-FDG-PET, and CT were separately evaluated, to determine 
the usefulness of each imaging modality. 
Results: The paƟents consisted of 64 males and 58 females, ranging in age from 17 to 91 years (57.9±16.1 years). 
Pathological diagnosis revealed 101 malignant and 21 benign lesions. The sensiƟvity, specificity, and accuracy for the 
cut oﬀ value of SUV max over 2.0 on PET, were calculated to be 85.9%, 29.0%, and 68.3%. Those for tumor size being 
over 5cm on CT, were 82.3%, 30.0%, and 69.7%. Those of integrated 18F-FDG-PET/CT were 82.2%, 33.3 %, 79.8%, 
respecƟvely. 
Conclusions: Integrated 18F-FDG-PET/CT was more accurate for the diﬀerenƟal diagnosis between benign and 
malignant soŌ Ɵssue tumors, compared with 18F-FDG-PET and CT alone.
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STHE CLINICAL VALUE OF CͳREACTIVE PROTEIN AND 
COMORBIDITY IN PREDICTING SURVIVAL OF PATIENTS WITH 
HIGH GRADE SOFT TISSUE SARCOMA
Tomoki Nakamuraa, MaƩhew Francisb, Jackie Charmanb, Louie Gastona, Lee Jeysa, Robert Grimera
aThe Royal Orthopaedic Hospital, Birmingham, United Kingdom
bWest Midlands Cancer Intelligence Unit, Birmingham, United Kingdom
Aims: The aim of this study was to determine whether C-reacƟve protein (CRP) levels and co-morbidity before 
treatment predict the overall survival and local tumour control in paƟents with high grade non-metastaƟc soŌ Ɵssue 
sarcoma (STS).
Methods: A total of 332 adult paƟents were retrospecƟvely reviewed.  The CRP levels were obtained before treatment 
for all paƟents.  Co-morbidity was evaluated by using the Charlson co-morbidity Index (CCI). The paƟents who were 
referred for addiƟonal resecƟon were excluded from this study.
Results: Elevated CRP levels were seen in 152 paƟents (range; 11-342mg/L, average; 75mg/L).  The histological 
grade, age, tumour size and AJCC stage were significantly higher than those in paƟents with normal CRP levels.  CCI 
score varied from 0 to 4.  265 paƟents had a score of 0 (no idenƟfied co-morbidity), and 67 paƟents had a score 
of 1 or more.  Age in paƟents with idenƟfied co-morbidity was significantly higher than those in paƟents with no-
idenƟfied co-morbidity. PaƟents with elevated CRP levels (>10mg/L) had a poorer overall survival than paƟents 
with normal CRP levels (p<0.0001).  The overall survival esƟmates at 5 years were 42.2% versus 81.8%, respecƟvely. 
PaƟents with elevated CRP levels had also poorer local tumour control rate than paƟents with normal CRP levels 
(p=0.0004).  The local tumour control rate esƟmates at 5 years were 74.5% versus 89.0%, respecƟvely.  MulƟvariate 
analysis showed that pre-treatment CRP levels were a strong independent predictor of survival (p<0.0001) and local 
tumour control (p=0.04)
Conclusions: Pre-treatment CRP level could be a marker of tumour aggressiveness and is a strong predictor of 
survival for STS.
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ULTRASONOGRAPHY IN PREOPERATIVE DIFFERENTIAL 
DIAGNOSIS BETWEEN MALIGNANT AND BENIGN SOFT TISSUE 
TUMORS
Naoto Oebisu, Manabu Hoshi, Jun Takada, Hiroaki Nakamura, 
Dept. of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Purpose: The aim of the present study was to elucidate the usefulness of contrast enhanced color doppler (CD) 
ultrasonography for preoperaƟve diﬀerenƟal diagnosis between benign and malignant soŌ Ɵssue tumors.
Material and Methods: The CD ultrasonography was applied to 76 paƟents with soŌ Ɵssue masses for preoperaƟve 
diagnosis prior to histopathological diagnosis. Blood-flow in the masses were evaluated and compared between 
benign and malignant lesions. ConvenƟonal criterion, according to classical Giovanglion classificaƟon was used 
for evaluaƟon, with or without contrast medium, Sonazoid. The elasƟcity of the tumor was also measured, and 
compared with normal fat Ɵssue, using elastography. Student’s t-test was used to compare diﬀerences between 
benign and malignant soŌ Ɵssue tumors.
Result:  A total of 44 benign and 32 malignant soŌ Ɵssue tumors were included in the present study. Contrast 
medium was used to evaluate blood-flow in 27 masses (14 benign and 13 malignant). Elastography was performed in 
37 masses (24 benign and 13 malignant). In diﬀerenƟaƟng malignant tumors from benign, the sensiƟvity, specificity 
and accuracy of CD with Sonazoid were respecƟvely 92.3%, 69.2% and 68.0%; while those without Sonazoid 
were respecƟvely 53.1%, 78.6% and 81.5%. ElasƟc raƟo average was 0.56 in benign and 0.21 in malignant tumors 
(P=0.004).
Conclusion: High accuracy of contrast enhanced CD, in disƟnguishing malignant from benign soŌ tumors, was 
confirmed. The result of this analysis indicates the usefulness of contrast enhanced CD for preoperaƟve diagnosis in 
soŌ Ɵssue tumors.
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SCT MARKING OF RESECTION MARGINS PRIOR TO RESECTION 
OF MALIGNANT BONE TUMORS
G. Ulrich Exner and Charles E. Dumont
orthopaedie zentrum zuerich, Zurich, Switzerland
IntroducƟon: For most musculo-skeletal sarcomas complete resecƟon with uncontaminated margins R0 resecƟon) 
is sƟll the most important part of treatment. For preservaƟon of limbs and especially joints  the margins may 
be criƟcally small. The precision of osteotomies controlled under standard X-ray or image intensifier control is 
influenced by parallax and the limitaƟon in 3-dimensional analysis of oblique planes.
ObjecƟves: Mobile CT scanners to provide real Ɵme 3D images during surgery are produced (e.g. the Oarm 
Medtronic) but because of the high cost not yet readily available.
We have therefore used to place marks (K-wires or ancres) in Standard CT-scanners immediately ort he day before 
surgery.
Method - Case example: 17 year old girl, osteosarcoma of the proximal fibula involving the Ɵbio-fibular joint 
and large contact with the Ɵbia. Following the neoadjuvant chemotherapy the day before the definiƟve tumor 
resecƟon 3 K-wires were placed unter CT-control to guide the osteotomies of the Ɵbia (1st above the Ɵbio-fibular 
joint, 2nd oblique proximally, 3rd oblique distally into the Ɵbia). The resecƟon then was performed leƫng the 
K-wires guide the saw blade avert from the tumor.
The Ɵbial plateau was supported by an allograŌ. Because of the resecƟon of the involved fibular nerve tendon 
transposiƟons were performed simultanously. ExaminaƟon of the tumor revealed uncontaminated margins and 
the paƟent presently one year aŌer surgery is diseasefree.
preoperaƟve MRI     postop. X-Ray
1st prox. transverse    2nd prox. oblique   3rd dist. oblique CT marking
Results: Using diﬀerent CT-assisted modes in performing tumor resecƟon (placing markers in the CT as guides for 
resecƟon or using CT navigaƟon) allows to perform resecƟons with a precision in the range of mm. 
Conclusion: In situaƟon where intraoperaƟve determinaƟon of planes, axes or points maybe diﬃcult and real Ɵme 
CT is not available seƫng of pre-operaƟve marks under CT-control maybe useful. 
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S 030THE ROLE OF SOMATOSTATIN RECEPTOR SCINTIGRAPHY ΈSRSΉ 
ON THE DIAGNOSIS OF DESMOID TUMORS
Joerg Friesenbichler1, Reingard Aigner2, Patrick Sadoghi1, BernadeƩe Liegl-Atzwanger3, Werner Maurer-Ertl1, ChrisƟan Weger1, 
U. Pirker-Frühauf1, Andreas Leithner1.
1Department of Orthopaedic Surgery, Medical University of Graz, Austria.
2Division of Nuclear Medicine Radiology, Department of Radiology, Medical University of Graz, Austria.
3InsƟtute of Pathology, Medical University of Graz, Austria.
Background: MagneƟc Resonance Imaging is considered as imaging modality of choice in diagnosis of desmoid 
tumors, though even this technique can lack to disƟnguish aggressive fibromatosis from other benign or malignant 
soŌ Ɵssue tumors.
The aim of this study was to invesƟgate if desmoid tumors would show an adequate tracer uptake in somatostaƟn 
receptor scinƟgraphy and moreover to correlate these results with immunohistochemical staining.
PaƟents and Methods: Thirteen paƟents with desmoid tumors were examined with somatostaƟn receptor scinƟgraphy. 
AddiƟonally, seven of these paƟents have been tested for the immunohistochemical expression of somatostaƟn 
receptor subtype 2A. The results of somatostaƟn receptor scinƟgraphy and the results of immunohistochemical 
staining (somatostaƟn receptor subtype 2A) were evaluated and correlated.
Results: SomatostaƟn receptor scinƟgraphy revealed that eight of 13 aﬀected paƟents (62%) showed an enhanced 
tracer uptake. On the other hand, the correlaƟon between the results of somatostaƟn receptor scinƟgraphy and 
immunohistochemical invesƟgaƟons was poor (two out of seven cases)
Conclusion: The current study demonstrated that desmoid tumors frequently express somatostaƟn receptor subtype 
2, while immunohistochemical invesƟgaƟons did not correlate with these findings. This may likely be due to lack of 
standardizaƟon of this technique and also due to heterogeneous receptor distribuƟon within the tumors.
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SINSULINͳLIKE GROWTH FACTORS ΈIGFΉ AND IGF BINDING 
PROTEINS IN BLOOD SERUM OF BONE TUMOR PATIENTS: 
INTERRELATION AND POSSIBLE CLINICAL IMPLICATIONS.
N.E.Kushlinskiy, I.V.Babkina, E.S.Gershtein, E.A.Solovykh, I.V.Bulytcheva, Yu.N.Solovyev
Russian N.N.Blokhin Cancer Research Center RAMS, Moscow
ObjecƟves: Insulin-like growth factors (IGFs) are mulƟfuncƟonal pepƟdes that regulate cell proliferaƟon, 
diﬀerenƟaƟon, and apoptosis, and they are important in both normal and tumor growth. IGF-1 and IGF-2 were 
isolated from human osteosarcoma and Ewing’s sarcoma cells. 
Study Aims: The goal of our study was to compare serum levels of IGF-1, IGF-2, IGFBP-1 and IGFBP-3 in paƟents with 
various bone tumors and healthy donors in order to evaluate possible clinical implicaƟon of these factors.
Methods: IGF-1, IGF-2, IGFBP-1 and IGFBP-3 concentraƟons were measured in blood sera of 112 untreated bone 
tumor paƟents (malignant - 74 (osteosarcoma - 25, chondrosarcoma - 21, Ewing tumor - 18, malignant fibrous 
hisƟocytoma – 5, chordoma - 5), boderline (giant-cell tumor) – 14, benign bone neoplasms - 24) 15–69 years of age, 
median – 27,5 and from 47 pracƟcally healthy subjects 14–63, median - 35 years old by standard direct sandwich 
ELISA assays (DSL, USA).
Results: IGF-1and IGF-2 levels in healthy paƟents’ sera were staƟsƟcally significantly lower than in paƟents with 
malignant and borderline bone tumors (p<0.05). IGFBP-1 and IGFBP-3 levels in paƟents with various types of aﬀected 
bones were higher than in pracƟcally healthy subjects. No significant diﬀerences in IGFBP-1 concentraƟons were 
revealed between various groups of bone tumor paƟents. The highest IGFBP-3 levels were found in paƟents with 
benign bone neoplasms. In pracƟcally healthy subjects no significant correlaƟons were revealed between serum 
levels of the parameters studied. In paƟents with benign bone neoplasms only posiƟve correlaƟon between serum 
IGF-2 and IGFBP-3 (r=0,58) was found, and paƟents with borderline giant-cell tumor were characterized by posiƟve 
correlaƟon between both IGF-2/IGFBP-3 (r=0,69), and IGF-1/IGFBP-3 (r=0,81) serum levels. Meanwhile, in malignant 
bone tumors group posiƟve correlaƟon was found between IGF-1/IGF-2 (r=0,51), IGF-1/IGFBP-3 (r=0,58), IGF-2/
IGFBP-3 (r=0,63) serum concentraƟons, and these associaƟons were mostly pronounced in osteosarcoma paƟents. 
No significant associaƟons of IGFs/IGFBPs levels with the type of aﬀected bone or tumor histologic type was found. 
Low serum IGF-2 (<620 ng/ml) and IGFBP-3 (<3,5 mcg/ml) were associated with shorter disease-free interval (DFI) 
in osteosarcoma paƟents: median DFI in this group comprised 7.25 months, while in paƟents with higher IGF-2 and 
IGFBP-3 levels it comprised 15.5 months. 
Conclusions: Disbalances in IGFs regulatory system in paƟents with malignant bone tumors as compared to those 
with borderline and benign bone tumors and pracƟcally healthy subjects, and possible prognosƟc role of serum IGF-
2 and IGFBP-3 levels in osteosarcoma paƟents were demonstrated. 
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S 063PROGNOSTIC SIGNIFICANCE OF PREͳTREATMENT CͳREACTIVE 
PROTEIN IN PATIENTS WITH HIGHͳGRADE SOFT TISSUE 
SARCOMAS
Monika Jagodic. InsƟtute of oncology, Ljubljana, Slovenia.
ObjecƟves: Elevated levels of CRP have been recognized as a prognosƟc factor in various human malignant tumors. 
To date there are only few previous reports about the prognosƟc significance of CRP in paƟents with sarcomas. So, 
the primary aim of this study was to assess the prognosƟc value of pre-treatment CRP in a group of paƟents with 
high-grade soŌ Ɵssue sarcomas.  
Material and methods: A total of 68 adult paƟents (35 females, 33 males, with an average age of 56 years) with high-
grade soŌ Ɵssue sarcomas (stage II in 43% of paƟents, stage III in 57% of paƟents) were retrospecƟvely analysed. 
PaƟents with evidence of distant metastases at the Ɵme of primary treatment, smokers and paƟents with concomitant 
infecƟon, inflammatory disease or cardio-vascular disease were excluded from this study. 48 (71%) paƟents had 
tumors in the extremiƟes, 20 (29%) paƟents had tumor locaƟon in the trunk. Surgical treatment was performed on 
all 68 paƟents. 59% of all paƟents also received radiotherapy. Chemotherapy was given to 12% of paƟents. AŌer 
compleƟon of primary treatment, the paƟents were regularly monitored (median follow-up 43 months, range 4-89 
months). PaƟents' blood to measure the level of serume CRP was obtained before start of treatment as part of a 
pretreatment clinical rouƟne. A serum CRP level of ≤5 mg/dl was regarded normal corresponding to our clinical 
rouƟne pracƟce. Pre-treatment CRP was correlated with pathological and clinical prognosƟc factors, disease-free 
survival (DFS) and overall survival (OS) in an uni-variate and mulƟ-variate staƟsƟcal model.
Results: Mean pre-treatment serum CRP was 10.38mg/dl (range 0-75 mg/dl, median 3mg/dl). 25 (37%) paƟents 
had CRP levels above the defined cut-oﬀ of 5 mg/dl. CRP was significantly associated with histologic grade, tumor 
stage, recurrent disease and death of underlying malignant disease, but not with paƟents' age, sex, tumor locaƟon, 
tumor depth or histological type. In univariate Cox analysis of DFS, CRP(>5 mg/dl vs. ≤5 mg/dl)), histological grade 
(3 vs. 2), tumor depth (deep vs. superficial), tumor stage (III vs. II), age of paƟents (≥60 years vs. <60 years) and 
adequate surgical margins (non- adequate vs. adequate) were staƟsƟcally significant prognosƟc factors. The three-
year DFS was only 23% in paƟents with CRP values >5 mg/dl and 69% in the group of paƟents with CRP values ≤5 
mg/dl. In mulƟvariate analysis (Cox model) of DFS, CRP (p=0.017, relaƟve risk (RR) 2.6) and age of paƟents (p=0.019, 
RR=2.53) had an idependent significant influence on DFS. Univariate analysis for OS selected the following variables 
as unfavorable prognosƟc factors: CRP>5, histological grade 3, age of paƟents >60 years and non-adequate surgical 
margins. The paƟents with the levels of CRP >5 mg/dl had significantly poorer prognosis than the paƟents with CRP 
values ≤5 mg/dl (40% three-year OS vs. 81% three-year OS). In mulƟvariate analysis of OS, including all significant 
prognosƟc factors from univariate analysis of OS, CRP (p=0.005, RR=3.46), age of paƟents (p=0.008, RR=3.21) and 
adequate surgical margins (p=0.047, RR=2.68) retained a staƟsƟcally significant independent prognosƟc impact. 
Conclusion: Pre-treatment serum CRP is an independent prognosƟc factor for DFS and OS in paƟents with high-
grade soŌ Ɵssue sarcomas. The normal CRP group showed significantly more favorable prognosis then the elevated 
CRP group. In our poor risk paƟents with soŌ Ɵssue sarcomas, CRP is even the strongest independent prognosƟcator 
of DFS and OS. Thus, CRP deserves further research helping us to classificate paƟents with high grade soŌ Ɵssue 
sarcomas into diﬀerent prognosƟc subgroups more accurately. We need long term results for confirmaƟon of  CRP 
as an important prognosƟc factor in paƟents with soŌ Ɵssue sarcomas on a large scale basis according to the rarity 
of this malignant disease.  
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SPERCUTANEOUS CORE NEEDLE BIOPSY VERSUS OPEN BIOPSY 
IN DIAGNOSTICS OF BONE AND SOFT TISSUE SARCOMA
Pohlig F.1, Kirchhoﬀ C.1, Lenze U.1, Schauwecker J.1, Rechl H.1, von Eisenhart-Rothe R.1
1 Department for Orthopaedic Surgery
Klinikum Rechts der Isar 
Technische Universitaet Muenchen 
Ismaningerstrasse 22 - 81675 Munich - Germany
ObjecƟves: Biopsy in paƟents with suspected bone or soŌ Ɵssue sarcoma represents one of the crucial steps in the 
diagnosƟc cascade. Open biopsy is sƟll considered the gold standard. However, recent literature suggests similar 
results for percutaneous biopsy techniques. Therefore the aim of this retrospecƟve study was to compare open and 
percutaneous core needle biopsy (CNB) in malignant musculoskeletal lesions.
Materials and methods: Overall 77 consecuƟve paƟents with a suspected malignant primary bone or soŌ Ɵssue 
tumor who underwent a percutaneous CNB or open biopsy and a subsequent tumor resecƟon in our department 
from January 2007 to December 2009 were idenƟfied and enrolled. The harvested samples were fixed in 10% formalin 
and rouƟnely stained with H&E. Immunohistochemical stains were applied if appropriate. SensiƟviƟes, specificiƟes, 
posiƟve predicƟve values (PPV), negaƟve predicƟve values (NPV) and diagnosƟc accuracy were calculated for both 
biopsy techniques and compared using the fisher’s exact test.
Results: SensiƟvity, specificity, PPV, NPV and diagnosƟc accuracy were 100% for CNB in bone tumors. SensiƟvity 
(95,5%) and NPV (91,7%) for open biopsy in bone tumors showed slightly inferior results without staƟsƟcal significance 
(p=1). In soŌ Ɵssue tumors favorable results were obtained in open biopsies compared to CNB with diﬀerences 
regarding sensiƟvity (100% vs. 81,8%), NPV (100% vs. 50%) and diagnosƟc accuracy (100% vs. 84,6%) again without 
staƟsƟcal significance (p>0,05). Overall the diagnosƟc accuracy was 92,9% for CNB and 98% for open biopsy. A 
specific diagnosis could be obtained in 84,2% and 93,9% respecƟvely (p=0,34). Inferior results were idenƟfied for 
CNB in soŌ Ɵssue tumors compared to bone tumors regarding sensiƟvity (81,8% vs. 100%, p=0,5), NPV (50% vs. 
100%, p=0,09) and diagnosƟc accuracy (84,6% vs. 100%).
Conclusions: In our study moderately inferior results were found for the percutaneous biopsy technique compared 
to open biopsy in soŌ Ɵssue tumors whereas almost equal results were obtained in bone tumors. Thus, CNB is a 
safe, minimal invasive and cost-eﬀecƟve technique for diagnosƟcs of bony lesions. In soŌ Ɵssue masses indicaƟon 
for percutaneous core needle biopsy needs to be set carefully by an experienced orthopedic oncologist with respect 
to suspected enƟty, size of necrosis and locaƟon to avoid incorrect or deficient results.
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MARKERS IN TUMOR CELLS IN OSTEOGENIC SARCOMA
Djamila Sh.Polatova, Khurshid G.Abdikarimov, Sundr D.Urunbaev 
NaƟonal Oncology Research Centre, Tashkent, Uzbekistan 
Aim: To establish prognosƟc role of expressions of apoptosis and proliferaƟon in osteogenic sarcoma.
Materials and methods: 46 paƟents Ɵll 30 have been examined, 30 - men and 16 - women (Т2N0-1M0).Expressions of 
genes р53, Bcl-2 и Ki-67 in tumor cells have been studied by the method of immune histochemistry with monoclonal 
(Novocastra).VisualizaƟon have been executed with using Streptavidin – HRP and DAB (DakocytomaƟon). 
Results: Organ-conserving operaƟons have been performed in 16 paƟents (10 men, 6 women). Full eﬀect and parƟal 
eﬀect was marked in these paƟents, but expressions of genes mtp53 Ki-67 was low (1+) or absent. Expressions of 
genes bcl-2 was also low (1+). Crippling operaƟons have been performed in 20 men and 10 women paƟents with 
osteogenic sarcoma, from them in 9 paƟents was detected metastasis further. ParƟal eﬀect and stabilizaƟon of 
tumor process was marked in all paƟent of these group, but the expressions of genes mtp53 and Ki-67 was high and 
moderate (3+, 2+), but expression of genes bcl-2 was moderate (2+) and high (3+). 
Conclusion: DefiniƟon the level of genes expressions mtp53, Ki-67 and bcl-2in tumor cells, we can use conducted 
therapy for eﬀecƟve prognosis  in the choice of osteogenic sarcoma treatment . 
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SDIAGNOSTIC VALUE OF AP2 EXPRESSION IN MALIGNANT SOFT 
TISSUE TUMOURS
TG KASHIMA, A DONGRE, F PEZZELLA , NA ATHANASOU *
Department of Pathology, NDORMS, University of Oxford, Nuﬃeld Orthopaedic Centre, Oxford OX3 7HE
OBJECTIVES:  aP2 (adipocyte P2), also known as FABP4 (faƩy acid-binding protein-4) is a faƩy acid binding 
protein found in the cytoplasm of cells of adipocyte diﬀerenƟaƟon. We and others have previously shown that 
immunohistochemistry with sa polyclonal anƟbody to aP2 is useful in detecƟng lipoblasts. In this study we examined 
a large number of soŌ Ɵssue tumours with a newly developed anƟ-ap2 monoclonal anƟbody to determine its uƟlity 
in the diagnosis of tumours of adipose diﬀerenƟaƟon.
MATERIALS & METHODS:  An anƟ-aP2 monoclonal anƟbody was raised against a mixture of syntheƟc pepƟdes 
corresponding to the amino acid sequence of residues 10 - 28 and 121-132 of the human aP2 protein. Hybridoma-
condiƟoned medium was tested for the producƟon of anƟ-aP2 anƟbody by an enzyme-linked immunosorbent 
assay using the immunized syntheƟc pepƟdes. Expression of aP2 was immunohistochemically determined using 
the selected supernatants in paraﬃn secƟons of normal adipose Ɵssue and a wide range of benign and malignant 
primary soŌ Ɵssue tumours (n=120)
RESULTS: Fat cells in normal adipose Ɵssue and benign lipomas expressed aP2/FABP around cytoplasmic lipid vacuoles. 
Hibernomas and lipoblastomas showed strong aP2 staining of brown fat cells and lipoblasts respecƟvely. Spindle cell 
lipomas showed posiƟve staining of the fat but not the spindle cell component. Lipoblasts in atypical lipomatous 
tumour/well diﬀerenƟated liposarcoma, sclerosing liposarcoma, myxoid/round cell liposarcoma and pleomorphic 
liposarcoma reacted strongly for aP2. No specific staining was seen in the tumour component of malignant 
tumours containing (lipoblast-like) clear or vacuolated cytoplasm including clear cell sarcoma, myxofibrosarcoma, 
leiomyosarcoma, alveolar soŌ part sarcoma and clear cell carcinoma. Capillary endothelial cells were posiƟve for aP2 
but fibroblasts, muscle and other cell types were negaƟve.
CONCLUSION: The 175D (anƟ-aP2) anƟbody reacts with mature and immature fat cells. aP2 is expressed in tumours 
of adipose diﬀerenƟaƟon. aP2 expression is useful in idenƟfying lipoblasts and should thus be useful in disƟnguishing 
liposarcoma from other sarcomas and malignancies which contain (lipoblast-like) tumour cells with a clear or 
vacuolated cytoplasm. 
 Tumour type number of cases lipoblasts detected by IHC
®ÖÊùã® ãçÃÊçÙ
½®ÖÊÃ 16 0
«®ÙÄÊÃ 3 3
½®ÖÊ½ÝãÊÃ 5 5
ÝÖ®Ä½ ½½ / Ö½ÊÃÊÖ«® ½®ÖÊÃ 6 0
ãùÖ®½ ½®ÖÊÃãÊçÝ ãçÃÊçÙ / ó½½ 
®¥¥ÙÄã®ã ½®ÖÊÝÙÊÃ 22 22
Ý½ÙÊÝ®Ä¦ ½®ÖÊÝÙÊÃ 3 3
ÃùøÊ® ½®ÖÊÝÙÊÃ 4 4
ÙÊçÄ ½½ ½®ÖÊÝÙÊÃ 4 4
Ö½ÊÃÊÙÖ«® ½®ÖÊÝÙÊÃ 4 4
®¥¥ÙÄã®ã ½®ÖÊÝÙÊÃ 2 0
ãçÃÊçÙÝ Ý«Êó®Ä¦ 
ÃùøÊ® «Ä¦
ÃùøÊÃ 8 8
ÃùøÊ¥®ÙÊÝÙÊÃ 11 0
ÝÊ½®ãÙù ¥®ÙÊçÝ ãçÃÊçÙ / «ÃÄ¦®ÊÖÙ®ùãÊÃ 3 0
Oã«Ù ÝÙÊÃÝ ½®ÊÃùÊÝÙÊÃ 4 0
½òÊ½Ù ÝÊ¥ã ÖÙã ãçÃÊçÙ 1 0
TOTAL  96  
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S 089THE IMPORTANCE OF 3D PLANNING: TUMOR RESECTION OF 
THE PROXIMAL RADIUS SPARING THE RADIAL HEAD.
K.Modaressi, L.Nagy, A.Schweizer, B.Fuchs
University Hospital Balgrist, Orthopedic Research, Forchstrasse 340, 8008 Zürich 
IntroducƟon: SophisƟcated radiological imaging studies nowadays allow the precise delineaƟon of a musculoskeletal 
tumor preoperaƟvely. This in turn paves the way for precise resecƟons accepƟng closer margins with respect to the 
tumor. PreoperaƟve 3D planning and intraoperaƟve navigaƟon plays therefore an increasingly important role in 
tumor surgery. Herein, we report our experience with 3D planning for a paƟent in whom the proximal radius was 
resected but sparing the radial head.
Results/Case Report: PreoperaƟve CT imaging was used to 3D-print a plasƟc radius model. Then, the resecƟon 
margins were determined and a custom made Ɵtanium plate as well as a cuƫng block device including the drill 
holes were manufactured. The proximal resecƟon margin was chosen that only 1.5cm of the radial head could 
be preserved. IntraoperaƟvely, the tumor was exposed and the cuƫng device was mounted. The drill holes were 
prepared in the radial head such that aŌer resecƟon, it could be fixed in the correct 3D posiƟon as before. An allograŌ 
was carpentered to precisely fit into the defect, and then the custom made Ɵtanium plate was used to fix it.
Conclusions: 3D planning and the manufacturing of a custom made cuƫng/pre-drill device can be very helpful for 
tumor resecƟons at anatomically diﬃcult locaƟons and when a remaining bone has to be precisely retained in its 
original anatomic posiƟon.
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SIN VIVO MICROͳCOMPUTED TOMOGRAPHY CAN VISUALIZE 
AND QUANTIFY OSTEOSARCOMA PRIMARY TUMOR GROWTH 
AND PULMONARY METASTASES OVER TIME.
S. BoƩer, K. Husmann, M. Arlt, C. Campanile, A. Gvozdenovic, W. Born, B. Fuchs
University Hospital Balgrist, Orthopedic Research, Forchstrasse 340, 8008 Zürich
IntroducƟon: In osteosarcoma (OS), one important imaging tool to assess the extent of primary tumor growth, 
metastaƟc spread (mainly in the paƟents’ lungs), and thus paƟent prognosis is computed tomography (CT). In the 
past two decades, this technique has been adapted in order to image small laboratory animals like mice. As such, 
micro-CT imaging proved its funcƟonality in a number of other cancer types. In our laboratory, we established a 
method to visualize the presence of single OS tumor cells ex vivo, by means of LacZ tagging. However, what exactly 
occurs during the course of the disease process remains largely unknown, since in vivo visualizaƟon methods are 
not yet commonly employed in preclinical OS models. We therefore tested if in vivo micro-CT can be employed to 
monitor the growth of both the primary tumor as well as the pulmonary metastases in a preclinical OS model.
Methods: Female SCID mice received an intraƟbial injecƟon with LacZ-tagged osteoblasƟc SAOS-2 or osteolyƟc 
143B OS cells. AŌer growth of the primary tumor, mice were anestheƟzed and scanned in the Skyscan 1176 in vivo 
microtomography system using the 35 μm seƫng. Two separate scans were made, one of the chest area and one of 
the hind limbs. Scan duraƟon per scan was 8-10 minutes, with a dose of ~0.5 Gy. AŌer two weeks, the scans were 
repeated. As verificaƟon, mice were sacrificed immediately aŌer the second scan, and their lungs were excised, 
X-Gal stained, air-dried, and scanned again at high (9 μm) resoluƟon.
Results: In mice injected with SAOS-2 cells, mineralized foci could be observed inside the primary tumor mass, as 
well as in the pulmonary metastases. The size of the smallest detectable metastasis was 0.5 mm. In the second scan, 
the mineralized foci became more pronounced. In 143B tumors, bone destrucƟon at the proximal Ɵbia could be 
visualized in detail. X-Gal stained and re-scanned lungs showed a perfect match between X-Gal staining and micro-
CT-detected metastaƟc sites ex vivo.
Conclusions: Micro-computed tomography can be used to monitor both primary and distal OS tumor growth in vivo, 
and reveals detailed 3D informaƟon of micro-metastasis distribuƟon ex vivo. Future challenges will be to increase 
the contrast between tumor Ɵssue and normal Ɵssues, e.g. by using gold-labeled anƟbodies directed against specific 
tumor markers, and thus to be able to idenƟfy and monitor even smaller metastases over Ɵme.
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S 091CD44 OVEREXPRESSION ENHANCES METASTATIC PROPERTIES 
OF HUMAN OSTEOSARCOMA SAOSͳ2 CELLS IN VITRO AND IN 
VIVO
A. Gvozdenovic, M. Arlt, C. Campanile, P. Brennecke, W. Born, R. Muﬀ, B. Fuchs
University Hospital Balgrist, Orthopedic Research, Forchstrasse 340, 8008 Zürich
IntroducƟon: Pulmonary metastases are the major cause of death in paƟents suﬀering from OS, a disease mainly 
aﬀecƟng children and adolescents. At the Ɵme of diagnosis, up to 15-20% of paƟents already have detectable 
metastases. PaƟents with metastaƟc or recurrent disease conƟnue to have a poor prognosis, with a 5-year survival 
rate of 10-20%. Thus, it is of substanƟal importance to idenƟfy molecular markers in OS associated with increased 
metastaƟc potenƟal. CD44 is frequently found overexpressed in tumour cells and has been implicated in metastasis 
of diﬀerent cancer types. It is a cell-cell and cell-matrix adhesion molecule and the principal receptor for hyaluronan 
(HA), a major component of the extracellular matrix. CD44 has a wide repertoire of funcƟons in biological processes, 
including development, wound healing, inflammaƟon, haematopoiesis, immune response and tumor progression. 
Here, we invesƟgated the eﬀects of stable CD44 overexpression on in-vitro and in-vivo metastaƟc properƟes of low 
metastaƟc human LacZ-transduced SaOS-2 (SaOS-2/LacZ) OS cells expressing low levels of endogenous CD44. 
Methods: To assess the relevance of CD44-HA interacƟon in promoƟng metastaƟc ability of OS cells, we overexpressed 
both, the standard CD44 isoform CD44s and the HA binding-defecƟve mutant CD44s R41A in SaOS-2/LacZ cells using 
retroviral gene transfer. Overexpression was examined on Western blots. The biological impact of CD44s and CD44s 
R41A overexpression was then studied in-vitro in adhesion, transwell migraƟon and proliferaƟon assays. Eﬀects of 
CD44s and mutant overexpression on tumor progression and metastasis in-vivo were invesƟgated in an intraƟbial 
xenograŌ OS model in SCID mice.
Results: SaOS-2/LacZ cells overexpressing CD44s showed increased adhesion to HA, whereas overexpression of 
binding-defecƟve CD44s R41A did not aﬀect the adhesion when compared to empty vector (EV) transduced SaOS-
2/LacZ control cells. Overexpression of CD44s and CD44s R41A resulted in HA-independent higher migraƟon rates. 
In the orthotopic mouse model of OS, CD44s overexpression led to faster primary tumor growth and increased 
numbers of micro- and macrometastases in the lungs in a HA-dependent manner. 
Conclusions: These results highlight the important role of CD44/HA interacƟon in determining tumor malignancy in 
experimental OS in mice.
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PRECLINICAL MODELS OF OSTEOSARCOMA
Campanile C1, Arlt M1, Honer M2, Kraemer SD2, Ametamey SM2, Schibli R2, Born W1, Fuchs B1
1University Hospital Balgrist, Orthopedic Research, Zurich
2InsƟtute of PharmaceuƟcal Sciences, ETH Zürich
INTRODUCTION: Osteosarcoma (OS) is the most common malignant bone tumor in children and adolescents 
characterized by the producƟon of immature bone, osteoid. In normal bone, the resorbƟon by osteoclasts is linked 
to bone formaƟon. In OS, osteolyƟc and osteoblasƟc phenotypes, as a result of imbalanced bone resorpƟon and 
formaƟon, are disƟnguished radio- and histologically. The diﬀerent phenotypes, associated with diﬀerences in 
tumor proliferaƟon and hypoxia, determine at least in part the response to chemotherapy and, consequently, the 
paƟent’s outcome. Novel minimally-invasive diagnosƟc tools are needed for future more paƟent-tailored treatment 
depending on more precisely defined tumor phenotypes. Here, Positrion Emission Tomography (PET) with 18F-FDG, 
indicaƟng glucose metabolism, 18F-Fluoride, indicaƟng bone remodelling and 18F-FMISO indicaƟng hypoxia, is used 
in 3 diﬀerent mouse models with well-defined phenotypes, reflecƟng OS heterogeneity, to evaluate the respecƟve 
predicƟve power of the 3 PET tracers in OS diagnosƟcs. 
METHODS: 2 human (143B, osteolyƟc; and SaOS-2, osteoblasƟc) and 1 mouse OS cell line (LM8-osteoblasƟc) were 
intraƟbially injected in SCID immunosuppressed and C3H immunocompetent mice, respecƟvely. IntraƟbial primary 
tumor development was monitored by X-ray. PET was performed at the Animal Imaging Center at ETH-Hönggerberg 
3 weeks aŌer tumor cell injecƟon in the 143B and LM8 models and between 2 and 5 months aŌer injecƟon of human 
SaOS-2 cells in SCID mice. Tracer uptake in the tumor leg was quanƟfied with p-mod soŌware and compared to the 
control leg. 
RESULTS: In the 143B cell line, a significantly higher uptake of FDG and FMISO is observed in the tumor compared 
to the control leg, but there is no diﬀerence in Fluoride uptake which is consistent with the histological results. 
The SaOS-2 cell derived tumors, on the other hand, display high uptake of FDG, FMISO and Fluoride, reflecƟng a 
proliferaƟve and hypoxic osteoblasƟc phenotype. LM8 mouse OS cell derived tumors show a high tumor selecƟve 
accumulaƟon of FDG, but only moderate uptake of FMISO and Fluoride consistent with low osteoblasƟc acƟvity and 
hypoxia. 
CONCLUSIONS: FDG, FMISO and Fluoride proofed to be predicƟve in the 3 intraƟbial OS mouse models with well 
characterized phenotypes and therefore suitable for primary tumor monitoring in pre-clinical studies invesƟgaƟng 
novel phenotype- and histotype-specific treatment modaliƟes. 
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DIAGNOSIS AND PREDICTION OF EVENTͳFREE SURVIVAL IN 
PATIENTS WITH BONE SARCOMAS 
I. Begun 1,2, I. Papkevich1, R. Tarasevich1, O. Bydanov1, A. Mikhailov2  
1. Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk region, Belarus
2.  Belarusian Medical Academy of Post-Graduate EducaƟon, Minsk, Belarus
Purpose: Study   the   eﬀecƟveness   of   ultrasound   for   diagnoses   and   prognosƟc significance of Doppler pulsaƟlity 
index (PI) for common femoral   arteria (CFA) in paƟents with osteogenic sarcoma (OS) and Ewing’s sarcoma (SE).
Material and Methods: We analyzed data of integrated ultrasound invesƟgaƟon in 47 children and adolescents 
aged 7-17 years with prospecƟvely confirmed diagnosis of osteogenic sarcoma (27) and Ewing’s sarcoma (20). In all 
cases process was localized in the tubular bones of the lower extremiƟes. In Comparison group were 42 children of 
similar age with benign tumors and tumor-like condiƟons (osteoid osteoma, cyst, fibrous dysplasia, osteochondroma, 
calcified hematoma, venous dysplasia). When evaluaƟng the diagnosƟc indicators we used mathemaƟcal apparatus 
of ROC analysis. Data are presented as the values  of percentage deviaƟons of resisƟve index (RI%), pulsaƟlity index 
(PI%) and volumetric blood flow velocity (Q%) in the common femoral artery (CFA) of the aﬀected limb compared 
with the contralateral. PaƟents with SE and OS received chemotherapy according to protocols EURO-EWING-99 and 
COSS-96, EURAMOS respecƟvely. We invesƟgated too the prognosƟc significance   of   PI%   for   event-free   five-year 
survival    (EFS). Analysis was by Kaplan-Meier.
Results:  Predominance of the size of the aﬀected area of  malignant neoplasms compared   with   benign   noted. 
The average volume of tumor was 257 ± 244cm³.  The soŌ-Ɵssue component of bone sarcomas was presented 
as heterogeneous echostructure. It was adjacent to the bone with altered in varying degrees of corƟcal integrity. 
The common features of malignant bone tumors in most cases were: irregular shape, fuzzy contours, low acousƟc 
density, heterogeneity of echostructure. In 32% of paƟents were determined ultrasound signs of X-ray analogues 
periosteal reacƟon. In 80% - the degree of tumor vascularizaƟon was high and average. The cited symptoms above 
are allowed to help qualitaƟvely diﬀerenƟate between benign and malignant neoplasms. The eﬃciency of diagnosis 
has been increased with the use of quanƟtaƟve data of triplex ultrasound scanning. We noted an increase in the 
volume velocity of blood flow in CFA for the aﬀected limb and a decrease in RI and PI for CFA compared with the 
contralateral side (p <0.01), which could indicate a decrease in resistance for the distal circulatory bed on the side 
of the tumor. Analysis of quanƟtaƟve data showed that the sensiƟvity and specificity in the diﬀerenƟal diagnosis 
of sarcomas and benign tumors of bone of the lower limbs   by criterion of reducing PI%, RI% and increasing of Q% 
(at   threshold   values  - 23%, 10% and 15% respecƟvely) were 79-96%.
For studying event-free survival cut-oﬀ value of the predictor PI% were selected that so informaƟon content of 
data analysis was maximal. For paƟents of all groups (OS, SE, OS+SE) best staƟsƟcal representaƟveness of forecast 
EFS five-year for PI% were obtained when it’s a threshold value there was 33%. Percentages of values deviaƟon 
(downward) of PI for  the aﬀected limb  were associated with 100%  EFS  in the event of occurrence in the range 33% 
and  less, or with the EFS of 26±7% in  case of entry into a range of more than 33% (p<0,01).
Conclusions: By mulƟ modaliƟes ultrasound were obtained by quanƟtaƟve and qualitaƟve characterisƟcs bone 
sarcomas in children and adolescents. ComparaƟve analysis of quanƟtaƟve characterisƟcs proximal blood flow in 
both healthy and the aﬀected limb helps eﬀecƟvely disƟnguish between sarcomas and benign tumors of bones. It 
is established that the relaƟve magnitude of the PI,   characterizing changes in hemodynamic of aﬀected limb, and, 
consequently, to a certain extent its supply blood, is associate with predicƟng EFS five- year in paƟents with bone 
sarcomas. Thus, relaƟve changes of the Doppler pulsaƟlity  index  in  femoral  arteria  of aﬀected limb is opening  a 
new  features for predicƟon  of event-free survival in paƟents with bone sarcomas.
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OF INADVERTENTLY EXCISED SUPERFICIAL SOFT TISSUE 
SARCOMAS? A CLINICOͳPATHOLOGIC STUDY
CL Gaston, VP Sumathi, RJ Grimer
Royal Orthopaedic Hospital Birmingham, UK
IntroducƟon: Superficial soŌ Ɵssue sarcomas (SSTS) treated by previous inadvertent surgery require re-excision of 
the surgical bed for local control of residual and recurrent tumour.  Recommended excision margins in literature 
range from 1, 2, or 3-5 cenƟmeters.  This study aimed to determine the eﬀect of diﬀerent skin excision margins on 
final surgical margin and outcomes (local recurrence, adjuvant treatment)
Methods: A retrospecƟve review was done for the 115 paƟents with superficial STS treated at our insƟtuƟon aŌer 
inadvertent excision from August 2004 – Dec 2011.  Photographs of the resecƟon specimens were analysed to 
determine the narrowest skin margin circumferenƟally from the previous surgical scar.  This was correlated with the 
resulƟng surgical margin, need for adjuvant therapy, and local recurrence.
Results: The average skin margin for re-excision was 16.1 mm (range 4 – 30mm).  Residual tumour was found in 
56%.  Skin margins were significantly narrower in paƟents with inadequate circumferenƟal margins (12.6 vs 21.5mm, 
p<0.001).  84% of those with inadequate circumferenƟal margins were excised with a skin margin of less than 2cm, 
92% were excised with less than 3cm.  Using 3cm skin margin as a cut-oﬀ was significantly associated with the need 
for further treatment (re-excision, adjuvant radiotherapy).  No associaƟon to local recurrence was found.  Six of 9 
paƟents (67%) with myxofibrosarcomas were excised with inadequate circumferenƟal margins despite the majority 
being excised with at least 2cm skin margins.
Conclusions: Narrow skin margins in re-excising the surgical scars of inadvertently excised superficial soŌ Ɵssue 
sarcomas are associated with inadequate circumferenƟal margins and consequently to further treatment with wider 
re-excision and/or adjuvant radiotherapy.  We recommend that re-excision be made with at least a 3cm margin even 
without gross residual tumour to help prevent inadequate margins.
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S 130DIAGNOSTIC PERFORMANCE OF TRUCUT BIOPSY IN 
MUSCULOSKELETAL TUMOURS
Pedro Cardoso, Daniel Carquejo, Vânia Oliveira
Hospital Santo António – Porto - Portugal
ObjecƟves: Currently, percutaneous needle biopsy is a diagnosƟc method widely used and well accepted, minimally 
invasive, safe and cost-eﬀecƟveness. Requires only local anesthesia and has reduced risk of complicaƟons and is 
becoming the preferred technique for diagnosing musculoskeletal lesions. The purpose of this study was to analyze 
the diagnosƟc performance of percutaneous core needle biopsy in musculoskeletal lesions in our Unit and whether 
this was influenced by the gauge of the needle used.
Materials and methods: it was performed a retrospecƟve review of 142 cases of musculoskeletal lesions undergoing 
percutaneous core needle biopsy aided by imaging over a period of four years (January 2007 to December 2010). 122 
biopsies corresponded to lesions of bone (65 cases with 11 gauge needle and 57 with 8 gauge needle) and 20 to soŌ 
Ɵssue lesions (needle gauge 16). The diagnosƟc accuracy and diagnosƟc yield were the parameters used to evaluate 
the diagnosƟc performance.
Results: The overall diagnosƟc yield was 90.1% and diagnosƟc accuracy was 90.9%. In the pelvic biopsies diagnosƟc 
yield (77.1%) was significantly lower (p = 0.006) as compared to other anatomical sites (94.4%). The diagnosƟc 
yield was 89.3% in bone and 95% in soŌ Ɵssue (p = 0.381), and diagnosƟc accuracy was 93.3% in bone lesions and 
85.7% in soŌ Ɵssue injuries (p = 0,379). The diagnosƟc yield (p = 0.965) and diagnosƟc accuracy (p = 0.313) were not 
significantly diﬀerent between the 11 gauge needle (89.2% and 88.2%, respecƟvely) and 8 gauge needle (89.5% and 
100%, respecƟvely).
Conclusion: This study demonstrates that percutaneous core needle biopsy is useful and important as a diagnosƟc 
procedure in musculoskeletal disorders, and  the results obtained in this insƟtuƟon are comparable or slightly 
beƩer than other studies.
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SANALYSIS OF CLINICAL AND DIAGNOSTIC PROPERTIES OF THE 
OSTEOSARCOMA LUNG METASTASIS.
Rahim R. Abdurasulov1, Mirza A. Gafur-Akhunov1, Khurshid G. Abdikarimov2
1The Tashkent InsƟtute of Postgraduate Medical EducaƟon, Tashkent, Uzbekistan
2 NaƟonal Oncology Research Centre, Tashkent, Uzbekistan 
Background: to study clinical manifestaƟons and properƟes of pulmonary metastaƟng  process of osteosarcoma 
(OS).
Material and methods: we had analyzed 33 paƟents with OS pulmonary metastasis, which had been treated in the 
Republic Oncology ScienƟfic Center of Uzbekistan, during 2007-2010 years. Female - 19 (58%), male – 14 (42%). 
PaƟents ages from 14 to 38 years, median age – 17. From 33 paƟents in 20 (60.6%) primary tumor localized in distal 
femur, in 8 (24.2%) – proximal Ɵbia and in 5 (15.2%) – diﬀerent parts of fibula. In 30 paƟents from 33 lung metastases 
were detected by x-ray examinaƟon and in 3 paƟents by computer tomography (CT). 
Results: bilateral metastaƟc lesions of lungs detected in 20 (60.6%) and unilateral in 13 (in 6 (9.4%) – upper lobe 
of leŌ lung, in 4 (12.4%) – lower lobe of right lung and in 3 (12.1%) – upper lobe of right lung) paƟents. Of the 33 
paƟents in 31 (94%) lung metastases developed during from 1 to 24 months follow up, and in 2 (6%) at diagnosis of 
primary tumor. The numbers of metastaƟc nodules were 1-7, middle 2 nodules. Lung metastases were single in 9 
(27.2%) and mulƟple in 24 (72.8%) paƟents. MetastaƟc nodules sizes in detected Ɵme were from 5mm to 25 mm, 
median 14.3 mm. Of 33 paƟents in 4 aŌer lungs x-ray examinaƟon were carry out CT examinaƟon, so were detected 
addiƟonal metastaƟc nodules and diﬀerence in nodules size. 
Conclusions: the target organ of OS metastaƟc spread is the lungs and in most cases had aﬀected both lungs. 
ProperƟes of metastaƟc OS is mulƟple aﬀecƟng of the lungs. 
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S 133DOES A PREVIOUS INADVERTENT EXCISION AFFECT OUTCOME 
IN SUPERFICIAL SOFT TISSUE SARCOMAS?
Rob Grimer and Lee Jeys
Superficial soŌ Ɵssue sarcomas (STS) represent approximately 25% of all STS and about 50% have a previous 
inadvertent excision. We have invesƟgated whether a previous inadvertent excision aﬀects outcome.
Method: A retrospecƟve review of a prospecƟve database has been carried out. Only paƟents with treatment and 
follow up at our centre are included.
Results: there were 525 paƟents with a mean age of 55. The average size of the STS was 6cm. The most common 
site was the thigh, 83% were high grade. 281 paƟents (54%) had undergone a previous inadvertent excision and 
the others were treated primarily at our unit. The paƟents with previous excision had significantly smaller tumours 
(4.8cm vs 7.4cm., p<0.0001) and paƟents with DFSP or leiomyosarcoma were more likely to be diagnosed in this way. 
Most paƟents (400) underwent aƩempted wide re-excision with skin graŌ if primary closure could not be obtained 
(100). Wide margins were achieved in 60%, marginal in 33% and intralesional in 7%. Local recurrence arose in 16% 
of paƟents and was related to margins of excision, grade and age of the paƟent whilst overall survival was related to 
grade, age and size of the tumour. Previous inadvertent excision did not aﬀect either LR or survival.
Conclusion: Having a previous inadvertent excision has no aﬀect on either local recurrence or overall survival. Wide 
excision gives the best chance of local control. The very large size of these STS at diagnosis is a cause for great 
concern and undoubtedly worsens overall survival.  
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PATHOLOGISTS?
Rob Grimer and Lee Jeys
Pathologists are usually considered to be the arbiters of defining what margin has been achieved following resecƟon 
of a sarcoma. Surgeons are usually thought to be too opƟmisƟc and will usually state ‘excised with clear margins’ 
when a pathologist will find the tumour is closer than anƟcipated. This study sets out to find who is beƩer by 
comparing margins and outcomes in terms of local recurrence.
Method: 1208 paƟents with a variety of bone and soŌ Ɵssue sarcomas had their margins of excision prospecƟvely 
assessed by the surgeon immediately following the operaƟon and an opinion on the actual margin was then given 
by the pathologist. The Enneking system of intrlesional, marginal and wide was used. Outcomes were assessed using 
the rate of local recurrence split by margin type, highlighƟng diﬀerences between pathologists and surgeons. 
Results: 1208 paƟents had an assessment of margins by both surgeon and pathologist. Of these there was agreement 
in 984. In the other 224 cases the surgeon felt he had a worse margin than the pathologist in 112 and the pathologist 
worse than the surgeon in 112. The crude local recurrence rates are shown in the table below:
Status Number Crude LR rate
Agreed intralesional 276 35%
Surgeon intralesional, pathol marginal 21 45%
Pathol intralesional, surgeon marginal 36 29%
Agreed marginal 143 23%
Surgeon marginal, pathol wide 58 21%
Pathol marginal, surgeon wide 51 16%
Agreed wide 335 11%
Discussion: These results show that surgeons are in fact more realisƟc about their margins than might be expected. 
If they state that they have an intralesional or a marginal margin then the local recurrence rates will be higher than if 
they both agree. If the pathologist says a margin is closer than the surgeon thinks it is then the LR rate is not as bad 
as if the surgeon is worried. 
Conclusion: Surgeons opinions on margins are important and can add value to a pathologists report. Taking the 
worse of the two values as the agreed margin would seem to make sense! 
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S 146SERUM ALKALINE PHOSPHATASE AND LACTIC 
DEHYDROGENASE ͵ PROGNOSTIC SIGNIFICANCE IN 
TREATMENT OF CHILDHOOD OSTEOSARCOMA
Bekic Z1, Ilic V1, Lujic N2, Vucinic Z2, Pudrlja-Slovic M1
1InsƟtute for Oncology and Radiology of Serbia, Belgrade;
2InsƟtute for Ortopedic Surgery Banjica, Belgrade, Serbia
Aim: The aim of the study was to evaluate the value of serum alkaline phosphatase (SALP) and lacƟc dehydrogenase 
(SLDH) in children with nonmetastaƟc osteosarcoma (OS).
Methods: From 1988-2003, we treated 123 paƟents with classic high-grade OS,  median age 15 years (range 3-18). 
The majority of paƟents (80%) had tumor in the region of the knee joint. At the moment of diagnosis, the level of 
SALP was increased in 51 pts (41%) and SLDH in 32 pts (26%). 
Adjuvant chemotherapy aŌer amputaƟon was administered in 32 pts. Neoadjuvant  chemotherapy was administered 
in  91pts  followed by surgery (amputaƟon, rotaƟnoplasty or tumor resecƟon). Tumor necrosis over 90% was found 
in 43 pts. Chemotherapy regimens were administered in all paƟents (Adr/CDDP, T-10, COSS 96).
Results: During the 18 - 238 months follow up period, overall survival (OS) rate aŌer 5, 10 and 15 years was 61%, 
50% and 47%, respecƟvely.  
In the group of pts with iniƟally elevated SALP level, the survival rate was significantly lower than in the group with 
the normal SALP level (p<0.01).  Survival rate was also significantly lower in the group of pts with iniƟally elevated 
SLDH than in the group with normal level (p=0.026).
Conclusion: The prognosƟc significance of SALP and SLDH are sƟll controversial. However, in our study, they had 
significant prognosƟc value and might be used, in correlaƟon with other parameters,  to straƟfy paƟents in new 
clinical trials.
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SDEEP VENOUS THROMBOSIS: A PITFALL IN THE DIAGNOSIS OF 
THE SOFT TISSUE SARCOMA OF THE LOWER LIMB
Perisano C, Graci C, Spinelli MS, Del Bravo V, Valenzi E, Di Giacomo G, Fabbriciani C, Maccauro G.
Department of Orthopaedics and Traumatology, University Hospital AgosƟno Gemelli, Catholic University of the Sacred Heart 
School of Medicine, Rome, Italy
ObjecƟve: Deep venous thrombosis (DVT) mainly aﬀects the large veins in the lower leg and thigh and is one of the 
most prevalent medical problems today, with an annual incidence of 80 cases per 100,000. On the contrary soŌ 
Ɵssue sarcomas are rare tumors, with an esƟmated incidence averaging 4/100 000/year in Europe. Tumors in the hip 
or thigh may be associated with a parƟcularly high risk of thromboembolism. The aim of the study is to analize as the 
DVT or pulmonary embolism may be a piƞall in the early diagnosis of soŌ Ɵssue sarcoma of the lower limb because 
the rarity of these lesions and the imaging may not iniƟally reveal a sarcoma as the cause for DVT.
Material and Methods: The authors report two clinical cases of a 47 years old man who presented a DVT of the right 
lower extremity, managed convenƟonally with oral anƟcoagulant and the case of a 42 years old women who presented 
a pulmonary embolism . Physical examinaƟon and ultrasound didn’t reveal a tumor but only the signs of DVT. Both 
were treated for DVT for 8 and 4 months respecƟvely. In view of persistent symptoms and ineﬃcacy anƟcoagulant 
therapy, magneƟc resonance imaging and biopsy were undertaken to uncover the underlying pathology.
Results: Imaging and biopsy revealed in the first case a leyomiosarcoma, adherent to the femoral vein, in the 
second case a MFH localized in thigh closed to the femoral vein that were the cause of persistent symptoms despite 
anƟcoagulaƟon, possibly by its local mass eﬀect and also by its potenƟal to create a thrombogenic milieu; Excision 
of the tumor followed by chemiotherapy and radiotherapy in the first case and by brachitherapy and radiotherapy in 
the second case, led to symptom regression and at 2 years of follow-up the paƟents are free from disease.
Conclusion: Vascular leiomyosarcoma or  SoŌ Ɵssue sarcomas can present or mimick or be misdiagnosed with the 
DVT. This two cases want to highlight the importance of considering neo-plasƟc masses as diﬀerenƟal in painful leg 
swelling. Diagnosis is made with MRI. Treatment involves surgical excision that provides symptom relief as well as 
avoids potenƟal tumour extension. A delay of diagnosis and treatment of sarcoma may result in the poor prognosis in 
tumor with survival rates if treated early ranged from 73% to 79% at 5 years; it is important that all physicians know 
that soŌ Ɵssue sarcoma can present iniƟally as DVT in parƟcular in younger paƟents and in those with recurrent or 
refractory thrombosis or symptoms.
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S 158PREGNANCY AT THE TIME OF DIAGNOSIS OF BONE 
SARCOMAS 
Bartoli MS1, Gaston CL2, Grimer RJ2 
1Scuola di Specializzazione in Ortopedia e Traumatologia, Università degli Studi di Milano, Italy 2Orthopaedic Oncology Unit, 
Royal Orthopaedic Hospital, Birmingham, UK 
IntroducƟon: Women who are pregnant at the Ɵme of diagnosis of a primary malignant bone tumour pose significant 
challenges in terms of treatment both of the pregnancy and the tumour. There is a percepƟon that they may do 
worse than other paƟents because of this. We have evaluated our unit’s experience of this. 
Method: RetrospecƟve review of a prospecƟvely collected database. 
Results: 20 paƟents developed a bone tumour while they were pregnant. Their mean age was 28 (range 17 to 
39). There were 6 osteosarcomas, 7 chondrosarcomas, 2 Ewings, 4 spindle cell sarcomas and 1 giant-cell rich high 
grade sarcoma. The most common site was the pelvis followed by the distal femur. Tumours were diagnosed during 
pregnancy in 10 out of 20 paƟents. Three women were in their first trimester, 2nd trimester in 6 paƟents, and 1 was 
in 3rd trimester. The other 10 paƟents developed symptoms related to the tumour during pregnancy, but histologic 
diagnosis was made 2 days to 6 months aŌer delivery. Of the 9 paƟents who underwent chemotherapy, 3 had 
terminaƟons and 2 had premature inducƟon of labour. Limb salvage was done in 17 (85%) but 3 (15%) needed an 
amputaƟon. 5 had surgery whilst pregnant and there were no adverse outcomes from this. Survival was 86% at 2 
years and 59% at 5 years but this decreased to 75% and 50% respecƟvely in paƟents who needed chemotherapy. 
Local recurrence arose in 3 (15%) and lung metastasis in 5 (25%). One of the newborns developed acute meningiƟs 
and died within the first month.  There were no other adverse events among the other 16 neonates.
Conclusions: Fortunately primary bone sarcomas arising in pregnancy are rare. There are oŌen diﬃcult decisions 
to be made about treatment especially when chemotherapy is needed. Diagnosis and treatment was oŌen delayed 
unƟl aŌer pregnancy and this along with common pelvic involvement, accounts for those with bad outcomes. In 
paƟents whom treatment was not delayed, survival rates were comparable. A mulƟdisciplinary approach, including 
oncologist, radiologist, orthopaedic surgeon, psychologist, and gynaecologist is mandatory.  
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Daniel Soares, Vânia Oliveira, Luciana Leite, Luís Costa, Pedro Leite, Pedro Cardoso 
Department of Orthopaedics
Centro Hospitalar do Porto – Hospital Geral de Santo António - Oporto, Portugal - www.chporto.pt
IntroducƟon and ObjecƟves: In orthopaedic oncology it is clear-cut that diagnosis should be based on history, clinical 
and imaging data, both macroscopic and histological.
However, it is not infrequent to be confronted with inadequate conducts of irreparable consequences, such as 
excision biopsies of “benign tumours”, of which histological diagnosis confirms malignancy, demanding large or 
radical excisions. Similarly, there are some metabolic and reacƟve lesions that can mimic bone neoplasms but should 
be recognised aŌer anamnesis and imaging, without need, someƟmes, for biopsy.
This revision pretends to stress the importance of an accurate evaluaƟon in orthopaedic oncology, therefore avoiding 
unnecessary exams and allowing opportune and adequate therapeuƟc choices.
Material and Methods: In order to emphasise the importance and to contribute to improvement in clinical approach 
and management, the authors present an interesƟng collecƟon of cases and imaging documentaƟon of non-neoplasic 
pathologies simulaƟng bone neoplasies: myosiƟs ossificans, myosiƟs ossificans progressiva, reacƟve lesions of the 
bone surface (florid reacƟve periorƟƟs, Nora’s lesion, subungueal exostosis), exuberant fracture callus, avulsion and 
stress injuries, posƩraumaƟc and  pubic osteolysis, tumoral calcinosis, tophaceous gout and pseudogout, chronic 
recurrent mulƟfocal osteomyeliƟs, hyperparathyroidism brown cells’ tumour, amyloidosis of bone.
All the cases presented were studied, diagnosed and treated at the musculoskeletal tumors unity of the Orthopaedics 
Department of Centro Hospitalar do Porto.  
Discussion and Conclusion: There are several non-neoplasic pathologies that can simulate bone neoplasies and 
should, therefore, be kept in mind by every orthopaedic surgeon. The collecƟon presented by the authors serves as 
a complete and systemaƟsed compilaƟon of these condiƟons
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S 222ASPIRATION CYTOLOGY OF SOFT TISSUE SARCOMAS ͵ 
EVALUATING THE ACCURACY OF THE METHOD
T. Perlaky, K. Szurián, Z. Sápi,  M. Szendrői
Semmelweiss University, Department of Orthopedics
Semmelweiss University, I. Department of Pathology
Budapest, Hungary
ObjecƟves: A precise histological diagnosis is fundamental in the treatment of soŌ Ɵssue tumors. The gold standard 
and the most reliable method is incisional biopsy. Although it gives an almost 100% accurate result, it comes along 
with a relaƟvely high risk of tumor contaminaƟon – an unwanted side eﬀect of the diagnosƟc algorythm.  AspiraƟon 
cytology is an easy way of obtaining a diagnose, however its accuracy and sensiƟvity is someƟmes quesƟoned. In 
the present study, malignant soŌ Ɵssue sarcoma cases of our department were evaluated to define the diagnosƟc 
accuracy of aspiraƟon cytology. 
Materials and methods: 480 soŌ Ɵssue sarcoma cases have been evaluated for the study, that have been treated at 
our department in the past 15 years. The cases with previous aspiraƟon cytology had been selected, then preoperaƟve 
diagnose was compared to the final diagnose given by the histological examinaƟon of the excised tumor. 
Results: AspiraƟon cytology has been performed in 43% of all malignant cases. The findings were divided into four 
groups by the opinion of the pathologist: I.: benign, II.: malignant without diagnosis, III.: tumor of quesƟonable 
nature and IV.: malignant with exact diagnosis. All the false negaƟve cases were enrolled into the I. group, that 
covered 8 % of all cases. The II. and IV. groups referred to the sensiƟvity of the procedure, which achieved 84 %. The 
III. group extended 8 % of the cases. In this group of paƟents the nature of the tumor was determined by the help of 
imaging examinaƟons or by other biopsy methods. 
Conclusions: Open biopsy is sƟll the gold standard in the diagnosƟc algorythm of soŌ Ɵssue sarcomas. AspiraƟon 
cytology with combined cytopathology and ancillary techniques, like fluorescence in situ hybridizaƟon (FISH), DNA 
cytometry, and immunocytochemistry is almost as eﬀecƟve and reliable as incisional biopsy. For the best results, 
the cooperaƟon of an experienced pathologist and the surgeon is essenƟal. According to this study, we recommend 
aspiraƟon cytology for preoperaƟve, minimal invasive diagnosƟc step in the treatment of soŌ Ɵssue sarcomas.
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SCYTOLOGICAL DIAGNOSIS OF RECURRENT SOFT TISSUE 
SARCOMAS.
Martynkov DV, Kondratjeva TT,  KharaƟshvili TK, Aliev MD
FGBU N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Moscow, Russian FederaƟon
ObjecƟve: To analyze approaches to the cytological diagnosƟc of recurrence of STS.
Materials and methods: We analysed 174 paƟents treated in RCRC RAMS in 2000-2010 years with recurrent soŌ 
Ɵssue sarcomas. 96 (55,2%) of paƟents performed cytologic evidence of tumor by puncture with fine needle. Among 
these paƟents were 46 (47,9%) male and 50 (52,1%) female. Mean age years 43,8±14,2 (range 18-77). Histological 
type of the primary tumor was: MFH – 28,1%, synovial sarcoma – 17,7%, liposarcoma – 21,9%, malignant peripheral 
nerve sheath tumors – 18,8%, leiomyosarcoma – 7,3%, etc. Fine needle aspiraƟon cytology (FNAC) under ultrasound 
guide was performed once in 76 cases (79,2%), twice in 6 cases (6,3%), three Ɵmes – 14 cases (14,6%). Scar structure 
made  it diﬃcult to visualize the tumor.
Results: Cytological evidence of tumor was obtained in 84/96 (87,5%) of cases. Other 12 samples were unhelpful. 
Diagnosis of malignant lesion was in 78/96 (81,3%) cases. Diagnosis of soŌ Ɵssue sarcoma – in 64/96 (66,7%)cases. 
Of the sarcoma aspirates, 28/64 (43,8%) could be subtyped. FNA diagnosis was confirmed histologically in all cases.
Conclusions: The cytological examinaƟon is necessary to confirm the recurrent process for further treatment, 
especially in cases where amputaƟon is needed. A cytopathologic diagnosis of malignant lesion was found in 78/96 
cases (81,3%). A FNAC is useful and accurate method in the detecƟon of local recurrences of soŌ Ɵssue sarcomas.
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S 239ULTRA SOUND GUIDED CORE NEEDLE BIOPSY OF SOFT TISSUE 
MASSES: AN INTERDISCIPLANARY PROCEDURE.
Simona Pozza, Armanda De Marchi, Paola De Petro, Federica Guneƫ, *Alessandra Linari, **Elena Brach del Prever, ***Raimondo 
Piana, ***Gian Carlo Gino, Carlo Faleƫ.
Department of Radiology, AO CTO/Maria Adelaide of Turin, Italy
*Department of Pathology, AO OIRM-S.Anna of Turin, Italy
**Department of Traumatology, Orthopaedics and Health Medicine, University of Turin, Italy
***Department of Oncological Orthopaedics and ReconstrucƟve Surgery, AO CTO/Maria Adelaide of Turin, Italy
Background and aim: Diagnosis of soŌ Ɵssue masses can be a diﬃcult, long and expensive procedure. Biopsy is the 
last diagnosƟc step and can be an “hazard”: if the Ɵssue sample is not representaƟve for quality and/or quanƟty, 
biopsy can conduct to a wrong or delayed diagnosis; if the approach is not correct, biopsy can contaminate the 
surrounding Ɵssue and compartments, with consequences on surgical resecƟon Ɵll impossibility of limb salvage. 
Core needle biopsy (CNB) can be a good diagnosƟc technique if ultrasound (US) guided and aŌer a correct and 
planned interdisciplinary diagnosƟc strategy. Aim of this work is to evaluate the adequacy, sensibility and specificity 
of US guided CNB performed aŌer Contrast Enhancement study (CEUS) in soŌ Ɵssue masses of limbs and trunk.         
Materials and Methods: In the last ten years more than 1200 US guided CNBs of soŌ Ɵssue masses were performed 
at CTO Hospital in Turin, Regional Referral Center for Bone and SoŌ Tissue Sarcoma (STS). The strategy for diagnosis 
is interdisciplinary, coordinated by the orthopaedic surgeon, who will perform eventually the surgical procedure. 
Standard US study is completed by Power Doppler and CEUS. The contrats medium consists of micro-bubbles filled 
with sulphur hexafluoride (SonoVue® Bracco, Milan, Italy), evaluated by a low Mechanical Index dedicated devices. 
All paƟents are informed and give their informed consent. When necessary, Ethic CommiƩee is informed and gives 
ist authorisaƟon. CNB is performed focusing the needle in the area with more anarchic vascular supply, typical of 
tumoral neangiogenesis; necroƟc and hemorragic area are easily idenƟfied and not sampled in order to improve the 
quality and adequacy of the samples. At least two-three samples are obtaned with two-three CNB. All biopsies are 
perfomed using the same “surgical approch” as for definiƟve oncological en-bloc surgical resecƟon: in this way the 
surgeon can resect the biopƟcal tract en bloc with the tumour. The correct procedure was obtained, at the beginning, 
with a “joint contemporary interdisciplinary technique”: the radiologists studied by CEUS and idenƟfied the more 
rapresentaƟve area; the orthopaedic surgeons showed the correct approach; the pathologist controlled the quality 
of samples. With Ɵme and experience, now the radiologists alone perform the US guided CNB aŌer discussion of the 
case at the interdisciplinary meeƟng, when hypothesis on histology and surgical definiƟve procedure are advanced 
according to clinical history, physical exam, imaging.  
Technique of US guided CNB aŌer CEUS study:. Cutaneous or local-regional anesthesia are not necessary: a detailed 
explanaƟon of the procedure has allowed us in all cases to obtain full cooperaƟon from paƟents. The procedure is 
conducted with sterile methods: accurate disinfecƟon of the skin, two medical operators with sterile gloves. The 
ultrasound probe is covered with a sterile plasƟc cover; a dedicated device is used to focus the biopsy (Mylab®, 
Esaote, Genova, Italy). Needles usually are 14 or 16 G... Two-three samples are obtained: their macroscopic quality 
is controlled before to place them in a sterile container with 4% formaldehyde; they are sent within 3 hours to the 
pathology laboratory. The CNB is focused in areas highlighted by CEUS, using the same approach as for an eventually 
definiƟve surgical treatment, respecƟng anatomical compartments. AŌer the procedure, the paƟent rest for one 
hour with local ice. US is performed aŌer at least one hour in order to exclude bleeding. 
Results: No major complicaƟons occurred; no disseminaƟons along the needle track were observed. No modificaƟon 
for surgery occurred due to CNB. Our procedure allowed us to achieve excellent results in terms of adequacy to 
disƟnguish between benign and malignant masses, sensiƟvity and specificity in idenƟfying histotype and grading, 
also when mixoid area were present. 
Conclusions: Prof. Mario Campanacci, a great surgeon and teacher, usually said: “AmputaƟon will be done by my 
youngest assistent, biopsy is my duty”. US guided CNB, as part of an interdisciplinary strategy, could be a new way to 
have good samples for histological diagnosis without any hazard for the correct treatment.    
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SAN UNBIASED AUTOMATED METHOD OF QUANTIFYING THE 
FUNCTIONAL CELLULAR HETEROGENEITY OF PROGNOSTIC 
BIOMARKERS IN TUMOURS
Claudia Buehnemann1*,  Simon Li2*, Haiyue Yu2, Harriet Branford White1, J Alison Noble2, A Bassim Hassan1 (*equal 
contributors)
1Sir William Dunn School of Pathology, University of Oxford, UK
2InsƟtute of Biomedical Engineering, University of Oxford, UK
ObjecƟves staƟng concisely why the study was conducted: Ewing’s sarcoma is the second most common cancer of 
bone in children and adolescents. It is diagnosƟcally defined by a translocaƟon resulƟng in the fusion protein EWS/
FLI1 which drives the up-regulaƟon of the IGF (Insulin growth factor) pathway. Despite IGF dependency, 70% of 
paƟents treated with an IGF1 receptor inhibitor respond poorly. To invesƟgate the basis for this variability in response 
we have developed unbiased automated segmentaƟon and measurement tools to quanƟfy the heterogeneity in IGF 
signalling responses.
Material & Methods: Tissue microarrays from 119 Ewing sarcoma biopsy samples were labelled with fluorescent 
anƟbodies against IGF pathway signalling proteins including pS6, Foxo3a and Egr1, the membrane bound glycoprotein 
CD99 which is expressed in 95% of Ewing sarcoma, the proliferaƟon marker Ki67, and DAPI. Boundaries for nuclei and 
cells were idenƟfied from the DAPI and CD99 markers using automated and validated algorithms, and measurements 
of the marker intensiƟes in single cells were obtained and used to create an overall distribuƟon for each paƟent. 
Random survival forests (RSF) were used to analyse these marker distribuƟons with respect to paƟent survival.
Results: We found evidence that the distribuƟon of Ki67 is predicƟve of overall survival as suggested by exisƟng 
research, and this was confirmed by manual grading of images. Contrary to our expectaƟons the RSF suggested 
that cells with lower levels of CD99 in the cytoplasm were most discriminaƟve, for reasons which are sƟll to be 
determined. There was also evidence of diﬀerences correlated with the research centres providing the biopsies.
Conclusions: We have developed a method for the automated analysis of fluorescently labelled biopsies at a 
single cell level, and demonstrated its applicaƟon to predicƟng paƟent survival. We have also idenƟfied the lack of 
standardisaƟon in protocols as a confounding factor in the characterisaƟon of tumour heterogeneity.
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S 276HIGH PREVALENCE OF SPECIFIC ANTIBODIES REACTING WITH 
SV40 CAPSID PROTEIN MIMOTOPES IN SERUM SAMPLES 
FROM BONE TUMOR PATIENTS.
Mauro Tognon,1 Alfredo Corallini,2 Elisa Mazzoni,1 Angelo Taronna,2 Maria Serena Benassi,3 Piero Picci,3 Giovanni Carandina,5 
Giovanni Guerra,5 Ferruccio Casali,6 Riccardo Dolceƫ,7 Caterina Palmonari,8 Fernanda MarƟni,1 Giovanni BarbanƟ-Brodano.4
1SecƟons of Cell Biology and Molecular GeneƟcs and of 2Microbiology, University of Ferrara, Ferrara, University of Ferrara, 
Ferrara. 3Laboratory of Oncology Research, and 4Spine Unit, Rizzoli Orthopaedic InsƟtute, Bologna, 5Clinical Laboratory Analysis, 
University Hospital St. Anna Ferrara, Ferrara, 6Clinical Laboratory Analysis, City Hospital of the Repubblica di San Marino. 
6Bioimmunotherapy Unit, Oncology Center, Aviano, 7Clinical Laboratory Analysis, County Hospital Delta, Ferrara. Italy.
ObjecƟves: SV40 is a small DNA tumor virus found to be associated  with human bone tumors. SV40 sequences 
have also been detected, at lower prevalence, in blood specimens from healthy donors. However, some studies have 
failed to reveal SV40 footprints in human samples, and its associaƟon with tumors. The purpose of our study was to 
verify whether specific anƟbodies reacƟng against SV40 are present in human sera from paƟents aﬀected by bone 
tumors.
Materials and Methods: Our study was addressed to idenƟfy in serum samples from bone tumor aﬀected paƟents 
and normal individuals anƟbodies reacƟng against SV40 VP anƟgens. Indirect ELISA was set up and developed 
employing, as anƟgens, two mimotopes/pepƟdes corresponding to SV40 VP capsid proteins. 
Results: ELISA data indicate that a high prevalence of SV40 VPs -posiƟve sera was detected in paƟents aﬀected 
by osteosarcomas compared to those from normal individuals. No staƟsƟcally significant diﬀerence in prevalence 
was revealed in sera from paƟents with breast cancer or undiﬀerenƟated nasopharyngeal carcinoma compared to 
samples from healthy subjects.
Conclusions: Our data indicate an associaƟon of SV40 with human bone malignancies and that SV40, or a closely 
related not yet discovered polyomavirus, circulates in the human populaƟon. 
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Per-Ulf Tunn2, Andreas Leithner1
1 Department of Orthopedic Surgery, Medical University of Graz, Graz, Austria
2 The Royal Orthopaedic Hospital Oncology Service, Northfield, Birmingham, UK
3 Department of Orthopedic Oncology, Sarcoma Center Berlin-Brandenburg, Helios Klinikum Berlin-Buch, Berlin, Germany
4 Orthopedic Hospital, Gersthof, Vienna, Austria
5 InsƟtute of Pathology, Medical University of Graz, Graz, Austria
ObjecƟves: Tumors of the calcaneus are exceedingly rare. As clinical examinaƟon oŌen starts with X-rays, we wanted 
to ascertain whether X-rays alone were a suﬃcient diagnosƟc tool. Diard´s classificaƟon was applied to define whether 
diﬀerent types of lesion were characterisƟcally distributed in the bone. Finally, we wanted to analyze whether type 
and/or duraƟon of symptoms were possible indicators of malignancy. 
Materials & Methods: Ninety-two paƟents’ files (59 m, 33 f) were retrospecƟvely reviewed. Parameters analyzed 
were sex, side, type and duraƟon of symptoms, tentaƟve diagnosis, biopsy prior to surgery, operaƟve procedure, age 
at surgery, recurrence rate, revision, followup and localizaƟon of the lesion according to Diard. 
Results: TentaƟve radiological and definiƟve histological diagnosis diﬀered from each other in 38 (41%) of 92 cases. 
In eight (osteosarcoma n = 5, Ewing`s sarcoma n = 2, metastases n = 1) of 17 malignant cases radiological examinaƟon 
iniƟally gave no evidence of malignancy, resulƟng in an unplanned excision (“whoops procedure”) in three cases of 
osteosarcoma. Applying Diard´s system trabecular area number 6 (radiolucent area) was highly aﬀected in 64 (80%) 
of 80 invesƟgated plain X-rays. 
Conclusions: In each case of an osteolyƟc lesion of the calcaneus a malignant tumor must be ruled out and thus, 
preoperaƟve plain X-rays in two planes alone are not suﬃcient and should therefore be followed by MRI. Applying 
the Diard system diﬀerent types of lesions are not characterisƟcally distributed in the bone. Increasing pain without 
medical history for more than ten days should always jusƟfy further examinaƟons. 
036
222
PO
ST
ER
RA
RE
 T
U
M
O
RS 043NEUROTHEKEOMAͳ A RARE BENIGN NERVE SHEATH TUMOR: 
A  CASE  REPORT
M. Ornig, J. Friesenbichler, W.Maurer- Ertl, B. Liegl-Atzwanger, A. Leithner
Department of Orthopedic Surgery, Medical University of Graz, Austria.
InsƟtute of Pathology, Medical University of Graz, Austria.
IntroducƟon:  Neurothekeoma is an extremely rare benign soŌ Ɵssue tumor of nerve sheath origin with fairly 
disƟncƟve histological features characterized in a variable myxomatous stroma. These tumors can mainly be found 
in head , neck and upper extremiƟes. The ´classic´ type has been reported in middle aged adults, the ´cellular´ type 
has been observed in younger adults, more common in females. The treatment of choice is resecƟon with clear 
margins.
Case: Here we present the case of a 25- year old woman with a neurothekeoma of the suprapatellar region, accidently 
found during the removal of ostesynthƟc material in proximal Ɵbial area. AŌer non in sano resecƟon of the tumor, 
the paƟent was  admiƩed to our department for a wide surgical excision. In the surgical specimen tumor foci were 
sƟll present. The paƟent was discharged aŌer a few days, MRI controls were scheduled.
Conclusion: ReporƟng such a case should increase awarenes about the possible diﬀerenƟal diagnosis of 
neurothekeoma. The treatment of choice is a resecƟon with marginal or wide surgical margins.
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ObjecƟves: Simple bone cysts are benign cysƟc lesions, mainly seen in childhood. Pathological fracture may be 
repeated, and various treatment methods have been reported. To this moment, liƩle can be definitely said on 
eƟology or on raƟonale for treatment. The aim of the present study was to analyze the cyst fluid and evaluate the 
clinical characterisƟcs of simple bone cysts, to seek a key to pathogenesis and eﬃcient treatment. 
Material and Methods: Cyst fluid was obtained during the operaƟon, from 31 cysts in 31 paƟents which were 
surgically treated. There were 22 male and 9 female paƟents, and mean age at surgery was 11.8 years (5 to 18). The 
cyst was located in the calcaneus in 14 paƟents, in the humerus in 12, and in the femur in 5. CureƩage and graŌing 
with bone subsƟtute material was performed in 25 paƟents, and 6 paƟents were treated with cannulated pins. Cyst 
fluid was compared with blood serum obtained preoperaƟvely.
Results: Secondary procedure was performed due to recurrence in 5 cysts. No recurrence was seen in the calcaneal 
cysts. In the biochemical studies of cyst fluid, alkaline phosphatase (ALP) concentraƟon was significantly higher than 
that in the blood serum. ALP concentraƟon of cyst fluid in calcaneal cysts was significantly lower than that in other 
sites, whereas cholesterol concentraƟon was significantly higher. 
Conclusions: The cyst fluid is similar to blood serum, but shows signs of increased bone turnover. In calcaneal cysts, 
the good prognosis, the low ALP concentraƟon and high cholesterol concentraƟon in cyst fluid, suggests diﬀerence 
in eƟology.
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ObjecƟves: The terminology and the classificaƟon of vascular tumors remain considerable controversy. We 
hypothesize that a beƩer understanding of the molecular signature of vascular tumors may help to refine the 
present classificaƟon system based on immunophenotype alone. A prior t(1;3)(p36.3;q25) was idenƟfied in 2 cases 
of epithelioid hemangioendothelioma (EHE), however no follow-up studies have been performed to idenƟfy the 
gene fusion or to assess its prevalence in a larger cohort of paƟents. 
Material and Methods: In this study, we performed a systemaƟc molecular analysis of 17 cases of EHE, characterized 
by classic morphologic and immunophenotypic features, including lesions arising from various anatomic locaƟons and 
lesions with diﬀerent biological potenƟals. Gene rearrangements were analyzed by fluorescence in situ hybridizaƟon 
(FISH), and reverse transcriptase-polymerase chain reacƟon (RT-PCR). Also included for comparison was a group of 
epithelioid hemangioma, epithelioid angiosarcoma and epithelioid sarcoma.. 
Results: An idenƟcal geneƟc translocaƟon involving the CAMTA1 and WWTR1 genes, respecƟvely on chromosomes 
1 and 3 [t(1;3)(p36.23:q25.1)] was shown by FISH in all cases. RT-PCR applied in 3 tumors with available frozen Ɵssue 
confirmed the chromosomal rearrangement. None of the other vascular tumors examined had a WWTR1-CAMTA1 
fusion. 
Conclusion: CAMTA1 and WWTR1 genes have been shown to play an important role in oncogenesis. Our results 
demonstrate the presence of CAMTA1-WWTR1 fusion in all EHE tested from bone, soŌ Ɵssue and visceral locaƟon 
(liver, lung) in keeping with a single tumor enƟty. This chromosomal translocaƟon may serve as the ulƟmate biomarker 
for EHE, as it appears to be specific for this disƟnct histopathologic tumor type, so it may help to diﬀerenƟate EHE 
from other vascular tumors. Furthermore, as more oncogenic properƟes of the WWTR1-CAMTA1 fusion protein and 
cooperaƟve events are elucidated, therapeuƟc strategies can be tailored to interrupt these oncogenic processes.
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IntroducƟon and ObjecƟve: Lumbosacral lipoma is a parƟcular group that is extremely rare and deserves recogniƟon 
because of its close relaƟon to the spinal cord and its coverings. It is characterized by a diﬀuse proliferaƟon of mature 
fat and can be intradural or extradural. They are always associated with spina bifida or a similar laminar defect or 
sacral dysgenesis. Clinically, it tends to be iniƟally asymptomaƟc and when the diagnosis is made a large infiltraƟve 
tumor is expected.
CT and MR images are essenƟal for diagnosis and for therapy planning. However, because of large size, deep locaƟon 
and infiltraƟng growth paƩern, the disƟncƟon between lipoma and well-diﬀerenƟated liposarcoma is diﬃcult and 
biopsy is mandatory.
Total resecƟon with laminectomy and division of the stalk and fibrous bands that have formed at the upper margin of 
the spinal defect has a good prognosis and should be performed as early as possible, preferably prior to the onset of 
neurologic symptoms. However, does not always prevent the development of leg paralysis and neurogenic bladder. 
In case of subtotal excision, the recurrence rates reported in the literature vary widely. 
As opposed to superficial lipomas, liƩle is known about the eƟology or histogenesis of intramuscular lipomas. This 
case report is a rare lumbosacral lipoma to increase knowledge about this parƟcular enƟty of lipomas. 
Case Report: A thirty-five year old female presented low back pain radiaƟng to the right buƩocks, without neurological 
changes, with an evoluƟon of 2 years and progressive worsening. It was associated to a large right paraspinal tumor, 
painless on palpaƟon, soŌened consistency and deep-seated. The paƟent has no congenital disorders or anatomical 
defects.
Imaging study revealed a large bilateral intramuscular infiltraƟve mass lesion from L2 to S1, homogeneous, extradural, 
with paraspinal muscular atrophy and faƩy degeneraƟon, right predominance, without any neurological compromise. 
The diﬀerenƟal diagnosis was intramuscular lipoma with well-diﬀerenƟated liposarcoma.
The result of the incisional biopsy was compaƟble with a lipoma. The surgical resecƟon was intralesional because of 
the infiltraƟve margin and close relaƟon to neurological structures. The histopathological examinaƟon confirmed the 
diagnosis of intramuscular infiltraƟve lipoma, without malignant changes. The paƟent has no recurrence at 1-year 
follow-up.
Discussion: Lumbosacral lipoma is a rare enƟty and is always associated with spina bifida or a similar laminar defect, 
and there is a stalk-like connecƟon between the faƩy growth and a porƟon of the spinal cord that oŌen also harbors 
an intradural or extradural lipoma. The stalk may cause tracƟon and ischemia. 
This lumbosacral lipoma is a parƟcular case that presents posterior extradural lipomatosis at L3-L4 associated with 
thickening of the ligamentum flavum and deformity of the posterior epidural fat, although it does not present any 
congenital anomalies. 
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IntroducƟon and ObjecƟve: Primary venous leiomyosarcomas arise from vascular smooth-muscle cells and growth 
paƩern may progress from intramural to endoluminal, extraluminal or mixed forms. In the literature, leiomyosarcoma 
of vascular origin is rare and most commonly aﬀects the larger veins such as the inferior vena cava.
Symptoms are defined by the anatomic locaƟon of the lesion, local vascular physiology and drainage paƩerns. The 
definiƟve diagnosis is oŌen delayed and complete resecƟon is usually not possible. MetastaƟc disease occurs in a 
half of paƟents at the Ɵme of diagnosis. However, an aggressive surgical approach assuring a free margin tumour 
resecƟon can be curaƟve despite reported local recurrence rates in selected cases of 40 to 60%. It has a poor prognosis 
and mulƟdisciplinary teamwork is essenƟal.
The aim of this case report is to remember this pathology that comprises a seemingly rare group of tumors illustrated 
by the fact that only a few hundred cases have been reported in the literature.
Case Report: An eighty-three years old female presented a 4 months evoluƟon tumor at the right popliteal fossa, 
4x6cm, hardened consistency and adherent to deep planes. She had numbness and oedema of the lower leg and a 
dorsal pedal pulse was present. 
MRI revealed a tumor involving the enƟre Ɵbial neurovascular bundle. The diagnosis of pleomorphic leiomyosarcoma 
of high degree of malignancy was achieved by Tru-Cut needle biopsy.
Staging imaging studies did not revealed distant metastasis. The lower limb arteriogram showed intact arterial flow 
of anterior and posterior tbial artery.
Wide tumor excision was performed. The sacrifice of the Ɵbial nerve and anterior Ɵbial artery was necessary and the 
leŌ great saphenous vein was inverted and anastomosed end-to-end to the Ɵbioperoneal arterial trunk.
The diagnosis of primary venous leiomyosarcoma and free margin resecƟon were confirmed by histopathology. 
The paƟent presents a favourable funcƟonal outcome and is disease free aŌer one year of follow-up.
Discussion: The morbidity and mortality associated with these tumors are primarily a result of direct extension of 
the tumor along vessels, compromising the circulaƟon.
One of the greatest problems when treaƟng this disease is that the localizaƟon itself may preclude surgical resecƟon 
but in this case the localizaƟon permiƩed a safe free-margin excision.
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Nuno Sevivas2, César Silva3, M. Vieira da Silva4
*At Hospital de Braga, Portugal
Orthopedic Surgery department, Resident, Braga Hospital, Braga, Portugal1. 
Orthopedic Surgery department, Chairman Shoulder Unit, Braga Hospital, Braga, Portugal 2. 
Orthopedic Surgery department, Chairman Hand Unit, Sto António Hospital, Porto, Portugal3. 
Chairman Orthopedic Surgery Department, Braga Hospital, Braga, Portugal 4. 
Purpose: Schwannomas are the most common neurogenic tumours of the torax, especially in the posterior 
mediasƟnum, whereas in the peripheral nervous system they are relaƟvely uncommon. Only about 5% arise from 
the brachial plexus but should always be considered in the diﬀerenƟal diagnosis of shoulder pain. Due to its rarity 
and complex anatomical locaƟon they can be a challenge to orthopaedic surgeons. 
We present a case of a 57-year-old man referred to our centre aŌer six months of shoulder pain, with no other 
complaints.
Methods: Complete shoulder pain invesƟgaƟon was done and MRI suggested a 4,5x3,5cm brachial plexus tumour. 
Schwannoma was diagnosed by ultrasound-guided biopsy.
Surgical exploraƟon showed the tumor arising from the fascicles of brachial plexus and complete tumor excision was 
done.
Results: The paƟent had no sign of neurological disorders postoperaƟvely and 8 weeks aŌer surgery returned to his 
acƟve life with no pain or limitaƟon. 
Conclusion: Complete surgical excision is the most indicated treatment for schwannoma. Even in rare anatomical 
locaƟons, it is very eﬀecƟve. 
Beware of neurogenic tumours when considering shoulder pain diﬀerenƟal diagnosis.
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Purpose: “Ganglion” is a rare cysƟc lesion, usually asymptomaƟc without any classic signs. Rarely described in the 
knee, when they appear, these lesions are usually of small dimension. There are very few cases of giant “ganglion” 
reported.
The authors present the case of a 47-year old male paƟent who had an infra-patellar mass in the leŌ knee, with 5 
years of progressive growth, spherical, with about 10cm in diameter. 
Methods: Surgical tumor excision was done by cross-cuƫng approach with skin flap following the cleavage plane.
Results: Follow-up performed 4 weeks aŌer surgery revealed that the paƟent was asymptomaƟc and returned to his 
acƟve life.
Conclusion: The case presented is uncommon either by locaƟon or by the size of the lesion.
MagneƟc Resonance Imaging (MRI) characterized the lesion and its relaƟons with neighboring structures. Giant 
“ganglion” is an extremely rare benign knee injury and surgical excision demonstrated to be an eﬀecƟve treatment. 
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ObjecƟves: Myoepithelial tumors (MT) are increasingly recognized at extra-salivary anatomic sites, including the 
bone and soŌ Ɵssues. Overall, in the extragnaƟc skeleton they are exceedingly rare neoplasms, and their clinico-
pathological features have been described only in single case reports. The objecƟve of this presentaƟon is to describe 
the clinico-pathological, immunohistochemical and molecular features of three primary juxtacorƟcal MT of bone.
Materials and Methods: Clinical charts, imaging studies and paraﬃn embedded tumor Ɵssue fragments were 
retrieved from our files. 
Results: The paƟents were two male subjects (13 and 23 years of age) and a 15-year-old female. The juxtacorƟcal 
lesions were all located in the femur, and involved the adjacent soŌ Ɵssues and corƟcal bone. All paƟents underwent 
surgical resecƟon of the tumor, two with wide margins and one with marginal margins. This laƩer tumor recurred 
locally 18 months later, and it was removed with wide margins. The three paƟents are currently free of disease at 4 
to 17 months follow-up. Histologically, all lesions showed a prominent mulƟnodular architecture, and were formed 
by epithelioid and stellate elements, with liƩle or no atypia, organized in solid sheets or embedded in myxoid or 
chondroid matrix. Areas of osteoid formaƟon were also observed. One tumor had the appearance of classical mixed 
tumor, showing aspects of duct formaƟon and focal squamous diﬀerenƟaƟon. Immunohistochemically, all cases 
showed diﬀuse and intense posiƟvity for cytokeraƟns, EMA and S100 protein. The expression of other myoepithelial 
markers, including GFAP and calponin was more limited. The notochordal marker brachyury was negaƟve, while 
diﬀuse nuclear immunostaining for INI-1 was observed in all lesions. The three tumors were screened for the presence 
of EWSR1 and FUS gene abnormaliƟes by fluorescent in situ hybridizaƟon, and no rearrangement was observed. 
Conclusions: To our knowledge, this is the first report of primary MTs of bone arising at juxtacorƟcal sites. These 
lesions must be disƟnguished from other benign and malignant bone and carƟlage forming surface tumors, including 
periosteal chondroma and chondrosarcoma, juxtacorƟcal chondromyxoid fibroma, and periosteal and paraosteal 
osteosarcoma. The clinico-radiologic presentaƟon and their histological and immunohistochemical features are 
disƟncƟve enough to allow the separaƟon from these enƟƟes. Overall, juxtacorƟcal MTs appear to behave as locally 
aggressive tumors, that should be surgically removed with wide margins.
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Greater Manchester and Oswestry Bone and SoŌ Tissue Tumour Service, Robert Jones & Agnes Hunt Orthopaedic Hospital, UK
IntroducƟon: Pigmented villonodular synoviƟs (PVNS) is a rare benign aggressive disease of the synovium of weight-
bearing joints and tendon sheaths. There are two forms of the disease: diﬀuse and localised (nodular). It aﬀects the 
foot and ankle in less than 10% of cases. PaƟents complain of localised swelling and/or pain. Typically monoarƟcular, 
it can be locally erosive, and synovectomy is the well described management. Treatment outcomes are poorly 
understood; we aimed to review our results using aggressive complete synovectomy.
Materials and Methods: We followed up 24 paƟents with histologically confirmed PVNS in a prospecƟve study 
between 2000 and 2011; 7 were excluded with localised (nodular) PVNS. AŌer local ethical approval, quesƟonnaires 
including the Toronto Extremity Survival Score (TESS) were posted to paƟents, and non-responders were reminded 
to return their forms by telephone. The response rate aŌer reminder was 100%.
Results: Seventeen paƟents have been prospecƟvely followed for mean 4.8 years (range 1-11.3 years).  Six paƟents 
were male, 11 female. Mean age at presentaƟon was 42 years (range 10-73 years).  All histological samples were 
classified as diﬀuse PVNS and involved arƟcular joints of the foot and ankle. All paƟents had MagneƟc Resonance 
Imaging at presentaƟon. Thirteen of the 17 paƟents underwent aggressive complete synovectomy, all without 
radiotherapy.  The four non-operaƟvely managed paƟents remain asymptomaƟc and under clinical and radiological 
surveillance. Mean Toronto Extremity Survival Score was 91.55 (95% CI 3.3 to 6.5) at final follow-up. There was one 
case of radiological recurrence in the surgical group which resolved radiologically without further intervenƟon. No 
paƟents have required arthrodesis to date.
Conclusions: This demonstrates saƟsfactory medium-term outcomes in this rare disease with surgical debridement 
alone.
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TIBIA: CASE REPORT AND CYTOGENETIC FINDINGS
Edgard E. Engel, Marcello H. Nogueira-Barbosa, Maria Sol Brassesco, Gyl E.B. Silva, Elvis T. Valera, Fernanda M. Peria, TaƟane C. 
MoƩa and Luis G. Tone
Faculty of Medicine of Ribeirão Preto / University of São Paulo
Osteochondroma is a carƟlage capped benign tumor developing mainly at the juxta-epiphyseal region of long bones. 
The rate of malignant transformaƟon, mainly into chondrosarcoma, is esƟmated to be less than 1-3%. TransformaƟon 
into osteosarcoma is very rare and has been reported only thirteen Ɵmes. There is liƩle informaƟon on treatment 
and outcome. We report the case of a secondary osteosarcoma arising in the leŌ Ɵbia of a 23-year-old male, 10 years 
aŌer the iniƟal diagnosis of osteochondroma and aŌer two parƟal resecƟons. Malignant transformaƟon occurred at 
the stalk and not at the carƟlage cap, as would normally be expected. Chromosome banding analysis revealed the 
karyotype: 46,XY, t(3;13)(q21;q34) [2]/46,XY [18]. Records from addiƟonal cases will help determine the parameters 
that define these rare secondary bone lesions.
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Aim: IdenƟfy treatment modaliƟes and local recurrence rates.
Methods: RetrospecƟve review of a prospecƟvely collected database amassed over 25 years. PaƟent demographics 
were recorded along with management and local recurrence rates.
Results: 11 paƟents idenƟfied. 4 male, 7 female. Mean age at presentaƟon 29.7 years. All referred to our unit with 
pain and/or swelling to the aﬀected area; 8 lower limb, 3 upper limb. 5 paƟents treated with detailed cureƩage. Of 
those paƟents, 1 developed significant local recurrence and required a below knee amputaƟon to control the disease. 
2 paƟents underwent aƩempted wide-local excision. Both had posiƟve margins on histological analysis but neither 
developed local recurrence at two-year follow-up. 1 paƟent underwent primary endo-prostheƟc replacement of the 
proximal Ɵbia. Wide excision margins were found on histological review and, at 13 years post primary replacement, 
no local recurrence has been idenƟfied. 2 paƟents refused any surgical intervenƟon. 1 paƟent was lost to follow-
up.
Conclusion: DesmoplasƟc fibroma is an extremely rare tumor. The 1 paƟent in our series who required a below knee 
amputaƟon due to local recurrence had presented with pain and swelling to right ankle. Radiological examinaƟon 
revealed near complete destrucƟon of the calcaneum, with biopsy confirming desmoplasƟc fibrosis. Detailed cureƩage 
was aƩempted but the paƟent had no relief from pain. A below knee amputaƟon was, therefore, performed. From 
our review, excision seems to provide adequate disease control even with posiƟve histological margin and we would 
advocate wide-local excision as primary surgical management.
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BahƟyar Demiralp, Department of Orthopaedics and Traumatology, Gülhane Military Engin Ilker Cicek, Department of 
Orthopaedics and Traumatology, Golcuk Military Hospital, Kocaeli/Turkey 
Bulent Kurt; Pathology, Gülhane Military Medical Academy, Ankara, Turkey 
Mert Keskinbora; Department of Orthopaedics and Traumatology, Gülhane Military Medical Academy, Ankara, Turkey 
Cagri Neyisci; Department of Orthopaedics and Traumatology, Gülhane Military Medical Academy, Ankara, Turkey 
Mustafa Basbozkurt Department of Orthopaedics and Traumatology, Gülhane Military Medical Academy, Ankara, Turkey 
INTRODUCTION: Intraosseous hemangioma is a rare bone tumor, accounƟng for less than 1% of bone neoplasms. In 
most cases, the tumor that is progressing slowly is located in the skull or vertebrae. When the disease arises in long 
bones, most cases are located in the metadiaphysis or diaphysis. Epiphyseal-based juxta-arƟcular hemangiomas of 
long bones have rarely been reported.
OBJECTIVES: Although the first preliminary diagnosis that comes to mind in paƟents of young adult age group with 
epiphyseal localized tumors are chondroblastoma, giant cell tumor of bone, chondromyxoid fibroma, this study aims 
to emphasize that excepƟonal results can occur. as like our case.
METHODS: FiŌy-year-old-male had progressive leŌ knee pain for 4 years. His medical history, the physical examinaƟon 
and rouƟne laboratory tests were normal. LeŌ knee AP / L showed an osteolyƟc lesion  in proximal leŌ Ɵbia epiphysis. 
This lesion was aproximately 2x2 cm with no corƟcal involvement. Limited marginal sclerosis was idenƟfied. 
Chondroblastoma and giant cell tumor of bone were preoperaƟvely considered as preoperaƟve diagnosis. 
RESULTS: Histopathologic diagnosis was  intraosseous hemangioma as a result of excisional biopsy. 
CONCLUSIONS: As a rare tumoral lesion, intraosseous hemangioma could also be  considered in the diﬀerenƟal 
diagnosis of epiphyseal located bone tumors. 
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DIAGNOSED CASES 
Engin Ilker Cicek, Department of Orthopaedics and Traumatology, Golcuk Military Hospital, Kocaeli/Turkey 
BahƟyar Demiralp, Department of Orthopaedics and Traumatology, Gülhane Military Medical Academy, Ankara, Turkey 
Selim Sanel, Department of Orthopaedics and Traumatology, Golcuk Military Hospital, Kocaeli/Turkey
Mert Keskinbora; Department of Orthopaedics and Traumatology, Gülhane Military Medical Academy, Ankara, Turkey 
Mustafa Basbozkurt Department of Orthopaedics and Traumatology, Gülhane Military Medical Academy, Ankara, Turkey 
ObjecƟves: The aim of this study is to illustrate the diﬃculƟes in the diagnosis of  osteoid osteoma and the role of 
imaging modaliƟes and medical evaluaƟons in the paƟents with chronic pain and someƟmes limited ROM treated 
with unrelated diagnosis. Also, we aim to point out the diagnosƟc clues and follow up modaliƟes related actual 
literature reviews.  
Material and Method: We retrospecƟvely search our cases diagnosed as osteoid osteoma. Their history and diagnosƟc 
studies were evaluated. We add the challenging and delayed cases for diagnosis of osteoid osteoma in our study.  
Results: Osteoid osteoma is a relaƟvely common benign skeletal neoplasm of unknown eƟology that is composed 
of osteoid and woven bone. This lesion can occur in any bone, but in approximately two thirds of paƟents there 
is a predilecƟon for  the appendicular skeleton, with %50 or more of lesions occurring in the femur and Ɵbia. The 
characterisƟc radiolucent nidus, that is believed to be responsible for severe pain, may not always be present. 
Although, the clinical, radiological and scinƟgraphic features of osteoid osteoma have been well described, they can 
be misleading or altered, especially in the cases of intraarƟcularly or metaphyseally located tumors. 
Conclusion: When the lesion is localized intra-arƟcularly or metaphyseal, the other dignosis related to that joint can 
be  delayed the real diagnosis and cause osteoid osteoma to be overlooked.  
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CASE REPORT 
Engin Ilker Cicek, Golcuk Military Hospital, Orthopaedics and Traumotology Department, Kocaeli/Turkey.
BahƟyar Demiralp, Gulhane Military Medicine Academy, Orthopaedics and Traumotology Department, Ankara/Turkey
Mustafa Başbozkurt, Gulhane Military Medicine Academy, Orthopaedics and Traumotology Department, Ankara/Turkey
Selahaƫn Ozyurek, Izmir Military Medicine Academy, Orthopaedics and Traumotology Department, Izmir /Turkey
Selim Sanel, Golcuk Military Hospital, Orthopaedics and Traumotology Department, Kocaeli/Turkey.
Chondromxoid fibroma is rarely seen benign bone tumor of carƟlage origin observed less than 0.5 to 1% of all 
skeletal neoplasms and was first described by Jaﬀe and Lichtenstein as a disƟncƟve benign tumor. 
Chondromyxoid fibroma occurs in almost any osseous site. It is most frequent in the long bones including proximal 
Ɵbia and distal femur. Chondromyxoid fibroma in a long bone is typically in a metaphyseal as an eccentric, sharply 
marginated tumor. Rarely, bones are affected contiguously or the tumor may be juxtacortical.  C h o n d ro m xo i d 
fibroma is commonly presented in the second and third decades of life. However, it was rarely reported in the first 
decade. 
We presented a 6-year-old child with pain and gradually enlarging mass on the superolateral aspect of the right knee 
for 5 months. EvaluaƟon of the histopathologic and radiologic images was confirmed our diagnosis of chondromyxoid 
fibroma of bone 
We discussed this case as its rareƟty and importance in disƟncƟve diagnosƟc evaluaƟon.
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Levin D 1, Kollender Y 2, Issacov J3, Elhasid R1
Tel-Aviv Sourasky Medical Center  Israel  1-Pediatric Hemato-Oncology department  ,2- Oncological Orthopedic  Oncology 
department, 3- Pathology department.
Neurofibromatosis type 1( NF1) is un autosomal dominant disorder that aﬀects one in 3000 live births. NF1 
predisposed for both benign and malignant tumors. The typical benign tumors are Neurofibroma and Schwannoma, 
while the typical malignant tumors are Malignant peripheral nerve sheath tumor and Rhabdomyosarcoma.
We present three cases of NF1 paƟents who had unexpected diagnosis of bone or soŌ Ɵssue tumor. One paƟent had 
benign rare tumor (Brown tumor) and two paƟents had relaƟvely rare malignant tumor (triton tumor and synovial 
sarcoma). 
We review the literature on soŌ Ɵssue tumors in NF1 paƟents and emphasize the broad spectrum diﬀerenƟal 
diagnosis. 
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ATYPICAL LIPOMATOUS TUMOURS?
Bartoli MS¹, Gaston CL², Sumathi V², Abudu S², Carter SR², Jeys LM², Tillman RM², Grimer RJ²
¹Scuola di Specializzazione in Ortopedia e Traumatologia, Università degli Studi di Milano, Italy ²Royal Orthopaedic Hospital 
Birmingham, UK
IntroducƟon: Atypical lipomatous tumours (ALT) are common large soŌ Ɵssue tumours arising in limbs.  Treatment 
is marginal excision to prevent them from increasing in size and avoid the risk of dediﬀerenƟaƟon.  This study 
invesƟgates risk factors for dediﬀerenƟaƟon of ALT.
Methods: All paƟents with a diagnosis of either ALT or dediﬀerenƟated liposarcoma arising in the limbs or limb girdle 
were included and risk factors for dediﬀerenƟaƟon were invesƟgated.
Results: There were 290 paƟents with ALT who never had any dediﬀerenƟaƟon and in whom local recurrence 
occurred in 11% at a mean Ɵme of 51.5 months from the first excision (range 4 – 162 months).  The mean Ɵme 
for dediﬀerenƟaƟon was 12 years from original diagnosis (range 2 – 34 years) with paƟents having 2 – 4 local 
recurrences prior to dediﬀerenƟaƟon.  DediﬀerenƟaƟon was significantly associated with ALT with local recurrence 
and >2 excisions on univariate and mulƟvariate analysis.  The risk for dediﬀerenƟaƟon was 2% at 5 years and 6% 
at 10 years in paƟents who had undergone excision of an ALT.  This risk increased to 9% and 22% respecƟvely in 
paƟents who had a local recurrence.  Metastases occurred in 43% who had dediﬀerenƟaƟon while none were seen 
in paƟents with ALT.
Conclusions: Marginal excision remains the treatment of choice for atypical lipomatous tumours. DediﬀerenƟaƟon 
is a rare complicaƟon of ALT and must be suspected in paƟents who have mulƟple local recurrences aŌer excision. 
Regular follow-up may be recommended for those who have had more than 2 local recurrences.
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BOY
U.M. Pirker-Frühauf, J. Friesenbichler, W. Maurer-Ertl, A. Leithner
Dept. of Orthopaedic Surgery, Medical University Graz, Graz, Austria
INTRODUCTION: Dermatofibrosarcoma protuberans (DFSP) presents the most common sarcomatous tumour of the 
skin. Nevertheless, its occurrence is very rare, usually aﬀecƟng young adults. The tumour grows locally aggressive 
with high recurrence rates aŌer resecƟon. Slowly growing, DFSP is mainly localized on the trunk or trunk-close 
parts of the extremiƟes. In most cases it presents immunohistochemical characterisƟcs and a translocaƟon between 
chromosomes 17 and 22, which helpfully supports diagnosis. First line therapy is a wide local excision. Further, 
therapeuƟc success has been reported with ImaƟnib in advanced disease.
CASE PRESENTATION: We report the case of a 2-year old boy with histological verified dermatofibrosarcoma 
protuberans of the leŌ lateral ankle. The paƟent was assigned to our department aŌer non-in-sano resecƟon 
of the lesion, which primarily presented itself as a therapy resistant swelling for about two months. A lipoma 
(2.8x0.7x2.9cm) was first line diagnosed by ultrasound. Histology of the intralaesonal resecƟon Ɵssue presented 
the micromorphology and immunohistochemistry of partly a giant cell fibroblastoma (a juvenile form of the 
dermatofibrosarcoma protuberans) as well as parts of DFSP. Follow-up-MRI showed a local recurrence aŌer one year. 
The following wide resecƟon was performed at our department. Primary staging was done by computer tomography 
(lungs) and ultrasound (lymph nodes/abdomen). Follow up will include local MRI and abdominal ultrasound, no 
systemic therapy. 
CONCLUSION: We focus on a very rare enƟty of tumour, which occurred atypically concerning age and localizaƟon. 
Our main intent is to sensiƟze that dermatofibrosarcoma protuberans should be considered as a potenƟal diagnosis 
in young sarcoma paƟents. 
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A SINGLE CENTER EXPERIENCE
J.Panotopoulos, PT. Funovics, V.Stockhammer, J. Holinka, R. Windhager, A. Wanivenhaus
Department of Orthopaedics, Medical UniversƟty of Vienna, Austria
ObjecƟves: Hemophilic pseudotumor was defined by Fernandez de Valderrama and MaƩhews as a progressive cysƟc 
swelling involving muscle, produced by recurrent hemorrhage and accompanied by roentgenographic evidence of 
bone involvement. The most common site for the hemophilic pseudotumor is the proximal skleleton around the 
femur and pelvis.
Methods: We retrospecƟvely reviewed all clinical histories of 87 paƟents with bleeding disorders treated between 
1967 to 2011 because of musculoskeletal aﬀecƟon due to congenital bleeding disorders. We idenƟfied 6 paƟents 
with a hemophilic pseudotumor who were treated at our department. 
Results: The mean age at surgery was 45.9 (range: 40-61) years. The iliac bone was aﬀected in 3 paƟents (one right, 
two leŌ), the right Ɵbia (distal diaphysis) in one, the right thigh in two and the right ulna (proximal part) in one 
paƟent. One paƟent had two pseudotumors. The perioperaƟve course was easily controllable with adequate factor 
VIII subsƟtuƟon. At the latest follow up aŌer 8.4 (4-24) years, normal healing with no recurrence was observed. 
Discussion: The hemophilic pseudotumor is a rare but severe complicaƟon of hereditary bleeding disorders. In the 
internaƟonal literature the resecƟon and postoperaƟve course are described as challenging and diﬃcult and as 
requiring detailed preoperaƟve planning. OperaƟon done in specialised centres with close cooperaƟon between 
surgeons and hematologists is advisable.
Keywords: Hemophilic pseudotumor, Haemophilia, Surgery
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METASTASIS ARISING IN AN EXTRAPLEURAL SOLITARY 
FIBROUS TUMOR ͵ A CASE REPORT.
S. Scheipl1, E.V. Froehlich1, B. Rinner2, B. Lohberger1, F. Moinfar3, A. Leithner1, B. Liegl3.
1 Department of Orthopaedics and Orthopaedic Surgery, Medical University Graz, Austria
2 Center for Medical Research, Cell Culture Facility, Medical University of Graz, Austria
3 InsƟtute of Pathology, Medical University of Graz, Austria 
Background: Tumor-to-tumor metastases are rare, but well-documented findings. This term refers to one tumor 
metastasizing to another tumor within the same individual. We report a unique case of a male breast cancer 
metastasis occurring in a solitary fibrous tumor (SFT) which was located in the subcutaneous Ɵssue of the back of a 
68 year-old paƟent. SFTs are rare, intermediate grade and seldom metastasizing mesenchymal neoplasms commonly 
occurring in subcutaneous Ɵssue. 
Case Report: A 68 year-old male suﬀered from a painless nipple inversion of the right breast for nearly one year. 
He was diagnosed with breast cancer in March 2006 (mixed-typed ductal-lobular). In addiƟon to mastectomy and 
axillar dissecƟon, he was treated with local irradiaƟon therapy and (neo-) adjuvant chemotherapy. Nevertheless, 
metastases to the lung and the bone were diagnosed 45 months aŌer iniƟal diagnosis.  In course of further staging, 
aƩenƟon was drawn to a subcutaneous expansion located at the leŌ side of his back (level Th2-3). The paƟent had 
noƟced this painless expansion for about fiŌeen years, with a minor progression during the last 12 months. To 
exclude a soŌ-Ɵssue breast cancer metastasis, excision biopsy was performed. Macroscopic examinaƟon revealed 
a solid, grayish lesion with a maximum diameter of 8 cm. Histological examinaƟon showed a mesenchymal tumor 
composed of bland round to spindle shaped tumor cells with indisƟnct cell boarders.  The tumor cells were set 
in and collagenous stroma, and arranged in a “paƩern less” paƩern. Mast cells were also present. A prominent 
haemangiopericytoma-like vascular paƩern was seen. Mitosis were scarce (2/10 HPF). Within the tumor, nests of 
epithelial cells and ductal structures were seen. 
Immunohistochemistry: The mesenchymal spindle cell component showed a strong posiƟvity for anƟbodies (AB) 
against CD34 and was completely negaƟve for various CKs and EMA. However, the ductal epithelioid structures 
showed a strong posiƟvity for AB against various CKs, EMA, Estrogen and Progesterone, but were negaƟve for PSA. 
In addiƟon, a, HER-2/neu overexpression was detected. The diagnosis of a SFT hosƟng a metastasis of a male breast 
cancer was made. The paƟent received palliaƟve chemotherapy and is alive with disease 71 months aŌer iniƟal 
diagnosis.  
Discussion: The spreading of carcinomas to mesenchymal tumors has been described in the context of tumor-to-
tumor metastases. Among mesenchymal neoplasms, parƟcularly benign and low-grade malignant lesions seem to 
be involved. Pleural SFT has once been reported as host for a renal cell carcinoma metastasis. Possibly, the high 
vascularisaƟon of SFTs may contribute to their role as hosts for haematogeneous metastases. Although breast 
cancer is a well-documented donor to tumor-to-tumor metastasis, male breast cancer is a rare enƟty by itself, and 
parƟcularly in this seƫng. In summary, this case combines several uncommon findings which have – to the best of 
our knowledge – not been described before. 
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FIBROMA OF THE PROXIMAL HUMERUS
Luciana Leite, Daniel Soares ; Pedro Leite; Luis Costa ; Vânia Oliveira; Pedro Cardoso
Orthopedic Surgical Department - Hospital de Santo António – Oporto - Portugal
ObjecƟves: Aneurysmal bone cyst is a benign, locally destrucƟve lesion of bone. According to WHO, this aﬀecƟon 
is an expansive osteolyƟc lesion consisƟng of spaces filled with blood in any segment of the skeleton, being most 
frequently encountered in the diaphysis of the long bones or spinal cord and can arise in many benign tumours an 
pseudotumours. 
This paper reports a case of aneurysmaƟc bone cyst with an aggressive behavior , , arising in a desmoplasic fibroma, 
imposing a wide resecƟon.
Material and Methods: Case report of a female paƟent, 11 years, with an aneurismal bone cyst of proximal  humerus 
diagnosed accidentally  in 2006 aŌer a fall from which resulted an osteolyƟc fracture. This lesion was interpreteted 
as a simple bone cyst , and the fracture was treated conservaƟvely, with good clinical evaluaƟon. PaƟent´s lesion 
remained on imagiological vigilance.
Between 2009-2010 the paƟent iniƟated clinical manifestaƟons of pain and limitaƟon of shoulder mobiliƟes. The 
x-ray showed an increased of the lesion. The new findings  led to others imaging studies and a cirurgic biopsy. The 
histologic study was compaƟble to a desmoplasƟc fibroma.
In 2011, with 16 years old, the paƟent was submiƩed to an extended  cirurgic excision of the lesion  ( the proximal 
cut was made in the “collum anatomicum” ) and subsequent vascularized  fibular bone-graŌing, and osteosynthesis 
with Philos plate.  
Results: The final histologic findings described an AneurysmaƟc Osseous Cyst arising in a  DesmoplasƟc Fibroma.
AŌer surgery the paƟent presented clinical signs suggesƟve of  transient radial nerve paralysis, but the neurovascular 
lesion reversed aŌer some months of physiotherapy`s treatment. 
The paƟent´s follow-up revealed an assyntomaƟc teenager with total fibular bone-graŌing integraƟon, without 
recurrence of the disease and with shoulder mobiliƟes totally preserved.
Conclusion: Aneurysmal  bone cyst arising in a desmoplasƟc fibroma led to a strange behavior and posed some 
diﬃculƟes in diagnosis. The aggressiveness of the aneurimal cyst imposed an aggressive ressecƟon and a technically 
demanding reconstrucƟon which succeded and gave the paƟent an excellent funcƟonal outcome.
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DIAGNOSIS AMONG PEDIATRIC STS
S. Kube1, D. Kosztyla1, I. Leuschner2, E. Hallmen1, T. Dantonello1, P. Winkler1, M. Greulich3, 
S. Bielack1, T. Klingebiel4, E. Koscielniak1
1 Klinikum StuƩgart, Olgahospital StuƩgart, Germany; 2Dep. Pathology, Univ. of Kiel, Germany; 3Diakonissenkrankenhaus, 
StuƩgart, Germany; 4University Children`s Hospital Frankfurt, Germany
IntroducƟon: Malignant fibrous hisƟocytoma (MFH) was formerly regarded as a disƟnct fibrohisƟocyƟc tumor 
type. However, it is now a diagnosis of exclusion in the group of soŌ Ɵssue sarcomas (STS) called undiﬀerenƟated 
pleomorphic sarcoma (UPS). The reason for this is an improvement in diagnosƟc techniques that revealed that 
some former “MFHs” belong to other groups of soŌ Ɵssue tumors. Correspondingly, the frequency of the diagnosis 
decreased enormously in adult soŌ Ɵssue sarcomas. Due to its rarity, liƩle is known about pediatric MFH/UPS. 
Materials and Methods: 4736 paƟents < 21 years have been registered with the CooperaƟve SoŌ Tissue Sarcoma 
Study Group (CWS) between 1981 and November 2011. Sixty-seven paƟents were registered under the collecƟve 
term “MFH” or UPS. A review of the pathology reports revealed that only 27 paƟents were diagnosed as MFH/UPS, 
while 25 were diagnosed as angiomatoid fibrous hisƟocytomas, 11 as benign or intermediate fibrohisƟocyƟc tumors, 
two as myxofibrosarcomas and two as unclear lesions. Of the 27 MFH, nine paƟents had to be excluded from the 
analysis because of having bone MFH, missing reference pathology or missing source documents to re-review the 
pathology report. Of the remaining 18 paƟents, 8 paƟents were diagnosed between 1981 and 1990, 5 pts between 
1991 and 2000, 4 pts between 2001 and 2010, and 1 paƟent since 2011. Thirteen of the 18 paƟents were further 
analyzed, while 5 paƟents with registraƟon at the Ɵme of recurrence or loss to follow-up less than 5 years were 
excluded. 
Results: Median age at diagnosis was 11 years (min 1.4y – max 18.5y). Tumor sites were extremiƟes (n=8), trunk 
(n=3) and parameningeal site (n=2). Tumor was completely resected in five paƟents iniƟally (IRS I). They are all 
alive aŌer 0.7 – 8 years. Gross resecƟon with microscopic residuals was seen in five paƟents. Four of them received 
radiochemotherapy, one only chemotherapy. One of the paƟents relapsed locally aŌer 1.3 years and is alive aŌer 
more than 10 years now. The one paƟent who did not receive radiotherapy was never in complete remission and 
died of progressive disease of a parameningeal MFH rapidly (OS 2 months). The two paƟents with IRS III received 
chemotherapy and second look surgery. One of the two paƟents developed metastaƟc disease (pulmonary) shortly 
aŌer complete remission. He died within one year aŌer diagnosis. The other paƟent is in complete remission for the 
follow-up period of 6 years. Only one paƟent presented with lymphaƟc metastaƟc disease at the Ɵme of diagnosis 
(IRS IV). He is in complete remission aŌer mulƟmodal therapy for the follow-up period of more than 12 years. 11 of 
13 paƟents are alive with a median follow-up of 7.6 years (min 0.7y – max 12.9y). 
Conclusion: The analysis of the pathology reports of pediatric paƟents registered within the CWS under the collecƟve 
term MFH revealed a decrease in frequency of the diagnosis MFH over Ɵme. The general doubt in the diagnosis of 
MFH is thus reflected in our pediatric paƟent populaƟon.  InteresƟngly, the decrease is most noƟceable aŌer the 
publicaƟon of C. Fletcher´s “Pleomorphic Malignant Fibrous HisƟocytoma: Fact or FicƟon” in 1992. In context of 
mulƟmodal therapy, primary complete resecƟon seems not to be the only condiƟon for survival, since other paƟents 
in our series have a nearly equal prognosis. RetrospecƟve reevaluaƟon of MFHs by reference pathology with current 
methods is indicated for MFHs diagnosed before ~1992 for further analysis regarding this paƟent group and resulƟng 
therapy advice. GeneƟc characterisƟcs of UPS might even bring more insight into the pathogenesis and allow for 
specific therapy. Nonetheless, pediatric oncologists have to make decisions in current paƟents with UPS despite the 
uncertainty that results from the pooling of a retrospecƟvely diverse group of pleomorphic sarcomas. The CWS-
Guidance recommends therefore to treat these paƟents as other Non-RMS-like STS. InteresƟngly, the diagnosis of 
MFH is sƟll accepted in the bone. Further analysis – pathologically and clinically – should be performed to invesƟgate 
the diﬀerences between bone MFH and soŌ Ɵssue UPS. 
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ObjecƟves: This paper reports a case of rib tumor in a 19-year-old male, discovered incidentally, which gave the false 
impression of aggressive behavior. 
Materials and Methods: The authors present the case of a 19-year-old male, with no history of trauma, with a 
right chest wall lesion incidentally discovered during the invesƟgaƟon of a respiratory infecƟon. Chest computed 
tomography showed localized expansive growth of the tumor, measuring 9,0 x 3,5 cm, centered in the right seventh 
rib, destroying it parƟally, with “sunray” periosteal reacƟon. MagneƟc resonance imaging revealed low signal on T1-
weighted images and a slightly high signal on T2-eighted images. A bone scan did not detect any other lesions. We 
performed a needle biopsy which revealed hemangioma of the rib. The paƟent underwent resecƟon of the right 
seventh rib and reconstrucƟon of the chest wall defect. He had an unevenƞul postoperaƟve course. The definiƟve 
pathological diagnosis was cavernous hemangioma. There has been no evidence of recurrence aŌer a 6-month 
follow-up. 
Discussion: Bone hemangiomas are benign vascular tumors, extremely rare in the ribs. Most of the paƟents are 
asymptomaƟc and the lesion is discovered incidentally as in the case described. Because more than half of primary 
rib tumors are malignant, accurate diagnosis is imperaƟve. It is challenging in the preoperaƟve period.  In this 
parƟcular case we used needle biopsy. 
Conclusions: The diagnosis of hemangioma should be considered in cases of an asymptomaƟc expansible rib lesion, 
although, not infrequently, radiographic findings can suggest malignant characterisƟcs. A biopsy or resecƟon may be 
required to establish the diagnosis. Surgical excision of the rib is the treatment of choice.  
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PATHOLOGICAL DISCUSSION
Cosker T, Gibbons M, Bayliss L, Takeshi T, Athanasou N, Whitwell D, Gibbons C L M
Nuﬃeld Orthopaedic Centre, Oxford, UK
INTRODUCTION: Schwannomas are benign tumours of the nervous system which originate from the neural sheath. 
They are usually seen as single, encapsulated, subcutaneous tumours in an otherwise normal individual. They can 
be found in the peripheral nervous system and have been reported in the brachial and lumbo-sacral plexus, nerves 
originaƟng from the spinal roots and in any of the major named peripheral nerves. Schwannomas occur rarely in 
bone because sensory fibres and their associated Schwann cell rarely traverse bone during their normal anatomical 
course. 
CASE SERIES DISCUSSION: Schwannoma of bone is an inherently rare condiƟon with only around one hundred 
cases described in the English literature.  Two cases are discussed here. Surgical resecƟon and Ɵbia diaphyseal 
reconstrucƟon was undertaken and was curaƟve in both cases with a good funcƟonal outcome both in terms of 
the Oxford Disability Score and TESS scores. Neither paƟent has demonstrated any evidence of recurrence. The 
geneƟc basis of this condiƟon is becoming increasingly well understood and will also be presented in the meeƟng.
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Branford White HA, Bayliss L, Cosker T, Giele H, Critchley P, Whitwell D, Gibbons CLM.
SubmiƩed by The Oxford Sarcoma Service, Oxford, UK
IntroducƟon: Primary soŌ Ɵssue sarcomas of the extremiƟes are uncommon. Many such lesions will present to 
specialists in other clinics such as specialist Hand or Foot and Ankle clinics.  Many are of a small size at presentaƟon 
and may appear to be alternate, more common pathology.
Methods: We collected data from all those paƟents with acral soŌ Ɵssues sarcomas and referred to the Oxford 
Sarcoma Service over a thirteen year period from 1997 – 2010.  Data were collected regarding the primary suspected 
diagnosis, the final diagnosis, the referral route and whether paƟents had undergone previous inadvertent 
excision.
Results: 43 paƟents were treated (28 foot, 15 hand tumours). The commonest histological subtype was synovial 
sarcoma in the foot group, and leiomyosarcoma in the hand group. 25 of the 43 paƟents had a lesion of less than 
5cm at presentaƟon. For those paƟents in whom a wide excision was performed 50% underwent complex plasƟc 
surgical reconstrucƟon. 
Discussion: This study shows that 30% of paƟents with acral tumours required further surgery due to previous 
inadequate / inadvertent excision. 5cm as a benchmark for specialist referral should not be applied to lesions in the 
hand or feet and we recommend the use of the “marble rule” i.e. any lesion the size of a marble should be referred 
urgently and no paƟent should undergo surgery without imaging.
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REPORT.
Huseyin Botanlioglu, Rifat Erginer,  Gokhan Kaynak, Muharrem Babacan,  Atakan Karabiber, Mustafa Caliskan 
ObjecƟves: Juxta arƟcular myxomas (JAM) are rare bening tumors of the connecƟve Ɵssue  which have high 
recurrence rate. JMA are occasionaley seen in large joints, like knee joint. The diﬀerenƟal diagnosis for such an 
intra- or periarƟcular mass should include  ganglion cyst, synovial lipoma, lipoma arborescens, or pigmented or 
nonpigmented villonodular synoviƟs  and even sarcomas. We present a case of intraarƟcular myxoma of the knee.
Materials and Methods: A 51 year-old paƟent presented with complaints of pain and swelling of the knee without a 
history of trauma. Physical examinaƟon of the knee was normal but MagneƟc Resonanse Imaging (MRI) revealed an 
intra-arƟcular mass in of the knee. PreoperaƟve diagnosis was unclearly. Sarcomas, siynoviƟs or ganglion cycts were 
considered as a diﬀerenƟal diagnosis. DiagnosƟc artroscopy were performed and the specimen revealed spindle 
cells and mesenchimal cells which had mixoid change. İn our case, this lesion was hidden to medial patellofemoral 
joint and because of that palpaƟon of the mass was diﬃcult.The lesion was removed by marginal resecƟon by open 
surgical prosedure. The size of the lesion was 5x4x1,7 cm.
Results: Metastasis and reccurence was not noted follow-up.
Conclusion: The peak incidence of myxoma  is between the 3rd and 5th decades of life. As in our paƟent, these lesions 
were slow-growing and well-circumscribed. Recent case, diagnosis of the lesion was confirmed with  pathological 
examinaƟon and size of the lesion may be ranged from 0,6cm to 12cm. Godolinium-MR imaging is important for 
the diﬀerenƟal diagnosis. The tumor appears hyperintens on T-2, hypointens on T-1 on the MRI. Such lesions are 
characterized as mulƟlobulated and bound with in a capsular rim. JMA has a high reccurence rate but no metastasis 
noted and relaƟonship with osteoarthrosis of the concomiƩant joint have been reportedOccasionally juxta arƟcular 
myxomas are found incidentally during knee or hip arthroplasty and diagnosed as a bening lesion. For the 23% of 
the cases diaognosis of sasrcoma was considered or proved by the specimen. JuxtaarƟcular myxoma  should to be 
considered in paƟents whom are presented with a painful restricted moƟon of the knee, DefiniƟve diagnosis of 
these lesions are very important especially in paƟents whom are present with pain and swelling of the knee, because 
it can mimick sarcoma and can be misdiagnosied. It should be kept in mind that the lesion can hide joint.
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QuaƩrini I,1 Pazzaglia L,1 Mosakhani N,  Borze I,2 Novello C,1 KnuuƟla S2, Picci P, 
1  and Benassi MS1
1 Laboratory of. Experimental Oncology  -IsƟtuto Ortopedico Rizzoli,  Bologna-Italy
2Laboratory of Cytomolecular GeneƟcs Research-Haartman InsƟtute -University of Helsinki
Background: Giant Cell Tumor (GCT) is a benign bone tumor that has a relaƟvely high local aggressiveness, while 
development of lung metastases is a rare event, occurring in 2%-5% of cases. MicroRNAs are approximately 22 
nucleoƟde-long noncoding RNAs involved in several biological processes including development, diﬀerenƟaƟon and 
proliferaƟon. Recent studies suggest that knowledge of miRNA expression profile in cancer may have substanƟal 
value for diagnosƟc and prognosƟc determinaƟons as well as for possible therapeuƟc treatments. Our aim was to 
integrate mRNA and microRNA expression profile in GCT clinical specimens in order to idenƟfy a specific signature 
correlated to disease progression. 
Materials and Methods: Using miRNA microarray, we analyzed miRNA profile in 10 GCT, from 5 metastaƟc and 5 non 
metastaƟc paƟents. Expression levels of selected miRNAs will be confirmed by Real Ɵme PCR in a larger cohort of 
tumors and the correlaƟon between miRNA and mRNA expression data will be perform by bioinformaƟc tools.
Results: We found 12 miRNAs diﬀerenƟally expressed in metastaƟc and non-metastaƟc tumors. In parƟcular let-7a* 
and miR-513a-3p were exclusively expressed in metastaƟc tumors, while miR-1 and miR-136 were up-regulated 
in all non-metastaƟc tumors. The decreased level of miR-136 in metastaƟc compared to non-metastaƟc GCTs was 
significantly confirmed by qRT-PCR (p=0.04). 
The correlaƟon between miRNA and mRNA expression data revealed that NFIB  gene, a progression-associated gene 
in cancer, is a potenƟal target of miR-136. 
Conclusions: Our data suggest that miR-136 expression could be relevant in the biological  behaviour of GCT. 
Proteomic  analysis are ongoing to asses the expression level of NIFB protein and  expected downstream acƟvated 
pathways. 
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PROTEIN SIGNAL PATHWAY MAPPING IN THE METASTASIS 
MICROENVIRONMENT
ConƟ A.1,2, Chiechi A.1,2, Novello C.1, Magagnoli G.1, Benassi M.S.1, Picci P.1, LioƩa L.2, Espina V.2
Laboratory di Experimental Oncology, IsƟtuto Ortopedico Rizzoli, Bologna, Italy1. 
Center for Applied Proteomic and Molecular Medicine, George Mason University, Manassas, Virginia2. 
IntroducƟon: SoŌ Ɵssue sarcomas (STS) are a heterogeneous group of benign and malignant diseases. More than 
99% of these tumors are benign. For the 1% of STS that are malignant, 7-10% are from pediatric paƟents. The rarity 
of these tumors makes the diagnosis, grading and therapy selecƟon diﬃcult. 
Proteomic molecular profiling can be used to idenƟfy pathways or specific proteins as potenƟal drug targets or 
molecules useful for straƟficaƟon of paƟents with STS and for the idenƟficaƟon of paƟents with poor prognosis.
We used Reverse phase protein arrays (RPMA) to analyze extracts of STS bone metastases and normal counterpart 
bone. We measured proteins involved in bone metabolism, tumor-host interacƟon, hormone response, growth-
proliferaƟon, stress-inflammaƟon and adhesive-cytoskeletal pathways.
The aim of this study was to idenƟfy prognosƟc biomarkers and potenƟal targets for molecular targeted therapies.
Materials and Methods: 35 fresh frozen bone metastasis samples from paƟents diagnosed with primary STS, 
10 primary STS specimens, and 10 adjacent normal Ɵssues, were completely homogenized using CryoPrepTM 
and AdaptaƟve Focus AcousƟcTM (AFATM) technology by Covaris, with very good protein extracƟon eﬃciency. The 
expression of 50 proteins belonging to mulƟple signal transducƟon pathways was quanƟfied by RPMA.
Results: In the first phase of this study we evaluated the expression of 23 key proteins involved in bone metabolism, 
tumor-host interacƟon, hormone response, growth-proliferaƟon, stress-inflammaƟon and adhesive-cytoskeletal 
pathways. Altered expression (p < 0.05) was found for proteins involved in bone metabolism, matrix breakdown, 
growth-proliferaƟon and hormone and inflammaƟon response. In parƟcular, diﬀerences between the group of normal 
counterpart Ɵssues and primary STS were found in the levels of Ezrin Y353 and RANK; Her3 Y1229, MMP11, mTOR 
S2448, RANK between primary tumors and bone metastasis; Ezrin Y353, MMP14, mTOR S2448, PERK, Serotonin, 
TNFR1 between adjacent normal and bone metastasis.
Conclusions: This pilot study demonstrates that quanƟtaƟve proteomic analysis can be readily conducted on sarcoma 
bone metastasis. For this underpowered study diﬀerences were noted in bone and connecƟve Ɵssue remodeling 
pathways between primary tumors, metastasis and benign bone. An expansion of this pilot series to a larger study 
set may provide strategies to improve diagnosis, grading and therapy for STS.
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LONGͳTERM RESULTS IN MASSIVE ENDOPROSTHESES?
H. Wafa, R.J. Grimer, V. Neelapala, S.R. Carter, R.M. Tillman, A. Abudu, L. Jeys
The Royal Orthopaedic Hospital Oncology Service, Birmingham, United Kingdom. 
Corresponding author: Hazem Wafa email: hazem.wafa@nhs.net
ObjecƟves: This study evaluates the long term outcomes of two-stage revisions of infected endoprostheses, in 
parƟcular funcƟon, re-infecƟon, and amputaƟon.
IntroducƟon: InfecƟon around an endoprosthesis implanted for bone tumour is a disaster for the paƟent. It is costly 
to treat and the results are uncertain.  Two-stage revision seems to be the most successful way of resolving infecƟon 
around an endoprosthesis, with reported success rates of 70-85%. 
Material and Methods: All paƟents who had undergone a two stage revision for infecƟon of a massive endoprosthesis 
for a bone tumour were idenƟfied from a prospecƟve database. The paƟents were treated by removal of the 
implant and all infected material, inserƟon of an anƟbioƟc spacer (usually Gentamicin and Vancomycin), intravenous 
anƟbioƟcs for a minimum of 4 weeks then aspiraƟon followed by reimplantaƟon if the aspirate was negaƟve. 
84 paƟents had adequate follow up and were included in the study of whom 57 were male and 27 female. The 
paƟents had a mean age of 23.1 years (range, 2-70 years) at the Ɵme of diagnosis of the neoplasm and 28.8 years 
(range, 10-71 years) at the Ɵme of infecƟon. EndoprostheƟc replacements were of the distal femur (44), proximal 
Ɵbia (28), proximal femur (7), proximal humerus (2) and three others. SoŌ Ɵssue coverage of the prosthesis was 
provided by local pedicled flaps in 9 paƟents and by free flaps in six.
Results: Mean follow up was 6.9 years (range, 0.5-21.8 years) from the date of the second stage of prostheƟc 
revision. The 84 paƟents had an average of 3.4 operaƟons before the development of infecƟon. The mean Ɵme to 
infecƟon was 5.5 yrs from original inserƟon of the first prosthesis. In 49 paƟents (58.3%), preriprostheƟc infecƟon 
was detected within 6 months from the last surgical procedure. The most common pathogenic organisms were 
coagulase-negaƟve staphylococci (61.9%) and staphylococcus aureus (16.7%).
The overall success rate in controlling infecƟon was 72% at 1 year and 65% at 5 and 10 yrs. Fourteen paƟents 
(16.7%) ended up with amputaƟons due to uncontrolled periprostheƟc infecƟons. 26 paƟents (30.1%) had posiƟve 
cultures of the samples taken at the Ɵme of the 2nd stage of the prostheƟc revision despite negaƟve cultures of 
the preoperaƟve aspiraƟon.  11 of these 26 paƟents (42%) eventually had an amputaƟon compared with 5% if the 
cultures were negaƟve (p= 0.0001).
Twenty-four paƟents have received silver-enhanced implants at the Ɵme of revision surgery while the remaining sixty 
paƟents had convenƟonal endoprostheses. Eight of the 10 paƟents (80%) with posiƟve cultures at the second stage 
surgery and who received silver implants had no clinical evidence of infecƟon at the Ɵme of their latest follow-up. 
Fourteen of those sixteen paƟents (87.5%) with posiƟve 2nd stage cultures and who received convenƟonal implants 
had clinical relapse of infecƟon. The mean MSTS score was 78.6%.
Conclusions: InfecƟon is the most serious complicaƟon of endoprostheƟc replacement in limb salvage surgery. 
The risk of amputaƟon is parƟcularly high in those paƟents with posiƟve cultures at second-stage surgery. Silver-
enhanced implants maybe of value in this subgroup of paƟents. 
Fig 1. Survivorship of paƟents without reinfecƟon aŌer a two stage revision split by whether they had a posiƟve 
culture result or not at the second stage procedure. 
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OF LIMB IN CLOSE PROXIMITY TO MAJOR NEUROVASCULAR 
STRUCTURES.
Dept. of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Naoto Oebisu, Manabu Hoshi, Jun Takada, Makoto  Ieguchi, Susumu Taguchi, Hiroaki Nakamura
Background: When soŌ-Ɵssue sarcoma is excised, the surgical margin according to the histological grading is 
important. When soŌ-Ɵssue sarcomas occur near neurovascular structures, only preoperaƟve images cannot always 
reveal the accurate relaƟonship between the tumor and these structures. Previously, the surgical method, namely 
“In Situ PreparaƟon”, was introduced in 2002. This method enables the preparaƟon of neurovascular bundles and 
the intraoperaƟve evaluaƟon of the surgical margin without contaminaƟon by tumor cells and then addiƟonal 
procedures, including alcohol soaking, and disƟlled water soaking of the preserved neurovascular bundle can also 
be performed to preserve the conƟnuity of vessels. 
Method: Between January 2006 and October 2009, ISP was applied to 8 paƟents (5 women and 3 men) with soŌ 
Ɵssue sarcomas of limbs in close proximity to major neurovascular structures.. The average age is 60.5 years old 
(from 35 to 78 years old) and average follow up period is 319 days.The pathological diagnosis confirmed myxoid 
liposarcoma in 2, pleomorphic liposarcoma in 4, myxoinflammatory fibroblasƟc sarcoma in 1, and phosphaturic 
mesenchymal tumor in 1. The tumors occurred in thigh in 5, lower extremiƟes in 1, and forearms in 2.
Result: Complete local controls were achieved in all paƟents at last follow-up. Oncological outcomes were DOD in 5 
paƟents, and CDF in 3. No complicaƟons, including nerve palsy, embolism, and infecƟon were observed,
Conclusion: ISP enabled intraoperaƟve evaluaƟon of the surgical margin without contaminaƟon, and preserved limb 
funcƟons without unnecessary sacrifice. 
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AFTER RESECTION FOR BONE TUMORS: REPORT OF TWO 
CASES.
*N.Salducca, °V.Ippolito, *U. Prencipe, *L. Favale, *C. Zoccali, *G. Marolda, *R. Biagini
*S.C. ORTOPEDIA IFO- ISTITUTO REGINA ELENA – ROMA – ITALY
° REP. ORTOPEDIA CIVIL HOSPITAL – BRESCIA – ITALY
ObjecƟves: Authors present two cases of paƟents treated at two diﬀerent insƟtuƟons with a custom made 
prosthesis of distal Ɵbia and ankle aŌer resecƟon for bone tumors. 
Materials and Methods: At the Civil Hospital of Brescia and IFO-IsƟtuto Regina Elena of Rome two paƟents were 
treated with a Custom Made Prosthesis of Distal Tibia and Ankle aŌer resecƟon for bone tumors. Diagnosis 
were osteosarcoma (one case) and Ewing’s sarcoma (one case). The prostheƟc stem proximally was fixed in 
both cases by press-fit and distally in one case by press-fit and one by cementaƟon. 
FuncƟonal analyses (according to the MSTS) was performed. 
Results: FuncƟonal results were excellent in both cases: we observed a good acƟve movement without 
lameness when walking. The MSTS score was more than 80%. We haven’t observed complicaƟons or local 
recurrences or metastases.
Conclusions: Implantcast prosthesis of distal Ɵbia is an excellent way to improve ankle funcƟon aŌer resecƟon 
for bone tumors and it is an important way to avoid rigidity and abnormal deambulaƟon expecially in young 
adult paƟents.
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Y 025PATIENTͳSPECIFIC GUIDES FOR BONE TUMOR SURGERY. FROM 
INͳVITRO VALIDATION TO CLINICAL CASES.
Paul L1, Docquier PL1, CarƟaux O1,2, Delloye C1, Banse X1.
1 Computer Assisted and RoboƟc Surgery (UCL/CARS). Avenue Mounier, 53 Tour Pasteur +4. 1200 Brussels. Belgium.
2 Ecole Polytechnique de Montréal. Department of Mechanical Engineering. 6079, StaƟon centre-ville, Montréal, Canada 
H3C3A7.
ObjecƟves: Bone tumor oŌen requires a surgical resecƟon of the tumor. Some tools have been developed to assist 
the surgeon during the pre-operaƟve and intra-operaƟve steps. The planning leads to accurately define the extension 
of the tumor, plan resecƟon trajectories (including a safe margin) and select an opƟmal allograŌ (if required). The 
transfer into the operaƟve room has been achieved using a specifically modified navigaƟon system. Since few 
months, paƟent-specific devices have came up to guide the saw blade during bone cuƫngs, such as total knee 
arthroplasty. This technology has been transposed to resect bone tumors. An experimental study has been led on 
sawbones to assess the accuracy of the method and compare the results with the one of a previous experiment using 
convenƟonal and navigated methods. We present the preliminary results of this new experiment and some clinical 
cases that have already benefited from the technique.
Materials and methods: The pre-operaƟve planning consists in localizing the tumor, posiƟoning cuƫng planes around 
the tumor adding a user-defined safe margin, and, if required, selecƟng an allograŌ. Once these steps have been 
achieved, paƟent-specific guides are built using a Computer Assisted Design soŌware (CAD). The surgeon checks 
whether their shape is consistent with the surgical approach and the available bone surface. A rapid prototyping 
machine is used to manufacture the devices. During the surgery, the guide is posiƟoned onto the bone surface and 
temporarily fixed using K-Wire.
These stages have been used to perform a virtual tumor resecƟon located on a pelvic sawbone. Specific guides have 
been manufactured, and provided to operators who were asked to resect the bone tumor. The safe margin and 
the posiƟon of the cuƫng plane (locaƟon; ISO standard for evaluaƟng the error between two planes) have been 
used to quanƟfy the accuracy of the method. Six bone tumors have already been resected using this technique. An 
addiƟonal guide is also provided when an allograŌ is used, to opƟmally adjust the allograŌ
Results: To date, the accuracy of the resecƟon using the specific guide is excellent. The obtained safe margin is very 
closed to the target 10 millimeters (average error of 0.63 millimeters). The error between target and actual planes 
(e.g. locaƟon) is 1.34 millimeters.
The clinical cases have systemaƟcally shown a tumor-free resecƟon. The reconstrucƟons using an allograŌ have 
shown an excellent contact at osteotomy sites, and thus a saƟsfying reconstrucƟon of the anatomy.
Conclusions: The experiment has shown that paƟent-specific guides can be trusted for bone tumor resecƟons. 
They provide a high accuracy and a high repeatability of osteotomies. Clinical cases has proven the feasibility of 
the technique and shown some advantages. They are quick and straighƞorward to use, no addiƟonal material is 
required, biomaterial is cerƟfied for clinical use. Pre-operaƟveley, the surgeon has to provide some guidelines to 
the engineer for creaƟng smart guides (desired safe margin, diameter of K-Wires, available bone surface, saw blade 
thickness). He receives them ready to be sterilized and used during the surgery. We think this technique has a high 
added value and is very promising for surgical oncology.
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OF LARGE JOINTS IN PATIENTS WITH BONE TUMORS
N.N.Blokhin Russian Cancer Research Center , Russian Academy of Medical Sciences,  Moscow 2012
VA Sokolovskiy, PS Sergeev , AA Babalaev, AV Sokolovskiy, MN Kubirov, MD Aliev 
Materials and Methods: During the period from 1979 to 2010 year in  RCRC 1181 primary operaƟons performed 
in the volume of replacement of large joints of various locaƟons, among the intervenƟons were resected bones 
forming the shoulder (n = 134), elbow (n = 10), hip (n = 167), knee (n = 786), and ankle joints ( n = 8). Endoprosthesis 
with total hip replacement n = 50, humerus, n = 16, Ɵbia n = 1. The defect is replaced by the individual and modular 
endoprosthesis. The defeat of the bones were due to primary tumors in 92% of paƟents, metastaƟc - 8%. The 
average age of paƟents was 28 ± 14 years (from 10 to 80 years), 53.5% were men, women - 46.5%. Osteosarcoma 
predominated (46%) in the remaining cases were diagnosed chondrosarcoma (10%), Ewing’s sarcoma (5%), giant cell 
tumor (14%), other morphological forms consisted of 25%.
Results: The average follow-up was 10 years old. Overall survival is 61%. The recurrence rate was 12%. Among the 
complicaƟons of infecƟon are marked (11%), instability of the prosthesis (13.7%). The prosthesis survival  corresponded 
to 54%. FuncƟonal evaluaƟon of MSTS score was 70% for operaƟons on the shoulder joint endoprosthesis, 80% - 
for the hip. MSTS aŌer arthroplasty of the femur consistent 58% - with its total replacement and 92% - of the distal 
resecƟon, evaluaƟon aŌer resecƟon of the proximal Ɵbia - 75% and 72% at the distal.
Conclusion: EndoprostheƟc  reconstrucƟon gave saƟsfying funcƟonal and oncological results and low rate of 
complicaƟons in most paƟents aŌer long-term survival. Limb salvage surgery is the gold standard of modern onco-
orthopedics
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Y 031DISASTROUS FAILURE OF THE HINGED TIBIAL INSERT OF A 
ROTATING HINGE DESIGN: A RETROSPECTIVE DATA ANALYSIS
Joerg Friesenbichler1, Ran Schwarzkopf2, Patrick Sadoghi1, ScoƩ E. Marwin2, Mathias Glehr1, Werner Maurer-Ertl1, Ulrike Pirker-
Frühauf1, Andreas Leithner1.
1Department of Orthopaedic Surgery, Medical University of Graz, Graz, Austria.
2Department of Orthopaedic Surgery, NYU Hospital of Joint Disease, New York, NY, USA.
Purpose: RotaƟng hinge knee prostheses are used for knee reconstrucƟon following resecƟon of malignant bone 
tumours because these prostheses provide inherent stability. Yoke fractures of the hinged Ɵbial insert of modern 
generaƟon rotaƟng hinge devices are a maƩer of conƟnued concern. The aim of the study was to describe incidence 
and management of yoke fractures of the hinged Ɵbial insert of a modern rotaƟng hinge design. 
Materials & Methods: RetrospecƟve data analysis of two insƟtuƟons idenƟfied 40 paƟents who were treated with 
a Limb PreservaƟon System (LPSTM, DePuy, Warsaw, IN) for distal femoral reconstrucƟon following wide tumour 
resecƟon. Implant survival to prostheƟc complicaƟons was calculated according to Kaplan-Meier.
Results: Out of the group of 40 paƟents, four fractures of the metal yoke occurred in four cases (failure rate: 10%). 
Furthermore, a second fracture re-occurred in two paƟents. The overall revision-free prostheƟc survival was 57% at 
38 months, while prostheƟc survival unƟl yoke fracture was 86% at 38 months.
Conclusion: Handling yoke fractures as mechanical complicaƟon includes; replacing the hinged insert, stabilizaƟon 
of the joint and joint line height preservaƟon in order to decrease the canƟlever eﬀect at the insert-base plate 
interface. Nevertheless, a failure rate of 10% for this specific complicaƟon is not acceptable and as a salvage opƟon, 
we recommend the exchange of the prosthesis to another rotaƟng hinge design.
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YDRACON® ARTIFICIAL LIGAMENTOPLASTY IN LARGE LONG 
BONE TUMORAL RECONSTRUCTIONS.  LONG TERM  REVIEW .
SEGURA, Florencio – MD, PhD – PROFESSOR IN ORTHPOAEDICS
SEGURA, Florencio Pablo
SEGURA Facundo
ZECCHINI, Lorena
CARPINELLA, Pablo
MUSCULOSKELETAL TUMOR UNIT
UNIVERSIDAD NACIONAL DE CORDOBA
CORDOBA –ARGENTINA
INTRODUCTION: The proximal humerus and femur have serious inconveniencies for their reconstrucƟon with 
massive endoprosthesis aŌer the resecƟon of high grade bone sarcoma. The compromise of the soŌ Ɵssues which 
funcƟon as joint stabilizers, due to the pathology in itself or due to surgery, determines the need to use a technical 
resource which prevents post-surgical instability. 
MATERIAL AND METHOD: A retrospecƟve evaluaƟon was done of 8 paƟents treated between 2000 and 2009 with 
non convenƟonal endoprosthesis with a dracon covering to anchorage the soŌ parts aŌer wide resecƟon of malignant 
tumoral lesions. Six of these cases corresponded to lesions of the proximal humerus and two of them to lesions of 
the proximal femur. The base diagnosis corresponded in 5 cases to an osteosarcoma, in 2 cases to a giant cell tumor, 
and in 1 of them to thyroid carcinoma metastasis.     
OUTCOMES: The average follow up Ɵme consisted of 5 years and 6 months. The MSTS/ISOLS score was 70 % of the 
normal funcƟon for the 6 proximal humerus cases and 80% of the normal funcƟon for the 2 femur proximal cases. 
No episodes of acute instability were registered. Out of the 6 proximal humerus cases, 3 present a subluxaƟon of the 
prostheƟc head of 2 to 4 mm in its long term evoluƟon. 
DISCUSSION: The use of syntheƟcs covering  the prosthesis’ surface consƟtutes a valid choice to avoid post surgical 
instability in large oncologic resecƟons of the proximal femur or humerus. Dacron ® is an aƩracƟve material not only 
for its biological properƟes and mechanics, but also for its low cost and availability. 
KEY WORDS: Endoprothesis. High grade bone sarcoma. Instability. Ligamentoplasty. Dracon.
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Y 041RECONSTRUCTION IN ONCOLOGICAL RESECTIONS OF THE 
PROXIMAL HUMERUS
SEGURA, Florencio – MD, PhD – PROF. IN ORTHPOAEDICS - SURGEON IN CHIEF
SEGURA, Pablo
SEGURA, Facundo
ZECCHINI, Lorena
CARPINELLA, Pablo
MUSCULOSKELETAL TUMOR UNIT
 UNIVERSIDAD NACIONAL DE CORDOBA
CORDOBA –ARGENTINA
INTRODUCTION: The proximal humerus is a challenge for its reconstrucƟon aŌer the resecƟon of bone sarcomas. 
The compromise of soŌ Ɵssues which funcƟon as joint stabilizers, due to the pathology in it or due to the surgery, 
determines the need to use diﬀerent types of technical resources.
MATERIAL AND METHOD: A retrospecƟve evaluaƟon of 16 paƟents treated between 2000 and 2009 with resecƟons 
of the proximal humerus is presented.
OUTCOMES: The average Ɵme of follow up was 5 years and 6 months. The MSTS/ISOLS was 70% of the normal 
funcƟon.
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YREVERSE SHOULDER PROSTHESIS IN BONE TUMORS AT 
THE IFOͳISTITUTO REGINA ELENA S.C. ORTOPEDIA. EARLY 
RESULTS.
N.Salducca, C. Zoccali, L. Favale, U. Prencipe, G. Marolda, G. Teori, F. Erba, R. Biagini
IFO- ISTITUTO REGINA ELENA – ROMA - ITALY
ObjecƟves: Authors present 4 cases of paƟents treated with a reverse shoulder prosthesis aŌer resecƟon for bone 
tumors of proximal humerus. 
Materials and Methods: At the IFO-IsƟtuto Regina Elena S.C. ORTOPEDIA, from Jun. 2009 to Dic. 2011, 4 paƟents 
were treated with a reverse shoulder prosthesis (Mutars® Implantcast) aŌer a Malawer type Ia or Ib resecƟon for 
bone tumors. In three cases they were female (75%). Diagnosis were osteosarcoma (two cases), GCT (one case) and 
breast solitary methastasis (one case). The prostheƟc stem was fixed  in 2 cases by cementaƟon and in two cases by 
press-fit. 
FuncƟonal analyses (according to the MSTS) was performed. 
Results: FuncƟonal results were good or excellent in all the cases: we observed a minimum acƟve abducƟon of 65 
degrees, reaching 90 degrees or more in all the paƟents. The mean MSTS score was more than 80%. We haven’t 
observed complicaƟons or local recurrences or metastases.
Conclusions: Reverse shoulder prosthesis is an excellent way to improve shoulder funcƟon aŌer resecƟon for bone 
tumors of proximal humerus expecially when you can avoid the delthoid muscle and axillari (circumflex) nerve 
resecƟon.
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Y 057FUNCTIONAL OUTCOMES AFTER SCAPULECTOMY FOR 
MALIGNANT TUMORS IN THE SHOULDER GIRDLE
Suguru Nakamura, Takaaki Kuroda, Masanari Aono, Kenichi Kazuki
Department of Orthopaedic Surgery, Osaka-City General Hospital - Tomoaki Suzuka
IntroducƟon: Treatment and reconstrucƟon for malignant tumors of the shoulder girdle associated with postoperaƟve 
funcƟonal outcome of the enƟre upper limb.
Purpose: The purpose of this study was to assess the funcƟonal outcomes aŌer total scapulectomy.
PaƟents and Methods: We describe the cases of five paƟents (three men and two women) who underwent 
reconstrucƟve surgery for malignant tumors of the scapula and the proximal humerus between February 2008 and 
July 2012. The age of the paƟents ranged from 67 to 74 years. Pre-operaƟve histopathological diagnosis revealed 
rhabdomyosarcoma (one paƟent), extraskeletal myxoid chondrosarcoma (one), recurrence of malignant fibrous 
hisƟocytoma (one), and metastaƟc bone tumors of the adrenal and thyloid (two). Scapular resecƟons were performed 
according to the surgical classificaƟon of shoulder girdle resecƟons described by Malawer. Four paƟents underwent 
subtotal scapulectomy surgery. In three of these paƟents (Type IIa resecƟon), the neck of the scapula and the glenoid 
were retained, whereas in the other paƟent (Type IIb) only the glenoid was retained. The remaining paƟent (Type 
VI) underwent total scapulectomy and amputaƟon of the upper limb. FuncƟonal outcome was evaluated using the 
Enneking score.  
Results: The paƟents received an average follow-up Ɵme of 24 months (range 5~47 months).
In all cases, there was no local recurrence.  In two paƟents, metastasis occurred during the follow-up period, whereas 
the other paƟents remained disease-free aŌer surgery.
The mean Enneking score in Type IIa paƟents was 84.7% (80%–87%), whereas the score for the Type IIb paƟent was 
67%, and that for the Type VI paƟent was 16%.     
Discussion: Recently, it has been reported in some arƟcles that shoulder girdle funcƟon decreases dramaƟcally 
following total scapulectomy. Other arƟcles suggest that residual shoulder funcƟon aŌer surgery depends on both 
retenƟon of the glenoid and reconstrucƟon of the muscle around the shoulder girdle. We agree that, if tumor-free, 
every eﬀort should be made to preserve the glenoid.
In our study, all three paƟents who underwent a Type IIa resecƟon had excellent funcƟonal outcomes, compared 
with Type IIb and Type VI paƟents. We found that upper limb movement is greater with retenƟon of not only the 
glenoid but also the abductor mechanism within the upper part of the scapula. We consider that this is a promising 
technique that allows for future range of moƟon, parƟcularly abducƟon movement of the shoulder joint.  
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YEXTRACORTICAL TRIPLATE FIXATION FOR TUMOR PROSTHESIS 
OF UPPER LIMBS ΈBIOMECHANICAL STUDYΉ
Vyrva Oleg, Burlaka Victor, Karpinsky Mikhailo, Mikhanovsky Dmitro
Sytenko InsƟtute of Spine and Joint Pathology, Kharkiv, Ukraine
IntroducƟon: The one of the most common complicaƟons of tumor prosthesis replacements (TPR) are prostheƟc 
stem fractures (1,6-18,2% of all number TPR) and periprostheƟc fractures (0,7-8,1% of  all number complicaƟons). 
These complicaƟons are related uneven load on the diﬀerent elements of the “endoprosthesis – bone” system. 
Maximal peak of load is on base of the endoprosthesis intramedullary stem. The main goal of this invesƟgaƟon was 
to create mathemaƟcal models for stress load calculaƟon of diﬀerent external and internal fixing prosthesis parts 
and to compare stability of fixaƟon for diﬀerent types of bone forms.   
Materials and methods: Using the finite elements method we have studied of mechanical properƟes of the 
“endoprosthesis – bone” system. We used a model of radius bone. For this research mathemaƟcal model of the 
system “endoprosthesis – raduis” we studied   three types of radius bone with round, oval and triangle forms for 
bone. Also we studied biplate, triplate and cylindrical tube form of  extracorƟcal fixaƟon of the endoprosthesis 
respecƟvely. Study was performed with two types of loading: tension and bend. Strength of load was 100 N that 
corresponds to usually everyday loading of the forearm.
Results: Tension (stretch) loading. Maximal tensions were in the proximal part of the stem, on surfaces of the bone 
canal in places of contact with stem, on external surface of bone in places of contact with extracorƟcal plates and in 
extracorƟcal plates. Strength of loading was 1,5 МPа in the system with the round form of the bone and cylindrical 
extracorƟcal tube of the endoprosthesis. Strength of loading was 1,3 МPа in the system with the oval form of the 
bone and biplate extracorƟcal fixaƟon. Strength of loading was 1,1 МPа in the system with the triangle form of the 
bone and triplate extracorƟcal fixaƟon. Bending loading. Maximal tensions were on external surface of  bone in 
places of contact with extracorƟcal plates and in extracorƟcal plates. Tensions were less on upper and low surfaces 
of the stem and on surfaces of the bone canal in places of contact with stem. Maximal strength of loading was 
42,0 МPа in external parts of the system with the round form of the bone and cylindrical extracorƟcal tube of the 
endoprosthesis and 35,0 МPа in internal parts of the same system. Maximal strength of loading was 44,5 МPа in 
external parts of the system with the oval form of the bone and biplate extracorƟcal fixaƟon of the endoprosthesis 
and 32,0 МPа in internal parts of the same system. Maximal strength of  loading was 38,0 МPа in external parts of 
the system with the triangle form of the bone and triplate extracorƟcal fixaƟon of the endoprosthesis and 30,0 МPа 
in internal parts of the same system.
Conclusion: Endoprostheses with combined type fixaƟon have even load on all elements of connecƟon. Endoprosthesis 
with triplate external fixaƟon with bone of triangle form is most opƟmal system. Maximal tensions are in external 
parts of fixaƟon devices of the same system. This system is most approximate to natural bone. These date and results 
are very useful for custom made and modular tumor prosthesis manufacturing.  
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Y 062FEMUR METASTATIC DEFECTS REPLACEMENT DEPENDING ON 
THEIR LOCATION
Vyrva Oleg, Golovina Yanina, Malik Roman, Shevchenko Igor
Sytenko InsƟtute of Spine and Joint Pathology,
Kharkiv, Ukraine
IntroducƟon: According to the literature the lower limb bones are the common site of metastaƟc lesions (67%) and 
especially the femur (54%). Most metastases are lyƟc lesions. There is the high risk of development a pathological 
fractures for these lesions. At the same Ɵme, lost support ability of the aﬀected limb and significantly decreases 
the paƟent’s ability to self-service. Wide tumor resecƟon and replacement of bone defects by diﬀerent implants 
combined with bone cement (plates, intramedullary nails, endoprosthesis) are performed  with solitary bone 
metastases of diﬀerent localizaƟon. The fractures of the implants occur in some cases. The femur and the various 
opƟons for replacement of post-resecƟon defects depending on the localizaƟon of tumors in the bones were chosen 
for this study. The main goal of this invesƟgaƟon was to determine the most opƟmal replacing method of post-
resecƟon femur metadiaphysis defects for paƟents with solitary metastases.
Materials and Methods: The custom made Ɵtanium construcƟon to replace post-resecƟon distal femur metadiaphysis 
defects was designed. The design consists of the L - shaped plate, cylindrical module, intramedullary stem, which 
are joined together by screws. The finite element method was used in this study. The femur with simulaƟng defects 
in diﬀerent locaƟons was the base model. The study included 4 models of the femur with various types of the 
replacement post-resecƟon defects: a model with parƟal distal femur defect which was replaced by L-shaped 
plate and the bone cement; L-shaped plate, bone cement and two intramedullary nails, metal construcƟon and a 
model with a parƟal distal femur defect which was replaced by intramedullary nail and bone cement. Stress-deform 
condiƟons were studied at three main types of load: axial, flexion, rotaƟon.
Results:
maximum stresses during work of construcƟon which consists of L-shaped plate and bone cement arises in  
the “implants-bone” contact zone of distal femur;
load peak is localized in the contact zone “implants-bone” in proximal femur during work of construcƟon  
which consists of intramedullary nail and bone cement.
Conclusions: The lowest stresses was observed in the “implant-bone” contact zone using bone cement, L-shaped 
plate and intramedullary rods, as well as the use of the proposed construcƟon for replace defects in the metadiaphysis 
of distal femur. Also modular endoprosthesis replacement is method of choice for replacement of proximal femur 
defect according to high risk of implant fracture using intramedullary nail and cementaƟon this part of femur bone.
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YSURGICAL TREATMENT RESULTS OF SOFT TISSUE SARCOMA 
IN THE SHOULDER GIRDLE.
Khurshid G.Abdikarimov
NaƟonal Oncology Research Centre, Tashkent, Uzbekistan 
Aim: Analysis of surgical treatment results of tumor in the soŌ Ɵssue in brachial girdle. 
Materials and methods: Analysis of surgical treatment results of 83 paƟents with tumor of soŌ Ɵssue in brachial 
girdle was performed.  Men - 44, women- 39. PaƟents age was vibrated from 15 Ɵll 76, in average - 38, 8 . In 50 cases 
tumor was localized in 2 shoulders, 10 – scapular, 9 –suprascapular, 8 – axillary, 3 – supraclavicular and 3 – clavicular 
regions. By histological structure 43 paƟents with fibro sarcoma were prevailed, in others rhabdomyosarcoma - 12, 
synovial sarcoma - 9, angiosarcoma - 7, unclassified tumors – 6, lip sarcoma – 2, mix sarcoma – 1 and desmoids tumor 
- 3 were observed. In 68 cases organ conserving operaƟons – wide excision of tumor in the volume of muscular- facial 
membrane - 56, wide excision of tumor with lymph dissecƟon of axillary lymph nodes - 4, combined operaƟons - 8 
(excision of tumor with edge resecƟon of brachial girdle - 2, with resecƟon of ribs – 2, with resecƟon of scapula – 1, 
with scapula ectomy – 2 and in 1 –excision of tumor with resecƟon and autoplasƟc of axillary artery). In 15 cases 
crippling operaƟons - interscapular-thoracic amputaƟon -13, exarƟculaƟon on the level of brachial joint- 2.
Results: In the period of observaƟon 10 – 180 months, in 26 paƟents (31, 3%) appeared relapse, in 8 paƟents were 
some relapses in the course of disease. In (37, 3%) paƟents – remote metastasis. Remote metastasis prevailed in the 
group of paƟents aŌer crippling operaƟons.
Conclusion: The basic method of treatment paƟents with sarcoma of soŌ Ɵssue remains –surgical. OpƟmal value of 
operaƟve intervenƟon is wide excision of tumor in the volume of muscular-facial membrane. Combined operaƟons 
were shown in spreading of process on brachial girdle bones. Crippling operaƟons were shown in large volume of 
tumor with damage of some anatomical structure, involving the great vessels and nerve, and major destrucƟon of 
brachial bones. 
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Y 075TREATMENT RESULTS OF MALIGNANT TUMOR OF SOFT TISSUE 
IN EXTREMITIES.
Khurshid G.Abdikarimov, Rasul R.Davletov, Mirza A.Gafur-Akhunov, Djamila Sh.Polatova, Ulugbek F.Islamov, Fahriddin 
E.Nasritdinov, Kamol Iskandarov 
NaƟonal Oncology Research Centre, Tashkent, Uzbekistan 
Aim: To study the eﬃcacy of treatment methods paƟents with malignant tumors of soŌ Ɵssue in extremiƟes. 
Materials and methods: Analysis of surgical and combined methods of treatment results was performed in 144 
paƟents with malignant tumors of soŌ Ɵssue in extremiƟes.  Men were 100 (69, 4%), women - 44 (30, 6%), aged from 
16 Ɵll 82, at an average - 40, 5. Size of tumors by these instrumental methods of invesƟgaƟon (MRT, CT, USD) was 
from 5 Ɵll 22 sm in maximal measurement. In all paƟents were performed morphological verificaƟon of diagnosis by 
incisional biopsy with trepanaƟon and open method. By histological structure of tumor : fibro sarcoma in 99 (68,7 %) 
paƟents, rhabdomyosarcoma - 18 (12,5%), synovial sarcoma - 9 (6,5%), angiosarcoma - 7 (4,9%), fibro mix sarcoma- 6 
(4,2%), neurosarcoma - 2 (1,4%), malignant fibrous hisƟocytoma - 2 (1,4%),  1 (0,7%) – lip sarcoma were determined. 
In 104(72, 2%) paƟents with high degree of malignant tumor (G3, 4) and with size of more than 5 sm was performed 
combined treatment, including no adjuvant chemo or beam therapy. Pure surgical therapy was performed in 40 
(37, 8%) paƟents with low degree of malignancy. In 112 cases (77, 8%) conservaƟve, in 32 (22, 2 %) – crippling 
operaƟons were performed (in the volume of amputaƟon, disarƟculaƟon, hemipelvectomy, interscapular–thoracic 
amputaƟon). 
Results: Relapse of tumor appeared in 19 (18,3 %) paƟents  from 6 months to 3 years old in the group of combined 
treatment in the term of observaƟon,remote metastasis in 18 (17,3 %) ,in the group of surgical treatment in  4 (10 
%) – relapse and in 14 (35%) -  metastasis were observed.   
Conclusion: Combined method is the method of choice in treatment of paƟents with sarcoma of soŌ Ɵssue in 
extremiƟes with high degree malignancy, eﬀect from no adjuvant component allows to paƟent 85 (81,7%) to conserve 
extremity and to decrease metastasis in  2 Ɵmes by comparison with pure surgical treatment.
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AND SHIN BONE TUMOR.
Mirza A.Gafur-Akhunov, Khurshid G.Abdikarimov, Ulugbek F.Islamov, Djamila Sh.Polatova, Sundr D.Urunbaev, Fakhriddin 
E.Nasritdinov    
NaƟonal Oncology Research Centre, Tashkent, Uzbekistan 
Aim: analysis of endoprostheƟcs results of knee joint in the treatment of tubular bone tumor.
Materials and methods: EndoprostheƟcs of knee joint have been performed in 96 paƟents, on the occasion of tumor 
of distal part of thigh (70) and proximal part of shin bone. Men were 62, women-34. Average-24, 7. Length of damage 
by bones was composed from 6 Ɵll 20 sm. By morphological structure, in 44 paƟents has been detected osteosarcoma, 
in 15 – chondrosarcoma, in 1 –paraostal sarcoma, in 36 – giant cellular tumor. To the course of no adjuvant and 
adjuvant chemotherapy have been performed in osteogenic and low diﬀerenƟated form of chondrosarcoma. 
The resecƟon length of bones composed from 10 Ɵll 24 sm. In the tumor of proximal part of shin bone was used 
muscular plasƟcs from medial legs of sural muscles. 
Results: ComplicaƟons appeared in 22 paƟents (22, 9%) – infecƟons of prostheƟcs area (10), instability endoprostheƟcs 
(12), in the third cases these complicaƟons have been combined .In 4 cases (40%) infecƟous complicaƟons have been 
stopped conservaƟvely. OperaƟve intervenƟon in diﬀerent volume was made in 6cases: 4 – crippling operaƟons, 
1 - reendoptostheƟcs, 1 – removal of endoprostheƟcs with imposiƟon of compression-destrucƟon osteo synthesis 
apparatus. The cause of instability in  4 (33,3%)  cases was loosening legs of endo prostheƟcs in marrowy channels, 
in 7 (58,3%) – disorders of construcƟon (fracture of leg-5, fracture of arƟculate  part-2) in 1 (8,4%) – reducƟon of 
construcƟon (screw of arƟculate part).  Crippling operaƟons have been performed in 3 paƟents with loosening 
of endoprostheƟcs legs in combinaƟon with contaminaƟon and in 2 with leg fractures of endoprostheƟcs.
ReendoprostheƟcs was performed in 4cases, in 1 – endoprostheƟcs reconstrucƟon and at present knee joint has been 
fixed by external removable joint -immobilizer in 2 paƟents with fracture of arƟculated part. FuncƟonal condiƟon of 
knee joint by scale MSTS 76% aŌer resecƟon of proximal part of shin bone and 91% aŌer resecƟon of distal part of 
thigh bone. 
Conclusion: EndoprosthiƟcs is a standard of surgical treatment in bone tumors consƟtuent of knee joints, which 
allows to get saƟsfactory funcƟonal results and improves the quality of paƟents life.     
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Y 098LIMB PRESERVATION SURGERY IN THE LOCALLY ADVANCED 
SOFT TISSUE SARCOMA OF THE ELBOW JOINT REGION.
Matsumoto S., Shimoji T., Ae K., Tanizawa T., Gokita T.,
Department of Orthopedic Oncology, Cancer InsƟtute Hospital, Tokyo, Japan
IntroducƟon: The elbow joint region has structurally important funcƟons such as median, radial and ulnar nerves, 
and brachial vessels. This explains that aŌer removal of locally advanced tumor around the region, reconstrucƟons 
of joint funcƟon, major skin defect and nerve funcƟon are prerequisite. We have successfully treated subjects of 
severely advanced sarcoma around the region. 
Methods: Extracapsular resecƟon for the elbow joint was performed in all cases. Neurovascular bundles were made 
In Situ PreparaƟon (ISP). In the reconstrucƟon treatments, an elbow joint was replaced by an arƟficial joint, Coonrad-
Morrey, and recycled bone. In the upper arm skin defect treatment, funcƟonal LD flap for the Triceps and shortening 
of humerus in 2-3 cm were introduced, while for the forearm skin, free anterolateral thigh was performed. And for 
the funcƟonal defects of radial nerve, tendon transfer was adequately performed. 
Cases: From 2008 to 2009, four (4) subjects with STS around elbow joint were performed without making a 
preoperaƟve treatment. Pathological diagnoses performed were two (2) cases of synovial sarcoma; one in MFH and 
another in Extraskeletal OS. 
Results: The surgical margin in all cases was adequately maintained. There was no local recurrence created. Prognoses 
were three (3) cases in CDF and one (1) case in AWD. Concerning the funcƟonal outcome aƩained was 79 to 90 
degrees in acƟve ROM, and 22-26 points in ISOLS. ComplicaƟons confirmed were temporary nerve palsy in two (2) 
cases and one case of infecƟon. 
Conclusions: CombinaƟon treatments with the state-of-the-art techniques including arƟficial joint, recycled bone, 
skin flap, shortening of humerus and ISP contribuƟng to the limb preservaƟon surgery in locally advanced sarcoma 
around elbow joint region were successfully made.  
Reference: Matsumoto S. et al.: “In situ preparaƟon”: new surgical procedure indicated for soŌ-Ɵssue sarcoma of a 
lower limb in close proximity to major neurovascular structures. Int J Clin (2002)7:51-56
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YMICROSCOPIC INTEGRATION OF EXTENSOR MECHANISM 
ALLOGRAFT: A CASE REPORT
AlberƟni Ugo1, Boﬀano Michele1, Boux Elena1, Marone Stefano1, Linari Alessandra2, Gino Gian Carlo1, Brach del Prever Elena1, 
Piana Raimondo1
1 Oncologic and ReconstrucƟve Orthopaedics – AO CTO/Maria Adelaide Torino, Italy
2 Pathology Department – AO OIRM/Sant’Anna Torino, Italy
ObjecƟves: AllograŌ is one of the opƟons in the reconstrucƟon of the extensor mechanism aŌer bone and soŌ Ɵssue 
sarcoma resecƟon, quadriceps aor patellar tendon rupture aŌer total knee replacement and knee replacement 
revision surgery. The aim of the study is to understand the healing process at the juncƟon allograŌ-patellar tendon 
through a microscopic study.
Materials and Methods: Woman, 61 years old, malignant fibrous hisƟocytoma of the distal femur with intra-arƟcular 
involvement underwent an extra-arƟcular resecƟon with wide margins aŌer preoperaƟve chemotherapy. The distal 
femur was replaced with a modular megaprostheses (Megasystem C, Link Italia, Milano) and the extensor mechanism 
was reconstructed with an allograŌ. The allograŌ was supplied by the local Musculoskeletal Tissue Bank. The suture 
was performed by Flexidene no.2 (Braun, Germany). FuncƟonal results: acƟve flexion (80°) and acƟve complete 
extension, walking unaided without any pain aŌer 4 months from surgery and stable Ɵll 9 months. Unfortunately 
aŌer 9 months the paƟent had a massive local recurrence and underwent a hip disarƟculaƟon. At the macroscopic 
examinaƟon of the limb the integraƟon between allograŌ and patellar tendon was complete and the juncƟon was 
sampled and sent for histopathologic examinaƟon. Histologic examinaƟon was performed with a light microscope 
(H&E stain).
Results: Histological analysis showed changes indicaƟve of chronic inflammaƟon, fibrosis and foreign body reacƟon 
in correspondence of the autologous tendon. These changes were observed to progressively modify towards the 
allograŌ, presenƟng degeneraƟve changes without abrupt disconƟnuity. 
Conclusions: The examined specimen shows that, although degeneraƟve changes are present, there is a good 
funcƟonal result. This is an important result which helps in the comprehension of the healing process of allograŌ and 
the integraƟon with autologous Ɵssues. To our knowledge no other studies invesƟgated the in vivo structure of the 
juncƟon allograŌ-tendon aŌer 9 months from surgery. Further studies are mandatory to comprehend and improve 
the healing process. In parƟcular they should be focused on long term changes and on the unpredictable evoluƟon 
of a chronic inflammaƟon process.
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Y 107SIXTEEN YEARS FOLLOWͳUP OF A DISTAL FEMUR GIANT CELL 
TUMOR PRESENTED WITH INTRAͳARTICULAR FRACTURE
Duarte R. ; Vieira Ferreira N.; Frada T.; Maia R.; Fidalgo R.; Igreja C.; Vieira da Silva M.; (Braga, Portugal)
IntroducƟon: Giant cell tumors (GCT) of bone are benign tumors that occur predominantly around the metaphyseal 
area of long bones.  The treatment remains controversial because of their high recurrence rate. The majority are 
treated by aggressive cureƩage or resecƟon followed by methacrylate cement reconstrucƟon.
Material and methods: A 40 year-old woman was admiƩed in our insƟtuƟon in January 1995 with a pathologic supra 
and intercondilary fracture of the right femur. Radiographically she presented a lucent lesion located eccentrically in 
the internal femoral condyle. She was submiƩed to open reducƟon, intralesional cureƩage followed by methacrylaƟon 
and fixaƟon with cancelous bone screw.  The histological findings confirmed the suspected diagnosis of a giant cell 
tumor – Campanaci grade one.
During the follow-up period there were no signs of local recurrence or radiolucent zone at the bone-cement 
interface. 
FiŌeen years aŌer the surgery, the paƟent started to present several gait limitaƟons and knee pain. Radiological 
examinaƟon demonstrated an extensive osteoarthriƟs (Kellegren-Lawrence 4). The MSTS score was 3/30.
The paƟent was elected for total knee replacement (TKR). Intra-operaƟvely the cemented area looked stable and 
the surgeons decided to remove the cancelous bone screw and to perform a primary TKR without removing the 
cement.
Results: One year aŌer TKR the paƟent was saƟsfied with the clinical and funcƟonal outcomes.  The range of moƟon 
of the right knee was 0 degrees extension and 110 degrees flexion, and the paƟent was able to walk without pain 
and gait supports. VAS score was 1 and the MSTS score changed from 3/30 preoperaƟvely to 26/30. No radiologic 
signs of failure in bone-cement interface were detected.
Discussion: OsteoarthriƟs of the knee joint occurred 15 years postoperaƟvely aŌer treatment of a GCT with an 
intraarƟcular fracture at presentaƟon. ReconstrucƟon of a knee that was damaged by cement used in the treatment 
of a giant-cell tumor is someƟmes diﬃcult. There are several surgical opƟons, such as cement removal and filling 
with autologous bone graŌ followed by TKR; en-bloc resecƟon of the distal femur and reconstrucƟon with a modular 
oncology femoral and knee prosthesis; and knee arthrodesis. Our opƟon, primary TKR without cement removal, as 
minimally aggressive soluƟon, becomes Ɵll now an excellent opƟon.   
Conclusions: Giant cell tumors with an associated intra-arƟcular fracture remain a challenging problem to treat at 
presentaƟon. Current soluƟons to this pathology evolve in high percentage to osteoarthriƟc changes upon several 
years post-op, which then, arouses as another surgical demanding problem.
The opƟon to maintain the cement becomes eﬀecƟve, safe and allows the use of a primary prosthesis that provides 
immediate mobility and stability.
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SARCOMA. 
Delépine G1., Delépine F2., Cornille H.1   Delepine N
1Oncologic unit Raymond Poincaré Hospital  Garches France
2Clinique du parc impérial 28boulevard du tzarevitch06045 Nice France
ObjecƟves: With eﬀecƟve chemotherapy the gold standard for limb salvage is wide resecƟon. ConsecuƟvely primary 
total femur resecƟon is nowadays rarely indicated. Nevertheless with long follow up some secondary indicaƟon 
appeared and jusƟfy this review of our cases.
Materials: Between 1981 and 2011 we performed 276 femoral resecƟon for bone sarcoma  among them 14 paƟents 
had total femur resecƟon. Median age of paƟent is 14.5 (79-4.9) Histology of tumour are osteosarcoma in 8, Ewing’s 
in 4 (2 iniƟally metastaƟc) and dediﬀerenƟated chondrosarcoma in 2.
The indicaƟon for total femur resecƟon were : very huge tumour in 3, inappropriate previous surgery with femoral 
nailing in 3, persistent infecƟon of an upper massive prosthesis in 1, local recurrence in 1, and mechanical failure in 
6.
The first paƟent was reconstructed with a monobloc custom made prosthesis; the other benefiƩed of composite 
implant including hip and knee prostheses, cement and someƟmes growing component or allograŌ. 
Results: 4 paƟents died of disease aŌer 6 to 18 months The 10 other are disease free survivors with  a median follow 
up of 15 years. 8/10 survivors have a sƟll their limb and their prostheses. 
ComplicaƟons included severe ischemia in 1 (monobloc prosthesis was  3 cenƟmeters too long) and, hip dislocaƟon 
in 2.
Deep infecƟon , secondary or late  appeared in 6 paƟents (50% of cases!), due to the bad coverage of the prosthesis 
or reoperaƟon for lengthening.  Deep infecƟon is the most frequent and most severe complicaƟon. It was the reason 
for secondary amputaƟon in 2. 
SƟﬀness of the knee (Average flexion 45°), leg discrepancy and frequent necessity of crushes for long walking (4/8) 
explain that the funcƟonal result of the 8 paƟents with prostheses is never excellent, but only good (5) or fair (3). 
Conclusions: Total femur reconstrucƟon give much beƩer funcƟon than amputaƟon even if knee sƟﬀness is usual 
.Composite reconstrucƟon is more flexible than custom made monobloc prosthesis and no loosening between the 2 
implants appeared even with very long follow up.
The adjuncƟon of high dose Vancomycine in cement decreases the infecƟous risk and seems the best prevenƟve 
measure of  the most severe complicaƟon  of this salvage procedure .
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BREAST CANCER
GL Cribb, P Cool, DH Williams
Robert Jones and Agnes Hunt Orthopaedic Hospital - Oswestry - UK 
ObjecƟves: Breast cancer is the most common cancer in the UK and over half of paƟents who develop metastaƟc 
disease will have bone metastases 
Proximal femoral replacement is oŌen the treatment of choice for impending or actual fractures of the proximal 
femur in metastaƟc breast disease as fixaƟon devices oŌen fail. It however is a costly procedure, which is poorly 
remunerated.
We were keen to establish the outcome of this procedure at our insƟtuƟon for metastaƟc breast disease.
Materials and Methods: Data was collected from our tumour database of all paƟents who had undergone proximal 
femoral replacement since 2004 with at least 6 months follow up.
Results: We idenƟfied 34 procedures, which had been performed in 32 paƟents (2 have bilateral implants). Seventeen 
procedures were performed for fracture, 15 for impending fractures and 2 for revision of failed internal fixaƟon 
devices. The average age of the paƟents at Ɵme of procedure was 59.92 (range 29-83). The procedure was performed 
on average 5.26 years (0.03-20.87) aŌer cancer diagnosis.
All procedures used the Modular Stanmore Mets Proximal Femoral Replacement. No paƟents had an acetabular 
procedure. 
Average inpaƟent stay post procedure was 13 days (range 6-29)
There was one inpaƟent complicaƟon of a chest infecƟon. A further paƟent developed deep sepsis seven months 
post surgery, she has several wash out procedures and remains well with a draining sinus. There have been no 
dislocaƟons.
There are 9 paƟents (10 implants) who are sƟll alive. The average Ɵme to death post procedure was at an average of 
14.01 months (1.05-63.45). There were no deaths during the inpaƟent stay for the procedure at our insƟtuƟon.
The average TESS score of the surviving paƟents is 48 (37-60) at 6 months post surgery.
Conclusion: In conclusion proximal femoral replacement is a safe procedure with a low complicaƟon rate.
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Vasileios Kontogeorgakos1, George Kyrgias2, SokraƟs VariƟmidis1, KonstanƟnos Malizos1
Department of Orthopaedic Surgery, University of Thessalia, Larissa, Greece  1. 
Department of RadiaƟon Therapy, University of Thessalia, Larissa, Greece2. 
IntroducƟon: Loss of the thumb results in almost 50% of the hand funcƟon.  This can be the result of either 
congenital thumb anomalies or traumaƟc or oncologic amputaƟon. Tumors of the thumb consƟtute a unique group 
as mulƟdisciplinary approach is important for diagnosis and funcƟonal treatment.  Here we report on a paƟent who 
presented with a 1rst ray resecƟon because of diﬀuse squamus cell carcinoma and bulky tumor recurrence.
Material and Method: A 47 years old man was treated for chronic skin infecƟon of the thumb with repeated wound 
dressings and per-os anƟbioƟcs for 6 months. The skin lesion and erythema was evolving and the paƟent underwent 
1rst ray resecƟon. Pathology report revealed a squamus cell carcinoma, with negaƟve resecƟon margins. No further 
treatment was oﬀered at that Ɵme.  The tumor locally recurred and the paƟent referred to us 4 months aŌer index 
operaƟon, for further evaluaƟon and treatment.  At presentaƟon the paƟent had a bulky tumor recurrence without 
nodal involvement. A 3cm wide resecƟon of the recurred tumor was performed followed by 45 Gy radiaƟon therapy. 
Twenty days later an index pollicizaƟon was performed with a free radial forearm flap for web reconstrucƟon. 
Results: The 2cond pos-op day, the paƟent was able to flex the policis-index finger and bring the terminal phalanx in 
opposiƟon to the middle finger. At one month, he was able to grasp and hold light items. SaƟsfactory funcƟon in daily 
acƟviƟes was achieved. However, 6 months aŌer presentaƟon to us, the paƟent developed axillary node metastaƟc 
disease rapidly evolving. The paƟent diseased 2 month later. 
Conclusion: Squamus cell carcinoma is well known for 2 characterisƟcs:  may present as infecƟon and gives metastases 
to regional nodes. However iniƟal biopsy and accurate pre-op diagnosis is important for staged treatment. Oncologic 
thumb amputaƟons are rare. ResecƟon of thenar muscles decreases the maximum funcƟonal result that can be 
achieved. However, even with extensive Ɵssue loss, combined reconstrucƟve procedures of index policizaƟon and 
soŌ Ɵssue flap for web reconstrucƟon can significantly improve hand funcƟon.
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CONSERVATIVE MANAGEMENT EVER SUCCESFUL?
AE Wijsbek, BL Vazquez-Garcia, R Grimer, S Carter, R Tillman, A Abudu, L Jeys.
Royal Orthopaedic Hospital – Birmingham (UK)
IntroducƟon: Giant cell tumour (GCT) of the proximal femur (PF) represents only 5.5% of all GCTs. Many will present 
with a pathological fracture and most will already have significant bone destrucƟon by the Ɵme of diagnosis. Although 
conservaƟve treatment with cureƩage (+/- bone graŌ) is usually used for most GCTs, we quesƟoned whether this 
was ever successful in GCT PF.
Methods: RetrospecƟve review of all paƟents treated for primary GCT PF. Case notes and imaging studies were 
reviewed to idenƟfy the success of treatment in terms of hip preservaƟon and tumour control.
Results: 24 paƟents had GCT PF over a 28-year period. 15 were male and 9 female and the mean age was 31.5 (range 
17-74). 11 had a pathological fracture at Ɵme of diagnosis; all were treated with either EPR or THR. Treatment was 
with a THR in 9, EPR in 5 and cureƩage in 10. Local recurrence arose in 5 paƟents (21%), all within 3 years. LR arose 
in 2 treated by THR (22%), 0 by EPR and 3 by cureƩage (30%). Further surgery for any cause was required in 8 and 
was due to LR in 5 and mechanical failure in 3. Of the 10 paƟents treated iniƟally with cureƩage, 3 had a THR for 
LR and 1 EPR for mechanical failure. Thus, eventually, 18 paƟents ended with an arthroplasty and only 6 (25%) kept 
their own hip joint.
Conclusion: GCT PF is fortunately rare. In our hands, paƟents without a pathological fracture treated with cureƩage 
(+/- bone graŌ) had in 60% a successful outcome – but there is a 30% rate of LR in this group and a 10% risk the 
construct will fail. In the presence of a pathological fracture, or older paƟent, arthroplasty is a safer opƟon.
271
PO
ST
ER
SU
RG
ER
YRECONSTRUCTION AFTER RESECTION OF PRIMARY OR 
SECONDARY TUMOURS IN PROXIMAL FEMORAL BONE: 
COMPARISON OF DIFFERENT TYPES OF DEVICES
M. Maechler1, J. Friesenbichler1, P. Sadoghi1, W. Maurer-Ertl1, A. Leithner1
1Department of Orthopaedic Surgery, Medical University of Graz, Auenbruggerplatz 5, A-8036 Graz, Austria
IntroducƟon: Life expectancy of paƟents with malignant soŌ Ɵssue and bone tumours or metastases has taken 
great improvement within the last decades due to the progress of modern chemotherapy regimes. InvesƟgaƟons 
proved that a limb-sparing therapy is possible in about 90% in of case of malignant bone or soŌ Ɵssue tumors in the 
upper and lower extremity is necessary. Therefore the quesƟon arises, which reconstrucƟve procedure allows the 
best outcome. The aim of this study was to evaluate the prosthesis´ survival rate and complicaƟons in paƟents with 
surgical reconstrucƟon aŌer treatment of proximal femoral tumors.
Material And Methods: Between April 1996 and September 2011, 198 paƟents underwent surgical reconstrucƟon 
aŌer surgical treatment of primary bone tumours or metastases (55 primary tumours; 143 metastases). These cases 
were reviewed retrospecƟvely. ComplicaƟons were analyzed according to the classificaƟon of Goslings and Gouma 
and Henderson et al. The prosthesis´ survival rate was calculated according to Kaplan-Meier.
Results: In 73 cases (group 1; f:m = 40:33 males (mean age: 56 years) a modular proximal femoral tumour prosthesis 
was implanted. There were 39 paƟents with primary bone tumours and 34 cases of metastases. In 110 cases (group 
2; f:m = 67:43 males (mean age: 66 years) a hemiarthroplasty was performed. This group included three paƟents 
with primary bone tumours and 107 paƟents with metastases. FiŌeen paƟents (group 3) with nine females and six 
males (mean age: 55 years) were treated with total hip arthroplasty (7 primary tumours and 8 metastases). There 
were 25 complicaƟons needing revision surgery (13 infecƟons, five cases of structural failures, four cases of soŌ 
Ɵssue failures and three cases of asepƟc loosening). Proximal femoral reconstrucƟon devices had a survival rate of 
77% aŌer 12 months and 65% aŌer 60 months. Calculated implant survival for hemiarthroplasƟes was 97% aŌer 12 
months and 91% aŌer 60 months, whilst total hip arthroplasƟes had a survival rate of 83% and 71% for the same 
period. In total, prosthesis’ survival rate was 86% aŌer 12 months and 75% aŌer 60 months. The diﬀerence between 
implant survival for several types of devices was staƟsƟcally significant (p=0,016).
Conclusion: Surgical reconstrucƟon aŌer resecƟon of proximal femoral bone tumours or metastases revealed 
adequate survival rates, independently from type of prosthesis, which was used for reconstrucƟon. However, longer 
follow-up is needed in order to address the mid-term and long-term survival rates.
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OF BENIGN TUMORS WITH UNSTABLE OSTEOSYNTHESIS 
WITHOUT GRAFTING
Edgard Eduard Engel, Leandro Rodrigues Brandi, Pedro Mendonça Cyranka, Nelson Fabrício Gava
Faculty of Medicine of Ribeirão Preto University of São Paulo, Ribeirão Preto, Brazil
Despite its popularity, the need to fill bone defects aŌer benign lesions cureƩage is not well established in the 
literature. Autogenous and allogeneic graŌs, bone subsƟtutes, and bone cemenƟng are uƟlized for this purpose and 
have advantages and disadvantages. The risk of relapse or fracture, and the capacity for bone remodeling are the 
parameters that guide the surgeon’s choice. 
Thirteen paƟents with a mean follow-up Ɵme of 19 months (6-48 months) underwent cureƩage and unstable fixaƟon 
without graŌing of benign tumors. Similar to bridge plate osteosynthesis, rigid internal fixaƟon permits a certain 
movement in the weakened region permiƫng bone remodeling according to Wolf’s law.  Radiographs immediately, 
one month, and six months aŌer surgery were analyzed and bone remodeling area was measured.
For paƟents with lower limbs lesions full weight bearing was alowed 3.5 weeks (0 to 12) aŌer surgery.   No paƟent 
presented fractures or complicaƟons related to the early weight bearing. Radiograph measurements showed a 
reducƟon of 20% of the bone defect aŌer the first month and of 56% aŌer sixth months. 
These preliminary results suggest that the unstable fixaƟon protects paƟents submiƩed to cureƩage from fractures, 
but does not interfere with bone remodeling, allowing the natural filling of the lesion. 
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RECONSTRUCTION IN BONE TUMOR SURGERY 
J.G. Gerbers, P.C. JuƩe
In the treatment of bone tumors margins are very important. The first goal is always to obtain an adequate margin. 
ResecƟon of for example bone tumors results in defects that require reconstrucƟon, the larger the defect, the more 
diﬃcult the reconstrucƟon and generally speaking the poorer the funcƟon. The reconstrucƟon and post op period 
are oŌen diﬃcult due to allograŌ formaƟon diﬃculƟes and complicaƟons as long in growth Ɵme, infecƟons and 
fractures.
The use of computer assisted surgery (CAS) navigaƟon systems can be an elegant alternaƟve to the standard approach 
of fluoroscopy assisted resecƟon and unassisted reconstrucƟon. CAS has already been described as able to reliably 
plan resecƟon planes creaƟng adequate margins in bone tumor operaƟons; furthermore it can be used to perform 
the reconstrucƟon with pre-planned resecƟon planes. As an example, CAS resecƟon and reconstrucƟon can be 
applied to hemicorƟcal resecƟons. 
Some low grade bone tumors can be resected close to the tumor leaving a parƟal defect in the host bone 
instead of a segmental defect. The reconstrucƟon can be done with a so-called inlay graŌ. In low grade 
malignant tumors margins can be smaller, resulƟng in less Ɵssue damage, smaller defects and beƩer funcƟonal 
outcome. Hemi-corƟcal resecƟons leave the cortex parƟally intact as a natural splint. This surgical technique 
for the treatment of low grade malignant bone tumors was first described in 1982 by Campannaci et al. 
HemicorƟcal resecƟon is considered a safe alternaƟve to a larger segmental resecƟon for low malignant bone 
tumors.  However the operaƟon is technically demanding and complicaƟons as fractures are reported. [2] 
 
First a fresh frozen donor bone has to be found in the bone bank with, opƟmally, comparable dimensions to the host 
bone. A CT-scan of the same configuraƟon (i.e. slice thickness) was performed from both the host and the allograŌ. 
These scans are imported in the CAS system and matched by hand to find the opƟmum overlay in order to find the 
best fiƫng part to take the inlay graŌ from. The planned resecƟon planes from the setup of the host bone are then 
copied to the setup of the allograŌ.
Normal CAS setup is performed with a tracker aƩached to the bone aŌer exposure of the bone. Matching is done 
with reference points- and surface-matching, Ɵll an accurate match is reported. The pointer tool is then used to 
idenƟfy and mark the edges and entry points of the planned trapezoid shape. The excision planes are marked with 
a pen and checked with the pointer tool for accuracy. An oscillaƟng bone saw is used to perform the preplanned 
trapezoid shaped resecƟon. The resecƟon planes were checked again aŌer resecƟon for accuracy. The exact same 
procedure can then be performed on the allograŌ bone. 
The means of using CAS in the reconstrucƟon aŌer tumor resecƟon is relaƟvely new in orthopedics; in craniomaxillofacial 
surgery it is becoming more common. Last year we reported on one case of CAS resecƟon and reconstrucƟon in an 
ademanƟnoma, in a 17 year old boy. The result was good, with rapid in-growth of the allograŌ. Currently we have 
operated four paƟents with benign bone tumors, all with good follow-up and no complicaƟons, using the computer 
assisted hemicorƟcal resecƟon and allograŌ reconstrucƟon approach. CT controls are currently being performed 
as to quanƟfy the accuracy of allograŌ reconstrucƟon by measuring the gap between host bone and allograŌ aŌer 
surgery. Results are not available as the scans are sƟll being analyzed. In our eyes the CAS approach to these, albeit 
rare condiƟons, is an improvement over the current approach. It proves that CAS can be used in all kinds’ of bone 
reconstrucƟve surgery. The Ɵme required for the surgery is greatly reduced, and the diﬃculty is decreased. We 
hypothesize that the increased accuracy in navigaƟon decreases the gap between the allograŌ and the host bone, 
promoƟng faster in growth, shorter recovery Ɵme and possibly lower fracture rates. 
AlternaƟves for assisted reconstrucƟon could be pre-planned saw blocks designed for both the paƟent bone and the 
allograŌ bone. NavigaƟon in this seƫng would in our eyes sƟll be required in aƩaining an accurate placement of the saw block. 
As the blocks are custom made this can be quite expensive. Another alternaƟve is the pre fabricaƟon by rapid prototyping 
or other means of a filler material. Accurate resecƟon has to be performed for the filler to fit, navigaƟon is again required. 
As the navigaƟon now oﬀers accurate guidance, the biggest factor of deviance is the means of resecƟon. As the 
oscillaƟng saw, as far as we now, cannot be accurately tracked by the CAS system, an alternaƟve means of resecƟon 
would be ideal in these types of operaƟons. Adjustable saw blocks that are placed with the CAS system can be a 
possibility. A fully automaƟc navigated means of resecƟon would have the preference. 
ReferenƟes:
 [1] Deijkers RL, Bloem RM, Hogendoorn PC, et al.: HemicorƟcal allograŌ reconstrucƟon aŌer resecƟon of low-grade 
malignant bone tumours. J Bone Joint Surg Br 2002;84:1009-1014. 
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INFECTIONS AND WOUND PROBLEMS AFTER WIDE RESECTION 
OF SARCOMAS
M . Ayvaz, K. Buyukdogan, M. Tokgozoglu (Ankara, Turkey)
OBJECTIVE: One of the most challenging complicaƟons of tumor surgery is covering of implant with healthy soŌ 
Ɵssue and prevenƟon of infecƟon. Generally a skin necrosis around the wound occurs in these paƟents aŌer surgery 
and this causes a great problem with co-applied chemotherapy. PaƟents with such problems who are applied Vacuum 
Assisted Closure (VAC) are assessed in this study.
METHOD: 13 paƟents treated with VAC for wound problems aŌer tumor resecƟon  between 2006-2009 were 
evaluated retrospecƟvely. Mean age of paƟents (10 male, 3 female) was 37 (15-74). Pathologic diagnosis were 
giant cell tumor in 3 paƟents (2 pelvis, 1 distal femur), chondrosarcoma in 3 paƟents (2 pelvis, 1 proximal Ɵbia), 
osteosarcoma in 4 paƟents (proximal Ɵbia), liposarcoma in 2 paƟents (1 thigh, 1 gluteal) and  malign mesenchimal 
tumor in proximal femur. Sponge used in VAC theraphy was changed every 72 hours and every Ɵme cultures revealed 
from wound base  and paƟents were followed by weekly infecƟon parametres (ESR, CRP). IV anƟbioƟc theraphy was 
administered according  to culture results. When the culture results were negaƟve and serological markers were 
normalized, permenant soŌ Ɵssue reconstrucƟon was performed.
RESULTS: Mean follow-up Ɵme of paƟents aŌer wound place reconstrucƟon was 21-3 months (14-38). In only 
one paƟent VAC was re-applied due to reccurent local enfecƟon. In the final assesment of the paƟents no tumor 
recurrence or distant metastases were found. There were no prosthesis infecƟon.. No complicaƟons due to VAC 
theraphywas seen.
CONCLUSİONS: VAC theraphy is safe and eﬀecƟve for treatment of wound problems and infecƟons aŌer wide 
resecƟon of sarcomas. 
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RESECTION OF CAMPANACCI’S GRADE III GIANT CELL TUMOR: 
CASE REPORT
Luís Dias da Costa; Vânia Oliveira; Daniel Soares; Luciana Leite; Pedro Leite; Pedro Cardoso.
Centro Hospitalar do Porto, Hospital Santo António – Oporto - Portugal
IntroducƟon: Giant cell tumor (GCT) is a benign but oŌen locally aggressive neoplasm and is known for its 
unpredictable behavior, characterized occasionally even by metastases.
GCTs of the proximal humerus make up a minority of reports cases, and their treatment is guided by Campanacci’s 
system and Enneking staging.
The gold standart treatment for GCT is the cureƩage and cementaƟon of the caviƟes, however when we talk about 
Campanacci’s grade III, the choice of a conservaƟve treatment or a wide resecƟon is controversy, but the most 
important issues of limb-salvage surgery of proximal humerus are to maximize local control of the tumor, to preserve 
both elbow and hand funcƟons and to improve shoulder funcƟon and stability.
Authors present a case report of a paƟent with an extensive GCT of the proximal third of the humerus treated by a 
wide resecƟon and reconstrucƟon with a reverse total shoulder arthroplasty, with a very good outcome funcƟonal 
result.
Case Report: A 53-year-old male with clinical history of severe pain and swelling in the right shoulder over a period 
of 3 months, associated to marked shoulder funcƟon incapacity. 
The radiographs showed a pathological fracture in the proximal third of the humerus through a huge osteolyƟc 
lesion. 
The computed tomography scans were suggesƟve of an aggressive lesion. 
The trucut biopsy confirmed a GCT.
Wide resecƟon of the proximal humerus was performed and the arƟculaƟon was reconstructed with a reverse total 
shoulder arthroplasty.
In the early follow-up (3 weeks), a dislocaƟon of the prosthesis occurred and an open reducƟons was needed.
No other dislocaƟon or complicaƟon was reported Ɵll the last follow-up (3 years).
No local recurrence was observed.
The paƟent keeps without pain and with an excellent shoulder funcƟon, aŌer physiotherapy 
The score of Constant was 76 in the last follow-up.
Discussion/Conclusion: The main treatment to Campanacci’s grade III sƟlls controversial. Some authors defends the 
cureƩage and bone graŌing or cement because the poor funcƟonal results of the wide resecƟon.
However, we believe that when lesions involve obliteraƟon of the corƟcal bone and extension into the soŌ Ɵssue, 
wide resecƟon should be performed, especially if a pathologic fracture is present, to prevent recurrence.
In our case report, despise the dislocaƟon of the prosthesis in the early follow-up, the paƟent presents an excellent 
range of moƟon, probably beƩer than if a conservaƟve procedure had been done.
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RECONSTRUCTION WITH NONͳVASCULARISED FIBULAR 
GRAFT IN CHILDREN: REPORT OF 2 CASES
Fredrik Vult von Steyern1 MD PhD and Antonio Abramo2 MD PhD
Departments of Orthopedics1 and Hand Surgery2,, Skåne University Hospital, Lund, Sweden
ObjecƟve: Autologous vascular fibular graŌs are useful for reconstrucƟon of skeletal defects in tumour surgery. 
However, there are reports showing that results from non-vascularised graŌs are comparable to vascularised (Krieg 
and HeŌi, 2007). GraŌs heal at a similar rate, and biological acƟvity, assessed as hypertrophy of the graŌ and callus 
formaƟon when fractures occur, has been observed irrespecƟve of method. Moreover, there are also considerable 
advantages with non-vascularised graŌs, eg less complicated surgery, shorter operaƟon Ɵme and less morbidity at 
the donor site. SƟll, some locaƟons with limited amount of surrounding soŌ Ɵssue/muscle mass, eg the lower arm/
wrist, have been suggested to be less suitable for non-vascularised graŌs. This may however not be true. A series 
of cases with distal radius tumours reconstructed with non-vascularised proximal fibular graŌs aŌer excision was 
published in 2004 (Maruthainar et al.). This study presented good funcƟonal outcome for the paƟents, but included 
only adult paƟents and the majority were not treated with chemotherapy. 
 We here report preliminary but promising results from 2 cases where non-vascularised fibular graŌs were used to 
reconstruct skeletal defects aŌer surgery of bone sarcomas in the lower arm/wrist in children.
 PaƟents and Methods:
Case 1; Girl, 10 y, with osteosarcoma of the leŌ distal radius. Localized disease. Chemotherapy was given, pre- 
and postoperaƟvely, according to the EURAMOS-1 protocol. Surgery was performed with excision of 11 cm of the 
distal radius.  Histopathologic examinaƟon showed free surgical margins and good chemotherapy response. A non-
vascularised proximal fibular graŌ, including the fibular head, from the ipsilateral side was used for reconstrucƟon. 
The graŌ was fixed to the proximal radius with a plate and a flap from the ECRB was used to adapt the distal radius/
ulna. The wrist was fixed with pins for 3 weeks. The graŌ was made longer than the excised radius to compensate 
for expected growth of the ulna.
Case 2: Girl, 13 y, with Ewings sarcoma of the right distal ulna. Localized disease. Chemotherapy, pre- and 
postoperaƟvely, was given according the Euro Ewing-99 protocol. Surgery was performed with excision of the distal 
ulna, osteotomy 11 cm proximal to the distal physis and through the physis, the epiphysis and TFCC-lig were spared. 
Histopathologic examinaƟon showed free surgical margins and good chemotherapy response. ReconstrucƟon was 
made using a diaphyseal non-vascularised fibular graŌ from the ipsilateral side. The graŌ was fixed with a plate 
proximally and with an ulnar pin-plate distally.
Both girls are followed according to protocols, but in addiƟon scinƟgraphy of the lower arms was performed 1 year 
postoperaƟvely. FU this far is 26 (case 1) and 16 (case 2) months with no evidence of disease.
Results: The graŌs healed radiographically with the anastomoses no longer visible aŌer 11 and 9 months, respecƟvely. 
In addiƟon, scinƟgraphy 1 year aŌer surgery revealed revascularisaƟon of the graŌs. In case 2 there is parƟal 
regeneraƟon of the fibula at the donor site. 
In case 1 the epiphysis of the graŌ slipped 4 months aŌer surgery. This was treated with cast for 6 weeks. There is 
now subluxaƟon of the carpus, but no pain. She has limited range of moƟon of the wrist (acƟve flexion/extension 
15 degrees and pro-/supinaƟon of about 45 degrees). Sensibility and moƟon of the fingers are normal. The leŌ, 
operated, hand/wrist was and is sƟll, aŌer surgery, her dominant hand. The ulna has grown and there is no longer 
any exterior sign of ulnar deviaƟon of the wrist. At the donor site she has occasionally light discomfort when running, 
but no pain. The ankle is stable.
In case 2 no complicaƟons occurred during healing of the graŌ. The wrist is stable and she has full range of moƟon. 
Radiographically there is parƟal regeneraƟon of the fibula at the donor site. She has occasional discomfort from the 
lower limb when running, but no pain and the ankle is stable.
Conclusion: We here report preliminary good clinical and radiological results using autologous non-vascularised 
fibular graŌs for reconstrucƟon of skeletal defects of the lower arm/wrist in 2 children. The graŌs healed although in 
the case with proximal fibular graŌ the epiphysis slipped, resulƟng in a subluxaƟon of the carpus. Maybe this event 
could have been avoided by internal fixaƟon of the epiphysis.
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USEFUL TECHNIQUE FOR UNUSUAL SITUATIONS! 
BL Vazquez-Garcia, AE Wijsbek, R Grimer, S Carter, R Tillman, A Abudu, L Jeys.
Royal Orthopaedic Hospital – Birmingham (UK)
IntroducƟon: Limb salvage in the upper limb is usually fairly straighƞorward but in certain situaƟons convenƟonal 
methods of limb salvage (amputaƟon or endoprosthesis) are not possible or lead to poor outcomes. We describe 14 
cases where irradiaƟon and reimplantaƟon of bone has been used to solve a diﬃcult challenge. 
Methods: RetrospecƟve review of all paƟents treated in our insƟtuƟon with irradiaƟon and reimplantaƟon of the 
upper limb. We assessed the case notes and imaging studies to determine the success of this technique. 
Results: 14 paƟents were treated with irradiaƟon and reimplanƟon of the bone graŌ in the past 15 years. Mean 
age was 24 years (5-65 years), 9 female and 5 male. The bone tumours were Ewing sarcoma (4), osteosarcoma (6), 
osteochondroma (1), chondrosarcoma (2) and epitheliod heamangioendothelioma  (1). They were situated in the 
humerus (9) (middle 3, distal 4, proximal 1, total 1), total scapula (3), ulna (1) and metacarpal (1). The mean follow-
up Ɵme was 51 months (1-124). 4 paƟents (29%) had a non-union following the reimplantaƟon, all were treated with 
bone graŌ, 2 preceded with fracture. 2 (14%) had a fracture following the reimplantaƟon. In three very young children 
the technique was used as a staged technique to replace the total humerus, all three having an endoprosthesis when 
they were older.  Two paƟents died of metastases but there were no local recurrences. Superficial infecƟon arose in 
one paƟent, ulnar nerve paralysis in one. 
Conclusion: IrradiaƟon and reimplantaƟon of bone is a useful method of biologic reconstrucƟon of upper limb 
tumours in selected paƟents. It should be considered when alternaƟves are not readily available or likely to have a 
worse outcome. 
189
278
PO
ST
ER
SU
RG
ER
Y 197RESULTS OF 19 REVERSE ALLOGRAFTͳPROSTHESIS COMPOSITE 
RECONSTRUCTIONS OF THE PROXIMAL PART OF THE HUMERUS 
AFTER ONCOLOGIC  RESECTION
Even J¹, Bartoli MS², Anract P¹
¹Pole osteo-arƟculaire Chirurgie Orthpedique, Oncologique et Traumatologique B, Hopital Cochin, Paris, France ²Scuola di 
Specializzazione in Ortopedia e Traumatologia, Università Statale di Milano, Italia
INTRODUCTION: Proximal humerus is the 3rd most common site for bone malignancies. Wide resecƟon of the aﬀected 
bone segment with the surrounding soŌ Ɵssues is mandatory in order to achieve adequate margins. OpƟons for 
reconstrucƟon include allograŌ arthroplasty, endoprostheƟc arthroplasty, allograŌ-composite prosthesis, clavicula 
pro humero and arthrodesis. Use of allograŌ-composite prosthesis is a soluƟon witch theoreƟcally combines both 
benefits of osteoarƟcular allograŌ and megaprosthesis. Compared with osteoarƟcular allograŌ, it avoids subchondral 
fracture; compared with megaprosthesis it allows soŌ Ɵssue tendinous and capsular aƩachment and restoraƟon of 
bone stock. We present our experience with reverse prosthesis combined with proximal humeral allograŌ.
MATERIALS AND METHODS: We retrospecƟvely reviewed paƟents treated in our insƟtuƟon for primiƟve tumours 
of the proximal part of the humerus who underwent reconstrucƟon with allograŌ reverse shoulder prosthesis aŌer 
resecƟon type I according to the Malawer classificaƟon or S345 according to the Musculoskeletal Tumor Society 
classificaƟon. We revised their clinical history, assessment, oncological treatment, surgical technique and follow-up. 
Clinical and radiographic outcome were evaluated.
RESULTS:
PopulaƟon
Between 2001 and 2010, we treated 19 paƟents with tumors of the proximal humerus preserving the deltoid (mean 
follow-up 40 months). Histological diagnosis was 9 chondrosarcomas, 2 Ewing sarcomas, 1 telangiectaƟc sarcoma, 1 
osteoblasƟc sarcoma, 1 parosteal osteosarcoma, 1 synovial sarcoma, 2 giant cell tumours, 1 hisƟocyƟc fibroma. One 
paƟent had pulmonary lesions at diagnosis.
Surgical procedure
Deltoid muscle was preserved in all paƟents except the anterior fibers of the muscle which were resected with the 
biopsy tract; deltoid distal inserƟon was detached and reinserted on the allograŌ. The anterior branch of the axillary 
nerve had to be sacrificed in 2 cases. Length of humeral resecƟon ranged from 10 cm to 18 cm (Average: 14 cm). 
ReconstrucƟon was achieved with total reverse shoulder prosthesis and fresh frozen allograŌ. Suture of the rotator 
cuﬀ on the host allograŌ tendon was realized.
COMPLICATIONS: One surgical procedure was stopped because of bleeding during the resecƟon of a giant cell 
tumour, reconstrucƟon was done 24 hours later.
2 paƟents died of pulmonary metastasis, 2 local recurrences arose, one chondrosarcoma in a paƟent with Ollier’s 
disease and one giant cell tumour.
8 paƟents had iteraƟve surgery: 2 resecƟons of local recurrence, 4 graŌs for non union between the allograŌ and 
the humerus, 1  inserƟon of a lateralized spacer for iteraƟve dislocaƟon and 1 exploraƟon and drainage for early 
infecƟon.
Clinical and radiographic outcome
Mean acƟve abducƟon at last follow-up was 115° (range 40° to 180°; median 130°). On plain x-ray, evaluated with 
ISOLS radiologic score, we observed a significant allograŌ resorpƟon in 50% of paƟents. This was not associated with 
loosening of the prostheƟc stem. 
CONCLUSION: Reverse composite prostheƟc replacement is a reliable reconstrucƟon technique for proximal humerus 
tumors. Its main advantages are the availability of tendon aƩachments to reconstruct the remnant host soŌ Ɵssues, 
parƟcularly the deltoid inserƟon, combined with the fixed fulcrum given by the reverse design. In our opinion, when 
it is possible to preserve a funcƟonal deltoid, this opƟon is to be considered, in order to achieve a good long-term 
upper limb funcƟon.
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PROSTHESIS IN CHILDREN WITH DISTAL FEMUR BONE 
SARCOMAS 
Marco Manfrini, Marco Colangeli, Laura Campanacci, Nicola Fabbri e Pietro Ruggieri AUTHOR’S 
IsƟtuto Ortopedico Rizzoli, Bologna, Italy
IntroducƟon: The use of expandable megaprostheses for knee reconstrucƟon aŌer distal femur resecƟon in children 
aﬀected by bone sarcoma has become more popular since the advent of custom-made devices that promised non-
invasive lengthening procedure. The Repiphysis prosthesis was the first non-invasive expandable prosthesis available 
on the market. The lengthening is achievable through the energy stored in a compressed spring and released by an 
external electromagneƟc field  The lengthening of the device is proposed in an outpaƟent basis. 
ObjecƟves:The authors reviewed the mid-term experience of a consecuƟve series of 15 children that received the 
Repiphysis  at IsƟtuto Ortopedico Rizzoli from 2002 to 2007. 
Method: The clinical-radiographic evoluƟon in a consecuƟve series of 15 children (9 males, 6 females; diagnosis: 
14 HG Osteosarcoma, 1 Ewing Family Tumour), that had implanted a distal femur custom-made non invasive 
expandable prosthesis (Repiphysis WRIGHT), was analyzed.. Mean age at surgery was 8 years (range 6-11) and all 
paƟents received pre- and postoperaƟve chemotherapy according to the diagnosis.
Results: At a 80 months (49-110), follow-up (f-up) 10 paƟents ) (67%)  are alive with no evidence of disease (NED). 
One paƟent died  under chemotherapy for drug toxicity. Two paƟents presented a LR and were retreated with an 
above-knee amputaƟon at 6 and 19 months from the implant. Both died  for diﬀuse disease at 11 at 28 months 
from the first surgery. Three other paƟents presented lung metastases during the follow-up. One paƟent is alive and 
NED, 60 months aŌer the last toracotomy. The 2 others died at 20 and 28 months from the implant (one of these 2 
children showed a postoperaƟve infecƟon and had the implant removed aŌer 8 months). In summary 10 paƟents in 
complete remission underwent the lengthening program and are available for the evaluaƟon. 
 The first 7 procedures (in 3 paƟents) were aƩempted in an outpaƟent basis with no anesthesia but they were 
unsaƟsfactory because of the diﬃculty to manage the young paƟents that reported sudden pain and burning sensaƟon 
. Moreover it was clear that only a minimal lengthening  was achievable without a complete muscle relaxaƟon. All 
the successive 38 lengthening procedures (mean 4 for paƟent , range 1-5)  were performed under anesthesia in a 
Day-hospital basis. The total lengthening of 381 mm was obtained but a great variability was observed with a range 
from 3 to 20 mm for procedure. Post-lengthening  inflammaƟon of the thigh with pain, sƟﬀness and radiographic 
appearance of a radiolucent layer around the prostheƟc body occurred in 6 cases aŌer the third procedure. Eight 
paƟents presented radiographic and clinical signs of implant failure (metallic debris in the soŌ Ɵssue, breakage of the 
spring, instability) and underwent a complete revision of the primary implant at a mean f-up of 61 months (range 
51-82 months). Five males were sƟll skeletally immature (age at revision 11-13) and were revised with other types of 
expandable megaprostheses while 3 females were revised with adult megaprostheses (age at revision 13-15) with a 
final limb length discrepancy from 0 to 3.5 cm. 
Conclusion: In our hands Repiphysis prosthesis maintained only parƟally the oﬀer of non invasiveness: general 
anesthesia was necessary to obtain the lengthening of the device and no control on the amount of lengthening was 
possible. Moreover the implant was too fragile and mechanically failed before the end of the expected complete 
lengthening determining the need of a second expandable prosthesis.
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Y 241IMPAIRED WOUND HEALING AFTER NEOADJUVANT 
RADIOTHERAPY AND RESECTION OF SOFT TISSUE SARCOMAS 
OF THE EXTREMITIES
Y. Bakhshai 1,*, J. Rauch 2, L. Lindner 2, V. Jansson 1, A. Baur-Melnyk 2, H. R. Dürr 1
1Orthopaedic Oncology, Dept. of Orthopaedic Surgery, 2Ludwig-Maximilians-University Munich, München, Germany
INTRODUCTION: There is an ongoing quesƟon whether radiotherapy in soŌ Ɵssue sarcoma should be applied pre- or 
postoperaƟvely.
OBJECTIVES: Analysis of the influence of neoadjuvant radiotherapy on wound healing aŌer tumor resecƟon in 
paƟents with soŌ Ɵssue sarcomas.
METHODS: 34 paƟents with soŌ Ɵssue sarcomas had an intented wide resecƟon . PreoperaƟve radiotherapy was 
applied (mean 52 Gy), postoperaƟve brachytherapy at a mean dose of 17 Gy. Impaired wound healing was analyzed 
prospecƟvely. The mean follow-up period was 7 months.
RESULTS: 34 paƟents had either neoadjuvant radiotherapy (n=8) or radiotherapy and chemotherapy including local 
hyperthermia (n=26). R0 resecƟon was achieved in 33 paƟents. Impaired wound healing occured in 20 paƟents 
(59%). 17 paƟents had second surgeries (50%, 85% of paƟents with impaired wound healing). 4 of those 17 PaƟents 
had 2 or more intervenƟons. 12 (71%) had had neoadjuvant chemo- and radiotherapy, 5 (29%) radiotherapy only. 
4 (44%) of the 9 paƟents with tumors <= 5cm had second surgery. 13 (52%) of the 25 paƟents with tumors > 5cm 
needed further surgery. Regarding age Group 1 (age 23-45 y, n=11) showed 7 paƟents (64%) with revision surgeries, 
group 2 (age 46-67 y, n=11) 3 (27%) and group 3 (age >68 y, n=12) 7 (58%) revisions. 12 (35%) paƟents had an 
implantaƟon of brachytherapie catheters following resecƟon and underwent aŌerloading. 50% had wound healing 
disorders, all of them needed further surgery. With the combinaƟon of neoadjuvant chemo- and radiotherapy and 
adjuvant brachytherapy 5 (42% of the aŌerloading group) paƟents needed secondary surgery. Of those 5 paƟents 
one had to be amputated. Of the 2 paƟents that had received neoadjuvant radiaƟon and adjuvant brachytherapy, 
without chemotherapy one had further surgery. 5 (15%) paƟents showed metastasis at the date of tumor resecƟon. 
The mean follow up of those paƟents was 3,4 months. 3 had progressive mulƟple metastases on the latest report, 
one was in a stable and one in a regressive status. Of the 29 paƟents with no metastaƟc disease at Ɵme of surgery, 
11 developed systemic tumor progression. We saw one paƟent (3%, resecƟon status R0) with a local recurrence. He 
had neoadjuvant radio- and chemotherapy. At the Ɵme of the latest follow-up 3 paƟents had deceased. One paƟent 
died due to a sepƟc complicaƟon following revision surgery, 2 paƟents died due to progressive disease.
CONCLUSION: Radiotherapy has proved to be eﬀecƟve in regard to local tumor control (3% local recurrence in this 
study). Were are some reports, that local wound healing is mildly disturbed aŌer neoadjuvant radiotherapy but on 
the long term the funcƟonal outcome seems to be beƩer. Neoadjuvant chemotherapy alone does not seem to have 
an eﬀect on wound healing aŌer resecƟon. In our series 59% of the paƟents developed wound healing problems, 
one paƟent died due to sepƟc complicaƟons following revision surgery, one paƟent has to be amputated. 50% of 
all paƟents needed at least one revision. In paƟents treated by radiotherapy only 5/8 (63%) needed revisions, the 
combinaƟon of neoadjuvant chemotherapy and radiotherapy showed 12/26 (46%) revisions. The risk of wound 
healing disturbances is highly increased aŌer neoadjuvant radiotherapy, more than reported in some of the 
someƟmes enthusiasƟc literature reports.
KEYWORDS: radiaƟon therapy, sarcoma, soŌ Ɵssue, surgery, tumor, wound complicaƟon
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YDESARTHRODESIS AND PROSTHETIC RECONSTRUCTION OF 
THE KNEE AFTER RESECTION OF BONE TUMORS
KasimaƟs G. (1), Errani C. (2), Bosco G. (2), Ruggieri P. (2). (1. Athens, Greece, 2. Bologna, Italy)
BACKGROUND AND OBJECTIVES: The aim of the present study was to review the long-term results in paƟents who 
had undergone modular prostheƟc reconstrucƟon of the knee, following a failed arthrodesis performed aŌer the 
resecƟon of bone tumors.
METHODS: We reviewed 16 desarthrodeses and prostheƟc reconstrucƟons of the knee following a failed arƟficial 
arthrodesis aŌer bone tumor resecƟon. Desarthrodeses and subsequent knee megaprosthesis were performed aŌer 
breakage of the arthrodesis implant in 11 cases and following presumed eradicaƟon of infecƟon in five cases.
RESULTS: The mean follow-up was 15.9 years. The mean post-operaƟve range of knee flexion was 70°, but only four 
paƟents had acƟve extension of the knee. FuncƟonal results, according to the MSTS system, were saƟsfactory in 11 
paƟents. ComplicaƟons included deep infecƟons in five paƟents, asepƟc loosening in three paƟents, breakage of the 
joint hinge in one paƟent, and patellar tendon avulsion in one paƟent. Despite a high rate of complicaƟons, all but 
two paƟents were saƟsfied.
CONCLUSION: Our findings indicate that conversion of oncological knee arthrodesis to total knee arthroplasty 
should be taken into consideraƟon only aŌer giving the paƟent extensive informaƟon about the high risk of serious 
complicaƟons.
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Y 252CUSTOMͳMADE ANTIBIOTIC IMPREGNATED CEMENT MEGAͳ
SPACERS FOR THE TREATMENT OF INFECTIONS IN MASSIVE 
BONE RESECTIONS
M. Galli Serra, W. Parizza, C. Autorino (Buenos Aires, ArgenƟna)
Background: InfecƟon is a devastaƟng complicaƟon following reconstrucƟon with tumor endoprosthesis aŌer 
massive bone resecƟons. Two-stage reconstrucƟve technique has been proved to be a safe and eﬀecƟve method 
in the treatment of this complex situaƟon. One of the major concerns is that between stages paƟents may be 
uncomfortable with limited mobility and acƟvity because of the magnitude of resecƟon for tumor and infecƟon 
control. The aim of the present study was to review a series of paƟents with massive bone resecƟons in which a 
custom-made anƟbioƟc impregnated cement mega-spacers during the first stage of a two-staged procedure for 
treatment of infecƟon was implanted. 
Materials and Methods: Between 2007 and 2010 10 cases with an infecƟon at the site of a segmental tumor 
endoprostheƟs were treated with a two-staged procedure; which includes placement of a custom-made anƟbioƟc-
impregnated cement mega-spacer aŌer removal of the endoprosthesis and thorough debridement, followed by 
a course of intravenous anƟbioƟcs and delayed second-stage endoprosthesis reconstrucƟon. Mega-spacers were 
prepared using “rapid prototyping” technology, metal-reinforced intramedullary femoral and Ɵbial stems and 
increased constricƟon devices. 
Results: There were 8 females and 2 males; the mean age of the paƟents was 59 (range 16-75). The spacers were 
implanted for a period of 15 weeks (range 12-20). The infecƟon was controlled in all cases, and all the paƟents 
had an endoprothesis reconstrucƟon. No spacer cracks or dislocaƟons were recorded during the study period. The 
anƟbioƟcs used were: vancomycin and gentamicin in 9 cases and vancomycin, gentamicin and clindamycin in the 
remaining case. The anatomic locaƟons for the mega-spacers were 9 distal femurs and one total femur. 
Conclusions: Currently, relevant aspects regarding spacers are being discussed, many of them controversial: range 
of moƟon, cost, roughness, anƟbioƟc release, fracture, dislocaƟon, and need for addiƟonal orthoƟc equipment. 
ResorƟng to specific technology it has been possible to uƟlize large spacers in special cases.
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WITHOUT MUSCULAR RECONSTRUCTION IN ELDERLY 
PATIENTS. FUNCTIONAL RESULTS 
M. Galli Serra, W. Parizza, C. Autorino (Buenos Aires, ArgenƟna)
Background: Surgery is the primary treatment and the only curaƟve loco-regional approach of localized resectable 
soŌ Ɵssue sarcoma (STS) in elderly paƟents with no evidence of metastaƟc disease. The aim of the present study 
was to analyze a group of paƟents with age between 65 and 85 years old with STS localized at the thigh in which 
a complete resecƟon of the muscular compartment was done without muscular or tendinous reconstrucƟon. 
FuncƟonal evaluaƟon was assessed. 
Material and Methods: We retrospecƟvely reviewed 20 paƟents with a mean age of 73 years (85-67) who had STS 
resecƟon of the thigh. There were 11 females and 9 males. Incisional biopsy was done in all cases prior to definiƟve 
surgery. PaƟents were followed for an average of 40.8 months (6-101).
Wide resecƟon of the thigh compartment was done in all cases according to the anatomic localizaƟon, in order to 
obtain negaƟve margins, no muscular or tendinous reconstrucƟon were done in the present series.  All paƟents 
received postoperaƟve radiotherapy (4500 – 6000 Cgy) according to our insƟtuƟonal protocol. FuncƟonal evaluaƟon 
was done with the MSTS score and the “Up & Go” test at their latest follow up.
Results: Of the 20 STS, 11 were localized at the anterior compartment, 5 at the medial compartment and 4 at the 
posterior compartment of the thigh. Histology confirmed 12 liposarcomas, 3 leiomyosarcomas, 2 undiﬀerenƟated 
pleomorphic sarcoma, 2 synovial sarcomas and 1 fibrosarcomas. AJCS: IB 6 cases, IIB 13 cases, IVA 1 case. Although 
all resecƟons achieve negaƟve margins, and the margins obtained were classified as “wide”, one  paƟents had a 
local recurrence (case 12). Six complicaƟons were registered. MSTS score: 25,7 (21-30). “Up & Go” test: 11 paƟents 
with free movement, 6 paƟents with independence and 3 paƟents with variable movement. 10 paƟents died (6 
pulmonary metastasis, 1 liver metastasis and 3 other medical condiƟons).
Conclusions: STS of the thigh in the elderly treated by muscular compartment resecƟons and postopoperatory 
radiotherapy without reconstrucƟon seems to be a reasonable therapeuƟc approach, it has a good funcƟonal result 
with no limitaƟons in daily living acƟviƟes and efecƟve disease control. 
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Y 256ONCOVASCOLARE SURGERY: MULTIDISCIPLINARY APPROACH 
IN THE REMOVAL OF THE MUSCULOSKELETAL TUMOR 
AND ASSOCIATED REVASCULARIZATION. RESULTS AND 
COMPLICATIONS.
IppoliƟ A., Ascoli Marcheƫ A., Di Giulio L., Morelli M., Watchouang S.
IntroducƟon: The radical strategy of the tumor’s removal associated with limb salvage has become a primary 
objecƟve. The purpose of this study is to describe the characterisƟcs and results of surgical opƟons for paƟents 
with musculoskeletal cancer and indicaƟon for radical resecƟon, in our recent experience in collaboraƟon with the 
oncology center of Rome and the IFO Division of Orthopedics University of Rome Tor Vergata.
Methods: Between 2007 and 2011, were treated 30 paƟents aﬀected by primiƟve and secondary musculoskeletal 
neoplasm with a mean age of 44 years (14-67 years) in 26 cases (86.6%) were required revascularizaƟon. Women 
accounted for 53.84% (14/26), 46.16% were men (12/26). The study included a preoperaƟve biopsy of the lesion and 
ultrasonography and angio-CT with mulƟplanar reconstrucƟons for the evaluaƟon of the vascular anatomy.
Results: The average postoperaƟve follow-up was 19.4 months. The reconstrucƟon of the vessels has been 
implemented in 12/26 (46%) mainly using the autologous saphenous contralateral vein. The use of the prosthesis 
was performed in the others cases (with PTFE and Dacron K prosthesis). In 4 cases the paƟents had lower limb edema, 
with a distance venous patency of 80% and arterial patency of 100%. We had no mortality at 30 days. Two paƟents 
underwent VAC therapy. No amputaƟons were performed at 30 days. In 14 paƟents was performed perioperaƟve 
chemotherapy or radiotherapy. The data were analyzed using SPSS 18.0 for Windows.
Conclusions: A long-term evaluaƟon is needed to determine the implicaƟons at a distance in paƟents undergoing 
radical resecƟon of cancer in which are necessary for skills vascular surgery. The mortality gap is condiƟoned on the 
prognosis of neoplasm.
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INVERSE MEGAͳPROSTHESIS FOR DEFECT RECONSTRUCTION 
AFTER PROXIMAL HUMERUS RESECTION
A.Streitbuerger, H. Ahrens, G. Gosheger, M. Henrichs, J. Hardes, W. Guder
Department of Orthopedics, University Hospital of Muenster, Münster, Germany 
IntroducƟon: The defect reconstrucƟon of the proximal humerus with convenƟonal tumour prosthesis aŌer tumor 
resecƟon results commonly in a disappoinƟng funcƟonal outcome. The loss of the aƩachment of the rotator cuﬀ 
and especially the loss of the axillary nerve restrict the acƟve shoulder funcƟon serverely. However, as experience in 
revision shoulder arthroplasty provide in paƟents with an intact deltoid funcƟon an inverse prosthesis improves the 
acƟve range of moƟon in the shoulder joint significantly, even if the funcƟon of the rotator cuﬀ is seriously limited. 
In the presented study we invesƟgated if the use of an inverse prosthesis is able to improve acƟve shoulder funcƟon 
aŌer segment resecƟon of the proximal humerus.
Material/Methods: We present the short and midterm results of 13 paƟents treated with an inverse tumour prothesis 
for the reconstrucƟon of the proximal humerus aŌer resecƟon of benigne (1 giant cell tumour) and malignant bone 
tumours (6 primary bone sarcoma, 1 mulƟple myeloma, 5 carcinoma). Mean age at operaƟon was 54 years. The 
mean postoperaƟve follow-up was 25 months (range 4-95). 
Results: ResecƟon margins were wide in 8, marginal in 2 and intralesional in 1 paƟent. Mean reconstrucƟon length 
was 12 cm (range 5-20). Mean operaƟon Ɵme was 192 minutes. The axillary nerve was preserved in 76% (n=10). 
At latest follow-up the paƟents presented a medium MSTS-score of 24,1/30. The mean acƟve arm abducƟon in 
the shoulder joint was 68° and 57° acƟve arm elevaƟon for all paƟents but significantly reduced for the 3 paƟents 
without deltoid funcƟon.  2 paƟents needed a surgical revision (1 prostheses removal because of deep infecƟon and 
1 revision because of joint instability). 
Conclusion: The inverse prosthesis oﬀers a significant improvement of acƟve shoulder funcƟon in paƟents in which 
the axillary nerve can be preserved, compared to convenƟonal proximal humerus endoprosthesis. For paƟents 
without deltoid funcƟon there is no benefit regarding to the acƟve range of moƟon.  
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CONSIDERATIONS ABOUT 3 CASES.
Delépine G1., Delépine F2., Markowska B.1
1Oncologic pediatric unit Raymond Poincaré Hospital  Garches France
2Clinique du parc impérial 28 boulevard du tzarevitch 06045 Nice France
ObjecƟves: With eﬀecƟve chemotherapy the gold standard for limb salvage is wide resecƟon. ConsecuƟvely primary 
total humeral resecƟon is nowadays rarely indicated. Three cases, one with very long follow up permit us to consider 
the aspects of reconstrucƟon.
Materials:
Case 1 A 35 year old man consult us for pain in the leŌ arm. Ct showed a tumour invading the whole humerus. Open 
biopsy confirms a low grade fibrosarcoma. Total humeral resecƟon was performed with an allograŌ replacement. 
Years later a sub capital fracture of the humerus compelled us to put an proximal humeral prosthesis. 12 years later 
the resorpƟon of distal allograŌ compelled us to insert an elbow hinge prosthesis.
 25 years aŌer resecƟon paƟent in first remission is cured. According to Enneking’s score funcƟon is rated good 
(paƟent works as police oﬃcer).
Case 2January 2010 a boy of 17 come for a pathological fracture of the proximal part of right humerus.  Without 
biopsy he is treated by nailing from the elbow. AŌer 2 months the fracture healed but pain and bone swelling 
increased. 
AŌer 1 year an open biopsy is performed showing a telangectasic osteosarcoma.
As nailing disseminated the tumour throughout the diaphysis.extratumoral surgery necessitates total humerus 
resecƟon. Replacement used a composite prosthesis with an upper humeral long stem prosthesis inserted in an wide 
elbow custom made prosthesis locked with a high dose Vancomycine loaded acrylic cement (8 grams of vancomycine 
in 80 grams of metacrylate). 
Post operaƟve dislocaƟon of shoulder appeared compelling to re operate aŌer compleƟon of chemotherapy.
At last follow up the paƟent is in first remission. EstheƟcal aspect of limb is nice.
According to Enneking’s score funcƟon is rated good
Conclusions: Despite the technical diﬃculƟes total humeral replacement give much beƩer funcƟon than forequarter 
amputaƟon of upper limb.
These observaƟons plea for primary replacement by total humeral prosthesis rather than by allograŌ.
A constrained shoulder prosthesis seems useful 
Adding high dose Vancomycine may help in decreasing the infecƟon risk.
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ENDOPROSTHESIS IN EAST EUROPEAN SARCOMA GROUP 
Sokolovskiy V.A., Nisichenko D.V., Kubirov M.S., Sergeev P.S., Aliev M.D.
The main target is to implement  principles of total Ɵbia endoprosthesis by oncological paƟents in Russia. Nowadays 
there are only few events of total Ɵbia endoprosthesis by oncological paƟents. We would like to introduce our own 
posiƟve experience of total Ɵbia endoprosthesis in Russia.
The female paƟent, aged 24, with diagnosis of Ewing’s sarcoma is the right Ɵbia. T2bN0M0, stage IIb. She has been 
ill since April, 2009. The first symptoms were: pain, lameness. The pain was geƫng harder, and with the lapse of 
Ɵme it stopped being removed with intake of nesteroidal anƟ-inflammatory medicines. The paƟent was executed a 
roentgenogram of the right Ɵbia, according to its results a malignant shaŌ formaƟon of the right Ɵbia was suspected. 
To make the diagnosis more exact, the paƟent was delivered to us. Trepanobiopsy was carried out. In accordance with 
the results of a histological and immunohistochemical conclusion, Ewing’s sarcoma was diagnosed. Chemotherapy 
by the scheme VIDE was started. Eight courses were held without any visual eﬀect. It was decided to hold a course of 
radiotherapy, total radiaƟon dose 40 gray and a course of chemotherapy by  the scheme VincrisƟn 2 mg intravenously 
1 Ɵme per week in duraƟon of 1-3 weeks, cyclophosphan 400 mg intravenously 1 Ɵme per week in duraƟon of 1-3 
weeks. The 10th course of chemotherapy by the scheme VIDE was held.
It was intraoperaƟvely idenƟfied involvement in the tumor process m.  flexor posterior, m. flexor digitorum longus, 
flex hallucis longus. ResecƟon of  m. flexor digitorum longus, flex hallucis longus was executed on the level of the 
lower third of shank within intact Ɵssues. The neurovascular bundle was saved. The bone defect was removed with 
the help of a module endoprosthesis Mutars (Implantcast, Germany). The knee joint was reconstructed with the 
help of M-O-M system. The ankle joint was reconstructed with the help of the original construcƟon. Arthrodesis of 
ankle and heel bones was done with the help of a distal leg of endoprosthesis. A femoral leg and a leg of the ankle 
joint were fixed with bone cement. The body of endoprosthesis is clothed with a cover “Trevira”. Endoprosthesis 
was sheltered with removed m. gastrocnemius caput medialis. Histological and immunohistochemical conclusions 
of surgical material showed a good response to executed treatment – the 3rd stage of medical pathomorphosis. Post-
operaƟve treatment was concluded in immobilizaƟon of the extremity with a brace by means of fixaƟon of knee 
and ankle joints, using means of addiƟonal support. The wound healed up aŌer primary tension. Roentgenograms 
showed stable fixaƟon of endoprosthesis’ legs. At this moment the paƟent is observed the 6th month aŌer the 
surgical operaƟon, adjuvant chemotherapy is held. The mark according to MSTS is 76% (23/30 possible points). 
MoƟon in the knee joint is 85 degrees, in the ankle joint is 25 degrees. 
Conclusions: Taking into account a posiƟve result of the first in East European Sarcoma Group  total Ɵbia endoprosthesis 
and a good funcƟonal result and social rehabilitaƟon, it is possible to recommend this kind of complicated prosthesis 
in specialized centers by oncological paƟents aŌer a thorough choice of paƟents.
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AFTER RESECTION OF ILIAC  SARCOMA OF ZONES 1,3 OR 4
Delépine G., Delépine N., Alkhalaﬀ S., Markovska B.
Oncologic pediatric unit Raymond Poincaré Hospital  Garches France
ObjecƟves: LocaƟon on iliac bone account for 20% to 30% of sarcoma.. Gold standard of local treatment is wide 
resecƟon but Ɵll now few papers have tried to evaluate the long term results of reconstrucƟve procedures when 
chemotherapy and /or radiotherapy are used.
Materials and method: 45 paƟents (26 males and 19 females aged 9 to 66 years) with bone sarcoma of innominate 
bone in Zone 1, 3 or 4 (without involvement of acetabulum) were treated and/or followed up by the same team in 
24 years.. Histology was: chondrosarcoma (28), Ewing (14), osteosarcoma (2), MH (1) 
PreoperaƟve screening of paƟents included standard X rays, CT and bone techneƟum scan in all cases and MRI in 16 
cases. Diagnosis was made by open biopsy except for 4 cases of chondrosarcoma for these preoperaƟve screening 
was suﬃcient (and diagnosis confirmed by postoperaƟve histological examinaƟon).
Following limb salvage using reconstrucƟon of pelvis was performed with methyl metacrylate without hip 
prosthesis. Titanium screws were inserted in remaining bone before moulding of acrylic cement (2 to 3 packs of 
anƟbioƟc loaded cement). 
Results: With a median follow-up of 16 years (minimal 2-maximal 23.5) 12 paƟents died from disease aŌer local 
recurrence (6) and / or metastases (8). One disease free survivor has been lost for follow aŌer 3 years. The 32 others 
are disease free survivors.
PrognosƟc value: in our paƟents the prognosis was directly correlated with the histological grading (low grade 
chondrosarcoma have a 85% DFS) and in high grade tumours with the eﬃcacy of the chemotherapy. For primary 
metastaƟc paƟents, when chemotherapy is  subopƟmal or margins contaminated , the prognosis is dismal. With our 
most eﬀecƟve protocols and free margins, metastaƟc lesions did not aﬀect the disease free survival of our paƟents.
Orthopaedic results : weight bearing was immediate in all cases. We observed 3 deep infecƟons (2 compelled to 
make ablaƟon of the cement) and 3 late mobilisaƟons of cement.
 In all other paƟents, the reconstrucƟve procedure gave a good and stable funcƟonal result even in very long follow 
up.
Conclusions: Acrylic reconstrucƟon is an easy and reliable reconstrucƟve procedure aŌer en bloc resecƟon of iliac 
bone for malignant tumours in zone 1, 3 or 4. It is more reliable than bone graŌ when chemotherapy or radiotherapy 
are necessary.
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TUMOR RESECTION WITH SEGMENTAL BONE TRANSPORT 
USING ILIZAROV CIRCULAR EXTERNAL FIXATOR
BahƟyar DEMIRALP, Assoc.Prof. , Orthopaedics and Traumatology Department, Gülhane Military Medical Academy 06018 Etlik 
ANKARA  TURKEY, Tel: +903123045513, e mail: bahƟdemiralp@yhoo.com 
Yuksel YURTTAS, Assistant Prof., Orthopaedics and Traumatology Department, Gülhane Military Medical Academy 06018 Etlik 
ANKARA  TURKEY, Tel: +903123045534, e mail: yukselmd@yahoo.com 
Ozkan KOSE, Specialist,. Orthopaedics and Traumatology Department, Antalya EducaƟon and Research Hospital, ANTALYA 
TURKEY, Tel: +905326422612, e mail: drozkankose@hotmail.com 
Cemil YILDIZ, Prof., Orthopaedics and Traumatology Department, Gülhane Military Medical Academy 06018 Etlik ANKARA 
TURKEY, Tel: +903123045531, email: cyorto@yahoo.com 
Mustafa BASBOZKURT, Prof., Orthopaedics and Traumatology Department, Gülhane Military Medical Academy 06018 Etlik 
ANKARA  TURKEY, Tel: +903123045501, e mail: mbasbozkurt@Ʃnet.net.tr 
ObjecƟve: The purpose of this retrospecƟve study is to report the long-term follow-up experience in the reconstrucƟon 
of bony defects by Ilizarov’s distracƟon osteogenesis using bone transport method following en bloc resecƟon of 
bone tumors. 
Materials and methods: En bloc resecƟon was performed 11 paƟents with bone tumors between October 
1991-December 2004 in our clinic. The mean age of the paƟents was 18 years (range, 7-42 years). Histological 
diagnosis was osteosarcoma in four cases, Ewing sarcoma in three cases, aggressive giant cell tumor in one, 
osteofibrous dysplasia in one, chondrosarcoma in one and osteoblastoma in one case. Either femur or Ɵbia was 
involved in all cases. 
Results: The average follow-up period was 101 months (range, 86-196 months) and bone defect aŌer resecƟon 
was 13 cm (range, 8-24 cm). The funcƟon of the aﬀected leg was excellent in six paƟents, good in four and poor  in 
one paƟent according to the modified system of the MSTS. One Osteosarcoma case died six year aŌer the surgery. 
In two paƟents addiƟonal plate fixaƟon had to be performed due to non-union at the docking site. Conclusion: 
Bone transport is biological reconstrucƟon technique. In paƟents with long life expectancies, reconstrucƟon with 
distracƟon osteogenesis seems to be an eﬃcient method in the long-term follow up. However, long external fixaƟon 
Ɵme is a disadvantage of this technique. Problems in paƟent compliance and possible complicaƟons such as nonunion 
should be promptly managed. 
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BONE SARCOMA: RIZZOLI EXPERIENCE
Dr. Massimiliano De Paolis, Dr. Alessio Biazzo, Dr. Nicola Fabbri, Prof. P. Ruggirei
IsƟtuto Ortopedico Rizzoli di Bologna, Italy.
ObjecƟves: TradiƟonally, sarcomas arising from the scapula have been treated with parƟal or total scapulectomy. 
ResecƟon of the total scapula or the glenoid results in major funcƟonal disability. The goal aŌer these resecƟons is 
to restore shoulder girdle stability and preserve a normal funcƟon of the elbow and the hand. 
We report our experience about three paƟents who had scapular reconstrucƟons aŌer scapulectomy for bone 
sarcoma.
Materials and Methods: From 2007 to 2010, three paƟents (all females), aﬀected by low grade central chondrosarcoma 
(Stage IA) of the scapula, were treated with a scapular resecƟon. The ages of the paƟents were 31 years, 59 and 69 
years. The skeletal resecƟons were classified according to the system of Musculoskeletal Tumor Society. Glenoid 
resecƟon (S1) was done in two paƟents and total scapulectomy in one (S1-S2). Massive osteoarƟcular allograŌ was 
implanted in two cases (parƟal and total scapulectomy) and custom made prostheses in one (parƟal scapulectomy). 
The scapular allograŌ was fixed with plates and screws. The custom-made prosthesis was fixed to the residual scapula 
with screws. The acromion-clavicular joint was fixed with K. wire and arƟficial ligament in 2 cases, 1 screw in one. 
The joint capsule, tendon and the periscapular muscles detached, during the resecƟon procedure, were reaƩached 
to their origins or sutured to their corresponding stumps of the allograŌ. Minimum follow-up was 2 years (range 2-5 
years). Musculoskeletal Tumor Society (MSTS) and Constant score to evaluate the funcƟonal result, at latest follow-
up, were used. 
Results: Shoulder dislocaƟon, asepƟc loosening of the prostheses, infecƟon, nonunions or fractures of the allograŌ 
was not noted during this period. The MSTS score was 80-86%, and the Constant score was 56-61%. All paƟents had 
a stable, cosmeƟc, painless shoulder and funcƟonal elbow and hand. 
Conclusion: Scapular reconstrucƟon with allograŌ or prostheses aŌer tumor resecƟon is safe procedure. Selected 
paƟents and accurate surgical technique were crucial to obtain good outcome. 
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METASTATIC OR PRIMARY TUMORS
Yang-Guk Chung, Yong-Koo Kang, Won-Jong Bahk, An-Hi Lee*, Jung-Mi Park**Hae-Kyoo Lee**
Department of Orthopedic Surgery, Clinical Pathology*, Radiology**, College of Medicine, The Catholic University of Korea, 
Seoul, Korea 
ObjecƟves: PreoperaƟve embolizaƟon in hypervascular metastaƟc or primary tumors may reduce the intraoperaƟve 
hemorrhage and transfusion, which will facilitate the tumor resecƟon and reconstrucƟon. We evaluated the eﬀect 
of preoperaƟve embolizaƟon in hypervascular tumors.
Materials and methods: Since April, 2007, we performed preoperaƟve embolizaƟon and tumor resecƟon in 10 
hypervascular metastaƟc or primary tumors. 
Amount of intra-operaƟve bleeding and transfusion and operaƟon Ɵme were evaluated. There were 5 men and 5 
women. Mean age was 54.5 years. Primary tumors were renal cell ca in 4, hepatocellular ca in 3, and aneurismal 
bone cyst, anaplasƟc thyroid ca and MPNST in one respecƟvely. The locaƟons of lesions were pelvis in 4, proximal 
humerus in 2, proximal femur in 2. Other rare sites were scapula and spine. Wide resecƟons were performed in 3 and 
cureƩage and cementaƟons with internal fixaƟon in 7. The mean number of vessel embolized was 3.88. 
Result: The average intra-operaƟve blood loss was 1467 ml, ranged from 600 ml to 2500 ml. The average transfusion 
amount was 1003 ml, ranged from 350 ml to 2290 ml. The operaƟon Ɵme ranged from 60 to 235 minutes. 
All ten paƟents were hemodynamically stable during tumor resecƟon or cureƩage. There was no embolizaƟon 
related complicaƟon. 
Conclusion: PreoperaƟve embolizaƟon and tumor resecƟon and/or reconstrucƟon facilitated the safe surgical 
treatment even in hypervascular metastaƟc or primary tumors.  
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ENDOPROSTHESES.  AN IN VIVO STUDY.
FENTON, P. KOTECHA, A. WAFA, H. ABUDU, A. CARTER, S. GRIMER, R. TILLMAN, R. JEYS, L.
BONE TUMOUR UNIT, ROYAL ORTHOPAEDIC HOSPITAL -  BIRMINGHAM, UK
Endoprostheses have expanded the limb salvage opƟons in surgery for bone tumours, however infecƟon remains 
a significant concern.  Silver has well recognised anƟmicrobial properƟes.  Recently there has been interest in the 
use of silver coated orthopaedic implants as a means of reducing infecƟon.  However the possible cytotoxic eﬀects 
of silver ions on osteoblasts have potenƟal implicaƟons for osteointegraƟon of uncemented implants.  The purpose 
of this study was to assess the bone ongrowth onto silver coated endoprotheses compared with implants without 
silver coaƟng.
From a prospecƟve bone tumour database we idenƟfied 31 paƟents who had silver coated primary endoprostheses 
implanted since 2005.  Six paƟents were excluded due to inadequate follow up.  In addiƟon we idenƟfied 26 paƟents 
who had rouƟne primary endoprostheses implanted over the same Ɵme period.  There was no staƟsƟcally significant 
diﬀerence in age, sex, or length of follow up between the 2 groups.  Radiographs were reviewed for all paƟents and 
the ongrowth of bone onto the collar of the prosthesis was assessed as present or absent.  The presence of bone 
ongrowth was compared between the 2 groups.
In the silver coated group the mean age was 36.3 years and mean follow up 19.4 months.  In this group 7 out of 
25 paƟents had radiographic evidence of bone ongrowth.  In the non-silver coated group the mean age was 39.5 
and the mean follow up was 17.3 months.  Sixteen out of 26 paƟents had evidence of bone ongrowth.  There was a 
staƟsƟcally significant diﬀerence in the presence of bone ongrowth between the 2 groups (p=0.016, fisher exact).
This is the first in vivo study to assess bone ongrowth with silver coated prostheses that we are aware of.  Our results 
suggest that ongrowth is reduced with silver coated endoprostheses.  This could lead to increased rates of asepƟc 
loosening with these implants.  
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PPOSITIVE THOUGHTS AS A MOTIVE IN PALLIATIVE TREATMENT: 
PRO AND CON
Sharon Cardoni S.W. M.A.
NaƟonal Unit of Orthopedic Oncology,
Tel-Aviv Sourasky Medical Center, Tel Aviv Israel
Background: The World Health OrganizaƟon defines palliaƟve care as a therapeuƟc approach for improving the 
quality of life of the paƟent and his family from the moment an illness is diagnosed and throughout its various 
stages. A global trend is developing that sees posiƟve thoughts as a therapeuƟc element in general, and in incurable 
illnesses, such as osteosarcoma, in parƟcular. Nevertheless, there are studies and evidence from paƟents that raise 
quesƟons regarding this therapeuƟc approach and even note a possible, and perhaps destrucƟve, negaƟve impact.
Coping with crisis: The concept due to illness emphasizes the way in which the individual perceives his condiƟon and 
ability to successfully handle it. Success has several implicaƟons in this process:
To infuse the paƟents with hope and thus to help the illnessu 
The paƟent’s ability to seek and find emoƟonal support u 
The ability to process medical informaƟon and to apply behaviors directed towards solving problems, while u 
considering the changing reality
The therapist’s percepƟon of the palliaƟve treatment: My hypothesis is that the encounter between the therapist 
and the paƟent that suﬀers from a life threaten disease, the palliaƟve treatment is of clinical significance and impact 
on the paƟent’s quality of life and his coping from both the dynamic and the pracƟcal aspects.
Conclusions: As part of the aƩempt to determine the correct approach to treaƟng a life threaten illness, when 
viewing the paƟent within the anamnesic process, personality, social and environmental factors should be considered 
because they aﬀect the paƟent’s style of coping, and not to only assume that posiƟve thought is the right path for 
him. Our key goal as therapists focuses on maintaining the quality of the paƟent’s life within the framework of the 
exisƟng condiƟons while considering two aspects – the medical and the emoƟonal. The emphasis is on providing 
support, enhancing the means of coping, reducing the disparity between the exisƟng resources and the resources 
needed, helping solve problems in diverse frameworks (community, hospice home base, and hospice), meeƟng 
requests in the current system, improving the immediate wellbeing and increasing the sense of control.
RecommendaƟons: The change in the therapeuƟc approach should focus on posiƟve thoughts and infusing hope as 
means of helping the paƟents and their families, rather than the therapeuƟc goal itself.
One should know how to make educated use that is suitable for the parƟcular paƟent, and to find the balance 
between posiƟve thoughts and infusing hope, and coping with the exisƟng and the changing reality.
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P AWARENESS DAY FOR SARCOMAS IN NORWAY
Synnøve Granlien, CharloƩ Våde
OUS- The Norwegian Hospital
Oslo - Norway
ObjecƟve: Increased aƩenƟon on sarcomas for Health Care Professionals and if possible decrease Ɵme from 
appointment with G.P. or local hospital to right diagnosis and start of treatment.
Organize a meeƟng were sarcoma paƟents can meet and support each other.
Materials and Methods: Awareness day for health care professionals with lessons about what sarcoma is, how to 
detect, how to refer to sarcoma centers and how we treat sarcomas.
Gathering for sarcoma survivors and their relaƟves with teaching lessons, entertainment, food and beverages.
Results: 164 G.P’s, Physiotherapists, Nurses and other Healthcare professionals parƟcipated at the Conference of 
Sarcoma Awareness.
250 Sarcoma Survivors and their relaƟves joined the evening event.
Conclusions: The response from the aƩendants shows that there is need for informaƟon and educaƟon about 
sarcomas for Healthcare professionals.
Former paƟents have responded that they need a fellowship to support and help each other during treatment and 
rehabilitaƟon. We also started a PaƟent AssociaƟon for sarcoma paƟents during the evening-event and by now have 
over 300 members.
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PCLINICAL CARE PATHWAY  FOR ORTHOPAEDIC ONCOLOGIC 
PAEDIATRIC PATIENTS.
AntonieƩa Nardella, 
IV clinica, IsƟtuto Ortopedico Rizzoli. Bologna Italy
The increasing of paediatric paƟents with orthopaedic oncologic pathology pushed us to: § Create a beƩer faciliƟes 
for both mother and child by creaƟng dedicated rooms, spaces for game and study. § DirecƟng the nurse’s training 
to beƩer care, skill in communicaƟons and apply new methodologies  without using drugs in painful procedures. 
§ Only for children dedicated spaces during the follow up visits, assuring the conƟnuity of care with a dedicated 
medical doctor. The above improvement’s acƟons have been realized during the last 4 years. Any diﬀerences of 
age among the paƟents in the same room during the hospitalizaƟon, as much as for the follow up was taken into 
account before of it. Thanks to the collaboraƟon of all managers of the InsƟtute and the sensibility to deal with the 
problem showed by both volunteers and benefactors, and the eﬀort of the hospital care and medical staﬀs it has 
been possible to realize a beƩer care and comfort faciliƟes targeƟng the necessity of the paediatric paƟents with 
orthopaedic oncologic diseases. 
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P TAKING CARE ABOUT CHILDREN WITH CANCER AND THEIR 
SOCIAL ENVIRONMENT
Berthold S.,Eisenreich B.
Department of Pediatric Oncology,Olgahospital StuƩgart,Germany
Used to talk about highly specialized medical procedures and therapies,newest drugs,anƟbodies....
In the recent years more and more ´peripheral`issues gained our interest,like quality of life,prevenƟon
of long term side eﬀects,family maƩers.In this spirit over the years  many groups in pediatric oncology developed 
programs beyond primary medical care.
We would like to present a selecƟon of these acƟviƟes at our department,some of the projects older than 20 years.
Quite popular is our summer camp `Prima Klima`for children who have been touched with cancer or other chronic 
diseases.Characterizing and pivotal point is the staﬀ:apart from some supporters all them recruit
from former members of the camp, all of them having suﬀered from disease and therapy and sharing this
experience with nowadays parƟcipants.This unique constellaƟon will be one focus our presentaƟon.
Acompanying acƟviƟest take care about siblings,during therapy and aŌerwards,one project evaluates the
influence of sports and physical acƟvity during chemotherapy.With adults there is evidence of eﬀecƟve
reducƟon of side eﬀects and even risak for cancer relapse.Trying to erstablish a similar program for children
hopefully we get comparable if not beƩer results.
At last we want to allude briefly the care of another group of concerned people:ourselves!In the past we had
a lot of psychological supervisions,but we discovered ,that we achieved the biggest eﬀect by becoming team-
players.So we have a lot of collecƟve acƟviƟes like to go skiing,having summer and christmas parƟes,
visiƟng StuƩgarts ´Óktoberfest`.These joint adventures  help us to handle our straining work.
A poster presentaƟon like this might be only a glimpse into these acƟviƟes,but we hope we can convey an image how 
important they are for a comprehensive treatment of cancer.
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